VIRUPAKSHA™

ANNUAL REPORT
2025-26

INNOVATION | INTEGRITY | SUSTAINABILITY | GLOBAL IMPACT

SCIENCE. SUSTAINABILITY.
BETTER HEALTH. A BETTER WORLD.

CORPORATE INFORMATION

BOARD OF DIRECTORS

Mr. Chandra Mouliswar Reddy Gangavaram	-	Managing Director (DIN: 00046845)
Mr. Balasubba Reddy Mamilla	-	Whole Time Director (DIN: 01998852)
Mr. Chandrasekhar Reddy Gangavaram	-	Whole Time Director (DIN: 03534167)
Mrs. Vedavathi Gangavaram	-	Non-Executive Director (DIN: 02870966)
Mr. Janardhana Reddy Yeddula	-	Independent Director (DIN: 03207357)
*Mrs. Shruti Gupta	-	Independent Director (DIN: 09090071)
#Dr. Veera Reddy Arava	-	Independent Director (DIN: 10832178)
#Mr. Murali Krishna Kurada	-	Independent Director (DIN: 11187456)
*#Dr. Padmanabhuni Venkata Appaji	-	Independent Director (DIN: 02614167)
##Mr. Sidda Reddy Kanuparthi	-	Additional Director (Independent) (DIN: 07156289)

**Resigned from the position of Independent Director of the Company w.e.f. 03.09.2025.*
#Appointed as Independent Directors of the Company w.e.f. 03.09.2025.
**#Appointed as Independent Director w.e.f. 03.09.2026, Resigned as Independent Director w.e.f. 26.09.2026.*
##Appointed as Additional Director (Independent) w.e.f. 26.09.2026.

COMMITTEES OF BOARD

AUDIT COMMITTEE

Mr. Janardhana Reddy Yeddula	- Chairperson
Dr. Veera Reddy Arava	- Member
Mr. Balasubba Reddy Mamilla	- Member
Mr. Murali Krishna Kurada	- Member

NOMINATION AND REMUNERATION COMMITTEE

Mr. Murali Krishna Kurada	- Chairperson
Mr. Janardhana Reddy Yeddula	- Member
Dr. Veera Reddy Arava	- Member
Mrs. Vedavathi Gangavaram	- Member

STAKEHOLDERS RELATIONSHIP COMMITTEE

Mrs. Vedavathi Gangavaram	- Chairperson
Mr. Sidda Reddy Kanuparthi	- Member
Mr. Balasubba Reddy Mamilla	- Member
Dr. Veera Reddy Arava	- Member

CSR COMMITTEE

Mr. Chandra Mouliswar Reddy Gangavaram	- Chairperson
Mrs. Vedavathi Gangavaram	- Member
Mr. Murali Krishna Kurada	- Member

RISK MANAGEMENT COMMITTEE

Mr. Balasubba Reddy Mamilla	- Chairperson
Mr. Janardhana Reddy Yeddula	- Member
Mr. Chandrasekhar Reddy Gangavaram	- Member
Dr. Veera Reddy Arava	- Member

CHIEF FINANCIAL OFFICER - Mr. Prasad Reddy Battinapatla
COMPANY SECRETARY - Mr. Vikas Kurada

AUDITORS

STATUTORY AUDITORS –	M/s. C. Ramchandram & Co., Chartered Accountants, Hyderabad
INTERNAL AUDITORS –	M/s. Suryachandra & Associates, Chartered Accountants, Hyderabad
SECRETARIAL AUDITORS –	M/s. Aakanksha Dubey & Co., Company Secretaries, Hyderabad
COST AUDITORS –	M/s. J K & Co., Cost Accountants, Hyderabad

BANKERS:

STATE BANK OF INDIA	– SME Branch, Saifabad, Hyderabad
ICICI BANK LTD	– Nanakramguda Branch, Hyderabad
AXIS BANK LTD	– Begumpet Branch, Hyderabad
KOTAK MAHINDRA BANK	- Somajiguda, Hyderabad

REGISTRAR AND TRANSFER AGENT

KFin Technologies Ltd.
Karvy Selenium Tower B, Plot No. 31-32, Gachibowli,
Financial District, Nanakramguda, Hyderabad-500 032.
Toll free no. 1- 800-309-4001

REGISTERED OFFICE

Plot No.: B-1&2, IDA, Gandhi Nagar,
Medchal-Malkajgiri (District), Hyderabad,
Telangana, Rangareddy, India – 500037;
Tel: +91-40-23075816
E-Mail: info@virupaksha.com

WEBSITE: www.virupaksha.com

CIN: U24110TG1997PLC028281

NOTICE

NOTICE OF TWENTY NINTH (29TH) ANNUAL GENERAL MEETING OF THE MEMBERS OF VIRUPAKSHA ORGANICS LIMITED TO BE HELD AT A SHORTER NOTICE:

NOTICE is hereby given that the Twenty Ninth (29th) Annual General Meeting (AGM) of the Members of **M/s. Virupaksha Organics Limited** (CIN U24110TG1997PLC028281) will be held at a shorter notice on **Friday, the 28th August, 2026 at 09:30 A.M.** at the Registered Office of the Company situated at # Plot No.: B-1& B-2, IDA Gandhi Nagar, Medchal-Malkajgiri (District), Hyderabad, Rangareddy, Telangana, India – 500037, to transact the following business:

ORDINARY BUSINESS:

1. To receive, consider and adopt the Audited Financial Statements of the Company for the financial year ended 31st March, 2026, together with the Reports of the Board of Directors and Auditors thereon.

2. To declare the Final dividend of 10% i.e., Re.1/- on equity shares of face value of Rs. 10/- for the financial year ended 31st March 2026

3. To appoint a director in place of Mr. Balasubba Reddy Mamilla (DIN: 01998852) who retires by rotation and being eligible offers himself for re-appointment.

4. To appoint a director in place of Mr. Chandra Mouliswar Reddy Gangavaram (DIN:00046845) who retires by rotation and being eligible offers himself for re-appointment.

SPECIAL BUSINESS:

5. **To Approve Related Party Transactions**

*To consider and if thought fit, to pass, with or without modification(s), the following resolution as an **Ordinary Resolution**:*

"RESOLVED THAT pursuant to the provisions of Section 188 of the Companies Act, 2013 and other applicable provisions, if any, read with Rule 15 of the Companies (Meetings of Board and its Powers) Rules, 2014, as amended, Regulation 23(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as and when applicable and subject to such approval(s), consent(s), permission(s) as may be necessary from time to time and pursuant to prior approval of the Audit Committee and the Board of Directors of the Company, approval of the Members of the Company be and is hereby accorded to the Board of Directors of the Company to continue with the existing contract(s)/arrangement(s)/ transaction(s) and/or enter into and/or execute new contract(s)/ arrangement(s)/ transaction(s), (whether by way of an individual transaction or a series of transactions taken together) for the Financial year 2026-27 with the following persons / entities, a related party pursuant to Section 2(76) of the Act as it may deem fit, within the limits mentioned below:

Related party transactions which may be entered during the Financial Year 2026-27					
S No.	**Name of Related Party**	**Name of the Related Party Including director, promoter or KMP who is related if any**	**Nature of Relationship**	**Maximum Transaction Value (in Millions)**	**Nature of Transaction**
1.	Oxygenta Pharmaceutical Limited	Virupaksha Organics Limited	Subsidiary Company of Virupaksha Organics Limited	1300	Purchases
2.	Oxygenta Pharmaceutical Limited	Virupaksha Organics Limited	Subsidiary Company of Virupaksha Organics Limited	1200	Sales
3.	Oxygenta Pharmaceutical Limited	Virupaksha Organics Limited	Subsidiary Company of Virupaksha	1000	Rendering of Loans

			Organics Limited		
4.	Oxygenta Pharmaceutical Limited	Virupaksha Organics Limited	Subsidiary Company of Virupaksha Organics Limited	100	Rendering of corporate guarantee
5.	Oxygenta Pharmaceutical Limited	Virupaksha Organics Limited	Subsidiary Company of Virupaksha Organics Limited	0.05	Rent
6.	Virupaksha Laboratories Private Limited	1. Mr. Chandra Mouliswar Reddy Gangavaram, MD 2. Mr. Balasubba Reddy Mamilla, WTD 3. Mrs. Vedavathi Gangavaram, Director	Common Promoters	900 300 2	Purchases & Job Work (Transactions are recurring in nature) for the FY 2026-27. Sales & Job Work (Transactions are recurring in nature) for the FY 2026-27 Rent (Transactions are recurring in nature) for the FY 2026-27
7.	Mr. Kondapalli Sandeep Reddy	Son in Law of Mr. Chandra Mouliswar Reddy Gangavaram, MD	Son in Law of Mr. Chandra Mouliswar Reddy Gangavaram, MD	9.0	Remuneration for the FY 2026-27
8.	Mr. Kotla Suraj Reddy	Son in Law of Mr. Chandra Mouliswar Reddy Gangavaram, MD	Son in Law of Mr. Chandra Mouliswar Reddy Gangavaram	9.0	Remuneration for the FY 2026-27
9.	Mr. Nagarjun Reddy Mamilla	Son of Mr. Balasubba Reddy Mamilla, WTD	Son of Mr. Balasubba Reddy Mamilla, WTD	9.0	Remuneration for the FY 2026-27

"RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorized to do all such acts and take all such steps as may be necessary, proper or expedient to give effect to this resolution."

6. To appoint Mr. Sidda Reddy Kanuparthi (DIN 07156289) as an Independent Director of the company:

*To consider and if thought fit, to pass, with or without modification(s), the following resolution as a **Special Resolution***:

"RESOLVED THAT, pursuant to the provisions of Sections 149 and 152 read with Schedule IV, Section 161 and other applicable provisions, if any, of the Companies Act, 2013 along with the rules made thereunder, including, the Companies (Appointment and Qualification of Directors) Rules, 2014, each as amended ("Companies Act"), Regulation 17 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (including any amendments, modification(s) or re-enactment(s) thereof, for the time being in force) ("SEBI Listing Regulations"), and other applicable provisions thereof, if any, and pursuant to the provisions of the articles of association of Virupaksha Organics Limited (the "Company"), Mr. Sidda Reddy Kanuparthi (DIN 07156289), who has provided his consent in writing to act as an independent director of the Company and possesses relevant expertise and experience and has submitted a declaration in writing that he meets the criteria for appointment as an independent director under the Companies Act and the SEBI Listing Regulations and is eligible for appointment, be and is hereby appointed as an independent director on the board of directors of the Company (the "Board"), who shall hold office for a term of five years commencing on 26th September, 2025, and shall not be liable to retire by rotation. Mr. Sidda Reddy Kanuparthi shall be entitled to receive [sitting fees and commission for attending meetings of the Board or any committees thereof] as detailed in the letter of appointment dated 26th September, 2025 issued to Mr. Sidda Reddy Kanuparthi, as may be determined by the Board from time to time."

"RESOLVED FURTHER THAT the Company does note the consent letter in the Form DIR-2, the disclosure of interest under Section 184 in the Form MBP-1 and the certificate issued by the Indian Institute of Corporate Affairs, in compliance with Rule 6 of the Companies (Appointment and Qualifications of Directors) Rules, 2014, received from Mr. Sidda Reddy Kanuparthi providing his consent and eligibility to act as an independent director of the Company."

"RESOLVED FURTHER THAT, the Company does note the declaration in writing from Mr. Sidda Reddy Kanuparthi in Form No. DIR-8 confirming that he is not disqualified under Section 164 of the Companies Act from acting as a director of the Company."

"RESOLVED FURTHER THAT the terms of appointment of independent directors in terms of the provisions of the Companies Act, 2013, a draft of which was circulated to the Board, be and are hereby approved and recorded."

"RESOLVED FURTHER THAT the 'code of conduct for the Board pursuant to the Companies Act be and is hereby placed before the Company for information and for further compliance thereof by Mr. Sidda Reddy Kanuparthi as Independent Director."

"RESOLVED FURTHER THAT any Director of the Company be and is hereby authorized to do all the acts, deeds, matters and things which are necessary to the appointment of Mr. Sidda Reddy Kanuparthi as an independent director of the Company, including filing of the necessary forms with the Registrar of Companies, Telangana at Hyderabad and things as may be required to be done to give effect to the abovementioned resolutions and to settle any question or difficulty that may arise with regard to the aforesaid purpose and which it may deem fit in the interest of the Company."

"RESOLVED FURTHER a copy of the above resolution, certified to be true by any Director or Company Secretary, be forwarded to concerned authorities for necessary actions."

7. Increase in Remuneration of Mr. Balasubba Reddy Mamilla (DIN:01998852) Whole Time Director of the Company.

*To consider and, if thought fit, to pass with or without modification(s), the following Resolution as a **Special Resolution**:*

"**RESOLVED THAT** pursuant to the provisions of Section 178 and 197 read with Schedule V and other applicable provisions, of the Companies Act, 2013 (including any statutory modification(s) or re-enactment thereof for the time being in force) and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, as amended from time to time, recommendation of the Nomination and Remuneration Committee and approval of the Board, consent of the members of the company be and is hereby accorded for revision and increase in remuneration payable to Mr. Balasubba Reddy Mamilla (DIN:01998852), Whole Time Director, of the Company from the existing remuneration of Rs.75,24,000/- per annum (Rupees Seventy Five Lakh Twenty Four Thousand only) per annum to a remuneration up to Rs.1,20,00,000/- per annum, together with the allowances and perquisites as set out below, with effect from 01.04.2026, for the remaining tenure of his appointment:

1) Free use of the Company's car with driver.
2) Encashment of Leave: as per the rules of the Company
3) Club fee: subject to maximum of two clubs.
4) Gratuity as per the rules of the Company subject to the ceilings as per the applicable provisions of Law in force from time to time.
5) Insurance.
6) Any other allowance as may be permitted under the provisions of the Companies Act read with Schedule V of the Companies Act."

"RESOLVED FURTHER THAT in case of inadequacy of profits in any of the financial years, Mr. Balasubba Reddy Mamilla be paid and allowed same remuneration, perquisites and allowances as minimum remuneration for the remaining tenure of his appointment."

"RESOLVED FURTHER THAT any Director and/or Company Secretary & Compliance Officer of the Company, be and is hereby authorized to take all such steps as may be deemed necessary, desirable proper or expedient and file necessary e-forms with the Registrar of Companies, Telangana to give effect to this resolution and for matters connected there with or incidental thereto."

8. Increase in Remuneration of Mr. Chandrasekhar Reddy Gangavaram (DIN:03534167) Whole Time Director of the Company.

*To consider and, if thought fit, to pass with or without modification(s), the following Resolution as a **Special Resolution**:*

"RESOLVED THAT pursuant to the provisions of Section 178 and 197 read with Schedule V and other applicable provisions, of the Companies Act, 2013 (including any statutory modification(s) or re-enactment thereof for the time being in force) and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, as amended from time to time, recommendation of the Nomination and Remuneration Committee, consent of the Board be and is hereby accorded for revision and increase in remuneration payable to Mr. Chandrasekhar Reddy Gangavaram (DIN: 03534167), as Whole Time Director, of the Company from the existing remuneration of Rs.63,36,000/- (Rupees Sixty Three Lakh Thirty Six Thousand only) per annum to a remuneration up to Rs.1,00,00,000/- per annum, together with the allowances and perquisites as set out below, with effect from 01.04.2026, for the remaining tenure of his appointment:

1) Free use of the Company's car with driver.
2) Encashment of Leave: as per the rules of the Company
3) Club fee: subject to maximum of two clubs.
4) Gratuity as per the rules of the Company subject to the ceilings as per the applicable provisions of Law in force from time to time.
5) Insurance.
6) Any other allowance as may be permitted under the provisions of the Companies Act read with Schedule V of the Companies Act."

"RESOLVED FURTHER THAT in case of inadequacy of profits in any of the financial years, Mr. Chandrasekhar Reddy Gangavaram be paid and allowed same remuneration, perquisites and allowances as minimum remuneration for the remaining tenure of his appointment."

"RESOLVED FURTHER THAT any Director and/or Company Secretary & Compliance Officer of the Company, be and is hereby authorized to take all such steps as may be deemed necessary, desirable proper or expedient and file necessary e-forms with the Registrar of Companies, Telangana to give effect to this resolution and for matters connected there with or incidental thereto."

9. Ratification of Cost Auditors' Remuneration:

*To consider and, if thought fit, to pass with or without modification(s), the following Resolution as an **Ordinary Resolution**:*

"RESOLVED THAT pursuant to Section 148 and other applicable provisions, if any, of the Companies Act, 2013 (''Act'') read with the Companies (Audit and Auditors) Rules, 2014, [including any statutory modification(s) or re-enactment(s) thereof] as amended from time to time, the Company hereby ratifies the remuneration of Rs. 3,00,000/- plus GST (Rupees Three Lakhs Only) and out of pocket expenses and XBRL conversion charges etc., payable to M/s J K & Co., Cost Accountants, Hyderabad (FRN 004010), who were being appointed by the Board of Directors as Cost Auditors of the Company to conduct cost audit relating to cost records of the Company for the year ending 31st March, 2027."

"RESOLVED FURTHER THAT the Board be and is hereby authorised to vary and /or revise the remuneration of the Cost Auditors within limits as approved by the aforesaid resolution and to do all such acts, deeds and things and execute all such documents, instruments and writings as may be required to give effect to the aforesaid Resolution."

10. **To provide Loan and give Guarantee or Provide Security in Connection with a Loan to the Entities, in which Directors of the Company are Interested or Deemed to be Interested under section 185 of the Companies Act, 2013.**

*To consider and, if thought fit, to pass with or without modification(s), the following Resolution as a **Special Resolution**:*

"RESOLVED THAT pursuant to Section 185 and other applicable provisions if any, of the Companies Act, 2013 and relevant rules made thereto including any statutory modifications or re-enactments thereof and in accordance with Memorandum and Articles of Association of the Company and pursuant to recommendations and approval of Audit Committee and Board, consent of the Members of the Company be and is hereby accorded to the Board of Directors of the Company to advance any loan(s), give any guarantee(s) or provide security in connection with any Financial Assistance / Loan taken / to be taken / availed / to be availed by entities, in which Directors of the Company are interested or deemed to be interested, provided that the loans, giving guarantee or providing security shall not at any time exceed the aggregate limit of Rs.300.00 Crores (Rupees Three Hundred Crores Only)."

"RESOLVED FURTHER THAT the aforementioned loans, giving guarantee or providing security on behalf of entities shall only be utilized for the purpose of its principal business."

"RESOLVED FURTHER THAT any Directors(s) of the Company be and is/are hereby severally authorised for and on behalf of the Company to do all such acts, deeds, matters and things as may be necessary, proper, expedient, or incidental to give effect to this resolution."

11. **Alteration of the Articles of Association of the Company**

"RESOLVED THAT pursuant to the provisions of Sections 5, 14, 15 and other applicable provisions, if any, of the Companies Act, 2013 and the rules and regulations made thereunder (including any amendments, modifications or re-enactment thereof)("Companies Act"), the applicable provisions of the Securities Contracts (Regulation) Act, 1956, as amended, the Securities Contracts (Regulation) Rules, 1957, as amended, and in accordance with the enabling provisions of the memorandum of association and articles of association of the Virupaksha Organics Limited (the "Company") and further subject to such other terms, conditions, stipulations, alterations, amendments or modifications as may be required, specified or suggested by the Registrar of Companies, and in order to align the articles of association of the Company with the requirements of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("SEBI Listing Regulations"), and the listing requirements of the stock exchange(s) where the securities of the Company are proposed to be listed and in accordance with the enabling provisions of the memorandum and articles of association and subject to the applicable provisions of any other applicable law, the consent and approval of the shareholders of the Company be and is hereby accorded for for alteration in the Articles of Association ("AOA") of the Company by inserting the following provisions under the respective clauses:

(i) Insertion / Addition in Clause 2 – Interpretation Under Clause

(ad) Depository(ies): "Depository(ies)" shall mean a depository as defined in Clause (e) of sub-section (1) of Section 2 of the Depositories Act, 1996.

(ae) Lock-in Period: "Lock-in Period" shall mean the period for which the entire pre-listing capital of the Company is required to be locked-in, in accordance with the applicable laws, including the provisions of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended.

(ii) Insertion / Addition in Clause 69A – Lock-in of Shares

(i) Notwithstanding anything to the contrary contained in these Articles, and as required under the applicable laws, where any Shares held by persons other than promoters of the Company are required to be locked-in and such lock-in cannot be created or recorded by Depositories for any reason whatsoever including where such Shares are (a) subject to pledge; or (b) under "freeze balance" or "safe balance", or (c) any other form of encumbrance as may be recorded with the Depositories, on a day prior to the commencement of the lock-in period, the Company shall have the power to issue instructions to the Depositories, directing them to record such Shares as “non-transferable” for the duration of the applicable lock-in period. The aforementioned Shares shall be treated as locked-in for the Lock-in Period as specified under the relevant laws.

(ii) In the event of invocation of the pledge of such Shares by the pledgee, whether in whole or in part, the Shares so transferred or received by the pledgee upon such invocation shall continue to remain locked-in in the account of the pledgee for the balance Lock-in Period.

(iii) In the event of release of the pledge of such Shares by the pledgee, whether in whole or in part, the Shares so released shall continue to remain locked-in in the account of the pledgor for the balance Lock-in Period.

The Board is authorised to take all steps, furnish all declarations and issue all instructions necessary to implement such lock-in and to remove such marking upon expiry of the relevant lock-in period or as otherwise permitted under applicable law.”

“**RESOLVED FURTHER THAT** any Director and/or Company Secretary of the Company be and is authorised severally to issue certified true copies of these resolutions to various authorities and to file necessary forms with the ROC, do and perform all such other acts, deeds and things as may be necessary or desirable and to sign, execute any application, undertaking or confirmation required to be provided to the ROC in this regard, or to give full effect to the abovementioned resolutions.”

“**RESOLVED FURTHER THAT** a copy of the above resolution, certified to be true by any Director or the Company Secretary, be forwarded to the concerned authorities for necessary action.”

For Virupaksha Organics Limited

Chandra Mouliswar Reddy Gangavaram
Managing Director
(DIN 00046845)

Place: Hyderabad
Date: 24th August, 2026

NOTES:

1. The Explanatory Statement pursuant to Section 102 of the Companies Act, 2013 ("Act") in respect of the business under item nos. 5-11 of the notice is annexed hereto.
2. A member of the Company entitled to attend and vote at the Annual General Meeting is entitled to appoint a proxy to attend and vote instead of himself / herself and the proxy need not be a Member of the Company.
3. The proxy form, in order to be effective, must be duly filled signed and deposited at the Registered Office of the Company not less than 48 hours before commencement of the Meeting.
4. A person can act as a proxy on behalf of members not exceeding fifty and holding in the aggregate not more than ten percent of the total share capital of the company carrying voting rights. A member holding more than ten percent of the total share capital of the company carrying voting rights may appoint a single person as proxy and such person shall not act as a proxy for any other person or member.
5. Corporate members intending to send their authorized representatives to attend the meeting are requested to send to the company, a certified copy of the board resolution authorizing their representative to attend and vote on their behalf at the meeting.
6. Members who have not registered/updated their e-mail addresses so far, are requested to register their e-mail address with the Company/RTA/ Depository Participants for receiving all communication including Annual Report, Notices, Circulars, etc. from the Company.
7. Members must quote their Demat Account number and contact details such as email address, contact number etc. in all correspondence with the Company/Registrar and Share Transfer Agents.
8. Members may note that the Board of Directors, in its meeting held on 24th August, 2026 has recommended a final dividend of Re.1/- per share for fiscal year 2025-26. The record date for the purpose of final dividend is 21st August, 2026. The final dividend, once approved by the members in the ensuing AGM will be paid within 30 days from the date of AGM, electronically through various online transfer modes to those members who have updated their bank account details. For members who have not updated their bank account details, dividend warrants / demand drafts / cheques will be sent out to their registered addresses.
9. Members are requested to kindly bring their copy of the annual report with them at the AGM, as no extra copy of the annual report would be made available at the AGM venue. Members/proxies should also bring the attached attendance slip, duly filled and hand it over at the Meeting.
10. In terms of the requirements of the Secretarial Standards -2 on "General Meetings" issued by the Institute of the Company Secretaries of India and approved & notified by the Central Government, the Route Map and google map link for the location of the aforesaid meeting is pasted below:

https://maps.app.goo.gl/NBN69rdV6vhkE2M28

EXPLANATORY STATEMENT PURSUANT TO SECTION 102 OF THE COMPANIES ACT, 2013

(Pursuant to Section 102 of the Companies Act, 2013 ("the Act"), the following explanatory statement sets out all material facts relating to the business mentioned under item nos. 5-11 of the accompanying notice)

Item No.5:

The company may enter into transactions with the entities, as mentioned in the resolution, which are falling under the definition of "related party" as defined under Section 2(76) of the Companies Act, 2013 and Regulation 2(1) (zb) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015) ("SEBI Listing Regulations") as and when applicable. Pursuant to provisions of Section 188(1) of the Companies Act, 2013 read with the Companies (Meeting of Board and its Powers) Rules, 2014, the Related Party Transactions as mentioned in clause (a) to (g) of the said Section requires a Company to obtain prior approval of the Audit committee, Board of Directors and the Shareholders of the Company by way of an Ordinary Resolution in case the value of the Related Party Transactions exceeds the stipulated thresholds prescribed in Rule 15(3) of the said Rules. On the basis of the same, the Company hereby proposes to seek shareholders' approval for the said / proposed transaction by way of an Ordinary Resolution under Section 188 of the Companies Act, 2013 read with the Companies (Meetings of Board and its Powers) Rules, 2014, to enable the Company to enter into Related Party Transactions in one or more tranches. The particulars of the Related Party Transactions, which are required to be stated in the Explanatory Statement, as per Rule 15(3) of the Companies (Meetings of Board and its Powers) Rules, 2014 are mentioned in the said resolution item no.5 of the Notice.

All entities falling under definition of related party shall abstain from voting irrespective of whether the entity is party to the particular transaction or not.

The Board of Directors recommends the ordinary resolution set forth at item no. 5 of this Notice for your approval.

Except Mr. Chandra Mouliswar Reddy Gangavaram, Managing Director, Mr. Balasubba Reddy Mamilla, Whole-time Director, Mrs. Vedavathi Gangavaram, Director, none of the Directors or Key Managerial Personnel or any relative of any of the Directors/ Key Managerial Personnel of the Company are, in any way, concerned or interested, financially or otherwise, in the resolution.

Item No.6:

Mr. Sidda Reddy Kanuparthi (DIN 07156289) is proposed to be appointed as an Independent Director of the Company, in accordance with applicable laws, including Sections 149 and 152 read with Schedule IV, Section 161 and other applicable provisions, if any, of the Companies Act, 2013 (including any amendments, modifications or re-enactment), along with the rules made thereunder, including the Companies (Appointment and Qualification of Directors) Rules, 2014, each as amended ("**Companies Act**")and the provisions of Regulation 17 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("**SEBI Listing Regulations**") each as amended, and other applicable provisions thereof, if any, and pursuant to the provisions of the articles of association of the Company, in connection with the Issue of the Equity Shares. In this connection, the board of directors of the Company (the "**Board**") is of the opinion that Mr. Sidda Reddy Kanuparthi fulfils the criteria for independent directors, as set out in the Companies Act, related rules framed thereunder and the SEBI Listing Regulations and that Mr. Sidda Reddy Kanuparthi is independent of the management of the Company.

Information of director seeking appointment at the forthcoming [annual] general meeting (pursuant to the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standard 2 issued by the Institute of Company Secretaries of India).

Name of the Director	Mr. Sidda Reddy Kanuparthi
DIN	07156289
Date of Birth (Age in years)	01.03.1955 (71 years)
Original date of appointment	26.09.2025
Qualifications	He holds B.Sc, M.A., CAIIB, PGDFA, L.L.B degrees and he is Banking professional with 31 years of rich and varied exposure in Business development, Branch and Region administration, Corporate Credit
Experience and expertise in specific functional area	Exposure in Business development, Branch & Region administration, Corporate Credit.
Shareholding in the Company	NIL
Remuneration last drawn	NIL
No. of Board meetings attended during the year	4
Terms and conditions of re-appointment and remuneration	Appointed as an Independent Director for a term of five years commencing on 26.09.2025.
Relationship with other Directors or KMPs	NIL
Directorships held in other companies in India	1.Oxygenta Pharmaceutical Limited 2.Harinandan Enterprises Private Limited
Membership / Chairmanship of committees in public limited and listed companies in India	03

The proposed Independent Directors have submitted a declaration that they meet the criteria for appointment as an independent director. Further, the Company has received the consent in writing from Mr. Sidda Reddy Kanuparthi to act as a Director in Form DIR-2, intimation to the effect that he is not disqualified to be appointed as a director in other companies in Form DIR-8 and the certificate issued by the Indian Institute of Corporate Affairs, in compliance with Rule 6 of the Companies (Appointment and Qualifications of Directors) Rules, 2014.

The Board has recommended the appointment of such Director as an Independent Director for a term of five years subject to such Directors continuing to satisfy the criteria of independence in terms of the Companies Act, 2013, the rules made thereunder and the SEBI Listing Regulations, and shall not be liable to retire by rotation.The Board recommends the resolution for your approval.

None of the Directors, key managerial personnel, senior management and relatives of Directors and/or key managerial personnel (as defined in the Companies Act, 2013) and/or senior management (as defined in the SEBI ICDR Regulations) are concerned or interested in the proposed resolution, except in the ordinary course of business.

Item No.7:

Pursuant to the recommendations of the Nomination and Remuneration Committee and having considered the contribution Mr. Balasubba Reddy Mamilla, Whole Time Director in terms of leadership, strategy formulation and execution, financial planning, maintaining relations both with the board and external entities, the Board in its meeting held on 24.08.2026 revised and increased the remuneration of the Mr. Balasubba Reddy Mamilla, Whole Time Director from the existing remuneration of Rs.75,24,000/- per annum (Rupees Seventy Five Lakh Twenty Four Thousand only) per annum to a remuneration up to Rs.1,20,00,000/- (Rupees One Crore Twenty Lakhs only) per annum, together with the allowances and perquisites as mentioned in the resolution, with effect from 01.04.2026, for the remaining tenure of his appointment.

Approval of the shareholders is being sought for the resolution no. 7 in the notice as a Special Resolution.

Except Mr. Chandra Mouliswar Reddy Gangavaram, Managing Director, Mr. Balasubba Reddy Mamilla, Whole-time Director, Mrs. Vedavathi Gangavaram, Director, none of the Directors or Key Managerial Personnel or any relative of any of the Directors/ Key Managerial Personnel of the Company are, in any way, concerned or interested, financially or otherwise, in the resolution.

INFORMATION IN ACCORDANCE WITH SCHEDULE V OF COMPANIES ACT, 2013:

I. GENERAL INFORMATION:

1.	**Nature of Industry:** Pharmaceuticals
2.	**Date or expected date of commencement of commercial operations:** 03.11.1997
3.	**In case of new companies, expected date of commencement of business activities as per project approved by financial institutions appearing in the prospects:** Not Applicable
4.	**Financial performance based on given indications:** **(Rs. In millions)**
5.	**Foreign investments or collaborations, if any:** Not Applicable
6.	**Remuneration proposed:** As set out in the resolutions for the Item No. 7 the revision in the remuneration of Mr. Balasubba Reddy Mamilla, Whole Time Director is recommended by the Nomination and Remuneration Committee and Board of Directors.
7.	**Comparative remuneration profile with respect to industry, size of the company profile of the position and person (in case of expatriates the relevant details would be w.r.t. the country of his origin):** Taking into consideration of the size of the Company, the profile of Mr. Balasubba Reddy Mamilla and the responsibilities shouldered on him, the aforesaid remuneration package is commensurate with the remuneration package paid to managerial positions in other companies.
8.	**Pecuniary relationship directly or indirectly with the Company, or relationship with the managerial personnel, if any:** Besides the remuneration proposed, he is holding 14,97,191 equity shares which amounts to approx. 2.43% of the paid-up capital of the company.

Particulars	25-26	24-25	23-24
Turnover	9255.86	8,113.95	7,659.91
Net PAT	895.29	791.34	736.84

II. OTHER INFORMATION:

1.	**Reasons of loss or inadequate profits:** Not Applicable
2.	**Steps taken or proposed to be taken for improvement:** Necessary efforts are being made to increase the production and efficiency, which in turn will add to the growth of the business as well as the profitability.
3.	**Expected increase in productivity and profits in measurable terms:** The Company is committed to build the business operations within budget and considering that the business operates on a going concern basis, it is believed that financial position of the company will increase considerably in the coming years.

Item No.8:

Pursuant to the recommendations of the Nomination and Remuneration Committee and having considered the contribution Mr. Chandrasekhar Reddy, Whole Time Director in terms of leadership, strategy formulation and execution, financial planning, maintaining relations both with the board and external entities, the Board in its meeting held on 24.08.2026 revised and increased the remuneration of the Mr. Chandrasekhar Reddy, Whole Time Director from the existing remuneration of Rs.63,36,000/- (Rupees Sixty Three Lakh Thirty Six Thousand only) per annum to a remuneration up to Rs. 1,00,00,000/- (Rupees One Crore only) per annum, together with the allowances and perquisites as mentioned in the resolution, with effect from 01.04.2026, for the remaining tenure of his appointment.

Approval of the shareholders is being sought for the resolution no. 8 in the notice as a Special Resolution.

None of the Directors or Key Managerial Personnel or any relative of any of the Directors/ Key Managerial Personnel of the Company are, in any way, concerned or interested, financially or otherwise, in the resolution.

INFORMATION IN ACCORDANCE WITH SCHEDULE V OF COMPANIES ACT, 2013:

I. GENERAL INFORMATION:

1	**Nature of Industry:** Pharmaceuticals
2	**Date or expected date of commencement of commercial operations:** 03.11.1997

3	**In case of new companies, expected date of commencement of business activities as per project approved by financial institutions appearing in the prospects:** Not Applicable
4	**Financial performance based on given indications:** **(Rs. In millions)**

Particulars	25-26	24-25	23-24
Turnover	9255.86	8,113.95	7,659.91
Net PAT	895.29	791.34	736.84

5	**Foreign investments or collaborations, if any:** Not Applicable
6	**Remuneration proposed:** As set out in the resolutions for the Item No. 8 the revision in the remuneration of Chandrasekhar Reddy Gangavaram, Managing Director is recommended by the Nomination and Remuneration Committee and Board of Directors.
7	**Comparative remuneration profile with respect to industry, size of the company profile of the position and person (in case of expatriates the relevant details would be w.r.t. the country of his origin):** Taking into consideration of the size of the Company, the profile of Mr. Chandrasekhar Reddy Gangavaram and the responsibilities shouldered on him, the aforesaid remuneration package is commensurate with the remuneration package paid to managerial positions in other companies.
8	**Pecuniary relationship directly or indirectly with the Company, or relationship with the managerial personnel, if any:** Besides the remuneration proposed, he is holding 4,68,297 equity shares which amounts to approx. 0.76% of the paid-up capital of the company.

II. OTHER INFORMATION:

1.	**Reasons of loss or inadequate profits:** Not Applicable
2.	**Steps taken or proposed to be taken for improvement:** Necessary efforts are being made to increase the production and efficiency, which in turn will add to the growth of the business as well as the profitability.
3.	**Expected increase in productivity and profits in measurable terms:** The Company is committed to build the business operations within budget and considering that the business operates on a going concern basis, it is believed that financial position of the company will increase considerably in the coming years.

Item No.9:

The Members are informed that on the recommendations of the Audit Committee, the Board, at its meeting, 24.08.2026, re-appointed M/s. J K & CO, Cost Accountants (FRN 004010), as Cost Auditors of the Company to conduct the audit of the cost records maintained by the Company for the financial year 2026-27 at a remuneration Rs. 3,00,000 (Rupees Three Lakh Only) (excluding all applicable taxes and reimbursement of out-of-pocket expenses).

In terms of the provisions of Section 148(3) of the Companies Act, 2013 read with Rule 14 of the Companies (Audit and Auditors) Rules, 2014, remuneration paid to the Cost Auditor of the Company shall be approved by the members of the Company by way of ratification. Accordingly, approval of the members is being sought by way of ratification for payment of remuneration of Rs. 3,00,000 (Rupees Three Lakh Only) (excluding all applicable taxes and reimbursement of out-of-pocket expenses) to M/s J K & CO, Cost Accountants (FRN 004010), for the financial year 2026-27.

The Board recommends the Ordinary Resolution set out at Item No.9 of the Notice for approval of the Members.

None of the Directors and/or Key Managerial Personnel (KMP) or relatives of directors and KMP is concerned or interested, either financially or otherwise, in the resolution at Item No. 9 of the accompanying Notice.

Item No.10:

Pursuant to the provisions of Section 185 of the Companies Act, 2013 read with the Companies (Meeting of Board and its Powers) Rules, 2014 (the “Rules”) (as amended from time to time), no company shall, directly or indirectly, advance any loan, including any loan represented by a book debt to, or give any guarantee or provide any security in connection with any loan taken by (a) any director of company, or of a company which is its holding company or any partner or relative of any such director; or (b) any firm in which any such director or relative is a partner.

However, a company may advance any loan including any loan represented by a book debt, or give any guarantee or provide any security in connection with any loan taken by any person in whom any of the director of the company is interested, subject to the condition that a special resolution is passed by the company in general meeting and the loans are utilized by the borrowing Company for its principal business activities.

In order to support for the business requirements of the entities in which directors of the Company is interested or deemed to be interested, the Board of Directors in its meeting held on 24.08.2026, has, subject to the approval of shareholders of the Company, Board approved and recommended for seeking the shareholders' approval

Accordingly, consent of the members is sought for passing a Special Resolution as set out at Item No. 10 of this Notice, in relation to the details as stated above and thus the Board of Directors recommends the said Resolution for the approval of the shareholders of the Company as a Special Resolution.

None of the other Directors, Key Managerial Personnel of the Company or any of their relatives, is concerned or interested, directly or indirectly, financially or otherwise, in the proposed resolution.

Item no 11.

The Company is in the process of undertaking measures in connection with its proposed listing of equity shares and, in this regard, it is considered appropriate to align the Articles of Association of the Company with the applicable provisions of the Companies Act, 2013, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("SEBI ICDR Regulations"), as amended from time to time, and other applicable laws and regulations.

Under the applicable regulatory framework, certain equity shares, including pre-listing capital, may be required to be subject to a specified lock-in period. In certain circumstances, the Depositories may not be able to create or record the prescribed lock-in where such equity shares are subject to a pledge, freeze balance, safe keep balance or any other form of encumbrance prior to commencement of the applicable lock-in period.

Accordingly, it is proposed to suitably amend the Articles of Association of the Company to provide an enabling framework whereby, in such circumstances and to the extent permitted under applicable laws, the Company may issue appropriate instructions to the Depositories to record such equity shares as "non-transferable" for the duration of the applicable lock-in period. The proposed provisions would also provide for the continued treatment of such equity shares as locked-in in the event of invocation or release of a pledge, or exercise of lien pursuant to an order or direction of a competent authority, for the balance period of the applicable lock-in.

For this purpose, it is proposed to insert the definitions of "Depository(ies)" and "Lock-in Period" in the Articles of Association and to insert a new Article 69A under the heading "Transfer and Transmission of Shares" immediately after the existing Article 69.

The proposed amendment is intended to facilitate compliance with the applicable lock-in requirements and provide the Company with the necessary enabling provisions in its Articles of Association for implementation of such requirements through the Depositories, wherever required and permissible under applicable laws.

Pursuant to Section 14 of the Companies Act, 2013, alteration of the Articles of Association of the Company requires the approval of the Members by way of a Special Resolution. Accordingly, the Approval of the Members is sought for the proposed alteration of the Articles of Association as set out in the resolution at Item No. 11 of the accompanying Notice.

The Board of Directors, at its meeting held on 24th August, 2026, considered and approved the proposed amendments to the Articles of Association, subject to the approval of the Members and such other approvals as may be required under applicable laws.

A copy of the existing Articles of Association and the proposed amended Articles of Association will be available for inspection by the Members at the registered office of the Company during business hours on all working days up to the date of the AGM and will also be made available for inspection electronically in accordance with applicable law.

None of the Directors, Key Managerial Personnel of the Company or their respective relatives is concerned or interested, financially or otherwise, in the proposed Special Resolution, except to the extent of their respective shareholding, if any, in the Company.

The Board of Directors recommends the Special Resolution set out at Item No. 11 of the Notice for approval by the Members.

For Virupaksha Organics Limited

Chandra Mouliswar Reddy Gangavaram
Managing Director
(DIN 00046845)

Place: Hyderabad
Date: 24th August, 2026

BOARDS' REPORT

Dear Members,

Your directors have pleasure in presenting 29th Annual Report together with the Audited Financial Statements for the year ended 31st March 2026.

1. FINANCIAL HIGHLIGHTS:

(₹ in Millions)

Particulars	Standalone		Consolidated	
	FY 26	FY 25	FY 26	FY 25
Revenue from Operations	9,255.86	8,113.95	8,999.16	8,117.09
Other Income	107.49	50.85	88.72	48.14
Total Income	**9,363.35**	**8,164.80**	**9,087.88**	**8,165.23**
Less: Total Expenditure	8,162.84	7,124.30	8,077.81	7,127.51
Profit Before Tax	**1200.51**	**1,040.50**	**1,009.60**	**1,035.84**
Less: Tax Expense	305.22	249.16	269.53	248.70
Profit After Tax	**895.29**	**791.34**	**740.07**	**787.14**

2. CURRENT YEAR PERFORMANCE REVIEW AND STATE OF COMPANY AFFAIRS:

During the year under review, on standalone basis total income was ₹ 9,255.86 million which has 14.07 % growth from previous year total income ₹ 8,113.95 million. Profit After Tax ("PAT") was ₹ 895.29 million which has 13.14 % growth from previous year PAT ₹ 791.34 million.

During the year under review on consolidation basis total income was ₹ 8,999.16 million which has 10.87 % growth from previous year total consolidated income ₹ 8117.09 Million. Profit After Tax ("PAT") was ₹740.07 million as compared to the previous year ₹ 787.14 million, reduction in PAT is mainly due to the consolidation of M/s Oxygenta Pharmaceutical Limited (subsidiary since 20th June 2025).

During the year under review our company has served 550+ customers located across 100+ countries.

3. GENERAL RESERVE

During the financial year under review, the Company has transferred Nil to General Reserve Account.

4. CHANGE IN CAPITAL STRUCTURE:

During the period under review, there were following changes in the Company's capital structure:

a) Authorised Capital:

During the year under the review, the Board of Directors and the shareholders in their meeting held on 13th September, 2025 respectively approved to increase the Authorised Share Capital of the Company from Rs. 45,00,00,000/- divided into 4,50,00,000 (Four Crores Fifty Lakhs Only) Equity Shares of Rs. 10/- (Rupees Ten Only) each to Rs. 85,00,00,000 (Rupees Eighty-Five Crores only) divided into 8,50,00,000 (Eight Crores Fifty Lakhs only) Equity Shares of Rs.10/- each.

The authorised share capital as on 31st March, 2026 stands at Rs. 85,00,00,000 i.e., 8,50,00,000 (Eight Crores Fifty Lakhs only) Equity Shares of Rs. 10 each.

b) Paid-up Capital:

During the year under the review the Board of Directors and the Company in their meeting held on 13th September, 2025 respectively approved to issue 2,05,10,650 Equity shares equity shares of Rs.10/- each as fully paid bonus shares to the existing shareholders of the Company whose names appears in the Register of Members maintained by the Company as on the Record date (i.e. 12.09.2025) in the ratio of 1 Bonus equity share of Rs.10/- each for every 2 existing equity share(s) of Rs.10/- each held by the Members by capitalizing a sum of Rs.20,51,06,500/- (Rupees Twenty Crores Fifty One Lakhs Six Thousand Five Hundred Only) out of the free reserves of the Company.

The paid-up share capital as on 31st March, 2026 stands at Rs. 61,53,19,370 i.e., 6,15,31,937 (Six Crores Fifteen Lakhs Thirty-One Thousand Nine Hundred and Thirty-Seven) shares of Rs.10/- each.

5. DIVIDEND:

The Directors are pleased to recommend a Dividend of 10% i.e., Re.1/- per equity share on the Paid-up Equity Share Capital of the Company for the financial year 2025-26. The total outgo on account of dividend, stands at Rs. 6,15,31,937/- for which necessary provision has been made in the accounts. In case the Dividend payable to any shareholder exceeds Rs.10,000/- a tax of 10% will be deducted at source from the gross dividend. A Resident individual shareholder with PAN and who is not liable to pay income tax can submit a yearly declaration in Form No. 15G/15H, to avail the benefit of non-deduction of tax at source. Shareholders are requested to note that in case their PAN is not registered, the tax will be deducted at a higher rate of 20%. Non-resident shareholders can avail beneficial rates under tax treaty between India and their country of residence, subject to providing necessary documents i.e. No Permanent Establishment and Beneficial Ownership Declaration, Tax Residency Certificate, Form 10F, any other document which may be required to avail the tax treaty benefits.

6. INVESTOR EDUCTION AND PROTECTION FUND (IEPF)

Pursuant to the provisions of Section 124 of the Act, Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 ("IEPF Rules") read with the relevant circulars and amendments thereto, the amount of dividend remaining unpaid or unclaimed for a period of seven years from the due date is required to be transferred to the Investor Education and Protection Fund ("IEPF"), constituted by the Central Government.

During the Year, no amount of dividend was unpaid or unclaimed for a period of seven years and therefore no amount/share is required to be transferred to Investor Education and Provident Fund under the Section 125(1) and Section 125(2) of the Act.

7. TRANSFER OF SHARES AND UNPAID/UNCLAIMED AMOUNTS TO INVESTOR EDUCATION AND PROTECTION FUND (IEPF)

Pursuant to the provisions of Section 124 of the Act, Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 ("IEPF Rules") read with the relevant circulars and amendments thereto, the amount of dividend remaining unpaid or unclaimed for a period of seven years from the due date is required to be transferred to the Investor Education and Protection Fund ("IEPF"), constituted by the Central Government.

The provisions of Section 125(2) of the Companies Act, 2013 (the Act) do not apply as there was no amount in the unclaimed dividend account remaining unpaid under sub-section (5) of section 124 of the Companies Act, 2013.

8. WEB LINK OF ANNUAL RETURN, IF ANY

The Annual Return of the Company as on March 31, 2026 will be made available on the Company's website and can be accessed at *www.virupaksha.com*

9. ALTERATION OF MEMORANDUM OF ASSOCIATION AND ARTCILES OF ASSOIATION

The Board and members of the Company in their meeting held on 13th September, 2025 had approved to increase the authorized share capital of the Company from Rs.45,00,00,000/- (Rupees Forty-Five Crores Only) divided into 4,50,00,000 (Four Crores Fifty Lakhs) Equity shares of 10/- (Rupees Ten Only) each to Rs. 85,00,00,000 (Rupees Eighty-Five Crores Only) divided into 8,50,00,000 (Eight Crores Fifty Lakhs) equity shares of Rs.10/- (Rupees Ten only) each and consequently the Memorandum of Association of the Company has been altered.

Further, the company in their same meeting approved to adopt the updated Articles of Association.

10. RESTATED FINANCIAL STATEMENTS

Pursuant to the recommendation of Audit Committee, the Board in their meeting held on 24th September, 2025 approved the restated financial statements as the Company proposes to raise funds through an initial public offering of its equity shares ("Issue"). In relation to such proposed initial public offering, the restated financial statements of the Company as at and for the financial years ending 2023, 2024 and 2025 along with the examination report by M/s. C. Ramachandram & Co., Chartered Accountants (Firm Registration No. 002864S), the statutory auditors of the Company ("Statutory Auditors"), prepared in accordance with applicable accounting standards in India, Section 26 of the Companies Act, 2013 and the rules notified thereunder, each as amended, Guidance Note on Reports in Company Prospectuses (Revised 2019) (as amended) issued by the Institute of Chartered Accountants of India and as restated in accordance in accordance with the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended and other applicable laws.

11. INSURANCE

The Company's assets have been adequately insured against major risks.

12. MEETINGS OF THE BOARD OF DIRECTORS

During the year under review, Eleven (11) Board Meetings were held on 23rd April, 2025, 15th July, 2025, 03rd September, 2025, *13th September, 2025, 13th September, 2025, 24th September, 2025, 26th September, 2025, 29th September, 2025, 07th October, 2025, 04th December, 2025 and 04th February, 2026 with requisite quorum present throughout the meetings.

**The board met twice on 13th September, 2025.*

Further the gap between two consecutive Board meetings held during the financial year was not more than 120 days. The Composition of the Board & their meetings held during the year under review as follows:

Name of Director	Category	No of meeting entitled to attend	No. of Meetings attended
Mr. Chandra Mouliswar Reddy Gangavaram	Managing Director	11	11
Mr. Balasubba Reddy Mamilla	Whole Time Director	11	11
Mr. Chandrasekhar Reddy Gangavaram	Whole Time Director	11	11
Mrs. Vedavathi Gangavaram	Non-Executive Director	11	11
Mr. Janardhana Reddy Yeddula	Independent Director	11	11
Mr. Sidda Reddy Kanuparthi	Independent Director	4	4
Dr. Veera Reddy Areva	Independent Director	8	7
Mr. Murali Krishna Kurada	Independent Director	8	8
*Mr. Padmanabhuni Venkata Appaji	Independent Director	3	3
**Ms. Shruti Gupta	Independent Director	2	2

*Resigned w.e.f. 26.09.2025
**Resigned w.e.f. 03.09.2025

13. FILING OF DRHP

During the Financial Year under review, the Company took a significant step towards its proposed Initial Public Offering by filing its Draft Red Herring Prospectus (DRHP) dated 29th September, 2025 with the Securities and Exchange Board of India (SEBI).

The filing of the DRHP marks an important milestone in the Company's growth journey and reflects its intent to access the capital markets and strengthen its financial position to support its future growth and expansion plans.

The proposed IPO is subject to applicable regulatory approvals, statutory requirements, market conditions and other customary conditions. The Company continues to work towards the successful completion of the IPO process in accordance with the applicable laws and regulations.

14. EVENTS SUBSEQUENT TO THE DATE OF FINANCIAL STATEMENTS

There were no material changes and commitments affecting financial position of the Company between 31st March, 2026 and the date of Board's Report i.e. 24th August, 2026.

However Pursuant to the Order dated 21 August 2026 passed by the Hon'ble National Company Law Tribunal, Hyderabad Bench, the Resolution Plan submitted by Virupaksha Organics Limited for the acquisition and revival of Vivin Drugs & Pharmaceuticals Limited and Vivin Laboratories Private Limited under the Group Corporate Insolvency Resolution Process was approved.

15. DIRECTORS' RESPONSIBILITY STATEMENT

Pursuant to Section 134(5) of the Companies Act, 2013, Directors of your Company hereby state and confirm that:

a) In the preparation of the annual accounts for the period ended 31st March, 2026, the applicable accounting standards had been followed along with proper explanation relating to material departures;
b) The directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the profit of the company for that period;
c) The directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities.
d) The directors had prepared the annual accounts on a going concern basis; and
e) The directors had laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and were operating effectively.
f) The directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively

16. STATEMENT ON DECLARATION GIVEN BY INDEPENDENT DIRECTORS

In terms of Section 149 of the Companies Act, 2013, the Company has received a declaration from all the Independent Directors confirming that they meet the criteria of independence as prescribed under Section 149(6) of the Act. As per Clause 7 of the Schedule IV of the Companies Act (Code for Independent Directors), a separate meeting of the Independent Directors of the Company (without the attendance of Non-Independent Directors) was held on 04th February, 2026.

The Independent Directors have also confirmed that they have complied with the Company's Code of Conduct. The Board is of the opinion that the Independent Directors of the Company possess requisite qualifications, experience and expertise in chemicals/ manufacturing industry, strategy, auditing, tax and risk advisory services, financial services, corporate governance, etc. and that they hold standards of integrity.

17. COMPANY'S POLCY ON DIRECTORS' APPOINTMENT AND REMUNERATION AND CRITERIA FOR DETERMINING QUALIFICATIONS, POSITIVE ATTRIBUTES AND INDEPENDENCE OF A DIRECTOR.

The Company has constituted a Nomination and Remuneration Committee which has been entrusted the responsibility of selecting and recommending the appointment and remuneration of Directors. The Committee while making appointments and fixing the remuneration of Directors will take into consideration the following:

- Their qualification,
- Past record, especially their credentials and achievements, experience, past remuneration
- Job profile and suitability
- Comparative remuneration with the industry in line with size and profits of the company
- Their pecuniary relationship with the promoters.

Further the Nomination and Remuneration Committee also, while recommending and appointing the Independent Directors, will evaluate the following:

- Their qualification,
- Credentials, past experience in the fields of finance, management, technology, taxation and other related fields
- Expertise in similar industry
- Confirmation from the internal auditors that there is no pecuniary relationship with the company or other parties in terms of section 149(6) of the companies act, 2013.

18. PARTICULARS OF LOANS, GUARANTEES AND INVESTMENTS

Pursuant to the provisions of Section 186 of the Companies Act, 2013, the details of loans and guarantees provided and investments made by the Company during the Financial Year 2025–26 are as follows:

S.No.	Name of the party	Nature of transaction	Amount (in Millions)
1.	Oxygenta Pharmaceutical Limited	Corporate Guarantees	466.00
2.	Oxygenta Pharmaceutical Limited	Loans and Advances	355.00
3.	Oxygenta Pharmaceutical Limited	Investment	455.35
4.	Genz Materials Private Limited	Investment	29.99

19. PARTICULARS OF CONTRACTS WITH RELATED PARTIES

The Company's transactions with Related Parties are at arm's length and are in the ordinary course of business only. All Related Party transactions have been reported in the notes to Accounts to the Financial Statements and do not cover under the provisions of Section 188(1) of the Companies Act, 2013 read with Rules made there under. **Annexure – I**

20. ACQUISITION BY WAY OF AN OPEN OFFER

During the year under review the Company had successfully acquired control of **"Oxygenta Pharmaceutical Limited"**, a listed entity, pursuant to an open offer made under Regulation 3 and 4 of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

The open offer was triggered following the acquisition of 2,04,77,458 (Two Crores Four Lakhs Seventy-Seven Thousand Four Hundred and Fifty-Eight Only) equity shares and voting rights, resulting in a total shareholding of 55.37% post-offer. The acquisition aligns with the Company's strategic objectives of expanding portfolio/ business.

Necessary disclosures and filings were made with SEBI, stock exchanges, and other regulatory authorities in compliance with applicable laws. The Company now holds controlling interest in **Oxygenta Pharmaceutical Limited**, which has become a subsidiary effective 20th June, 2025.

21. CHANGE IN THE NATURE OF BUSINESS

There was no change in the nature of the business of the Company during the financial year under review.

22. CHANGE IN THE REGISTRAR AND TRANSFER AGENT

There was a change in the Registrars of the Company from Bigshare Services Pvt. Ltd to KFin Technologies Ltd pursuant to the approval of Board in their meeting held on 25th August, 2025.

23. FINANCIAL PERFORMANCE / FINANCIAL POSITION OF THE SUBSIDIARIES / ASSOCIATES/ JOINT VENTURES

During the year under review, M/s. Progenerics Pharma Private Limited and M/s. Virupaksha Green Energy Private Limited are the subsidiaries company. Further, Bharath Advanced Therapeutics Private Limited is an associate company of the Company as per the Companies Act, 2013 (the Act). The Company is having investment in Virupaksha Lifesciences LLP. which is an associate being fully impaired due to continued operating losses and negative net worth. As a result, the carrying amount of the investment in the associate under the equity method stood at Nil. In accordance with Para 38 of Ind AS 28 – Investments in Associates and Joint Ventures, our Company discontinued recognition of its share of further losses in the associate, as the entity's share of losses exceeded the carrying amount of its investment and no legal or constructive obligations existed to fund further losses.

In terms of Section 129(3) of the Act read with as per the Provisions of Section 129 of the Companies Act, 2013 read with Companies (Accounts) Rules, 2014, a separate statement containing the salient features of the financial statements of the subsidiary companies and associate company is prepared in Form **AOC-1** and is attached as **Annexure -II** and forms part of this report.

24. CONSOLIDATED FINANCIAL STATEMENTS CONSOLIDATED FINANCIAL STATEMENTS

In compliance with the provisions of Section 129 of the Companies Act, 2013, the Consolidated Financial Statements which have been prepared by the Company in accordance with the applicable provisions of the Companies Act, 2013 and the applicable Indian Accounting Standards (Ind AS) forms part of this Annual Report.

As per the provisions of Section 129 of the Companies Act, 2013 read with Companies (Accounts) Rules, 2014, a separate statement containing the salient features of the

25. CHANGE IN THE DIRECTORS OR KEY MANAGERIAL PERSONNEL

As per the provisions of Section 152 of the Companies Act, 2013 read with Articles of Association of the Company; Mr. Balasubba Reddy Mamilla (DIN: 01998852), Whole Time Director and Mr. Chandra Mouliswar Reddy Gangavaram (DIN: 00046845), Managing Director are retiring by rotation at the ensuing Annual General Meeting and being eligible, offered themselves for re-appointment.

Further during the year under the review and as on the date of the report the following changes took place in the board/management of the Company:

Appointments during the year and after the end of financial year:

- The Board in its meeting held on 03rd September, 2025 Dr. Veera Reddy Arava (DIN: 10832178), Mr. Murali Krishna Kurada (DIN: 11187456), Dr. Padmanabhuni Venkata Appaji are appointed as Additional Directors of the Company in Independent Category and were regularised as Independent Directors of the Company in the Extra-ordinary General Meeting dated 13th September, 2025.

- Mr. Sidda Reddy Kanuparthi (DIN: 07156289) was appointed as Additional Director of the Company in Independent Category on 26th September, 2025 whose appointment will be regularised in this Annual General Meeting.

Resignations During the year and after the end of the financial Year:

- Mrs. Shruti Gupta resigned from the position of Independent Director w.e.f. 03rd September, 2025.

- Dr. Padmanabhuni Venkata Appaji resigned from the position of Independent Director w.e.f. 26th September, 2025

26. SUBSIDIARIES AND ASSOCIATES

The company has subsidiaries, details of which are mentioned below:

a) Progenerics Pharma Private Limited
b) Virupaksha Green Energy Private Limited
c) Oxygenta Pharmaceutical Limited

The company has an Associate, details of which are mentioned below:

a) Bharath Advanced Therapeutics Private Limited

The Company however, does not have any Joint Ventures.

27. NAMES OF THE COMPANIES WHICH HAVE BECOME OR CEASED TO BE ITS SUBSIDIARIES, JOINT VENTURES OR ASSOCIATE COMPANIES DURING THE YEAR.

During the year under review, no Company has become or ceased to be a subsidiary, joint venture or associate of the Company, except Oxygenta Pharmaceutical

Limited, which became a subsidiary of the Company with effect from June 20, 2025.

28. DEPOSITS

Company has not accepted any deposits within the meaning of Section 73 of the Companies Act, 2013 read with the Companies (Acceptance of Deposits) Rules, 2014. There are no unpaid or unclaimed deposits as the Company had never accepted deposits within the meaning of the Act and the rules made there under.

Since the Company has not accepted any deposits during the Financial Year ended March 31, 2026, there has been no non-compliance with the requirements of the Act.

Pursuant to the Ministry of Corporate Affairs (MCA) notification dated 22nd January 2019 amending the Companies (Acceptance of Deposits) Rules, 2014, the Company is required to file Form DPT-3 for every year with the Registrar of Companies (ROC) regarding outstanding deposits. The Company has complied with this requirement within the prescribed timelines.

29. DETAILS OF SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS, COURTS AND TRIBUNALS:

No significant and material order has been passed by the regulators, courts, tribunals impacting the going concern status and Company's operations in future except as mentioned below:

During the year the Company had filed compounding applications with the Regional Director (RD), Registrar of Companies (RoC) under Section 441 and one outstanding counting application with the Regional Director, RoC under Section 454(5) of the Companies Act ("***Compounding Applications***"). following are the details of suo moto compounding applications with the Regional Director (RD) and Registrar of Companies (RoC), as applicable, and details penalties imposed and paid by the Company and officers in default:

S.No.	Particulars	Penalties paid
1.	Order adjudicating the penalty under Section 454 of the Companies Act, 2013 ("the Act") for non-compliance with the provisions of Section 149(4) of the Act, read with Rule 4 of the Companies (Appointment and Qualification of Directors) Rules, 2014 for the default in the appointment of two Independent Directors during the period from 01st April, 2015 to 14th March, 2021.	Virupaksha Organics Limited -Rs. 3,00,000/- Mr. G Chandra Mouliswar Reddy - Rs. 1,00,000/- Mr. M Balasubba Reddy - Rs. 86,500/- Mr. G Chandrasekhar Reddy - Rs. 86,500/- Mr. Singamsetty Prathap Kumar - Rs. 71,000/-
2.	Order adjudicating the penalty under Section 454 of the Companies Act, 2013 ("the Act") for violation of Section 292A(1) of the Companies Act, 1956 and Section 177(1) of the Companies Act, 2013, read with Rule 6 of the Companies (Meetings of Board and its Powers) Rules, 2014 and Rule 4 of the Companies (Appointment and Qualification of Directors) Rules, 2014 for the default in the constitution of Audit Committee during the period from 13th January, 2012 to 14th March, 2021.	Virupaksha Organics Limited -Rs. 5,00,000/- Mr. G Chandra Mouliswar Reddy - Rs. 1,00,000/- Mr. M Balasubba Reddy - Rs. 1,00,000/- Mr. G Chandrasekhar Reddy - Rs. 1,00,000/- Mr. Singamsetty Prathap Kumar - Rs. 1,00,000/-
3.	Order adjudicating the penalty under Section 454 of the Companies Act, 2013 ("the Act") for non-compliance with the provisions of Section 178(1) of the Companies Act, 2013, read with Rule 6 of the Companies (Meetings of Board and its Powers) Rules, 2014 and Rule 4 of the Companies (Appointment and Qualification of Directors) Rules, 2014, punishable under Section 178(8) of the Companies Act, 2013 for the default in the constitution of Nomination and Remuneration Committee of the Board during the period from 01st April, 2014 to 10th May, 2023.	Virupaksha Organics Limited -Rs. 5,00,000/- Mr. G Chandra Mouliswar Reddy - Rs. 1,00,000/- Mr. M Balasubba Reddy - Rs. 1,00,000/- Mr. G Chandrasekhar Reddy - Rs. 1,00,000/- Mr. Singamsetty Prathap Kumar - Rs. 1,00,000/-
4.	Order adjudicating the penalty under Section 454 of the Companies Act, 2013 ("the Act") for non-compliance with the provisions of Section 203(5) of the Companies Act, 2013 for default in appointment of Company secretary and Chief Financial Officer during the period from 01st April, 2014 to 31st January, 2021.	Virupaksha Organics Limited -Rs. 10,00,000/- Mr. G Chandra Mouliswar Reddy - Rs. 10,00,000/- Mr. M Balasubba Reddy - Rs. 10,00,000/- Mr. G Chandrasekhar Reddy - Rs. 10,00,000/-

30. INTERNAL FINANCIAL CONTROLS

Internal financial control systems of the company are commensurate with its size and the nature of its operations. These have been designed to provide reasonable assurance about recording and providing reliable financial and operational information, complying with applicable accounting standards and relevant statutes, safeguarding assets form unauthorized use, executing transactions with proper authorization and ensuring compliance of corporate policies.

The company has well-defined delegation of authority with specified limits for approval of expenditure both capital and revenue.

The Board of Directors deliberated with the members of the management, considered the systems as laid down and met the internal auditors and statutory auditors to ascertain, their views on the internal financial control systems.

The Board of Directors satisfied itself as to the adequacy and effectiveness of the internal financial control system as laid down. However, the company recognizes that no matter how the internal framework, is it has inherent limitations and accordingly, periodic audits and reviews ensure that such systems are updated on regular intervals.

31. MAINTENANCE OF COST RECORDS

The Company has been maintaining Cost records as required under the provisions of the Companies Act, 2013.

32. DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

The Company has in place an Anti-Sexual Harassment Policy in compliance with the requirements of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013. The Company always endeavours to create and provide an environment that is free from discrimination and harassment including sexual harassment. The Internal Complaints Committee (ICC) has been set up to redress complaints regarding sexual harassment, if any.

The Directors further state that during the Financial Year under review, there were no cases filed pursuant to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

33. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS & OUT GO

Particulars as required under Section 134(3) (m) of the Companies Act, 2013 are annexed as **Annexure-III** to this Report.

34. RISK MANAGEMENT

Risks are classified in different categories such as Financial, Operational, Legal and Strategic risks. These risks are reviewed from time to time and controls are put in place with specific responsibility of the concerned Officer of the Company. However, the Board could not identify any major risks, which may threaten the immediate existence of the Company.

35. CORPORATE SOCIAL RESPONSIBILITY

The Company had constituted a 'Corporate Social Responsibility Committee' to decide upon and implement the Corporate Social Responsibility Policy (CSR policy) of the Company.

The brief outline of the Corporate Social Responsibility (CSR) policy of the Company and the initiatives undertaken by the Company on CSR activities during the year are set out in **Annexure-IV** to this Report in the format prescribed in the Companies (CSR policy) Rules, 2014.

36. VIGIL MECHANISM

The Company, as required under Rule 7 of Companies (Meetings of Board and its Powers) Rules, 2014, has established a Vigil Mechanism for their Directors and employees to report their genuine concerns or grievances.

The Audit Committee of the Company shall oversee the vigil mechanism, which provides for adequate safeguards against victimization of employees and Directors who avail of the vigil mechanism.

All the employees and Directors of the Company are provided direct access to the Chairman of the Audit Committee.

37. AUDITORS

Statutory Auditors:

Pursuant to the provisions of Section 139, 142 and other applicable provisions of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014 as amended from time to time, the Board of Directors of the Company, based on the recommendation of the Audit Committee, at its meeting held on December 06, 2024, and member s in 27th Annual General Meeting held on 30th December, 2024 M/s C. Ramachandram & Co., Chartered Accountants, Hyderabad (Firm Registration No. 002864S) were appointed as the Statutory Auditors of the Company to hold office for a period of 5 (five) consecutive years from the conclusion of the ensuing 27th Annual General Meeting until the conclusion of the 32nd Annual General Meeting to be held in the year 2029.

The Auditors have confirmed their eligibility for appointment as a Statutory Auditors for a term of 5 (five) years subject to the various certificate issued by the Peer Review Board of the Institute of Chartered Accountants of India.

The Independent Auditor's Report given by M/s C. Ramachandram & Co., Statutory Auditors of the Company does not contain any qualifications, reservation or adverse remarks. There were no frauds reported by the auditors as per Section 143 (12) of the Companies Act, 2013.

Internal Auditors:

During the period under review M/s. Suryachandra & Associates, Chartered Accountants (FRN 004297S), who were appointed/reappointed as an Internal Auditors of the Company for the year ending 31st March, 2026.

Cost Auditors:

During the period under review M/s J K & Co., Cost Accountants (FRN 004010), Hyderabad, who were being appointed/reappointed by the Board of Directors as Cost Auditors of the Company to conduct cost audit relating to cost records of the Company for the year ending 31st March, 2026.

Secretarial Auditors:

During the period under review, M/s. Aakanksha Dubey & Co., Practicing Company Secretaries, Hyderabad, were appointed as the Secretarial Auditors of the Company at the 28th Annual General Meeting held on 26th September, 2025, for a term of five years from FY 2025-26 to FY 2029-30. The Secretarial Audit report given by M/s. Aakanksha Dubey & Co., Company Secretaries, does not contain any qualifications, reservation or adverse remarks. **Annexure-V**

38. PARTICULARS OF EMPLOYEES

In terms of the provisions of Rules 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, **none** of the employees drawing remuneration in excess of the limits set out in the said Rules.

39. COMPOSITION OF COMMITTEES OF THE BOARD OF DIRECTORS

Audit Committee [Section 177]

The primary objective of the Audit Committee of the Company is to monitor and provide effective supervision of the management's financial reporting process with a view to ensure accurate, timely and proper disclosures and the transparency, integrity and quality of financial reporting.

The Audit Committee will review periodically the internal control systems, scope of audit including the observations of auditors, if any and review the half yearly and annual financial statements before submission to the Board and also ensures compliance with internal control system.

The terms of reference of the Committee are wide enough to cover matters specified for Audit Committees under Section 177 of the Companies Act, 2013.

During the year, Nine (9) Committee meetings were held i.e. on 23rd April, 2025, 03rd September, 2025, 13th September, 2025, 24th September, 2025, 26th September, 2025, 29th September, 2025, 07th October, 2025, 04th December, 2025 and 04th February, 2026.

The Composition of the Committee & their meetings during the year as follows:

**Resigned w.e.f. 03.09.2025
*Appointed w.e.f. 03.09.2025

Nomination and Remuneration Committee [Section 178]

The purpose of the Nomination and Remuneration Committee of the Company shall be to discharge the Board's responsibilities relating to remuneration of the Company's Executive Directors. The Committee has overall responsibility for formulating the criteria for determining qualifications and independence of a director and recommends to the Board a policy relating to the remuneration for the directors, key managerial personnel and other employees.

During the year the Committee meetings held Three (3) times i.e. on 03rd September, 2025, 26th September, 2025 and 04th February, 2026.

The Composition of the Committee & their meetings during the year under review as follows:

Name of the Director	Category	Meetings attended
Mr. Janardhana Reddy Yeddula	Independent Director	3
*Dr. Veera Reddy Arava	Independent Director	2
*Mr. Murali Krishna Kurada	Independent Director	2
Mrs. Vedavathi Gangavaram	Non-Executive Director	3

*Appointed w.e.f. 03.09.2025

Stakeholders Relationship Committee [Section 178]

The purpose of the Stakeholders Relationship Committee of the Company shall be to discharge the Board's responsibilities relating to the grievances of security holders of the company. The Committee shall be responsible for overseeing and reviewing the redressal of complaints and grievances of shareholders, debenture holders, deposit holders, and other security holders, including matters relating to transfer, transmission, non-receipt of dividends, annual reports, and other shareholder-related issues.

During the year the Committee held one meeting on

Name of the Director	Category	Meetings attended
Mr. Janardhana Reddy Yeddula	Independent Director	9
Mr. Balasubba Reddy Mamilla	Executive Director	9
*Dr. Veera Reddy Arava	Independent Director	7
*Mr. Murali Krishna Kurada	Independent Director	7
**Ms. Shruti Gupta	Independent Director	1

04th February, 2026.

The Composition of the Committee & their meetings during the year under review as follows:

Name of the Director	Category	Meetings attended
Mrs. Vedavathi Gangavaram	Non-Executive Director	1
**Mr. Sidda Reddy Kanuparthi	Independent Director	1
*Dr. Veera Reddy Arava	Independent Director	1
Mr. Balassubba Reddy Mamilla	Executive Director	1

*Appointed w.e.f. 03.09.2025
**Appointed w.e.f. 26.09.2025

Corporate Social Responsibility (CSR) Committee [Section 135]

The Company has constituted the 'Corporate Social Responsibility Committee' for formulating and recommending to the Board of Directors a Corporate Social Responsibility Policy for the Company, which shall indicate the activities to be undertaken by the Company as specified in the Companies Act, 2013 and the rules made there under.

The Corporate Social Responsibility Committee recommends the amount of expenditure to be incurred by the Company on CSR activities and monitor the

Corporate Social Responsibility Policy of the Company from time to time.

During the year the Committee met Once. i.e. on 04th February, 2026.

The Composition of the Committee & their meetings during the year under review as follows:

Name of the Director	Category	Meetings attended
Mr. Chandra Mouliswar Reddy Gangavaram	Executive Director	1
Mrs. Vedavathi Gangavaram	Non-Executive Director	1
Mr. Murali Krishna Kurada	Independent Director	1

Risk Management Committee

The Company recognizes that effective risk management is an integral part of achieving its strategic and operational objectives and safeguarding the interests of its stakeholders. Accordingly, the Company has established an appropriate risk management framework commensurate with the size, nature and complexity of its operations.

The Risk Management Committee assists the Board of Directors in overseeing the Company's risk management framework and in identifying, evaluating and monitoring material risks that may affect the Company's business and operations.

During the year the Committee met Once. i.e. on 04th February, 2026.

The Composition of the Committee & their meetings during the year under review as follows:

Name of the Director	Category	Meetings attended
Mr. Balasubba Reddy Mamilla	Executive Director	1
Mr. Janardhana Reddy Yeddula	Independent Director	1
Mr. Chandrasekhar Reddy Gangavaram	Executive Director	1
Dr. Veera Reddy Arava	Independent Director	1

40. PERFORMANCE EVALUATION OF BOARD, ITS COMMITTEES AND INDIVIDUAL DIRECTORS

As required under the provisions of Schedule IV of the Companies Act, 2013 the performance evaluation of independent directors has been done by the entire Board of Directors, excluding the director being evaluated.

The evaluation of all the directors and the Board as a whole was conducted based on the criteria and framework adopted by the Board.

The Nomination and Remuneration Committee has defined the evaluation criteria, procedure, and time schedule for the Performance Evaluation process for the Board, its Committees and Directors.

Directors were evaluated on aspects such as attendance and contribution at Board/ Committee Meetings and guidance/ support to the management outside Board/ Committee Meetings.

The Independent Directors of the Company had also convened a separate Meeting for this purpose. The results from this evaluation process have been informed to the Chairman of the Board of Directors.

41. SECRETARIAL STANDARDS

The Company is in compliance with the applicable Secretarial Standards.

42. EVENT BASED DISCLOSURES

1. Issue of sweat equity share: NA
2. Issue of shares with differential rights: NA
3. Issue of shares under employee's stock option scheme: NA
4. Disclosure on purchase by company or giving of loans by it for purchase of its shares: NA
5. Buy back of shares: NA
6. Disclosure about revision: NA
7. Change of name of the Company: NA
8. Preferential Allotment of Shares: NA
9. Scheme of Arrangement: NA
10. Issue of Bonus Shares: As mentioned in the capital structure section of the Boards' report.

43. HUMAN RELATIONS

The Company continues to have cordial and harmonious relationship with its employees.

44. DETAILS OF DIFFERENCE BETWEEN VALUATION AMOUNT ON ONE TIME SETTLEMENT AND VALUATION WHILE AVAILING LOAN FROM BANKS AND FINANCIAL INSTITUTIONS:

During the year under review, there has been no one time settlement of loans taken from banks and financial institutions.

45. INSOLVENCY AND BANKRUPTCY CODE, 2016:

No proceedings are pending under the Insolvency and Bankruptcy Code, 2016 (31 of 2016) during the year.

The details of difference between amount of the valuation done at the time of onetime settlement and the valuation done while taking loan from the banks or financial institutions along with the reasons thereof- **NOT APPLICABLE**.

46. INDUSTRY BASED DISCLOSURES AS MANDATED BY THE RESPECTIVE LAWS GOVERNING THE COMPANY:

The Company is not a NBFC, Housing Companies etc., and hence industry-based disclosures is not required.

47. COMPLIANCE WITH MATERNITY BENEFIT ACT, 1961

During the year under the review, the Company is in Compliance with Maternity Benefit Act, 1961

48. ACKNOWLEDGEMENTS

Your directors gratefully acknowledge the continued support, co-operation and wise counsel extended by the Government Authorities, Banks and Financial Institutions.

Your directors place on your record their sincere appreciation for the significant contribution made by the employees through their dedication, hard work and commitment.

Your directors sincerely acknowledge the confidence and faith reposed in the Company by the Shareholders, Medical Profession & trade and other stake holders.

By order of the Board of Directors
For Virupaksha Organics Limited

Chandra Mouliswar Reddy Gangavaram
Managing Director (DIN:00046845)

Balasubba Reddy Mamilla
Whole Time Director (DIN:01998852)

Date: 24.08.2026
Place: Hyderabad

ANNEXURE – I

FORM NO. AOC -2

(Pursuant to clause (h) of sub-section (3) of Section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014.

Form for Disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub section (1) of Section 188 of the Companies Act, 2013 including certain arm's length transaction under third proviso thereto.

1. **Details of contracts or arrangements or transactions not at Arm's length basis**: Nil
2. **Details of contracts or arrangements or transactions at Arm's length basis:**

S no	Particulars	Nature of contracts/arrangements/transactions	Duration of the contracts / arrangements/transactions	Salient terms of the contracts or arrangements or transactions including the value, if any:	Date(s) of approval by the Board, if any: Approved by Audit Committee and Board Meeting in last Financial Year:
1	Oxygenta Pharmaceuticals Limited	Revenue from Operations	As per terms	668.80	24-Sep-25
2	Bharath Advanced Therapeutics Private Limited	Revenue from Operations	As per terms	-	
3	Viruj Pharmaceuticals Private Limited	Revenue from Operations	As per terms	71.82	24-Sep-25
4	Virupaksha Laboratories Private Limited	Revenue from Operations	As per terms	197.50	24-Sep-25
5	Progenerics Pharma Private Limited	Revenue from Operations	As per terms	0.02	07-Nov-25
6	Oxygenta Pharmaceutical Limited	Sale of Property, Plant & Equipment	As per terms	14.26	24-Sep-25
7	Oxygenta Pharmaceutical Limited	Purchase of Raw Material	As per terms	709.03	24-Sep-25
8	Virupaksha Laboratories Private Limited	Purchase of Raw Material	As per terms	753.19	24-Sep-25
9	V Indaf Overseas Private Limited	Purchase of Raw Material	As per terms	0.23	24-Sep-25
10	Arya Fashion and Arts	Purchase of Raw Material	As per terms	2.80	24-Sep-25
11	Oxygenta Pharmaceutical Limited	Corporate guarantee given	As per terms	466.00	24-Sep-25
12	Chandra Mouliswar Reddy Gangavaram	Borrowings	As per terms	35.50	07-Nov-25
13	Balasubba Reddy Mamilla	Borrowings	As per terms	-	-
14	Vedavathi Gangavaram	Borrowings	As per terms	35.50	07-Nov-25
15	Chandra Mouliswar Reddy Gangavaram – HUF	Borrowings	As per terms	-	-
16	Chandra Mouliswar Reddy Gangavaram	Borrowings	As per terms	26.28	07-Nov-25
17	Balasubba Reddy Mamilla	Borrowings	As per terms	300.00	07-Nov-25
18	Vedavathi Gangavaram	Borrowings	As per terms	23.33	07-Nov-25
19	Chandra Mouliswar Reddy Gangavaram – HUF	Borrowings	As per terms	-	-
20	Chandra Mouliswar Reddy Gangavaram	Interest on Unsecured Loan	As per terms	0.73	07-Nov-25
21	Balasubba Reddy Mamilla	Interest on Unsecured Loan	As per terms	5.29	07-Nov-25
22	Vedavathi Gangavaram	Interest on Unsecured Loan	As per terms	18.04	07-Nov-25
23	Chandra Mouliswar Reddy Gangavaram – HUF	Interest on Unsecured Loan	As per terms	-	-
24	V Indaf Overseas Private Limited (Given)	Loans and Advances	As per Terms	-	-

25	V Indaf Overseas Private Limited (Returned)	Loans and Advances	As per Terms	-	-
26	Oxygenta Pharmaceuticals Limited (Given)	Loans and Advances	As per Terms	355.00	24-Sep-25
27	Oxygenta Pharmaceuticals Limited	Interest Income from Loans	As per Terms	19.08	24-Sep-25
28	Progenerics Pharma Private Limited	Interest Income from Loans	As per Terms	3.15	24-Sep-25
29	Oxygenta Pharmaceuticals Limited	Rental Income	As Per Terms	0.04	23-Apr-25
30	Virupaksha Laboratories Private Limited	Rental Income	As Per Terms	0.03	24-Sep-25
31	Progenerics Pharma Private Limited	Expenses	As per Terms	-	-
32	Oxygenta Pharmaceuticals Limited (Other Expenses)	Expenses	As per Terms	4.83	24-Sep-25
33	Virupaksha Laboratories Private Limited (Rent)	Expenses	As per Terms	1.25	24-Sep-25
34	Virupaksha Laboratories Private Limited (Other Expenses)	Expenses	As per Terms	0.94	24-Sep-25
35	Chandra Mouliswar Reddy Gangavaram	Short-term employee benefits - Director’s	As per Terms	36.00	03-Sep-25
36	Balasubba Reddy Mamilla	Short-term employee benefits - Director’s	As per Terms	7.01	03-Sep-25
37	Chandrasekhar Reddy Gangavaram	Short-term employee benefits - Director’s	As per Terms	5.90	03-Sep-25
38	Janardhana Reddy Yeddula	Sitting Fee - Director's	As per Terms	0.75	13-Sep-25
39	Murali Krishna Kurada	Sitting Fee - Director's	As per Terms	0.69	13-Sep-25
40	Veera Reddy Arava	Sitting Fee - Director's	As per Terms	0.64	13-Sep-25
41	Sidda Reddy Kanuparthi	Sitting Fee - Director's	As per Terms	0.25	13-Sep-25
42	Padmanabhani Venkata Appaji	Sitting Fee - Director's	As per Terms	0.07	13-Sep-25
43	Shruti Gupta	Sitting Fee - Director's	As per Terms	0.04	30-Dec-24
44	Prasad Reddy Battinapatla	Short-term employee benefits - Other than Director’s	As per Terms	5.43	07-Nov-25
45	Vikas Kurada	Short-term employee benefits - Other than Director’s	As per Terms	1.13	07-Nov-25
46	Mamilla Nagarjun Reddy	Short-term employee benefits - Other than Director’s	As per Terms	6.60	07-Nov-25
47	Kotla Suraj Reddy	Short-term employee benefits - Other than Director’s	As per Terms	6.60	07-Nov-25
48	Kondapalli Sandeep Reddy	Short-term employee benefits - Other than Director’s	As per Terms	6.60	07-Nov-25
49	G Rukmini	Short-term employee benefits - Other than Director’s	As per Terms	0.96	-

By order of the Board of Directors
For Virupaksha Organics Limited

Chandra Mouliswar Reddy Gangavaram
Managing Director (DIN 00046845)

Balasubba Reddy Mamilla
Whole Time Director (DIN 01998852)

Place: Hyderabad
Date: 24th August 2026

ANNEXURE II

Form AOC-1

(Pursuant to first proviso to sub-section (3) of section 129 read with
Rule 5 of the Companies (Accounts) Rules, 2014)

Statement containing salient features of the financial statement of subsidiaries/associate companies/joint ventures

Part "A": Subsidiaries:

AOC - 1

Statement containing salient features of the financial statements of Subsidiaries (Pursuant to proviso to sub-section (3) of section 129 read with Rule 5 of the Companies (Accounts) Rules, 2014)

1. Name of the Subsidiaries:
2. Reporting Period: 01.04.2025 to 31.03.2026
3. Reporting Currency: Indian Rupee

(Amount in Lakhs)

S. No.	Particulars	Oxygenta Pharmaceutical Limited	Progenerics Pharma Private Limited	Virupaksha Green Energy Private Limited
1.	Share Capital	3698.35	682.5	506.1
2.	Reserves and surplus	--	--	--
3.	Total Assets	11,968.06	755	501.3
4.	Total Liabilities	16,236.74	732.1	2.6
5.	Investments	--	--	--
6.	Turnover	11,298.19	260.5	--
7.	Profit / loss before Taxation	(2,218.02)	(184.8)	(1.00)
8.	Provision for Taxation	(460.86)	(9.4)	(0.2)
9.	Profit / loss after Taxation	(1,757.17)	(175.4)	(1.2)
10.	Proposed Dividend	--	--	--
11.	% of Shareholding	56.50%	100%	100%

The following information shall be furnished at the end of the statement:
1. Names of Subsidiaries which are yet to commence operation:
2. Names of subsidiaries which have been liquidated or sold during the year:

Part "B": Associates:

AOC - 1

Statement containing salient features of the financial statements of Subsidiaries (Pursuant to proviso to sub-section (3) of section 129 read with Rule 5 of the Companies (Accounts) Rules, 2014)

1. Name of the Associate:
2. Reporting Period: 01.04.2025 to 31.03.2026
3. Reporting Currency: Indian Rupee

(Amount in Lakhs)

S. No.	Particulars	**Bharath Advanced Therapeutics Private Limited**
1.	Share Capital	2.00
2.	Reserves and surplus	0.00
3.	Total Assets	1,007.00
4.	Total Liabilities	251.00
5.	Investments	622.00
6.	Turnover	0.00
7.	Profit / loss before Taxation	(19.00)
8.	Provision for Taxation	0.00
9.	Profit / loss after Taxation	(19.00)
10.	Proposed Dividend	0.00
11.	% of Shareholding	24.71%

The following information shall be furnished at the end of the statement:
1. Names of Subsidiaries which are yet to commence operation:
2. Names of subsidiaries which have been liquidated or sold during the year:

B
y
o
r
d

By Order of the Board
For virupaksha organics limited

Chandra Mouliswar Reddy Gangavaram
Managing Director (DIN 00046845)

Balasubba Reddy Mamilla
Whole Time Director (DIN 01998852)

Place: Hyderabad
Date: 24th August, 2026

ANNEXURE- III

Particular of Energy Conservation, technology Absorption and foreign Exchange Outgo required under the Companies (Accounts) Rules 2014

(A) Conservation of energy–

(i) The steps taken or impact on conservation of energy;

- Introduction of IE3 Motors and above for conservation of Energy.
- Purchase of Air Conditioners with 5-Star Rating, to improve energy savings.
- Introduction of LED lights replacing conventional filament bulb and tube lights.
- Watering/Waterjet vacuum pumps being replaced with dry vacuum pumps.
- Interlock of cooling tower Fans for tripping off when desired cooling water temperature is attained.
- Installing VFD's in higher capacity motors.
- Improved efficiency in natural plant lighting.
- Minimization of steam distribution losses through steam trap optimization.
- Increasing the cooling tower water quality for reducing power consumption of pumps.

(ii) the steps taken by the company for utilizing alternate sources of energy;

- Company is planning to use alternate source of energy in order to reduce the overall energy consumption.
- The Company has bought a solar power plant which has an installed capacity of 5 MW.

(iii) the capital investment on energy conservation equipment's: Nil

(B) Technology absorption-

(i) the efforts made towards technology absorption;
The company keeps funding research and development through capital expenditures as well as revenue-related expenses. The development of API technologies is the focus of this expenditure. It's possible that some of these products need specific manufacturing blocks. To continuously improve the scientific team's research understanding in the technologies and therapy areas of our interest, investments have been made in hiring highly qualified and experienced scientists, adding state-of-the-art equipment, sponsoring research, and hiring top-tier consultants.
New technologies have been developed with a focus on safety and continuous process studies using reaction calorimetry and other advanced process engineering tools; using green reagents for chemical transformations in API synthesis; using PAT tools in process development; and using advanced crystallization and powder processing techniques, such as ultrasonic crystallization, to achieve the required particle size and physical characteristics for formulation. For important products, product life cycle management has been used. One of our primary strategic goals is backward integration, which benefits a number of our products.
To cut costs and improve in-process capacity, process optimization based on the Quality by Design (QbD) idea and robustness by six sigma calculations has been applied for a variety of goods.
(ii) the benefits derived like product improvement, cost reduction, product development or import substitution;
Product improvement and product development is achieved.
(iii) in case of imported technology (imported during the last three years reckoned from the beginning of the financial year)- Not applicable
(iv) the expenditure incurred on Research and Development.

(C) Foreign exchange earnings and Outgo-

The foreign currency earnings were ₹ 1,638.73 million and outgo were ₹ 272.51 million for the period under review.

By order of the Board of Directors
For Virupaksha Organics Limited

Chandra Mouliswar Reddy Gangavaram
Managing Director (DIN 00046845)

Balasubba Reddy Mamilla
Whole Time Director (DIN 01998852)

Place: Hyderabad
Date:24.08.2026

ANNEXURE -IV
ANNUAL REPORT ON CORPORATE SOCIAL RESPONSIBILITY (CSR) ACTIVITIES

1. A brief outline of the Company's CSR policy.

In accordance with Section 135 of the Companies Act, 2013 and The Companies (Corporate Social Responsibility Policy) Amendment Rules 2021, Virupaksha Organics Limited (**VOL**) has formulated its CSR Policy duly approved by the Board of Directors. CSR is essentially a way of conducting business responsibly and VOL shall endeavour to conduct its business operations and activities in a socially responsible and sustainable manner at all times. VOL will strive to contribute to inclusive growth and sustainable development with emphasis on development of weaker sections of society and in the preference to local areas, where it operates. As per broad objectives of the Policy, CSR activities are being implemented in project/ program mode, in areas or subjects specified in Schedule VII of the Act, on thrust areas of education and health care, in the periphery of project areas of VOL (local area). The CSR Committee of the Board reviews and sanctions CSR project proposals, received from gram panchayats, local authorities, for implementation. VOL is utilizing the services of NGOs/ specialized external agencies, registered with the Ministry of Corporate Affairs and having a CSR Registration Number for implementation of CSR projects.

2. Composition of CSR Committee:

S.no	Name	Designation	No. of Meetings held	No. of Meetings attended
1.	**Mr. Chandra Mouliswar Reddy Gangavaram**	Executive Director	1	1
2.	**Mrs. Vedavathi Gangavaram**	Non-Executive Director	1	1
3.	**Mr. Murali Krishna Kurada**	Independent Director	1	1

3. Provide the web-link where Composition of CSR committee, CSR Policy and CSR projects approved by the board are disclosed on the website of the company. www.virupaksha.com

4. Provide the details of Impact assessment of CSR projects carried out in pursuance of sub-rule (3) of rule 8 of the Companies (Corporate Social responsibility Policy) Rules, 2014, if applicable (attach the report). Not applicable

5. Details of the amount available for set off in pursuance of sub-rule (3) of rule 7 of the Companies (Corporate Social responsibility Policy) Rules, 2014 and amount required for set off for the financial year, if any:

S.no	Financial year	Amount available for set-off from preceding financial years (₹ in lakhs)	Amount required to be set-off for the financial year, if any (₹ in lakhs)
1.	24-25	0	18.97

6. Average net profit of the company as per section 135(5): **Rs. 8756.05 Lakhs**

7. (a) Two percent of average net profit of the company as per section 135(5): **Rs. 175.10 Lakhs.**

(b) Surplus arising out of the CSR projects or programmes or activities of the previous financial years: NA

(c) Amount required to be set off for the financial year, if any: **Rs. 18.97 Lakhs**

(d) Total CSR obligation for the financial year (7a+7b-7c): **Rs.156.13 Lakhs**

8. (a) CSR amount spent or unspent for the financial year:

Total Amount Spent for the Financial Year. (in ₹)	Amount Unspent (in ₹)				
	Total Amount transferred to Unspent CSR Account as per section 135(6).		Amount transferred to any fund specified under Schedule VII as per second proviso to section 135(5).		
	Amount.	Date of transfer.	Name of the Fund	Amount.	Date of transfer.
FY 25-26	**0**	**0**	**0**	**0**	**0**

(b) Details of CSR amount spent against ongoing projects for the financial year:

(1)	(2)	(3)	(4)	(5)		(6)	(7)	(8)	(9)	(10)	(11)	
Sl. No.	Name of the Project.	Item from the list of activities in Schedule VII to the Act.	Local area (Yes/No).	Location of the project.		Project duration.	Amount allocated for the project (in ₹).	Amount spent in the current financial Year (in ₹).	Amount transferred to Unspent CSR Account for the project as per Section 135(6) (in ₹).	Mode of Implementation - Direct (Yes/No).	Mode of Implementation - Through Implementing Agency	
				State.	District.						Name	CSR Registration number.
1.	NA	NA	NA	NA		NA	NA	NA	NA	NA	NA	NA
	Total	NA	NA	NA		NA	NA	NA	NA	NA	NA	NA

(c) Details of CSR amount spent against **other than ongoing projects** for the financial year:

(1)	(2)	(3)	(4)	(5)		(6)	(7)	(8)	
Sl. No.	Name of the Project	Item from the list of activities in schedule VII to the Act.	Local area (Yes/ No).	Location of the project.		Amount spent for the project (Rs in million	Mode of Implementation – Direct.	Mode of implementation - Through implementing agency.	
				State.	District.			Name.	CSR registration number.
1.	Health Care	Promoting health care including preventive health care	No	Andhra Pradesh	Tirupathi	2,90,000	No	Bio Medix Optotechniks & Devices Pvt Ltd	CSR00008730
2.	Health Care	Promoting health care including preventive health care	Yes	Telangana	Hyderabad	1,00,000	No	LCH Sadhuram Eye Hosital	CSR00003841
3.	Health Care	Promoting health care including preventive health care	Yes	Telangana	Hyderabad	2,00,000	No	Sahara Health & Development Society	CSR00011639
4.	Health Care	Promoting health care including preventive health care	Yes	Telangana	Hyderabad	2,00,000	No	Sparsh hospice an entity of Rotary club	CSR00002050
5.	Eradicating Hunger, Poverty and Malnutrition	Eradicating Hunger, Poverty and Malnutrition	Yes	Telangana	Sangareddy	2,41,500	Yes	Mantri Distributors	NA
6.	Eradicating Hunger,	Eradicating Hunger,	Yes	Telangana	Hyderabad	11,00,000	No	SRI JAYA LAKSHMI	CSR00059444

	Poverty and Malnutrition	Poverty and Malnutrition						MATA YOGA CENTRE	
7.	Promoting education	Promoting education	Yes	Telangana	Medchal, Malkajgiri	2,05,874	Yes	Asian Scientific Instruments	NA
8.	Promoting education	Promoting education	Yes	Telangana	Secunderabad	3,00,000	No	Banjara Seva Samithi	CSR00074626
9.	Promoting education	Promoting education	Yes	Telangana	Hyderabad	1,00,000	No	Chavadi Child Welfare Society	CSR00061631
10.	Promoting education	Promoting education	Yes	Telangana	Sangareddy	50,000	Yes	Government College of Nursing, Andole, Sangareddy	NA
11.	Promoting education	Promoting education	No	Andhra Pradesh	YSR Kadapa	4,26,000	Yes	Maddun Enterprises	NA
12.	Promoting education	Promoting education	Yes	Telangana	Sangareddy	19,00,000	No	Savithramma Memorial Charitable Trust	CSR00012297
13.	Promoting education	Promoting education	No	Andhra Pradesh	YSR Kadapa	4,00,000	No	Shed Construction at Koramguttaplyy Kadapa	NA
14.	Promoting education	Promoting education	Yes	Karnataka	Maniknagar	3,00,000	No	Shri Manik Prabhu Shikshan Samiti	CSR00015719
15.	Promoting education	Promoting education	Yes	Telangana	Medchal, Malkajgiri	61,916	Yes	SR publications	NA
16.	Promoting education	Promoting education	Yes	Telangana	Medchal, Malkajgiri	26,314	Yes	SS Computers	NA
17.	Promoting education	Promoting education	Yes	Telangana	Sangareddy	4,23,728.82	Yes	Tack on Knowledge Solutions (OPC) Private Limited	NA
18.	Promoting education	Promoting education	Yes	Telangana	Sangareddy	50,000	Yes	Towards ZPHS Isnapur	NA
19.	Promoting education	Promoting education	Yes	Telangana	Medchal, Malkajgiri	54,400	Yes	Valson Agencies	NA
20.	Promoting education	Promoting education	Yes	Telangana	Hyderabad	60,000	Yes	Venkata Sai Fabrication & Engg.Shed at MPPS Ranga Reddy Nagar School	NA
21.	Promoting education	Promoting education	Yes	Telangana	Kamareddy	11,51,886	Yes	Wood World	NA

22.	Animal Welfare	Animal Welfare	Yes	Telangana	Hyderabad	32,391	Yes	Nutan Medical Hall Towards Medicines	NA
23.	Animal Welfare	Animal Welfare	Yes	Telangana	Hyderabad	28,700	Yes	Pooja Milk Booth Rice 35bags	NA
24.	Animal Welfare	Animal Welfare	Yes	Telangana	Hyderabad	2,00,000	Yes	Sri Rama Jeeva Seva Sadan (gosahala)	CSR00029125
25.	Promotion of Sports	Promote Sports	Yes	Telangana	Medchal, Malkajgiri	3,04,000	No	Suchitra Batminton Academy Trust	CSR00034371
26.	Rural development projects	Rural development projects	Yes	Telangana	Sangareddy	3,00,000	Yes	Gram Panchyat, Munipalli Towards CSR	NA
27.	Rural development projects	Rural development projects	Yes	Telangana	Sangareddy	4,22,100	Yes	Krishna Enterprises for LED lights forr street lighting	NA
28.	Rural development projects	Rural development projects	Yes	Telangana	Sangareddy	6,54,000	Yes	Smaat India Pvt Ltd	NA
29.	Rural development projects	Rural development projects	Yes	Telangana	Sangareddy	68,99,058.42	Yes	Venkata Krishna Reddy Kunam	NA
	Total					1,64,31,868.24			

(d) Amount spent in Administrative Overheads: **Not Applicable**

(e) Amount spent on Impact Assessment, if applicable: **Not Applicable**

(f) Total amount spent for the Financial Year (8b+8c+8d+8e): **Rs. 164.31 Lakhs**

(g) Excess amount for set off, if any

Sl. No.	Particular	Amount
1.	Two percent of average net profit of the company as per section 135(5)	Rs. 175.30 Lakhs.
2.	Surplus arising out of the CSR projects or programmes or activities of the previous financial years, if any	Rs. 18.97 Lakhs
3.	CSR Obligation for the year (After the set off deductions from previous year)	Rs.156.33 Lakhs
4.	Total amount spent for the Financial Year	Rs. 164.31 Lakhs
5.	Excess amount spent for the financial year [(3)-(2)]	Rs. 7.99 Lakhs
6.	Surplus arising out of the CSR projects or programmes or activities of the previous financial years, if any	NA
7.	Amount available for set off in succeeding financial years [(iii)-(iv)]	Rs. 7.99 Lakhs

9. (a) Details of Unspent CSR amount for the preceding three financial years: Not Applicable

(b) Details of CSR amount spent in the financial year for ongoing projects of the preceding financial year(s): Not Applicable

10. In case of creation or acquisition of capital asset, furnish the details relating to the asset so created or acquired through CSR spent in the financial year: **No**

a) Date of creation or acquisition of the capital asset(s). **Not Applicable**

b) Amount of CSR spent for creation or acquisition of capital asset. **Not Applicable**

c) Details of the entity or public authority or beneficiary under whose name such capital asset is registered, their address etc. **Not Applicable**

d) Provide details of the capital asset(s) created or acquired (including complete address and location of the capital asset). **Not Applicable**

11. Specify the reason(s), if the company has failed to spend two per cent of the average net profit as per section 135(5). **Not Applicable**

By order of the Board of Directors
For VIRUPAKSHA ORGANICS LIMITED

CHANDRA MOULISWAR REDDY GANGAVARAM
Managing Director (DIN 00046845)

BALASUBBA REDDY MAMILLA
Whole Time Director (DIN 01998852)

Place: Hyderabad
Date:24th August, 2026

Annexure-V

Secretarial Audit Report

FORM MR-3
SECRETARIAL AUDIT REPORT
(Pursuant to section 204(1) of the Companies Act, 2013 and
Rule 9 of the Companies (Appointment and Remuneration Personnel) Rules, 2014
FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2026

To
The Members of
Virupaksha Organics Limited
Plot No. B1 & B2, IDA Gandhinagar,
Kukatpally, Medchal, Malkajgiri District,
Hyderabad- 500037 Telangana, India

We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **Virupaksha Organics Limited** (hereinafter called "the Company"). Secretarial Audit was conducted in a manner that provided me a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

Based on our verification of the Company's Books, Papers, Minute Books, Forms and Returns filed and other Records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we hereby report that in our opinion, the company has, **during the financial year commencing from 1st April, 2025 and ended 31st March, 2026,** complied with the statutory provisions listed hereunder and also that the Company has proper Board process and compliance mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

1. We have examined the books, papers, minute books, forms and returns filed and other records maintained by Virupaksha Organics Limited ("The Company") for the financial year ended on 31st March, 2026, according to the provisions of:

    ii. The Companies Act, 2013 (the Act) and the rules made there under:

    iii. The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the Rules made there under;

    iv. The Depositories Act, 1996 and the Regulations and Bye-laws framed there under

    v. Foreign Exchange Management Act, 1999 and the Rules and Regulations made there under to the extent of Foreign Direct Investment (FDI) and Overseas Direct Investment and External Commercial Borrowings;

2. The Company is an unlisted Public Company and hence provisions of the SEBI Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 (SEBI Act) were not applicable.

3. The Company has identified the following laws applicable specifically to the Company:

    a) Drugs and Cosmetics Act, 1940 and amendments thereto from time to time.
    b) Drugs and Cosmetics Rules, 1945
    c) Labour Laws (wages, bonus, provident fund, gratuity etc)
    d) Environment Protection Act, 1986
    e) Explosives Act, 1884 read with Gas Cylinder Rules, 2004;
    f) Air (Prevention and Control of Pollution) Act, 1981 and rules made thereunder;
    g) Water (Prevention and Control of Pollution) Act, 1974;
    h) Payment of Wages Act, 1936
    i) Minimum Wages Act, 1948
    j) Employees' Provident Funds and Miscellaneous Provisions Act, 1952
    k) Employees State Insurance Act,1948
    l) Payment of Gratuity Act,1972
    m) Employee's Compensation Act,1923
    n) Contract Labour (Regulation & Abolition) Act, 1970
    o) Income Tax Act, 1961
    p) GST Acts and Rules made thereunder
    q) The Insurance Act, 1938 as amended.
    r) Contract Labour (Regulation & Abolition) Act, 1970
    s) Employment Exchange (Compulsory Notification of Vacancies) Act, 1959
    t) The Factories Act, 1948 and Andhra Pradesh Factories Rules. 1980

u) Hazardous and Other' Wastes (Management & Trans boundary Movement) Rules, 2016
v) Customs Act, 1962
w) The Boilers Act, 1923 and Indian Boilers Regulations – 1850

4. We have also examined compliance with the applicable clauses of the Secretarial Standards issued by The Institute of Company Secretaries of India.

5. During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above including the following:

   a) During the year the Company has conducted Eleven (11) meetings of the Board of Directors, 9 Meetings of Audit Committee, 3 Meetings Nomination and Remuneration Committee, 1 Meeting of Corporate Social Responsibility Committee, 1 Meeting of Stakeholders Relationship Committee, 1 Meeting of Risk Management Committee and 1 Meeting of Independent Directors.

   b) As per the information and explanations provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we report that

   (i) the provisions of the Foreign Exchange Management Act, 1999 and the Rules and Regulations made there under to the extent of:

   - External Commercial Borrowings were not attracted to the Company under the financial year under report;
   - Foreign Direct Investment (FDI) was not attracted to the company under the financial year under report;
   - Overseas Direct Investment by Residents in Joint Venture/Wholly Owned Subsidiary abroad.

   (ii) As per the information and explanations provided by the company, its officers, agents and authorized representatives during the conduct of Secretarial Audit, we report that the Company has not made any GDRs/ADRs or any Commercial Instrument under the financial year under report.

We further report that: -

- Mr. Prasad Reddy Battinapatla is the Chief Financial Officer of the Company; Mr. Kondapalli Sandeep Reddy is the Deputy Chief Executive Officer of the Company; Mr. Kotla Suraj Reddy is the Chief Operating Officer; Mr. Mamilla Nagarjun Reddy is the Chief Technical Officer and Mr. Vikas Kurada is the Company Secretary and Compliance Officer of the Company.

- The Company has Statutory Auditor namely C. Ramachandram & Co, Chartered Accountants, Hyderabad; Internal Auditors namely M/s. Suryachandra & Associates, Chartered Accountants, Hyderabad; Secretarial Auditors Namely, M/s. Aakanksha Dubey & Co., Practicing Company Secretaries, Hyderabad; and Cost Auditors Namely M/s. JK & Co., Cost Accountants.

- The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes, if any in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

- Adequate notice of board meeting is given to all the directors along with agenda at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and meaningful participation at the meeting.

- As per the minutes of the meeting duly recorded and signed by the Chairman, the decisions of the Board were unanimous and no dissenting views have been recorded.

- We, further report that there are adequate systems and processes in the company commensurate with the size and operations of the company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

- The compliance by the Company of applicable financial laws like Direct and Indirect tax laws has not been reviewed in this audit since the same have been subject to review by statutory financial audit and other designated professionals.

- The Board and members of the Company had approved to increase the authorized share capital of the Company from Rs. 45,00,00,000/- (Rupees Forty-Five Crores Only) divided into 4,50,00,000 (Four Crores Fifty Lakhs Only) equity shares of Rs.10/- (Rupees Ten Only) to Rs. 85,00,00,000/- (Eighty) divided into 8,50,00,000 (Eight Crores Fifty Lakhs Only) equity shares of Rs. 10/- (Rupees Ten Only) each. Later, the Board allotted the 2,05,10,650 equity shares of Rs.10/- each as fully paid bonus shares to the existing shareholders of the Company whose names appears in the Register of Members maintained by the Company as on the Record date (i.e. 12.09.2025) in the ratio of 1 Bonus equity share of Rs.10/- each for every 2 existing equity share(s) of Rs.10/- each held by the Members by capitalizing a sum of Rs. 20,51,06,500/- (Rupees Twenty Crores Fifty-One Lakhs Six Thousand Five Hundred Only) out of the free reserves of the Company.

<u>Observations/ Non-Compliances/ Adverse Remarks/ Qualifications in respect of the Companies Act, 2013 or any other act Rules, Guidelines, Notifications, Circulars made there under are as follows:</u>

i. *The Company had delayed in filing the Annual Return on Foreign Liabilities and Assets (FLA Return) for the financial year 2024-25, which was required to be filed during the financial year 2025-26, with the Reserve Bank of India within the prescribed timeline. The said return was subsequently filed by the Company.*

ii. *The Company has filed certain forms with Registrar of Companies with a slight delay by payment of additional fees.*

iii. *During the year under review, the Company filed the following suo moto compounding applications with the Regional Director (RD) and Registrar of Companies (RoC), as applicable, and paid the penalties imposed pursuant to the respective orders of the RD and RoC.*

S.No.	***Particulars***	***Penalties paid***
1.	*Order adjudicating the penalty under Section 454 of the Companies Act, 2013 ("the Act") for non-compliance with the provisions of Section 149(4) of the Act, read with Rule 4 of the Companies (Appointment and Qualification of Directors) Rules, 2014 for the default in the appointment of two Independent Directors during the period from 01st April, 2015 to 14th March, 2021.*	*Virupaksha Organics Limited -Rs. 3,00,000/- Mr. G Chandra Mouliswar Reddy - Rs. 1,00,000/- Mr. M Balasubba Reddy - Rs. 86,500/- Mr. G Chandrasekhar Reddy - Rs. 86,500/- Mr. Singamsetty Prathap Kumar - Rs. 71,000/-*
2.	*Order adjudicating the penalty under Section 454 of the Companies Act, 2013 ("the Act") for violation of Section 292A(1) of the Companies Act, 1956 and Section 177(1) of the Companies Act, 2013, read with Rule 6 of the Companies (Meetings of Board and its Powers) Rules, 2014 and Rule 4 of the Companies (Appointment and Qualification of Directors) Rules, 2014 for the default in the constitution of Audit Committee during the period from 13th January, 2012 to 14th March, 2021.*	*Virupaksha Organics Limited -Rs. 5,00,000/- Mr. G Chandra Mouliswar Reddy - Rs. 1,00,000/- Mr. M Balasubba Reddy - Rs. 1,00,000/- Mr. G Chandrasekhar Reddy - Rs. 1,00,000/- Mr. Singamsetty Prathap Kumar - Rs. 1,00,000/-*
3.	*Order adjudicating the penalty under Section 454 of the Companies Act, 2013 ("the Act") for non-compliance*	*Virupaksha Organics Limited -Rs. 5,00,000/- Mr. G Chandra Mouliswar*

	with the provisions of Section 178(1) of the Companies Act, 2013, read with Rule 6 of the Companies (Meetings of Board and its Powers) Rules, 2014 and Rule 4 of the Companies (Appointment and Qualification of Directors) Rules, 2014, punishable under Section 178(8) of the Companies Act, 2013 for the default in the constitution of Nomination and Remuneration Committee of the Board during the period from 01st April, 2014 to 10th May, 2023.	*Reddy - Rs. 1,00,000/- Mr. M Balasubba Reddy - Rs. 1,00,000/- Mr. G Chandrasekhar Reddy - Rs. 1,00,000/- Mr. Singamsetty Prathap Kumar - Rs. 1,00,000/-*
4.	*Order adjudicating the penalty under Section 454 of the Companies Act, 2013 ("the Act") for non-compliance with the provisions of Section 203(5) of the Companies Act, 2013 for default in appointment of Company secretary and Chief Financial Officer during the period from 01st April, 2014 to 31st January, 2021.*	*Virupaksha Organics Limited -Rs. 10,00,000/- Mr. G Chandra Mouliswar Reddy - Rs. 10,00,000/- Mr. M Balasubba Reddy - Rs. 10,00,000/- Mr. G Chandrasekhar Reddy - Rs. 10,00,000/-*

For Aakanksha Dubey & Co.

Aakanksha Sachin Dubey
Practicing Company Secretary
C.P. No. 20064
& M. No. 49041
UDIN: A049041H001197155
Peer Review Cer. No. 3363/2023

Place: Hyderabad
Date: 24.08.2026

Annexure-A

To
The Members of
Virupaksha Organics Limited
Plot No. B1 & B2, IDA Gandhinagar,
Kukatpally, Medchal, Malkajgiri District,
Hyderabad- 500037 Telangana, India

Our report of even date is to be read along with this letter.

1. Maintenance of secretarial record is the responsibility of the management of the company. Our responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.
3. We have relied on the reports given by the concerned professionals in verifying the correctness and appropriateness of financial records and books of accounts of the company.
4. Where ever required, we have obtained the Management representation about the compliance of laws, rules and regulations and happening of events etc.
5. The compliance of provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedures on test basis.
6. The secretarial audit report is neither an assurance as to future viability of the company nor of the efficacy or effectiveness with which the management has conducted the affairs of the company.

For Aakanksha Dubey & Co.

Aakanksha Sachin Dubey
Practicing Company Secretary
C.P. No. 20064
& M. No. 49041
UDIN: A049041H001197155
Peer Review Cer. No. 3363/2023

Place: Hyderabad
Date: 24.08.2026

Independent Auditor’s Report

To the Members of
Virupaksha Organics Limited

Report on the Audit of the Standalone Financial Statements

Opinion

We have audited the accompanying standalone financial statements of **Virupaksha Organics Limited** (the “Company”), which comprise the Standalone Statement of Assets and Liabilities as at March 31, 2026, and the Standalone Statement of Profit and Loss (including Other Comprehensive Income), the Standalone Statement of Cash Flows and the Standalone Statement of Changes in Equity for the year ended on that date, and notes to the standalone financial statements, including a summary of material accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 (the “Act”) in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under Section 133 of the Act, (“Ind AS”) and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2026, and its profit including other comprehensive income, its cash flows and the changes in equity for the year ended on that date.

Basis for Opinion

We conducted our audit of the standalone financial statements in accordance with the Standards on Auditing (“SA”s) specified under Section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor’s Responsibility for the Audit of the Standalone Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (“ICAI”) together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI’s Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion on the standalone financial statements.

Information other than the Standalone Financial Statements and Auditor's Report thereon

The Company's Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the Director's Report including annexures to the Director's Report, but does not include the consolidated financial statements, standalone financial statements and our auditor's report thereon.

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether such other information is materially inconsistent with the standalone financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the Management and Those Charged with Governance for the Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Act with respect to the preparation and presentation of these standalone financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income, cash flows and changes in equity of the Company in accordance with the accounting principles generally accepted in India, including Ind AS specified under Section 133 of the Act, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgements and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intend to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Company's Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibility for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgement and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to standalone financial statements in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

- Obtain sufficient appropriate audit evidence regarding the financial information of the Company to express an opinion on the standalone financial statements.

Materiality is the magnitude of misstatements in the standalone financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the standalone financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the standalone financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal financial controls that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

2. As required by Section 143(3) of the Act, based on our audit we report that:

a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books except for the matters stated in paragraph 2(i)(vi) below on reporting under Rule 11(g) of the Companies (Audit and Auditor's) Rules, 2014.

c) The Standalone Statement of Assets and Liabilities, the Standalone Statement of Profit and Loss including Other Comprehensive Income, the Standalone Statement of Cash Flows and the Standalone Statement of Changes in Equity dealt with by this Report are in agreement with the relevant books of account.

d) In our opinion, the aforesaid standalone financial statements comply with the Ind AS specified under Section 133 of the Act, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended.

e) On the basis of the written representations received from the directors as on March 31, 2026 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2026 from being appointed as a director in terms of Section 164(2) of the Act.

f) The modification relating to the maintenance of accounts and other matters connected therewith are as stated in the paragraph (b) above on reporting under Section 143(3)(b) and in paragraph 2(i)(vi) below on reporting under Rule 11(g) of the Companies (Audit and Auditor's) Rules.

g) With respect to the adequacy of the internal financial controls with reference to standalone financial statements of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B". Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls with reference to standalone financial statements.

h) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of Section 197(16) of the Act, as amended, in our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of Section 197 read with Schedule V to the Act.

i) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended in our opinion and to the best of our information and according to the explanations given to us:

   i. The Company has disclosed the impact of pending litigations on its financial position in its standalone financial statements - Refer Note 49 to the standalone financial statements;

   ii. The Company did not have any long term contracts including derivative contracts for which there were any material foreseeable losses.

   iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

   iv.

      (a) The Management has represented that, to the best of its knowledge and belief, as disclosed in the note 58(e) to the standalone financial statements no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

      (b) The Management has represented, that, to the best of its knowledge and belief, as disclosed in the note 58(f) to the standalone financial statements, no funds have been received by the Company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

      (c) Based on the audit procedures performed that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.

v. As stated in Note No. 51 to the Standalone Financial Statements, the Board of Directors of the Company have proposed a final dividend for the year which is subject to the approval of the members at the ensuing Annual General Meeting. The amount of dividend proposed is in accordance with section 123 of the Act, as applicable until the date of this report.

vi. Based on our examination, which included test checks, the Company has used an accounting software for maintaining its books of account for the year ended March 31, 2026, which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software.

However, the feature of recording audit trail (edit log) facility was not enabled at the database level to log any direct data changes for the accounting software used for maintaining all books of accounts.

Further, during the course of our audit we did not come across any instance of the audit trail feature being tampered with. Additionally audit trail has been preserved by the Company as per the statutory requirements for record retention

For C. RAMACHANDRAM & Co
Chartered Accountants
FRN: 002864S

C. RAMACHANDRAM
Partner
Membership No.: 025834
UDIN: 26025834SFXEZF6106

Place: Hyderabad
Date: August 24, 2026

Annexure - A to the Independent Auditors' Report

(referred to in paragraph-1 under 'Report on Other Legal and Regulatory Requirements' section of our report on the Independent Auditor's Report of even date of Virupaksha Organics Limited on the Standalone Financial statements for the year ended March 31, 2026.)

In terms of the information and explanations sought by us and given by the Company and the books of account and records examined by us in the normal course of audit and to the best of our knowledge and belief, we state that:

(i) (a)

(A) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment, capital work-in-progress and relevant details of right-of-use of assets.

(B) The Company does not own any intangible assets, accordingly reporting under clause 3(i)(a)(B) of the said Order is not applicable to the company.

(b) The Company has a programme of verification of property, plant and equipment, capital work-in-progress and right-of-use of assets so as to cover all the items in a phased manner over a period of three years which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. Pursuant to the programme, certain property, plant and equipment were due for verification during the year and were physically verified by the Management during the year. According to the information and explanations given to us, no material discrepancies were noticed on such verification.

(c) Based on the examination of the registered sale deed/transfer deed provided to us, we report that, the title deeds of all the immovable properties of land and buildings (other than properties where the Company is the lessee and the lease agreements are duly executed in favour of the Company), disclosed in the standalone financial statements included in property, plant and equipment and capital work-in-progress, are held in the name of the Company as at the balance sheet date. Immovable properties of land and buildings whose title deeds have been pledged as security for loans are held in the name of the Company.

(d) The Company has not revalued any of its property, plant and equipment (including Right of Use assets) and intangible assets during the year.

(e) No proceedings have been initiated during the year or are pending against the Company as at March 31, 2026 for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (as amended in 2016) and rules made thereunder.

(ii)

(a) The inventories were physically verified during the year by the Management at reasonable intervals. In our opinion and based on information and explanations given to us, the coverage and procedure of such verification by the Management is appropriate having regard to the size of the Company and the nature of its operations. No discrepancies of 10% or more in the aggregate for each class of inventories were noticed on such physical verification of inventories, when compared with the books of account.

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has been sanctioned working capital limits in excess of ₹ 5 crores, in aggregate, at points of time during the year, from banks or financial institutions on the basis of security of current assets. In our opinion and according to the information and explanations given to us, the statements filed by the Company with such banks or financial institutions are in agreement with the unaudited books of account of the Company, of the respective months, except for the following:

(₹ in million)

Month ending	Particulars	Amount as per Unaudited Books of Accounts	Amount as reported in the monthly statement	Difference
July 31, 2025	Trade Receivable	1915.55	1906.10	9.45
December 31, 2025	Trade Receivable	2311.84	2346.20	(34.36)
	Trade Payable	1398.92	1399.12	(0.20)

(iii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not provided any security to Companies, Firms, Limited Liability Partnerships or any other parties during the year. The Company has made investments in, provided guarantee and granted unsecured loans to companies in respect of which the requisite information is as below. The company has not made any investments in, provided any guarantee or granted any unsecured loans to firms, limited liability partnership during the year.

(a) Based on the audit procedures carried on by us and as per the information and explanations given to us, the Company has made investments in, provided/ stood guarantee and granted unsecured loans during the year and details of which are given below:

(₹ in million)

Particulars	Loans	Guarantees
Aggregate amount granted during the year:		
- Subsidiaries	355.00	466.00
- Associates	-	-
- Others	-	-
Balance outstanding as at balance sheet date in respect of above cases:		
- Subsidiaries	535.00	466.00
- Associates	-	-
- Others	-	-

In our opinion, and according to the information and explanations given to us, the investments made, guarantees provided and the terms and conditions of the grant of all the above-mentioned loans and guarantees provided, during the year are, prima facie, not prejudicial to the interest of the Company.

(b) In respect of loans granted by the Company, the schedule of repayment of principal and payment of interest has been stipulated and the repayments of principal amounts and receipts of interest are regular as per the stipulation.

(c) There is no overdue amount for more than ninety days in respect of loans or advances in the nature of loans granted to such companies.

(d) There were no loans or advance in the nature of loan granted to companies which was fallen due during the year, that have been renewed or extended or fresh loans granted to settle the overdues of existing loans given to the same parties.

(e) According to information and explanations given to us and based on the audit procedures performed, the Company has not granted any loans either repayable on demand or without specifying any terms or period of repayment during the year. Hence, reporting under clause 3(iii)(f) of the Order is not applicable.

(iv) In our opinion, and according to the information and explanations given to us, the Company has complied with the provisions of Section 186 of the Act in respect of loans and investments made and guarantees and security provided by it, as applicable. Further, the Company has not entered into any transaction covered under Section 185 of the Act.

(v) In our opinion, and according to the information and explanations given to us, the Company has not accepted any deposits or there are no amounts which have been deemed to be deposits within the meaning of sections 73 to 76 of the Act and the Companies (Acceptance of Deposits) Rules, 2014 (as amended). Accordingly, reporting under clause 3(v) of the Order is not applicable to the Company.

(vi) The maintenance of cost records has been specified by the Central Government under Section 148(1) of the Companies Act, 2013. We have broadly reviewed the books of account maintained by the Company pursuant to the Companies (Cost Records and Audit) Rules, 2014, as amended, prescribed by the Central Government for maintenance of cost records under Section 148(1) of the Companies Act, 2013, and are of the opinion that, prima facie, the prescribed cost records have been made and maintained by the Company. We have, however, not made a detailed examination of the cost records with a view to determine whether they are accurate or complete.

(vii) In respect of statutory dues:

(a) Undisputed statutory dues, including Goods and Service tax, Provident Fund, Employees' State Insurance, Income-tax, duty of Customs, duty of Excise, cess and other material statutory dues applicable to the Company have generally been regularly deposited by it with the appropriate authorities though there has been a slight delay in few cases.

There were no undisputed amounts payable in respect of Goods and Service tax, Provident Fund, Employees' State Insurance, Income-tax, duty of Customs, duty of Excise, cess and other material statutory dues in arrears as at March 31, 2026 for a period of more than six months from the date they became payable.

(b) According to the information and explanations given to us and examination of records of the company, details of statutory dues referred to in sub-clause (a) above which have not been deposited as on March 31, 2026 on account of dispute, are given below:

₹ in millions

Name of the Statue	**Nature of the dues**	**Amount Demanded**	**Period to which the amount relates**	**Forum where Dispute is pending**	**Remarks, if any**
Income Tax Act, 1961	Income Tax	26.15	AY 2021-2022	Commissioner of Income Tax (Appeals)	NIL

(viii) The Company has not surrendered or disclosed any transaction, previously unrecorded in the books of account, in the tax assessments under the Income Tax Act, 1961 (43 of 1961) as income during the year. Accordingly, the requirement to report on clause 3(viii) of the Order is not applicable to the Company.

(ix)

(a) In our opinion and according to the information and explanations given to us, the Company has not defaulted in repayment of its loans or borrowings or in the payment of interest thereon to any lender.

(b) According to the information and explanations given to us including confirmations received from banks and representation received from the management of the Company, and on the basis of our audit procedures, we report that the Company has not been declared a wilful defaulter by any bank or financial institution or government or any government authority.

(c) To the best of our knowledge and belief, in our opinion, term loans availed by the Company were, applied by the Company during the year for the purposes for which the loans were obtained.

(d) On an overall examination of the standalone financial statements of the Company, funds raised on short-term basis have not been used during the year for long-term purposes by the Company.

(e) On an overall examination of the standalone financial statements of the Company, the Company has not taken funds from any entity or person on account of or to meet the obligations of its subsidiaries or associates.

(f) The Company has not raised loans during the year on the pledge of securities held in its subsidiaries or associate companies. Hence, the requirement to report on clause 3(ix)(f) of the Order is not applicable to the Company.

(x)

(a) The Company has not raised any money by way of initial public offer or further public offer (including debt instruments), during the year. Accordingly, reporting under clause 3(x)(a) of the Order is not applicable to the Company.

(b) During the year, the Company has not made any preferential allotment or private placement of shares or convertible debentures (fully or partly or optionally). Accordingly, reporting under clause 3(x)(b) of the Order is not applicable to the Company.

(xi)

(a) To the best of our knowledge and according to the information and explanations given to us, no fraud by the Company or no material fraud on the Company has been noticed or reported during the period covered by our audit.

(b) According to the information and explanations given to us including the representation made to us by the management of the Company, no report under subsection 12 of section 143 of the Companies Act has been filed by the auditors in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014, with the Central Government for the period covered by our audit.

(c) As represented to us by the Management, there were no whistle blower complaints received by the Company during the year and upto the date of this report.

(xii) The Company is not a Nidhi Company as per the provisions of the Companies Act, 2013. Therefore, the requirement to report on clause 3(xii)(a), 3(xii)(b) and 3(xii)(c) of the Order is not applicable to the Company.

(xiii) In our opinion and according to the information and explanations given to us, all transactions entered into by the Company with the related parties are in compliance with sections 177 and 188 of the Act, where applicable. Further, the details of such related party transactions have been disclosed in the standalone financial statements, as required under Indian Accounting Standard (Ind AS) 24, Related Party Disclosures specified in Companies (Indian Accounting Standards) Rules 2015 as prescribed under section 133 of the Act.

(xiv)

(a) In our opinion and according to the information and explanations given to us, the Company has an internal audit system which is commensurate with the size and nature of its business as required under the provisions of section 138 of the Act.

(b) We have considered the reports issued by the Internal Auditors of the Company till date for the period under audit.

(xv) According to the information and explanation given to us, in our opinion during the year the Company has not entered into any non-cash transactions with its directors or persons connected with its directors and accordingly, reporting under clause 3(xv) of the Order with respect to compliance with the provisions of section 192 of the Act are not applicable to the Company.

(xvi)

(a) The provisions of section 45-IA of the Reserve Bank of India Act, 1934 (2 of 1934) are not applicable to the Company. Accordingly, the requirement to report on clause (xvi)(a) of the Order is not applicable to the Company

(b) The Company is not engaged in any Non-Banking Financial or Housing Finance activities. Accordingly, the requirement to report on clause 3(xvi)(b) of the Order is not applicable to the Company.

(c) The Company is not a Core Investment Company as defined in the regulations made by Reserve Bank of India. Accordingly, the requirement to report on clause 3(xvi) of the Order is not applicable to the Company.

(d) There is no Core Investment Company as a part of the Group, hence, the requirement to report on clause 3(xvi)(d) of the Order is not applicable to the Company.

(xvii) The Company has not incurred cash losses in the current financial year as well as in the immediately preceding financial year.

(xviii) There has been no resignation of the statutory auditors during the year and accordingly reporting under Clause 3(xviii) of the Order is not applicable to the Company.

(xix) According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the standalone financial statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the company as and when they fall due.

(xx) The Company has fully spent the required amount towards Corporate Social Responsibility (CSR) and there is no unspent CSR amount for the year requiring a transfer to a Fund specified in Schedule VII to the Companies Act or special account in compliance with the provision of sub-section (6) of Section 135 of the said Act. Accordingly, reporting under clause 3(xx)(a) and 3(xx)(b) of the Order is not applicable for the year.

(xxi) The reporting under clause 3(xxi) of the Order is not applicable in respect of audit of standalone financial statements of the Company. Accordingly, no comment has been included in respect of said clause under this report

For C. RAMACHANDRAM & Co
Chartered Accountants
FRN: 002864S

C. RAMACHANDRAM
Partner
Membership No.: 025834
UDIN: 26025834SFXEZF6106

Place: Hyderabad
Date: August 24, 2026

Annexure “B” to the Independent Auditor’s Report

(Referred to in paragraph 2(g) under ‘Report on Other Legal and Regulatory Requirements’ section of our report of even date)

Report on the Internal Financial Controls with reference to standalone financial statements under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (the “Act”)

We have audited the internal financial controls with reference to standalone financial statements of Virupaksha Organics Limited (“the Company”) as of March 31, 2026, in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

Management’s Responsibility for Internal Financial Controls

The Company’s Management is responsible for establishing and maintaining internal financial controls with reference to standalone financial statements based on the internal control with reference to standalone financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (“ICAI”). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the Company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditor’s Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls with reference to these standalone financial statements based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) issued by the ICAI and the Standards on Auditing prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to standalone financial statements. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to these standalone financial statements was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to these standalone financial statements and their operating effectiveness. Our audit of internal financial controls with reference to standalone financial statements included obtaining an understanding of internal financial controls with reference to these standalone financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company’s internal financial controls with reference to these standalone financial statements.

Meaning of Internal Financial Controls with Reference to these Standalone Financial Statements
A company's internal financial controls with reference to standalone financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial controls with reference to standalone financial statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls with Reference to Standalone Financial Statements
Because of the inherent limitations of internal financial controls with reference to standalone financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to standalone financial statements to future periods are subject to the risk that the internal financial control with reference to standalone financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, adequate internal financial controls with reference to standalone financial statements and such internal financial controls with reference to standalone financial statements were operating effectively as at March 31, 2026, based on the criteria for internal financial control with reference to standalone financial statements established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the ICAI.

For C. RAMACHANDRAM & Co
Chartered Accountants
FRN: 002864S

C. RAMACHANDRAM
Partner
Membership No.: 025834
UDIN: 26025834SFXEZF6106

Place: Hyderabad
Date: August 24, 2026

VIRUPAKSHA ORGANICS LIMITED
CIN: U24110TG1997PLC028281
Standalone Statement of Asstes and Liabilities
(All amounts in ₹ millions, unless otherwise stated)

Particulars	Note No.	As at March 31, 2026	As at March 31, 2025
ASSETS			
Non-Current assets			
(a) Property, plant and equipment	2	4,268.45	4,090.97
(b) Capital work-in-progress	3	763.50	246.51
(c) Right of use assets	4	74.40	22.91
(d) Financial Assets			
(i) Investments	5	1,041.49	527.40
(ii) Loans	6	535.00	180.00
(iii) Other Financial assets	7	61.28	274.01
(e) Other non-current assets	8	176.32	144.54
Total Non-current assets		**6,920.44**	**5,486.34**
Current assets			
(a) Inventories	9	1,625.08	1,698.71
(b) Financial Assets			
(i) Trade Receivables	10	2,581.34	1,642.00
(ii) Cash and Cash Equivalents	11	87.17	136.03
(iii) Bank balances other than cash and cash equivalents	12	21.13	47.17
(iv) Other financial assets	13	33.57	15.75
(c) Other current assets	14	311.68	475.55
Total current assets		**4,659.97**	**4,015.21**
TOTAL ASSETS		**11,580.41**	**9,501.55**
EQUITY AND LIABILITIES			
Equity			
(a) Equity Share Capital	15	615.32	410.22
(b) Other equity	16	4,835.47	4,160.80
Total equity		**5,450.79**	**4,571.02**
Liabilities			
Non-current liabilities			
(a) Financial Liabilities			
(i) Borrowings	17	1,527.48	1,143.47
(ii) Lease Liabilities	18	63.34	18.30
(iii) Other Financial Liabilities	19	2.48	-
(b) Provisions	20	87.47	97.60
(c) Deferred Tax Liabilities (Net)	21	183.07	153.80
Total Non-current Liabilities		**1,863.84**	**1,413.17**
Current liabilities			
(a) Financial Liabilities			
(i) Borrowings	22	1,940.55	1,668.69
(ii) Lease Liabilities	18	9.40	3.74
(iii) Trade Payables	23		
(A) total outstanding dues of Micro and Small Enterprises		705.27	401.78
(B) total outstanding dues of Creditors Other than Micro and Small Enterprises		1,008.21	825.63
(iv) Other Financial liabilities	24	446.55	520.53
(b) Provisions	25	52.03	55.42
(c) Current Tax Liabilities (Net)	26	61.20	20.54
(d) Other Current Liabilities	27	42.57	21.03
Total Current Liabilities		**4,265.78**	**3,517.36**
TOTAL EQUITY & LIABILTIES		**11,580.41**	**9,501.55**

The accompanying notes are an integral part of these financial statements 1

As per our report of even date attached

For and on behalf of the Board of Directors

For **C. RAMACHANDRAM & Co**
Chartered Accountants
FRN: 002864S

M. BALASUBBA REDDY
Whole Time Director
DIN: 01998852

G. CHANDRA MOULISWAR REDDY
Managing Director
DIN: 00046845

C. RAMACHANDRAM
Partner
Membership No.: 025834

PRASAD REDDY BATTINAPATLA
Chief Financial Officer

VIKAS KURADA
Company Secretary
Membership No. A54105

Place: Hyderabad
Date: August 24, 2026

VIRUPAKSHA ORGANICS LIMITED
CIN: U24110TG1997PLC028281
Standalone Statement of Profit and Loss Account
(All amounts in ₹ millions, unless otherwise stated)

Particulars	Note No	For the year ended March 31, 2026	For the year ended March 31, 2025
Revenue from operations	28	9,255.86	8,113.95
Other income	29	107.49	50.85
Total Income		**9,363.35**	**8,164.80**
Expenses:			
Cost of materials consumed	30	5,177.73	4,875.66
Changes in inventories of finished goods and Work-in-Progress	31	85.38	(451.76)
Employee benefits expense	32	860.17	876.40
Finance Costs	33	276.75	211.51
Depreciation and amortization expense	2 & 4	223.50	191.59
Other Expenses	34	1,539.31	1,420.90
Total expenses		**8,162.84**	**7,124.30**
Profit before Tax		**1,200.51**	**1,040.50**
Tax expense:			
Current tax		270.69	217.42
Deferred tax		34.50	30.79
Prior period tax		0.03	0.95
Total Tax Expense		**305.22**	**249.16**
Profit after Tax		**895.29**	**791.34**
Other comprehensive income/(loss)			
(i) Items that will not be reclassified to Profit or Loss			
a) Changes in fair value of investments		(15.00)	8.34
Income tax on above		3.78	(2.10)
b) Actuarial gain/ (loss) on post-employment benefit obligations		(5.75)	(3.50)
Income tax on above		1.45	0.88
Other Comprehensive Income/ (Loss) for the year (Net of Tax)		**(15.52)**	**3.62**
Total Comprehensive Income / (Loss) for the Year		**879.77**	**794.96**
Earnings per equity share (Face value of ₹ 10 each fully paid)	34		
(1) Basic (in ₹)		14.55	13.24
(2) Diluted (in ₹)		14.55	13.24

The accompanying notes are an integral part of these financial statements — 1

As per our report of even date attached

For and on behalf of the Board of Directors

For C. RAMACHANDRAM & Co
Chartered Accountants
FRN: 002864S

M. BALASUBBA REDDY
Whole Time Director
DIN: 01998852

G. CHANDRA MOULISWAR REDDY
Managing Director
DIN: 00046845

C. RAMACHANDRAM
Partner
Membership No.: 025834

PRASAD REDDY BATTINAPATLA
Chief Financial Officer

VIKAS KURADA
Company Secretary
Membership No. A54105

Place: Hyderabad
Date: August 24, 2026

VIRUPAKSHA ORGANICS LIMITED
CIN: U24110TG1997PLC028281
Standalone Statement of Changes In Equity
(All amounts in ₹ millions, unless otherwise stated)

I. EQUITY SHARE CAPITAL

Particulars	As at March 31, 2026	As at March 31, 2025
Balance at the beginning of the year	410.22	374.48
Changes in equity share capital during the year (Refer Note 15)	205.10	35.74
Balance at the end of the year	**615.32**	**410.22**

II. OTHER EQUITY

Particulars	Share Application Money Pending Allotment	Reserves and Surplus				Items of Other Comprehensive Income (OCI)	Total Other Equity
		Capital Reserve	Capital Redemption Reserve	Securities Premium	Retained Earnings		
Balance as at March 31, 2024	**-**	**2.33**	**60.87**	**5.10**	**2,316.11**	**(5.73)**	**2,378.68**
Profit for the period	-	-	-	-	791.34	-	791.34
Dividend on Equity Shares (Refer Note 51)	-	-	-	-	(49.23)	-	(49.23)
Issue of Equity Share Capital	-	-	-	1,036.39	-	-	1,036.39
Other comprehensive income for the period	-	-	-	-	-	3.62	3.62
Balance as at March 31, 2025	**-**	**2.33**	**60.87**	**1,041.49**	**3,058.22**	**(2.11)**	**4,160.80**
Profit for the period	-	-	-	-	895.29	-	895.29
Bonus Issue of Equity Shares (Refer Note 15)	-	-	(60.87)	(144.23)	-	-	(205.10)
Issue of Equity Share Capital	-	-	-	-	-	-	-
Other comprehensive income for the period	-	-	-	-	-	(15.52)	(15.52)
Balance as at March 31, 2026	**-**	**2.33**	**-**	**897.26**	**3,953.51**	**(17.63)**	**4,835.47**

The accompanying notes are an integral part of these financial statements 1

As per our report of even date attached

For and on behalf of the Board of Directors

For C. RAMACHANDRAM & Co
Chartered Accountants
FRN: 002864S

M. BALASUBBA REDDY
Whole Time Director
DIN: 01998852

G. CHANDRA MOULISWAR REDDY
Managing Director
DIN: 00046845

C. RAMACHANDRAM
Partner
Membership No.: 025834

PRASAD REDDY BATTINAPATLA
Chief Financial Officer

VIKAS KURADA
Company Secretary
Membership No. A54105

Place: Hyderabad
Date: August 24, 2026

VIRUPAKSHA ORGANICS LIMITED
CIN: U24110TG1997PLC028281
Standalone Statement of Cash Flows
(All amounts in ₹ millions, unless otherwise stated)

Particulars	For The Year Ended March 31, 2026	For The Year Ended March 31, 2025
Cash flows from/(used in) operating activities		
Net profit/(loss) before tax	1,200.51	1,040.50
Adjustments for:		
Depreciation and amortisation expense	223.50	191.59
Interest income	(28.00)	(18.68)
Income from Mutual Fund	(0.22)	(6.58)
Finance costs	276.75	211.51
Actuarial gain/ (loss) on post- employment benefit obligations	(5.75)	(3.50)
Unwinding of guarantee obligation	(0.65)	-
Net (gain)/ loss on fair value change in investments	1.67	(0.72)
Loss/(profit) on sale of property, plant and equipment (net)	3.17	(0.69)
Operating profit before working capital changes	**1,670.98**	**1,413.43**
Changes in working capital		
Adjustments for (increase)/decrease in operating assets :		
Trade receivables	(939.34)	257.36
Inventories	73.63	(627.20)
Other financial assets	194.91	(187.31)
Other assets	132.09	(247.59)
Adjustments for increase/(decrease) in operating liabilities :		
Trade payables	486.07	129.49
Other financial liabilities	(71.50)	327.75
Provisions	(13.52)	41.88
Other liabilities	21.54	(2.76)
Cash generated from / (used in) operating activities	**1,554.86**	**1,105.05**
Income taxes paid, net	(230.06)	(209.24)
Net Cash generated from / (used in) operating activities (A)	**1,324.80**	**895.81**
Cash flow from/(used in) investing activities		
Capital expenditure on property, plant and equipment	(942.15)	(1,411.64)
Proceeds from sale of property, plant and equipment	24.04	6.93
Purchase of investments	(530.11)	(311.89)
(Increase) / Decrease in Bank balances other than cash and cash equivalents	26.04	30.28
Income from mutual funds	0.22	6.58
Interest Received	28.00	18.68
Loans given	(355.00)	(145.00)
Net cash generated from / (used in) investing activities (B)	**(1,748.96)**	**(1,806.06)**
Cash flow from/(used in) financing activities		
Proceeds from Borrowings	1,476.55	680.24
Repayment of from Borrowings	(820.68)	(511.57)
Proceeds from issue of equity shares	-	1,072.13
Payment of Lease Liabilities	(3.82)	(0.35)
Finance costs	(276.75)	(211.51)
Dividend paid	-	(49.23)
Net cash generated from/(used in) financing activities (C)	**375.30**	**979.71**
Net increase/ (decrease) in cash and cash equivalents (A+B+C)	(48.86)	69.46
Cash and cash equivalents at the beginning of the year	136.03	66.57
Cash and cash equivalents at the end of the year (Refer Note No: 11)	**87.17**	**136.03**
Note:		
Cash and cash equivalents comprise of:		
Cash in hand	1.66	1.43
Balances with banks	70.99	134.60
Balance in Demat Account	14.52	-
Cash and cash equivalents (Refer Note No: 11)	**87.17**	**136.03**

VIRUPAKSHA ORGANICS LIMITED
CIN: U24110TG1997PLC028281
Standalone Statement of Cash Flows
(All amounts in ₹ millions, unless otherwise stated)

Notes
1. Changes in liabilities arising from financing activities

	As at March 31,2026	As at March 31,2025
Borrowings		
Opening Balance	**2,812.16**	**2,643.49**
Proceeds during the year	1476.55	680.24
Repayments During the year	(820.68)	(511.57)
Closing Balance	**3,468.03**	**2,812.16**
Share Capital including securities premium		
Opening Balance	**1,451.71**	**379.58**
Proceeds during the year	-	1,072.13
Adjustment on account of bonus shares	60.87	-
Closing Balance	**1,512.58**	**1,451.71**
Lease Liabilities		
Opening Balance	**22.04**	**11.47**
Payment of interest portion of lease liabilities	2.34	1.27
Payment of principal portion of lease liabilities	(3.65)	(1.62)
Lease additions during the year	52.01	10.92
Closing Balance	**72.74**	**22.04**

2. The above standalone statement of cash flow from operating activities has been prepared under the "Indirect method" as set out in IND AS-7 "Statement of cash flows".

The accompanying notes are an integral part of these financial statements

As per our report of even date attached

For and on behalf of the Board of Directors

For C. RAMACHANDRAM & Co
Chartered Accountants
FRN: 002864S

M. BALASUBBA REDDY
Whole Time Director
DIN:01998852

G. CHANDRA MOULISWAR REDDY
Managing Director
DIN: 00046845

C. RAMACHANDRAM
Partner
Membership No.: 025834

PRASAD REDDY BATTINAPATLA
Chief Financial Officer

VIKAS KURADA
Company Secretary
Membership No. A54105

Place: Hyderabad
Date: August 24, 2026

Corporate Information and Material Accounting Policies

1.1 Corporate Information

Virupaksha Organics Limited (Corporate identity number: U24110TG1997PLC028281) ("the Company") is a public limited company domiciled in India and is incorporated on November 03, 1997 under the provisions of Companies Act applicable in India.

The Company is engaged in manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Generic Pharmaceuticals, Bulk Drugs, Intermediates and Differentiated Formulations. The Company has its registered office at Hyderabad, Telangana. The Company's principal research and development facility was located in the state of Telangana in India; it's principal manufacturing facilities are located in the states of Telangana and Karnataka.

1.2 Basis of Preparation, Measurement and Material Accounting Policies

a) Statement of Compliance and Basis of preparation

The standalone financial statements have been prepared in accordance with Indian Accounting Standards (hereinafter referred to as 'Ind AS') prescribed under section 133 of the Companies Act, 2013 ("the Act") read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016 as amended and presentation requirements of Division II of Schedule III to the Companies Act, 2013 as amended from time to time, and other relevant provisions of the Act and accounting principles generally accepted in India.

The accounting policies are applied consistently to all the periods presented in the standalone financial statements except where a newly issued accounting standard is initially adopted or a revision to an existing accounting standard requires change in accounting policy hitherto in use. These standalone financial statements have been prepared on a going concern basis. These standalone financial statements do not reflect the effects of events that occurred subsequent to the respective dates of board meeting held to approve and adopt the audited standalone financial statements as mentioned above.

b) Basis of measurement

The standalone financial statements have been prepared on the historical cost basis except for the following items:

- Certain financial assets and liabilities: Measured at fair value
- Borrowings : Amortised cost using effective interest rate method
- Net defined benefit (asset)/ liability : Present value of defined benefit obligations less fair value of plan assets

c) Use of judgements, estimates and assumptions

The preparation of the standalone financial statements in conformity with Ind AS requires management to make estimates, judgements and assumptions that affects the reported amounts of the assets and liabilities, the disclosure of contingent assets and liabilities at the date of financial statements and reported amounts of revenue and expenses during the period. Accounting estimates could change from period to period. Actual results could differ from those estimates. Appropriate changes in the estimates are made as and when management becomes aware of changes in circumstances surrounding the estimates. Changes in the estimates are reflected in the financial statements in the period in which the changes are made and, if material, such effects are disclosed in the notes to financial statements.

Assumptions and estimation uncertainties

Information about assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment in the amounts recognised in the standalone financial statements is included in the following notes:

• Note 1.3(b) - Assessment of functional currency;

• Note 1.3(c) - Financial instruments;

• Notes 1.3(f) and 1.3(h) - Useful lives of property, plant and equipment and intangible assets and residual value at the end of its life.

• Note 1.3(j) - Valuation of inventories;

• Note 1.3(k) - Measurement of recoverable amounts of cash-generating units;

• Note 1.3(m) - Contingencies, Provisions and other accruals;

• Note 1.3(n) - Measurement of transaction price in a revenue transaction (sales returns and rebates);

• Note 1.3(q) - Evaluation of recoverability of deferred tax assets, estimation of income tax payable and income tax expense in relation to uncertain tax positions;

d) Current vs. non-current Classification

The Schedule III to the Act requires assets and liabilities to be classified as either current or non-current. The Company presents assets and liabilities in the statement of assets and liabilities based on current/ non-current classification.

Assets

An asset is classified as a current when it is:

- it is expected to be realised in, or is intended for sale or consumption in, the Company normal operating cycle;
- it is expected to be realised within twelve months from the reporting date;
- it is held primarily for the purposes of being traded; or
- is cash or cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting date.

All other assets are classified as non-current

Liabilities

A liability is classified as a current when:

- it is expected to be settled in normal operating cycle
- it is due to be settled within twelve months from the reporting date;
- it is held primarily for the purposes of being traded;
- the Company does not have an unconditional right to defer settlement of liability for at least twelve months from the reporting date.

All other liabilities are classified as non-current.

Operating Cycle:

Operating cycle is the time between the acquisition of assets for processing and their realization in cash or cash equivalent. The operating cycle of the Group is less than 12 months.

1.3 Material accounting policies information:

a) New and amended standards adopted by the Company:

The Ministry of Corporate Affairs ("MCA") notifies new standards or amendments to the existing standards under Companies (Indian Accounting Standards) Rules as issued from time to time.

In May 2025, MCA notified amendments to Ind AS 21 - The Effects of Changes in Foreign Exchange Rates, applicable w.e.f. April 1, 2025. The Company has reviewed the amendment and based on its evaluation has determined that it does not have any significant impact in its financial statements.

In August 2025, MCA notified the following amendments to:

a. Ind AS 1, Presentation of Financial Statements, applicable w.e.f. April 1, 2025 – The amendment relates to classification of liabilities as current or non-current and non-current liabilities with covenants. In the context of classifying a liability as current, it removes the requirement of existence of a right to defer settlement for at least 12 months after the reporting date and instead requires that the said right should exist on the reporting date and have substance. The amendment also introduces guidance on classification of liabilities with covenants. The has reviewed the amendments and made appropriate disclosures in its financial statements including classification of current and non-current liabilities.

b. Ind AS 7, Statement of Cash Flows and Ind AS 107, Financial Instruments: Disclosures, applicable w.e.f. April 1, 2025 – The amendment in Ind AS 7 requires to inform users of financial statements of the existence of supplier finance arrangements and explain the nature of the arrangements, the carrying amount of liabilities and the range of payment due dates. Ind AS 107 has been amended to add supplier-finance arrangements as a factor that may cause concentration of liquidity risk. The Company has reviewed the amendment and made appropriate disclosures in its financial statements.

c. Ind AS 12, International Tax Reform – Pillar Two Model Rules applicable immediately – The amendments provide a temporary mandatory relief from deferred tax accounting for top-up tax and disclose that they have applied the relief. This relief is immediate and applies retrospectively. The Company has reviewed the amendment and based on its evaluation has determined that it does not have any impact in its financial statements.

b) Foreign currency

Functional and presentation currency

These standalone financial statements are presented in Indian rupees (₹), which is the functional currency of the company and the currency of the primary economic environment in which the company operates.

Foreign currency transactions

Transactions in foreign currencies are recorded at exchange rates prevailing on the date of the transactions. Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated into the functional currency at the exchange rate at that date. Non-monetary items that are measured based on historical cost in a foreign currency are translated at the exchange rate at the date of the transaction.

Exchange differences arising on the settlement of monetary items or on translating monetary items at rates different from those at which they were translated on initial recognition during the period or in previous financial statements are recognised in the statement of Profit and Loss in the period in which they arise.

c) Rounding of amounts

All amounts disclosed in the standalone financial statements which also include the accompanying notes have been rounded off to two decimal places to the nearest Millions as per the requirement of Schedule III to the Companies Act 2013, unless otherwise stated.

d) Financial instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

Financial assets

Initial recognition and measurement

All financial assets are recognised initially at fair value plus, in the case of financial assets not recorded at fair value through profit or loss, transaction costs that are attributable to the acquisition of the financial asset.

Trade receivables generally do not contain any significant financing component requiring separation and are therefore recognized initially at the transaction price determined as per Ind AS 115, "Revenue from Contracts with Customers".

Subsequent measurement

Financial assets carried at amortized cost:

A "financial asset" is measured at the amortised cost if both the following conditions are met:

a) the asset is held within a business model whose objective is to hold assets for collecting contractual cash flows; and
b) contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest ("SPPI") on the principal amount outstanding.
c)

After initial measurement, such financial assets are subsequently measured at amortised cost using the effective interest rate method and are subject to impairment. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the effective interest rate.

Interest income from these financial assets is included in finance income using the effective interest rate method. Any gain or loss arising on de recognition is recognised directly in statement of Profit and Loss and presented in other income. The losses arising from impairment are recognised in the statement of Profit and Loss.

Financial assets at fair value through other comprehensive income (FVTOCI):

A financial asset is subsequently measured at fair value through other comprehensive income if it is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. For equity instruments the Company may make an irrevocable election to present in Other comprehensive Income (OCI) subsequent changes in the fair value. The Company makes such election upon initial recognition on an instrument-by instrument basis. The classification is made upon initial recognition and is irrevocable.

If the Company decides to classify an equity instrument as at FVTOCI, then all fair value changes on the instrument, excluding dividends, are recognised in the OCI. There is no recycling of the amounts from OCI to the statement of Profit and Loss, even on sale of investment.

However, on sale the Company may transfer the cumulative gain or loss within equity.

The Company has made an irrevocable election for its investments in equity instruments other than in subsidiaries & associates to present the subsequent changes in fair value in other comprehensive income.

Financial assets at fair value through profit and loss (FVTPL):

A financial asset which is not classified in any of the above categories are subsequently fair valued through profit and loss.

Investments in subsidiaries and associates

Investments in Subsidiaries and Associates are carried at cost less accumulated impairment losses, if any. Where an indication of impairment exists, the carrying amount of the investment is assessed and written down immediately to its recoverable amount. On disposal of investments in Subsidiaries and Associates, the difference between net disposal proceeds and the carrying amounts are recognised in the statement of profit and loss.

De recognition

A financial asset (or, where applicable, a part of a financial asset or part of a company of similar financial assets) is derecognised (i.e. removed from the Company's statement of assets and liabilities) when:

- the rights to receive cash flows from the asset have expired; or
- Both (1) the Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a "pass-through" arrangement; and (2) either (a) the Company has transferred substantially all the risks and rewards of the asset, or (b) the Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Company has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if and to what extent it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the Company continues to recognise the transferred asset to the extent of the Company's continuing involvement. In that case, the Company also recognises an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Company has retained.

Financial liabilities

Initial recognition and measurement

Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss (FVTPL) and at amortized cost, as appropriate. All financial liabilities are recognized initially at fair value and, in the case of borrowings and payables, net of directly attributable transaction costs.

Subsequent measurement

The measurement of financial liabilities depends on their classification, as described below:

Financial liabilities at FVTPL

Financial liabilities at FVTPL include financial liabilities held for trading and financial liabilities designated upon initial recognition as at FVTPL. Financial liabilities at FVTPL primarily comprise derivative financial instruments entered into by the Company and not designated as hedging instruments in a hedging relationship as defined by Ind AS 109.

Gains or losses on such financial liabilities are recognised in the statement of Profit and Loss.

The Company has not designated any financial liability as FVTPL.

Financial liabilities at amortized cost

Financial liabilities that are not held-for-trading and are not designated as at FVTPL are measured at amortised cost in subsequent accounting periods. The carrying amounts of financial liabilities that are subsequently measured at amortised cost are determined based on the effective interest rate (EIR) method. Interest expense that is not capitalised as part of costs of an asset is included in the 'Finance costs' line item in the profit or loss. After initial recognition, such financial liabilities are subsequently measured at amortised cost using the EIR method. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included as finance costs in the statement of profit and loss.

For trade and other payables maturing within one year from the Balance Sheet date, the carrying amounts approximate fair value due to the short maturity of these instruments.

De-recognition

A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires. Gain or loss arising on de-recognition, measured as difference between, the carrying amount of financial liability and the settlement amount, is recognized under the head finance costs in the statement of Profit and Loss.

Offsetting Financial Instruments

Financial assets and liabilities are offset and the net amount is reported in the statement of assets and liabilities where there is a legally enforceable right to offset the recognised amounts and there is an intention to settle on a net basis or realise the asset and settle the liability simultaneously. The legally enforceable right must not be contingent on future events and must be enforceable in the normal course of business and in the event of default, insolvency or bankruptcy of the company or the counterparty.

e) Cash and cash equivalents

Cash comprises cash on hand, in bank and demand deposits with banks. Cash equivalents are short term (with an original maturity of three months or less from the date of acquisition), highly liquid investments that are readily convertible into known amounts of cash and which are subject to insignificant risk of changes in value.

Cash flows are reported using indirect method whereby profit/ (loss) before tax is adjusted for the effects of transaction of non-cash nature and any deferrals or accruals of past or future cash receipts and payments.

f) Business Combination and Goodwill

Business Combinations are accounted for using Ind AS 103 'Business Combination'. Acquisitions of businesses are accounted for using the acquisition method unless the transaction is between entities under common control.

The consideration transferred in a business combination is measured at fair value, which is calculated as the sum of the acquisition-date fair value of assets transferred by the Company, liabilities incurred by the Company to the former owners of the acquiree and the equity interest issued by the Company in exchange of control of the acquiree. Acquisition related costs are generally recognised in statement of profit and loss as incurred.

At the acquisition date, the identifiable assets acquired and the liabilities assumed are recognised at their fair value at the acquisition date, except that:

- deferred tax assets or liabilities and assets or liabilities related to employee benefit arrangements are recognised and measured in accordance with Ind AS 12 Income Taxes and Ind AS 19 Employee Benefits respectively;
- liabilities or equity instruments related to share-based payment arrangements of the acquiree or share-based payment arrangements of the Company entered into to replace share-based payment arrangements of the acquiree are measured in accordance with Ind AS 102 at the acquisition date (see below); and

- assets (or disposal groups) that are classified as held for sale in accordance with Ind AS 105 are measured in accordance with that Standard.

Business Combinations arising from transfer of interests in entities that are under common control, are accounted using pooling of interest method wherein, assets and liabilities of the combining entities are reflected at their carrying value. No adjustment is made to reflect fair values or recognise any new assets or liabilities other than those required to harmonise accounting policies. The identity of the reserves is preserved and appears in the financial statements of the transferee in the same form in which they appeared in the financial statements of the transferor.

Goodwill is measured at cost, being the excess of the sum of the consideration transferred, the amount of any non-controlling interests in the acquiree, and the fair value of the acquirer's previously held equity interest in the acquiree (if any) over the net of the acquisition date amounts of the identifiable assets acquired and liabilities assumed.

If the net of the acquisition-date amounts of the identifiable assets acquired and liabilities assumed exceeds the sum of the consideration transferred, the amount of any non-controlling interests in the acquiree and the fair value of the acquirer's previously held interest in the acquiree (if any), the excess, after remeasurement, is recognised in capital reserve through other comprehensive income or directly depending on whether there exists clear evidence of the underlying reason for classifying the business combination as a bargain purchase.

After initial recognition, goodwill is measured at cost less any accumulated impairment losses. Goodwill is not amortised but is reviewed for impairment atleast annually. For the purpose of impairment testing, goodwill acquired in a business combination is, from the acquisition date, allocated to each of the Company's cash-generating units expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the acquiree are assigned to those units.

g) Property, plant and equipment

Recognition and measurement

Property, plant and equipment are carried at cost less accumulated depreciation and impairment losses, if any. The cost of property, plant and equipment comprises its purchase price net of any trade discounts and rebates, any import duties and other taxes (other than those subsequently recoverable from the tax authorities), any directly attributable expenditure on making the asset ready for its intended use, other incidental expenses and borrowings costs attributable to acquisition of qualifying property, plant and equipment up to the date the asset is ready for its intended use. Freehold land has an unlimited useful life and therefore is not depreciated.

Software for internal use which is acquired from third-party vendors and forms an integral part of a tangible asset, including consultancy charges for implementing the software, is capitalised as part of the related tangible asset. Subsequent costs associated with maintaining such software are recognised as expense as incurred.

Advances paid towards the acquisition of property, plant and equipment outstanding at each reporting date and the cost of property, plant and equipment not ready to use before such date are classified as Capital Advances under other non-current assets. Assets not ready for use are not depreciated but are tested for impairment. An item of property, plant and equipment and any significant part initially recognised is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Gains and losses upon disposal of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of property, plant and equipment and are recognised net within “Other income/ Other expenses” in the statement of Profit and Loss.

Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds. Borrowing cost also includes exchange differences to the extent regarded as an adjustment to the borrowing costs. Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalized as part of the cost of the asset. All other borrowing costs are expensed in the period in which they occur.

Subsequent costs are included in the asset’s carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. All other repairs and maintenance cost are charged to the statement of profit and loss during the period in which they are incurred.

The carrying values of property, plant and equipment are reviewed for impairment when events or changes in circumstances indicate that the carrying value may not be recoverable.

Capital work-in-progress included in non-current assets comprises of direct costs, related incidental expenses and attributable interest. Capital work-in-progress are not depreciated as these assets are not yet available for use.

Depreciation

Depreciation on property, plant and equipment (other than freehold land) is calculated on the straight-line method based on the useful life of the assets as indicated under Schedule II of the Companies Act 2013. Depreciation is recognised in the statement of Profit and Loss. Land is not depreciated but subject to impairment.

When parts of an item of property, plant and equipment have different useful lives, they are depreciated separately based on their respective economic useful lives.

The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial year end and, if expectations differ from previous estimates, the changes are accounted for as a change in an accounting estimate and adjusted prospectively.

h) Leases

The Company evaluates if an arrangement qualifies to be a lease as per the requirements of Ind AS 116. Identification of a lease requires significant judgement. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The determination of whether an arrangement is (or contains) a lease is based on the substance of the arrangement at the inception of the lease. The arrangement is, or contains, a lease if fulfilment of the arrangement is dependent on the use of a specific asset or assets and the arrangement conveys a right to use the asset or assets, even if that right is not explicitly specified in an arrangement.

The Company assesses whether a contract contains a lease, at inception of a contract. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

To assess whether a contract conveys the right to control the use of an identified asset, the Company assesses whether: (i) the contract involves the use of an identified asset (ii) the Company has substantially all of the economic benefits from use of the asset through the period of the lease and (iii) the Company has the right to direct the use of the asset. The Company uses significant judgement in assessing the lease term (including anticipated renewals) and the applicable discount rate. The determination of whether an arrangement is (or contains) a lease is based on the substance of the arrangement at the inception of the lease. The arrangement is, or contains, a lease if fulfilment of the arrangement is dependent on the use of a specific asset or assets and the arrangement conveys a right to use the asset or assets, even if that right is not explicitly specified in an arrangement.

At the date of commencement of the lease, the Company recognises a right-of-use asset ("ROU") and a corresponding lease liability for all lease arrangements in which it is a lessee, except for leases with a term of twelve months or less (short term leases) and low value leases. For these short term and low value leases, the Company recognises the lease payments as an operating expense on a straight-line basis over the term of the lease.

The right-of-use assets are initially recognised at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or prior to the commencement date of the lease plus any initial direct costs less any lease incentives. They are subsequently measured at cost less accumulated depreciation and impairment losses.

Right-of-use assets are depreciated from the commencement date on a straight-line basis over the lease term and useful life of the underlying asset. The lease liability is initially measured at amortised cost at the present value of the future lease payments. The lease payments are discounted using the interest rate implicit in the lease or, if not readily determinable, using the incremental borrowing rates in the country of domicile of these leases. Lease liabilities are re measured with a corresponding adjustment to the related right of use asset if the Company changes its assessment if whether it will exercise an extension or a termination option.

Lease payments are allocated between principal and interest cost. The interest cost is charged to the statement of Profit and Loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period.

Lease liability and ROU asset have been separately presented in the statement of assets and liabilities and lease payments have been classified as financing cash flows.

Remeasurement of Lease- The lease liability is subsequently remeasured by increasing the carrying amount to reflect interest on the lease liability, reducing the carrying amount to reflect the lease payments made and remeasuring the carrying amount to reflect any reassessment or lease modifications or to reflect revised in-substance fixed lease payments. The company recognises the amount of the re-measurement of lease liability due to modification as an adjustment to the right-of-use asset and statement of profit and loss depending upon the nature of modification. Where the carrying amount of the right-of-use asset is reduced to zero and there is a further reduction in the measurement of the lease liability, the Company recognises any remaining amount of the re-measurement in statement of profit and loss.

Variable lease payments that do not depend on an index or rate are not included in the measurement the lease liability and the ROU asset. The related payments are recognized as an expense in the period in which the event or condition that triggers those payments occurs and are included in the line “other expenses” in the Statement of Profit or Loss. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made and remeasured (with a corresponding adjustment to the related ROU asset) when there is a change in future lease payments in case of renegotiation, changes of an index or rate or in case of reassessment of options.

i) Inventories

Inventories consist of raw materials, packing materials, stores, spares and consumables, work-in-progress, stock-in-trade and finished goods and are measured at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and costs necessary to make the sale.

Cost of inventories is determined on a weighted average basis.

However, materials and other items held for use in the production of inventories are not written down below cost if the finished products in which they will be incorporated are expected to be sold at or above cost.

Stores and spares are inventories that do not qualify to be recognised as property, plant and equipment and consists of consumables, engineering spares (such as machinery spare parts), which are used in operating machines or consumed as indirect materials in the manufacturing process.

Cost includes expenditures incurred in acquiring the inventories, production or conversion costs and other costs incurred in bringing them to their existing location and condition. In the case of finished goods and work-in-progress, cost includes an appropriate share of overheads based on normal operating capacity.

j) Impairment of assets

a) Financial Assets

The Company recognises loss allowances using the expected credit loss (ECL) model for the financial assets which are not fair valued through profit and loss. Loss allowance for trade receivables with no significant financing component is measured at an amount equal to lifetime ECL. For all other financial assets, expected credit losses are measured at an amount equal to the 12-month ECL, unless there has been a significant increase in credit risk from initial recognition in which case those are measured at lifetime ECL. The amount of expected credit losses (or reversal) that is required to adjust the loss allowance at the reporting date to the amount that is required to be recognised is recognised as an impairment gain or loss in profit and loss.

For trade receivables only, the Company applies the simplified approach permitted by Ind AS 109 Financial Instruments, which requires expected lifetime losses to be recognised from initial recognition of the receivables.

As a practical expedient, the Company uses a provision matrix to determine impairment loss of its trade receivables. The provision matrix is based on its historically observed default rates over the expected life of the trade receivable and is adjusted for forward looking estimates. The ECL loss allowance (or reversal) during the year is recognised in the statement of profit and loss.

b) Non-Financial Assets

The carrying amounts of the Company's non-financial assets, other than inventories and deferred tax assets, are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated for the asset or the cash generating unit to which the asset belongs. For goodwill and intangible assets that have indefinite lives or that are not yet available for use, an impairment test is performed each year or when circumstances indicate that carrying value may be impaired.

The recoverable amount of a CGU (or an individual asset) is the higher of its value in use and its fair value less costs to sell. Value in use is based on the estimated future cash flows, discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the CGU (or the asset). For the purpose of impairment testing, assets are grouped together into the smallest company of assets that generate cash inflows from continuing use that are largely independent of the cash inflows of other assets or group of assets (the "cash-generating unit").

An impairment loss is recognised in the statement of profit and loss if the estimated recoverable amount of an asset or its cash-generating unit is lower than its carrying amount. Impairment losses recognised in respect of cash-generating units are allocated first to reduce the carrying amount of any goodwill allocated to the units and then to reduce the carrying amount of the other assets in the unit on a pro-rata basis.

An impairment loss in respect of goodwill is not reversed. In respect of other assets, impairment losses recognised in prior periods are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed its recoverable amount, nor exceed the carrying amount that would have been determined, net of depreciation or amortisation, if no impairment loss had been recognised.

Goodwill that forms part of the carrying amount of an investment in associate is not recognised separately, and therefore is not tested for impairment separately. Instead, the entire amount of the investment in associate is tested for impairment as a single asset when there are indicators that the investment in associate may be impaired.

c) Impairment of investment in subsidiaries and associates

Determining whether the investments in subsidiaries are impaired requires an estimate of the value in use of investments. In considering the value in use, the management has anticipated the operating margins and other factors of the underlying businesses/operations of the investee Companies. Any subsequent changes to the cash flows due to changes in the above-mentioned factors could impact the carrying value of investments.

k) Employee benefits

Employee benefits include provident fund, employee state insurance scheme, gratuity fund and compensated absences.

Short-term employee benefits

Short-term employee benefit obligations are measured on an undiscounted basis and are expensed during the period as the related service is provided. A liability is recognised for the amount expected to be paid, if the Company has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee, and the amount of obligation can be estimated reliably.

Defined Contribution Plans

The Company's contribution to provident fund and employee state insurance scheme are considered as defined contribution plans and are charged as an expense to the statement of profit and loss based on the amount of contribution required to be made and when services are rendered by the employees.

Defined Benefit Plans

i. Gratuity

The Company has a defined benefit plan (the "Gratuity Plan"). The Gratuity Plan provides a lump sum payment to employees upon retirement, disability or termination of employment, being an amount based on the respective employee's last drawn salary and the number of years of employment with the Company. The Gratuity Plan, which is defined benefit plan, is managed by the company and maintained with Life insurance Corporation of India

For defined benefit retirement plans, the cost of providing benefits is determined using the projected unit credit method, with actuarial valuations being carried out at the end of each annual reporting period. Re-measurement, comprising actuarial gains and losses, the effect of the changes to the asset ceiling (if applicable) and the return on plan assets (excluding net interest), is reflected immediately in the statement of assets and liabilities with a charge or credit recognised in other comprehensive income in the period in which they occur. Re-measurement recognised in other comprehensive income is reflected immediately in retained earnings and is not reclassified to profit and loss. Past service cost is recognised in statement of profit and loss when the plan amendment or curtailment occurs. Gains or losses on settlement of a defined benefit plan are recognised when the settlement occurs. Net interest is calculated by applying the discount rate at the beginning of the period to the net defined benefit liability or asset.

Defined benefit costs are categorised as follows:

• service cost (including current service cost, past service cost, as well as gains and losses on curtailments and settlements);

• net interest expense or income; and

• re-measurement

The Company presents the first two components of defined benefit costs in the statement of profit and loss in the line item 'Employee benefits expense.

ii. Compensated absences

The Company's policy permits employees to accumulate and carry forward a portion of unutilized compensated absences and utilize them in future periods or receive cash in lieu thereof in accordance with the terms of such policy. The Company measures the expected cost of accumulating compensated absences as the additional amount that the Company incurs as a result of the unused entitlement that has accumulated at the reporting date. Such measurement is based on actuarial valuation as at the reporting date carried out by a qualified actuary. The resultant expenses are recognized in the statement of Profit and Loss.

Other long-term employee benefits

The Company's net obligation in respect of other long-term employee benefits is the amount of future benefit that employees have earned in return for their service in the current and previous periods. That benefit is discounted to determine its present value by independent actuaries using the projected unit credit method. The current service cost, past service cost as well as re-measurements are recognised in the statement of Profit and Loss in the period in which they arise.

l) Provisions and Contingencies

Provisions

Provisions are recognised when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that the Company will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation.

The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligation.

If the effect of the time value of money is material, provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost.

Contingent liabilities and contingent assets

A present obligation that arises from past events where it is either not probable that an outflow of resources will be required to settle or a reliable estimate of the amount cannot be made, is disclosed as a contingent liability. Contingent liabilities are also disclosed when there is a possible obligation arising from past events, the existence of which will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Company. Claims against the Company where the possibility of any outflow of resources in settlement is remote, are not disclosed as contingent liabilities.

Contingent assets are not recognised in the financial statements. A contingent asset is disclosed where an inflow of economic benefits is probable. Contingent assets are assessed continually and, if it is virtually certain that an inflow of economic benefits will arise, the asset and related income are recognised in the period in which the change occurs.

m) Revenue recognition

The Company’s revenue is derived from sale of goods and service income. Most of such revenue is generated from the sale of goods. The Company has generally concluded that it is the principal in its revenue arrangements.

Sale of goods

Revenue is recognised when the control of the goods has been transferred to a third party. This is usually when the title passes to the customer, either upon shipment or upon receipt of goods by the customer as per the terms agreed upon with the customer. Generally, at that point, the customer has full discretion over the channel and price to sell the products, and there are no unfulfilled obligations that could affect the customer’s acceptance of the product.

Revenue from the sale of goods is measured at the transaction price which is the consideration received or receivable, net of expected returns, taxes and applicable trade discounts and allowances. Revenue includes shipping and handling costs billed to the customer since the Company acts as a principal in rendering those services.

In arriving at the transaction price, the Company considers the terms of the contract with the customers and its customary business practices. The transaction price is the amount of consideration the Company is entitled to receive in exchange for transferring promised goods or services, excluding amounts collected on behalf of third parties. The amount of consideration varies because of estimated rebates, returns and chargebacks, which are considered to be key estimates.

Any amount of variable consideration is recognised as revenue only to the extent that it is highly probable that a significant reversal will not occur. The Company estimates the amount of variable consideration using the expected value method.

Rendering of services

Revenue from services rendered is recognised in the statement of profit and loss as the underlying services are performed. Upfront non-refundable payments received under these arrangements are deferred and recognised as revenue over the expected period over which the related services are expected to be performed.

Dividend and interest income

(i) Dividend Income

Dividend income from investments is recognised when the company's right to receive payment has been established, which is generally when shareholders approve the dividend, provided that it is probable that the economic benefits will flow to the Company and the amount of income can be measured reliably.

(ii) Interest income

Interest income from a financial asset is recognised when it is probable that the economic benefits will flow to the Company and the amount of income can be measured reliably. Interest income is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition.

n) Shipping and handling costs

Shipping and handling costs incurred to transport products to customers, and internal transfer costs incurred to transport the products from the Company's factories to its various points of sale, are included in other expenses.

o) Borrowing cost

Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds. Borrowing costs that are attributable to the acquisition, construction or production of a qualifying asset are capitalised as part of the cost of such asset till such time the asset is ready for its intended use and borrowing costs are being incurred. A qualifying asset is an asset that necessarily takes a substantial period of time to get ready for its intended use. All other borrowing costs are recognised as an expense in the period in which they are incurred.

Investment income earned on the temporary investment of specific borrowings pending their expenditure on qualifying assets is deducted from the borrowing costs eligible for capitalisation.

p) Income tax

Income tax expense comprises of current tax expense and deferred tax expense/benefit. Current and deferred taxes are recognised in the Standalone statement of profit and loss, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case, the current and deferred tax are also recognised in other comprehensive income or directly in equity.

(i) Current income tax

Current tax is the amount of tax payable on the taxable income for the year as determined in accordance with the provisions of the applicable income tax law of the respective jurisdiction. The current tax is calculated using tax rates that have been enacted or substantively enacted, at the reporting date and any adjustment to tax payable in respect of previous years. Current tax assets and tax liabilities are offset where the entity has a legally enforceable right to offset and intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

(ii) Deferred tax

Deferred tax is recognised using the Balance Sheet approach on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts.

Deferred tax assets are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences and the carry forward of unused tax credits and unused tax losses can be utilised, except when the deferred tax asset relating to the deductible temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss.

The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilised.

Unrecognised deferred tax assets are re-assessed at each reporting date and are recognised to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured using substantively enacted tax rates expected to apply to taxable income in the years in which the temporary differences are expected to be recovered or settled.

The Company recognises deferred tax liability for all taxable temporary differences associated with investments in subsidiaries and associates, except to the extent that both of the following conditions are satisfied:

- When the Company is able to control the timing of the reversal of the temporary difference; and
- It is probable that the temporary difference will not reverse in the foreseeable future.

Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets and liabilities

q) Export incentives

Export incentives from government authority are recognised in the statement of profit and loss as other operating revenue when the right to receive is established as per the terms of the scheme in respect of the exports made by the Company with no future related cost and where there is no significant uncertainty regarding the ultimate collection of the relevant export proceeds.

r) Segment Reporting

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. The Chief Operating decision-maker is responsible for allocating resources and assessing the performance of the operating segments and makes strategic decisions.

s) Earnings Per Share

The Company presents basic and diluted earnings per share (“EPS”) data for its ordinary shares. The basic earnings per share is computed by dividing the net profit attributable to equity shareholders for the period by the weighted average number of equities shares outstanding during the year. The weighted average number of shares outstanding during the year is adjusted for events such as bonus issue, bonus element in a rights issue, share split, and reverse share split (consolidation of shares) that have changed the number of shares outstanding, without a corresponding change in resources.

Diluted earnings per share is computed by dividing the net profit attributable to equity shareholders for the year relating to the dilutive potential equity shares, by the weighted average number of equity shares considered for deriving basic earnings per share and the weighted average number of equity shares which could have been issued on the conversion of all dilutive potential equity shares. Potential equity shares are deemed to be dilutive only if their conversion to equity shares would decrease the net profit per share

t) Dividend

The Company recognises a liability to pay a dividend when the distribution is authorised, and the distribution is no longer at the discretion of the Company.

The final dividend on shares is recorded as a liability on the date of approval by the shareholders at the Annual General Meeting of the Company and interim dividends are recorded as a liability on the date of declaration by the Company's Board of Directors.

The Company declares and pays dividends in Indian rupees. Companies are required to pay / distribute dividend after deducting applicable taxes. The remittance of dividends outside India is governed by Indian law on foreign exchange and is also subject to withholding tax at applicable rates.

1.4 Determination of fair values

The Company's accounting policies and disclosures require the determination of fair value, for all financial and certain non-financial assets and liabilities. Fair values have been determined for measurement and/or disclosure purposes based on the following methods. When applicable, further information about the assumptions made in determining fair values is disclosed in the notes specific to that asset or liability.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either: in the principal market for the asset or liability, or in the absence of a principal market, in the most advantageous market for the asset or liability. The principal or the most advantageous market must be accessible by the Company. The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

All assets and liabilities for which fair value is measured or disclosed in the standalone financial statements are categorized within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

- Level 1 — Quoted (unadjusted) market prices in active markets for identical assets or liabilities.
- Level 2 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable.
- Level 3 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable.

For assets and liabilities that are recognized in the standalone financial statements at fair value on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by re-assessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

2. PROPERTY, PLANT & EQUIPMENT

For the year 2025-26

Particulars	Freehold Land	Buildings	Plant & Equipment	Electrical Equipment	Lab Equipment	Furniture & Fixtures	Office Equipment	Vehicles	Computers	Total
Gross Carrying Value										
Balance as at April 1, 2025	**926.67**	**957.00**	**1,895.57**	**169.55**	**286.65**	**67.78**	**20.64**	**75.09**	**30.35**	**4,429.30**
Add: Additions	207.42	46.35	84.26	15.43	51.59	4.05	3.35	10.04	2.67	425.16
Less: Disposals	-	0.10	14.32	7.55	2.16	-	-	11.36	-	35.49
Balance as at March 31, 2026	**1,134.09**	**1,003.25**	**1,965.51**	**177.43**	**336.08**	**71.83**	**23.99**	**73.77**	**33.02**	**4,818.97**
Accumulated Depreciation										
Balance as at April 1, 2025	**-**	**46.04**	**153.61**	**26.59**	**63.64**	**10.49**	**7.99**	**15.69**	**14.28**	**338.33**
Add: Depreciation for the year	-	34.05	104.09	18.09	34.05	7.14	4.34	10.14	8.57	220.47
Less: Disposals	-	0.01	0.91	1.91	0.66	-	-	4.79	-	8.28
Balance as at March 31, 2026	**-**	**80.08**	**256.79**	**42.77**	**97.03**	**17.63**	**12.33**	**21.04**	**22.85**	**550.52**
Net Carrying Value										
As at 31-03-2026	**1,134.09**	**923.17**	**1,708.72**	**134.66**	**239.05**	**54.20**	**11.66**	**52.73**	**10.17**	**4,268.45**
As at 31-03-2025	**926.67**	**910.96**	**1,741.96**	**142.96**	**223.01**	**57.29**	**12.65**	**59.40**	**16.07**	**4,090.97**

For the year 2024-25

Particulars	Freehold Land	Buildings	Plant & Equipment	Electrical Equipment	Lab Equipment	Furniture & Fixtures	Office Equipment	Vehicles	Computers	Total
Gross Carrying Value										
Balance as at April 01, 2024	**455.32**	**546.68**	**1,305.83**	**104.49**	**261.75**	**49.15**	**14.90**	**63.31**	**22.32**	**2,823.75**
Add: Additions	471.35	410.32	597.49	65.06	24.90	18.63	5.74	11.78	8.03	1,613.30
Less: Disposals	-	-	7.75	-	-	-	-	-	-	7.75
Balance as at March 31, 2025	**926.67**	**957.00**	**1,895.57**	**169.55**	**286.65**	**67.78**	**20.64**	**75.09**	**30.35**	**4,429.30**
Accumulated Depreciation										
Balance as at April 01, 2024	-	19.52	67.10	11.73	29.78	4.74	3.62	6.28	6.33	149.10
Add: Depreciation for the year	-	26.52	88.02	14.86	33.86	5.75	4.37	9.41	7.95	190.74
Less: Disposals	-	-	1.51	-	-	-	-	-	-	1.51
Balance as at March 31, 2025	**-**	**46.04**	**153.61**	**26.59**	**63.64**	**10.49**	**7.99**	**15.69**	**14.28**	**338.33**
Net Carrying Value										
As at March 31, 2025	**926.67**	**910.96**	**1,741.96**	**142.96**	**223.01**	**57.29**	**12.65**	**59.40**	**16.07**	**4,090.97**
As at March 31, 2024	**455.32**	**527.16**	**1,238.73**	**92.76**	**231.97**	**44.41**	**11.28**	**57.03**	**15.99**	**2,674.65**

i. Refer to Note 37 for information on property, plant and equipment pledged as security by the Company.

3. Capital Work-in-Progress

Particulars	**As at March 31, 2026**	**As at March 31, 2025**
Balance at the Begining of the year	246.51	448.18
Add: Additions during the year	734.73	1,422.42
Less: Capitalized during the year	217.74	1,624.09
Balance at the end of the year	**763.50**	**246.51**

Capital Work-in-Progress Ageing Schedule

As at March 31, 2026

Particulars	**Amount in CWIP for a period of**				**Total**
	Less than 1 year	**1-2 years**	**2-3 years**	**More than 3 years**	
Projects in Progress	568.87	194.63	-	-	**763.50**

As at March 31, 2025

Particulars	**Amount in CWIP for a period of**				**Total**
	Less than 1 year	**1-2 years**	**2-3 years**	**More than 3 years**	
Projects in Progress	125.48	21.58	0.53	98.92	**246.51**

There are no projects where activity has been suspended or completion is overdue or exceeded its cost compared to its original plan.

4. Right-of-Use Assets

Particulars	**Land**	**Buildings**	**Total**
Gross Carrying Value			
Balance as at March 31, 2024	**13.82**	**-**	**13.82**
Additions during the year	-	10.92	10.92
Deletions during the year	-	-	-
Balance as at March 31, 2025	**13.82**	**10.92**	**24.74**
Additions during the year	54.06	0.46	54.52
Deletions during the year	-	-	-
Balance as at March 31, 2026	**67.88**	**11.38**	**79.26**

Accumulated Depreciation	**Land**	**Buildings**	**Total**
Balance as at March 31, 2024	**0.98**	**-**	**0.98**
Depreciation charge for the year	0.49	0.36	0.85
Deletions during the year	-	-	-
Balance as at March 31, 2025	**1.47**	**0.36**	**1.83**
Depreciation charge for the year	0.75	2.28	3.03
Deletions during the year	-	-	-
Balance as at March 31, 2026	**2.22**	**2.64**	**4.86**

Net Carrying Value	**Land**	**Buildings**	**Total**
Balance as at March 31, 2025	12.35	10.56	22.91
Balance as at March 31, 2026	65.66	8.74	74.40

VIRUPAKSHA ORGANICS LIMITED
CIN: U24110TG1997PLC028281
Notes to Standalone Financial Statements
(*All amounts in ₹ millions, unless otherwise stated)*

5. Non-Current Investments

Particulars	As at March 31, 2026	As at March 31, 2025
A. Investments in Equity Instruments (Quoted) - Carried at cost		
Investment in subsidiaries		
Oxygenta Pharmaceutical Limited*	455.35	-
(2,08,96,975 Equity Shares of Face value ₹10 each)		
Total Investments in Equity Instruments (Quoted) - Carried at cost	**455.35**	**-**
B. Investments in Equity Instruments (Unquoted) - Carried at cost		
Investment in subsidiaries		
Progenerics Pharma Pvt Ltd	115.00	115.00
(68,25,000 Equity Shares of Face value ₹ 10 each, fully paid up)		
Virupaksha Green Energy Pvt Ltd	50.61	50.61
(50,60,832 Equity Shares of Face value ₹ 10 each, fully paid up)		
Total Investments in Equity Instruments (Unquoted) - Carried at cost	**165.61**	**165.61**
C. Investments in Equity Instruments (Unquoted) - Carried at cost		
Investment in associates		
Bharath Advanced Therapeutics Private Limited	40.00	40.00
(5,142 Equity Shares of Face value ₹ 10 each, fully paid up)		
Total Investments in Equity Instruments (Unquoted) - Carried at cost	**40.00**	**40.00**
D. Investments in Equity Instruments (Quoted) - Designated at fair value through other comprehensive income (FVTOCI)		
Standard Glass Lining Technology Limited	38.34	53.34
(3,62,840 Equity Shares of Face value ₹ 10 each, fully paid up)		
Total Investments in Equity Instruments (Quoted) - Designated at fair value through other comprehensive income (FVTOCI)	**38.34**	**53.34**
E. Investments in Equity Instruments (Unquoted) - Designated at fair value through other comprehensive income (FVTOCI)		
Vamsi Labs Limited	25.00	25.00
(28,853 Equity Shares of Face value ₹ 10 each, fully paid up)		
ATGC Biotech Private Limited	61.47	61.47
(6,814 Equity Shares of Face value ₹ 100 each, fully paid up)		
Acintyo Local Oriented Customer Applications Pvt Ltd	20.00	20.00
(80,000 (March 31, 2023: 40,000) Equity Shares of Face value ₹ 10 each, fully paid up)		
AACT Inc	84.10	84.10
(500 Equity Shares of Face value US $ 0.001 each, fully paid up)		
Medrhans Pharmaceuticals Pvt Ltd	25.00	25.00
(2,22,221 Equity Shares of Face value ₹ 10 each, fully paid up)		
Sagar Life Sciences Pvt Ltd	10.00	10.00
(7,536 Equity Shares of Face value ₹ 10 each, fully paid up)		
Genz Materials Private Limited	29.99	-
(1,022 Equity Shares of Face value ₹10 each, fully paid up)		
Total Investments in Equity Instruments (Unquoted) - Designated at fair value through other comprehensive income (FVTOCI)	**255.56**	**225.57**

(All amounts in ₹ millions, unless otherwise stated)

Particulars	As at March 31, 2026	As at March 31, 2025
F. Investments in Limited Liability Partnership (LLP) - (Unquoted) - Carried at cost		
Investment in Associates		
M/s. Virupaksha Lifesciences LLP (Contributed towards 48% Share)	9.60	0.96
Less: Impairment in value of investment (Refer Note 48)	(9.60)	(0.96)
Total Investments in Limited Liability Partnership (LLP) - (Unquoted) - Carried at cost	-	-
G. Investments in Mutual Funds (Unquoted) - Carried at fair value through profit or loss (FVTPL)	**86.63**	**42.88**
Aggregrate Book value of Unquoted Investments (B+D+E+F+G)	**547.80**	**474.06**
Total (A+B+C+D+E+F+G)	**1,041.49**	**527.40**
Aggregrate Book value of quoted Investments	**493.69**	**53.34**
Aggregrate Market value of quoted Investments	**1,049.34**	**53.34**

* Includes investment of ₹ 4.16 million (March 31, 2025: ₹ 0) on account of fair valuation of corporate guarantee given by the Company on behalf of Oxygenta Pharmaceutical Limited, a subsidiary Company.

6. Non-Current Loans

Particulars	As at March 31, 2026	As at March 31, 2025
Considered Good, Unsecured		
Loans to Related Party	535.00	35.00
Loans to Others	-	145.00
Total	**535.00**	**180.00**

(Refer Note No 55 for more details)

7. Other Non-Current Financial Assets

Particulars	As at March 31, 2026	As at March 31, 2025
Unsecured, Considered Good		
Security Deposits	43.34	41.34
Advances to Employees	17.94	17.62
Advance for Investment	-	215.05
Total	**61.28**	**274.01**

8. Other Non-Current Assets

Particulars	As at March 31, 2026	As at March 31, 2025
Capital Advances	173.72	131.58
Prepaid Expense	2.60	12.96
Total	**176.32**	**144.54**

9. Inventories

Particulars	As at March 31, 2026	As at March 31, 2025
Raw Materials	494.48	554.75
Work-in-Progress	562.47	691.09
Finished Goods	437.00	393.76
Coal	8.51	1.82
Stores & Spares	67.30	34.61
Packing Material	8.63	4.45
Lab Material	46.69	18.23
Total	**1,625.08**	**1,698.71**

1. Refer note 1.3 (i) for basis of valuation of inventory.
2. Inventories have been pledged as security. Refer note 37 for the details of borrowings.

10. Trade Receivables

Particulars	As at March 31, 2026	As at March 31, 2025
Trade Receivables Considered Good - Unsecured	2,587.95	1,647.11
Trade Receivables - Credit impaired	9.24	9.24
Sub-Total	**2,597.19**	**1,656.35**
Less: Expected credit loss allowance	15.85	14.35
Total	**2,581.34**	**1,642.00**

Trade Receivables Ageing Schedule
As at March 31, 2026

Particulars	Outstanding for following periods from due date of payment					
	Less than 6 months	6 months-1 year	1-2 years	2-3 years	More than 3 years	Total
(i) Undisputed Trade Receivables - Considered Good	2,434.70	76.44	31.63	33.27	11.91	**2,587.95**
(ii) Undisputed Trade Receivables - which have significant increase in credit risk	-	-	-	-	-	**-**
(iii) Undisputed Trade Receivables - credit impaired	-	-	-	-	9.24	**9.24**
(iv) Disputed Trade Receivables - Considered Good	-	-	-	-	-	**-**
(v) Disputed Trade Receivables - which have significant increase in credit risk	-	-	-	-	-	**-**
(vi) Disputed Trade Receivables - credit impaired	-	-	-	-	-	**-**
Balance as at March 31, 2026	**2,434.70**	**76.44**	**31.63**	**33.27**	**21.15**	**2,597.19**

As at March 31, 2025

Particulars	Outstanding for following periods from due date of payment					
	Less than 6 months	6 months-1 year	1-2 years	2-3 years	More than 3 years	Total
(i) Undisputed Trade Receivables - Considered Good	1,553.51	55.11	34.23	1.91	2.35	**1,647.11**
(ii) Undisputed Trade Receivables - which have significant increase in credit risk	-	-	-	-	-	**-**
(iii) Undisputed Trade Receivables - credit impaired	-	-	-	-	9.24	**9.24**
(iv) Disputed Trade Receivables - Considered Good	-	-	-	-	-	**-**
(v) Disputed Trade Receivables - which have significant increase in credit risk	-	-	-	-	-	**-**
(vi) Disputed Trade Receivables - credit impaired	-	-	-	-	-	**-**
Balance as at March 31, 2025	**1,553.51**	**55.11**	**34.23**	**1.91**	**11.59**	**1,656.35**

Movement in expected credit loss allowance

Particulars	As at March 31, 2026	As at March 31, 2025
Balance at the beginning of the year	14.35	13.86
Add: Expected credit loss allowance	1.50	0.49
Balance at the end of the year	**15.85**	**14.35**

11. Cash and Cash Equivalents

Particulars	As at March 31, 2026	As at March 31, 2025
Balances with Banks		
- In Current Account	70.99	134.60
Cash on hand	1.66	1.43
Balance in Demat Account	14.52	-
Total	**87.17**	**136.03**

12. Bank balances other than cash and cash equivalents

Particulars	As at March 31, 2026	As at March 31, 2025
Bank deposits with original maturity for more than 3 months but less than 12 months	0.65	0.65
Margin Money Deposits	20.48	46.52
Total	**21.13**	**47.17**

13. Other Current Financial Assets

Particulars	As at March 31, 2026	As at March 31, 2025
Unsecured Considered Good		
Other Advances	5.00	15.75
Interest Receivable on Deposits and Loans	28.57	-
Total	**33.57**	**15.75**

14. Other Current Assets

Particulars	As at March 31, 2026	As at March 31, 2025
Balances with government authorities	96.45	247.20
Prepaid Expenses	175.84	58.51
Advances to Suppliers	28.54	166.14
Balances with insurance companies	10.04	-
Other assets	0.81	3.70
Total	**311.68**	**475.55**

15. Equity Share Capital

Particulars	**As at March 31, 2026**	**As at March 31, 2025**
Authorised capital^ 8,50,00,000 Equity Shares of ₹ 10/- each (March 31, 2025: 4,50,00,000; Equity Shares of ₹10/- each)	850.00	450.00
	850.00	**450.00**
Issued, Subscribed and Paid up 6,15,31,937 Equity Shares of ₹10/- each (March 31, 2025: 4,10,21,287; Equity Shares of ₹10/- each)	615.32	410.22
Total	**615.32**	**410.22**

^ The authorized share capital of the Company increased from ₹ 450.00 million (comprising of 4,50,00,000 equity shares having face value of ₹10 each) to ₹850.00 million, (comprising of 8,50,00,000 equity shares having face value of ₹10 each) pursuant to resolution passed by the Board of Directors on September 13, 2025 and approved by shareholders through extra-ordinary general meeting held on September 13, 2025.

At the Extraordinary General Meeting held on July 01, 2024, the members approved, by way of a Special Resolution, the increase in the Authorised Share Capital of the Company. The Authorised Share Capital of the Company was increased from ₹ 381.50 million , (comprising of 3,81,50,000 equity shares having face value of ₹10 each) to ₹ 450.00 million comprising of 4,50,00,000 equity shares of ₹ 10 each.

(a) Reconciliation of Shares Outstanding at the Beginning and at the End of the Reporting Period

Particulars	**As at March 31, 2026**		**As at March 31, 2025**	
	No. of Shares	**Amount**	**No. of Shares**	**Amount**
Shares Outstanding at the Beginning of the Year				
-Equity Shares	4,10,21,287	410.22	3,74,47,536	374.48
-Preference Shares	-	-	-	-
	4,10,21,287	**410.22**	**3,74,47,536**	**374.48**
Issued during the Year				
-Equity Shares				
Issued during the Year	-	-	35,73,751	35.74
On account of Bonus Issue*	2,05,10,650	205.10	-	-
Shares Outstanding at the End of the Year	**6,15,31,937**	**615.32**	**4,10,21,287**	**410.22**

*** Aggregate number of bonus shares issued, shares issued for consideration other than cash during the period of five years immediately preceding the reporting date**

- The Board of Directors, at its meeting held on September 13, 2025, approved and recommended the issuance of fully paid bonus shares in the ratio of 1:2 (one bonus share for every two existing shares).
Pursuant to the approval given by the shareholders in the Extraordinary General Meeting held on September 13, 2025, the Company has allotted 2,05,10,650 fully paid-up equity shares of face value ₹10 each as bonus shares.

- The Board of Directors, at its meeting held on March 23, 2024, approved and recommended the issuance of fully paid bonus shares in the ratio of 2:1 (two bonus shares for every one existing share) out of its free reserves created out of profits.
Pursuant to the approval given by the shareholders in the Extraordinary General Meeting held on March 28, 2024, the Company has allotted 2,49,65,024 fully paid-up equity shares of face value ₹10/- each as bonus shares. The bonus shares were issued by capitalizing Free Reserves of the Company.

- The Bonus shares, once allotted, shall rank pari passu in all respects and carry the same rights as the existing equity shares. They shall be entitled to participate in full in any dividend and other corporate actions recommended and declared after the new equity shares are allotted.

- Pursuant to the approval given by the shareholders in the Extraordinary General Meeting held on July 01, 2024, the Company has allotted 18,80,164 equity shares and 16,93,587 equity shares of ₹ 10 each and a premium of ₹ 290 each as a Preferential allotment and Private Placement on July 18, 2024 and August 14, 2024, to the provision of section 42 and section 62 and other applicable provisions, if any of the Companies Act, 2013.

(b) Rights, Preference and Restrictions attached to Shares

The Company has only one class of Equity Shares having a par value of ₹10 per share. Each holder of Equity Share is entitled to one vote per share. The dividend, if any, proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting, except in case of interim dividend. In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

(c) Details of Shareholders holding more than 5% of Equity Shares in the Company

Name of the Share holder	As at March 31, 2026		As at March 31, 2025	
	No. of Shares held	% of total shares	No. of Shares held	% of total shares
Equity Shares				
G. Vedavathi	1,06,12,161	17.25%	70,74,774	17.25%
G. Sri Lakshmi	61,39,121	9.98%	40,92,747	9.98%
G. Sri Vidya	58,36,725	9.49%	38,91,150	9.49%
G. Chandra Mouliswar Reddy	56,24,645	9.14%	37,49,763	9.14%

(d) Details of shares held by the promoters in the Company and change during the year:

Name of Promoter	As at March 31, 2026			As at March 31, 2025		
	No. of Shares held	% of Total Shares	% Change during the year	No. of Shares held	% of Total Shares	% Change during the year
G. Vedavathi	1,06,12,161	17.25%	50.00%	70,74,774	17.25%	0.00%
G. Sri Lakshmi	61,39,121	9.98%	50.00%	40,92,747	9.98%	0.00%
G. Sri Vidya	58,36,725	9.49%	50.00%	38,91,150	9.49%	0.00%
G. Chandra Mouliswar Reddy	56,24,645	9.14%	50.00%	37,49,763	9.14%	0.00%
Balasubba Reddy Mamilla	14,97,191	2.43%	50.00%	9,98,127	2.43%	0.00%
Chandrasekhar Reddy Gangavaram	4,68,297	0.76%	50.00%	3,12,198	0.76%	0.00%
Nagarjun Reddy Mamilla	3,42,930	0.56%	50.00%	2,28,620	0.56%	19.93%
Kotla Suraj Reddy	1,062	0.00%	50.00%	708	0.00%	0.00%

16. Other Equity *

Particulars	As at March 31, 2026	As at March 31, 2025
Capital Reserve	2.33	2.33
Capital Redemption Reserve	-	60.87
Securities Premium	897.26	1,041.49
Retained Earnings	3,953.51	3,058.22
Other Comprehensive Income	(17.63)	(2.11)
Total	**4,835.47**	**4,160.80**

* For movement in other equity, refer "Statement of Changes in Equity"

Nature of Reserve

a. Capital Reserve

Capital reserve is created on account of merger of TPS Laboratories Private Limited, being excess of assets acquired over the consideration paid.

b. Capital Redemption Reserve

Capital Redemption Reserve (CRR) is a statutory reserve created when the company has redeemed its preference shares.

c. Securities Premium

Amounts received on issue of shares in excess of the par value has been classified as securities premium. The utilisation of securities premium is governed by the Section 52 of the Companies Act, 2013.

d. Retained Earnings

Retained earnings comprises of undistributed earnings after taxes.

e. Other Comprehensive Income

Other comprehensive income consist of re-measurement of net defined benefit liability and changes in the fair value of financial instruments

17. Non-Current Borrowings

Particulars	As at March 31, 2026	As at March 31, 2025
A. Secured		
- Term Loan from Banks	1,256.83	373.30
- Term Loan from Financial Institutions	677.82	607.11
Less: Current Maturities of Long Term Loans*	(564.69)	(274.02)
B. Unsecured		
- Loan from Related Parties	157.52	437.08
Total	**1,527.48**	**1,143.47**

* Current maturities of non-current borrowings have been disclosed under the head "Current Borrowings"

Refer Note 37 for terms and security details

18. Lease Liabilities

Particulars	As at March 31, 2026	As at March 31, 2025
Non Current Lease Liabilities	63.34	18.30
Current Lease Liabilities	9.40	3.74

Refer Note 36 for details of leases

19. Other Non-Current Financial Liabilities

Particulars	As at March 31, 2026	As at March 31, 2025
Guarantee obligation	2.48	-
Total	**2.48**	**-**

20. Non-Current Provisions

Particulars	As at March 31, 2026	As at March 31, 2025
Provision for Employee Benefits		
- Gratuity	62.51	53.67
- Compensated absences (Leave Encashment)	24.96	43.93
Total	**87.47**	**97.60**

Refer Note 39 for details of gratuity & compensated absences

21. Deferred Tax Liability (Net)

Particulars	As at March 31, 2026	As at March 31, 2025
Opening Balance	153.80	121.80
Add: Deferred Tax Liability during the year	29.27	32.00
Closing balance	**183.07**	**153.80**

Refer Note 45(e) for movement in deferred tax liability

22. Current Borrowings

Particulars	As at March 31, 2026	As at March 31, 2025
A. Secured		
Working Capital Loans - From Bank*	1,045.36	1,148.84
Working Capital Loans - From Financial Institutions*	-	-
Current Maturities of Long-Term Borrowings**	564.69	274.02
B. Unsecured		
Bills Discounting	330.50	245.83
Total	**1,940.55**	**1,668.69**

*The working capital loans are secured by way of hypothecation of the company's goods, book debts, movables and other assets. Interest rate ranges between 9.00% to 10.5% p.a.

**Refer Note 37 for terms and security details

23. Trade Payables

Particulars	As at March 31, 2026	As at March 31, 2025
Total outstanding dues of micro and small enterprises (MSME)	705.27	401.78
Total outstanding dues of creditors other than micro and small enterprises	1,008.21	825.63
Total	**1,713.48**	**1,227.41**

Trade Payables Ageing Schedule
As at March 31, 2026

Particulars	Outstanding for following periods from due date of payment				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) MSME	705.27	-	-	-	705.27
(ii) Others	1,003.13	4.28	0.80	-	1,008.21
(iii) Disputed dues - MSME	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-
Balance as at March 31, 2026	**1,708.40**	**4.28**	**0.80**	**-**	**1,713.48**

As at March 31, 2025

Particulars	Outstanding for following periods from due date of payment				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) MSME	401.78	-	-	-	401.78
(ii) Others	818.53	6.58	0.28	0.24	825.63
(iii) Disputed dues - MSME	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-
Balance as at March 31, 2025	**1,220.31**	**6.58**	**0.28**	**0.24**	**1,227.41**

VIRUPAKSHA ORGANICS LIMITED
CIN: U24110TG1997PLC028281
Notes to Standalone Financial Statements
(*All amounts in ₹ millions, unless otherwise stated)*

24. Other Current Financial Liabilities

Particulars	As at March 31, 2026	As at March 31, 2025
Creditors for Capital Items	249.39	403.99
Expenses Payable	196.14	116.54
Guarantee obligation	1.02	-
Total	**446.55**	**520.53**

25. Current Provisions

Particulars	As at March 31, 2026	As at March 31, 2025
Provision for Employee Benefits		
- Gratuity	14.63	12.69
- Compensated absences	2.40	4.24
- Bonus	35.00	38.49
Total	**52.03**	**55.42**

26. Current Tax Liabilities (Net)

Particulars	As at March 31, 2026	As at March 31, 2025
Income Tax in respect of current year income	61.20	20.54
Total	**61.20**	**20.54**

27. Other Current Liabilities

Particulars	As at March 31, 2026	As at March 31, 2025
Advance from Customers	29.22	4.36
Statutory Payables	13.35	16.67
Total	**42.57**	**21.03**

28. Revenue from Operations

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Revenue from		
Sale of Products (Refer note 40)	9,218.68	8,082.91
Sale of Service (Refer note 40)	4.95	0.44
Other operating revenue		
Export Incentives	32.23	30.60
Total	**9,255.86**	**8,113.95**

29. Other Income

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Bad Debts Recovered	14.90	-
Net Gain on Foreign exchange transaction and translation	58.42	19.49
Income from Mutual Funds	0.22	6.58
Interest Income	28.00	18.68
Liabilities no longer required written back	0.01	-
Interest income on financial assets carried at amortised cost	0.35	2.37
Profit on sale of assets	-	0.69
Fair value gain on Investments	-	0.72
Unwinding of guarantee obligation	0.65	-
Rental Income	1.60	-
Miscellaneous Income	3.34	2.32
Total	**107.49**	**50.85**

30. Cost of Materials Consumed

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Raw-material at the beginning of the year	554.75	438.42
Add : Raw-material Purchases	5,117.46	4,991.99
Less : Raw-material at the end of the year	494.48	554.75
Total	**5,177.73**	**4,875.66**

31. Changes in Inventories of Finished Goods and Work-in-Progress

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Inventories at the begining of the year		
Finished Goods	393.76	226.55
Work-in-progress	691.09	406.54
	1,084.85	**633.09**
Inventories at the end of the year		
Finished Goods	437.00	393.76
Work-in-progress	562.47	691.09
	999.47	**1,084.85**
Total	**85.38**	**(451.76)**

32. Employee Benefits Expense

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Salaries & Wages	472.85	473.28
Contract Labour salaries & wages	245.80	227.72
Bonus	41.55	41.12
Staff Welfare Expenses	35.35	30.98
Directors Remuneration	48.92	48.60
Contribution to provident and other funds	15.70	54.70
Total	**860.17**	**876.40**

33. Finance Costs

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Interest on Working Capital Loans	93.40	69.63
Interest on Term Loans	122.16	95.34
Interest on Unsecured Loans	24.06	28.11
Letter of Credit Charges	13.32	13.63
Other Finance Charges	21.13	3.22
Amortised cost on Financial Assets	0.34	0.31
Interest on Lease liabilities	2.34	1.27
Total	**276.75**	**211.51**

(*All amounts in ₹ millions, unless otherwise stated)*

34. Other Expenses

Particulars	**For the year ended March 31, 2026**	**For the year ended March 31, 2025**
Power & Fuel	370.02	344.18
Conversion Charges	22.75	29.87
Stores & Consumables	188.04	179.65
Carriage Inwards & Outwards	118.64	96.87
Travelling & Conveyance	72.40	70.38
Printing & Stationery	12.73	8.73
Postage & Telephone Charges	3.54	3.27
Rates & Taxes	38.00	33.64
Research & Development expenses	105.67	81.06
Security Charges	20.77	20.19
Auditors Remuneration		
i) Statutory Audit	1.30	1.30
ii) Tax Audit	0.50	0.50
Effluent Treatment Charges	104.78	60.97
Factory Expenses	10.59	19.81
Office Maintenance	1.87	1.55
Professional & Legal Charges	77.24	49.31
Sales Commission	114.55	128.68
Insurance Charges	99.96	89.13
Membership & Subscriptions	0.26	0.30
Corporate Social Responsibility Expenses	18.33	12.42
Repairs & Maintenance		
- Building	30.10	46.95
- Plant & Machinery	39.47	33.87
- Vehicles	2.46	3.63
- Others	29.33	32.49
Testing Charges	6.61	5.00
Bank Charges	3.93	2.84
Business Promotion Expenses	35.54	29.50
Bad Debts Written Off	-	32.70
Expected credit loss allowance	1.50	1.26
Interest on GST	0.01	0.04
Donation	0.25	0.21
Rental Expense	0.38	0.60
Loss on Sale of Asset	3.17	-
Fair value loss on Investments	1.67	-
Miscellaneous expenses	2.95	-
Total	**1,539.31**	**1,420.90**

35. Earnings Per Share

Particulars	**For the year ended March 31, 2026**	**For the year ended March 31, 2025**
(A) Profit after tax attributable to equity shareholders of the company (in ₹ millions)	895.29	791.34
(B) (i) Weighted average number of equity shares before Bonus (refer note (a) below)	6,15,31,937	3,98,38,569
(B) (ii) Bonus shares adjustment (refer note (b) below)	-	1,99,19,285
(B) (iii) Weighted average number of equity shares outstanding used as the denominator in calculating EPS (i + ii)	6,15,31,937	5,97,57,854
Nominal value of equity shares (in ₹)	10	10
Earnings per share: ((A)/(B)(iii))		
Basic Earning Per Share (in ₹)	14.55	13.24
Diluted Earning Per Share (in ₹)	14.55	13.24

Notes:

(a) Weighted Average Number of Equity Shares:

i) For FY 2024-25, the weighted average number of equity shares includes 18,80,164 equity shares and 16,93,587 equity shares issued by way of Preferential Allotment (July 18, 2024) and Private Placement (August 14, 2025), respectively. [Refer Note 15(a)].

(b) Bonus Issues and Restatement of EPS:

i) Pursuant to the resolutions passed by the Board of Directors and Shareholders on September 13, 2025, the Company issued 2,05,10,650 fully paid equity shares as bonus shares in the ratio of 1:2 (one share for every two shares held).

ii) In accordance with Ind AS 33 – Earnings Per Share, the EPS for FY 2024-25 has been restated as if these bonus shares had been issued at the beginning of the earliest period presented. Comparative EPS figures for prior period have been retrospectively adjusted to ensure consistency and comparability.

36. Leases

The following is the movement in lease liabilities:

Particulars	**As at March 31, 2026**	**As at March 31, 2025**
Opening balance	22.04	11.47
Additions	52.01	10.92
Finance cost	2.34	1.27
Payment of lease liabilities	(3.65)	(1.62)
Closing Balance	**72.74**	**22.04**

The following is the break-up of current and non-current lease liabilities:

Particulars	**As at March 31, 2026**	**As at March 31, 2025**
Non-Current Lease Liability	63.34	18.30
Current Lease liability	9.40	3.74

Amounts recognised in standalone Cash Flow Statement:

Particulars	**For the year ended March 31, 2026**	**For the year ended March 31, 2025**
Payment of lease liabilities	3.65	1.62
Interest Component	2.34	1.27
Principle Component	1.31	0.35

Amounts recognised in standalone statement of Profit and loss:

Particulars	**For the year ended March 31, 2026**	**For the year ended March 31, 2025**
Interest Expense on lease liability	2.34	1.27
Expense relating to short term and low value leases	0.38	0.60

Contractual maturities of lease liabilities

The table below provides the details of contractual maturities of lease liabilities on undiscounted basis

Particulars	**As at March 31, 2026**	**As at March 31, 2025**
Within 1 year	9.40	3.74
1-2 years	10.27	3.86
2-5 years	29.44	11.90
More than 5 years	85.38	24.40
Total	**134.49**	**43.90**
Less: Financial component	61.75	21.86
Total	**72.74**	**22.04**

Weighted average incremental borrowing rate applied to lease liabilities recognised in the standalone Statement of Asstes And Liabilities are as follows:

Particulars	**As at March 31, 2026**	**As at March 31, 2025**
Weighted average incremental borrowing rate (p.a.)	9% to 10%	9% to 10%

The Company does not face a significant liquidity risk with regard to its lease liabilities as the current assets are sufficient to meet the obligations related to lease liabilities as and when they fall due.

VIRUPAKSHA ORGANICS LIMITED
CIN: U24110TG1997PLC028281
Notes to Standalone Financial Statements
(*All amounts in ₹ millions, unless otherwise stated)*

37. Terms and conditions of loans and Nature of security

As at March 31, 2026

Particulars	**No of Installments due**	**Rate of Interest**	**Within 1Year ***	**1 to 2 Years**	**2 to 5 Years**	**Above 5 Years**	**Loan outstanding**
Axis Bank Limited (Refer Note 4 below)	9 Monthly Installments	9.50% p.a. to 10.50% p.a.	22.49	0.08	-	-	22.57
ICICI Bank Limited (Refer Note 5 below)	21 Monthly Installments	7.90% p.a. to 9.60% p.a.	35.65	27.01	-	-	62.66
Bajaj Finance Limited (Refer Note 7 below)	23 Monthly Installments	9.45% p.a.	44.24	46.42	-	-	90.66
State Bank of India (Refer Note 8 below)	12 Monthly Installments	9.90% p.a. to 10.40% p.a.	25.74	-	-	-	25.74
State Bank of India (Refer Note 9 below)	14 Monthly Installments	9.90% p.a. to 10.40% p.a.	16.03	1.53	-	-	17.56
State Bank of India (Refer Note 10 below)	38 Monthly Installments	9.70% p.a. to 10.10% p.a.	17.63	19.40	24.26	-	61.29
Bajaj Finance Limited (Refer Note 11 below)	23 Monthly Installments	9.45% p.a.	11.45	11.97	-	-	23.42
Bajaj Finance Limited (Refer Note 12 below)	37 Monthly Installments	9.30% p.a. to 9.60% p.a.	30.00	30.00	32.10	-	92.10
Bajaj Finance Limited (Refer Note 13 below)	55 Monthly Installments	8.90% p.a. to 9.30% p.a.	64.00	64.00	165.03	-	293.03
ICICI Bank Limited (Refer Note 15 below)	25 Monthly Installments	8.50% p.a. to 10.00% p.a.	66.67	66.67	4.64	-	137.98
Kotak Mahindra Bank (Refer Note 16 below)	50 Monthly Installments	10.10% p.a. to 10.20% p.a.	40.00	40.00	86.72	-	166.72
ICICI Bank Limited (Refer Note 17 below)	48 Monthly Installments	8.20% p.a. to 9.60% p.a.	22.92	25.00	53.08	-	101.00
ICICI Bank Limited (Refer Note 17 below)	48 Monthly Installments	8.50% p.a. to 9.90% p.a.	57.29	62.50	129.81	-	249.60
ICICI Bank Limited (Refer Note 17 below)	48 Monthly Installments	8.10% p.a. to 9.50% p.a.	34.38	37.50	80.58	-	152.46
Axis Bank Limited (Refer Note 18 below)	70 Monthly Installments	9.00% p.a. to 9.50% p.a.	30.00	60.00	150.55	-	240.55
Bajaj Finance Limited (Refer Note 19 below)	63 Monthly Installments	9.00% p.a. to 11.00% p.a.	34.33	34.33	103.00	6.94	178.60
Vehicle loans from various banks /financial institutions (Refer Note 14 below)	9 to 32 Monthly Installments	7.90% p.a. to 11.30% p.a.	11.87	4.98	1.86	-	18.71
Loan from Related Parties	Repayable after 5 years from the date of receipt	9.00% p.a. to 12.00% p.a.	-	-	157.52	-	157.52
Total			**564.69**	**531.39**	**989.15**	**6.94**	**2,092.17**

* Current maturities of long term borrowings were reclasified to current borrowing in financial statements

VIRUPAKSHA ORGANICS LIMITED
CIN: U24110TG1997PLC028281
Notes to Standalone Financial Statements
(*All amounts in ₹ millions, unless otherwise stated)*

As at March 31, 2025

Particulars	No of Installments due	Rate of Interest	Within 1Year *	1 to 2 Years	2 to 5 Years	Above 5 Years	Loan outstanding
Axis Bank Limited (Refer Note 1 below)	9 Monthly Installments	8.80% p.a. to 9.40% p.a.	5.01	-	-	-	5.01
Axis Bank Limited (Refer Note 2 below)	9 Monthly Installments	9.00% p.a. to 9.20% p.a.	4.41	-	-	-	4.41
Axis Bank Limited (Refer Note 3 below)	3 Monthly Installments	10.30% p.a. to 10.70% p.a.	11.97	-	-	-	11.97
Axis Bank Limited (Refer Note 4 below)	21 Monthly Installments	9.20% p.a. to 11.00% p.a.	32.00	22.90	-	-	54.90
ICICI Bank Limited (Refer Note 5 below)	33 Monthly Installments	8.60% p.a. to 9.60% p.a.	35.65	35.65	27.26	-	98.56
State Bank of India (Refer Note 6 below)	8 Monthly Installments	9.00% p.a. to 9.80% p.a.	12.80	-	-	-	12.80
Bajaj Finance Limited (Refer Note 7 below)	35 Monthly Installments	8.40% p.a. to 9.50% p.a.	40.27	44.25	46.25	0.36	131.13
State Bank of India (Refer Note 8 below)	24 Monthly Installments	9.60% p.a. to 10.60% p.a.	25.16	27.11	-	-	52.27
State Bank of India (Refer Note 9 below)	27 Monthly Installments	9.60% p.a. to 10.70% p.a.	14.26	15.76	4.46	-	34.48
State Bank of India (Refer Note 10 below)	50 Monthly Installments	9.60% p.a. to 9.80% p.a.	15.90	17.54	44.54	-	77.98
Bajaj Finance Limited (Refer Note 11 below)	35 Monthly Installments	8.90% p.a. to 9.50% p.a.	10.43	11.46	11.96	-	33.85
Bajaj Finance Limited (Refer Note 12 below)	49 Monthly Installments	9.20% p.a. to 10.00% p.a.	29.95	30.00	63.11	-	123.06
Bajaj Finance Limited (Refer Note 13 below)	67 Monthly Installments	9.25% p.a	26.67	64.00	192.00	36.41	319.08
Vehicle loans from various banks /financial institutions (Refer Note 14 below)	9 to 46 Monthly Installments	8.80% p.a. to 10.40% p.a.	9.54	6.48	4.89	-	20.91
Loan from Related Parties	Repayable after 5 years from the date of receipt	9.00% p.a. to 12.00% p.a.	-	-	437.08	-	437.08
Total			**274.02**	**275.15**	**831.55**	**36.77**	**1,417.49**

* Current maturities of long term borrowings were reclasified to current borrowing in financial statements

Notes:

1) Term Loan facility under the Guaranteed Emergency Credit Line (GECL) from Axis Bank Limited is secured by way of a second pari passu charge over the Movable Fixed Assets created out of the term loans, the immovable properties comprising industrial lands and sheds situated in Telangana and Karnataka registered in the name of Virupaksha Organics Ltd., and the entire current assets and unencumbered movable fixed assets of the Company, both present and future. The facility is further backed by the personal guarantees of Mr. G. Chandra Moulishwar Reddy, Managing Director, Mr. Balasubba Reddy, Executive Director and Mrs. G. Vedavathi, Director of the company.

2) Term Loan facility under the Guaranteed Emergency Credit Line (GECL) from Axis Bank Limited is secured by way of a second pari passu charge over the Movable Fixed Assets created out of the term loans, the immovable properties comprising industrial lands and sheds situated in Telangana and Karnataka registered in the name of Virupaksha Organics Ltd., and the entire current assets and unencumbered movable fixed assets of the Company, both present and future. The facility is further backed by the personal guarantees of Mr. G. Chandra Moulishwar Reddy, Managing Director, Mr. Balasubba Reddy, Executive Director and Mrs. G. Vedavathi, Director of the company.

3) Term Loan facility from Axis Bank Limited is secured by way of an exclusive charge on the movable fixed assets created out of the term loan. Further, a first charge is created over immovable assets comprising industrial lands and sheds situated in Telangana and Karnataka, registered in the name of Virupaksha Organics Ltd. A second charge is also created over the entire current assets and unencumbered movable fixed assets of the Company, both present and future. The facility is additionally secured by the personal guarantees of Mr. G. Chandra Moulishwar Reddy, Managing Director, Mr. Balasubba Reddy, Executive Director and Mrs. G. Vedavathi, Director of the company.

4) Term Loan facility from Axis Bank Limited is secured by way of an exclusive charge on the movable fixed assets created out of the term loan. Further, a first charge is created over immovable assets comprising industrial lands and sheds situated in Telangana and Karnataka, registered in the name of Virupaksha Organics Ltd. A second charge is also created over the entire current assets and unencumbered movable fixed assets of the Company, both present and future. The facility is additionally secured by the personal guarantees of Mr. G. Chandra Moulishwar Reddy, Managing Director, Mr. Balasubba Reddy, Executive Director and Mrs. G. Vedavathi, Director of the company.

5) Term Loan facility under the Emergency Credit Line Guarantee Scheme (ECLGS) from ICICI Bank Limited is secured by way of a second charge over the immovable assets comprising various industrial lands and sheds situated in Telangana and Karnataka, registered in the name of Virupaksha Organics Ltd. The security also extends to a second charge on the entire current assets and unencumbered movable fixed assets of the Company, both present and future. The facility is further secured by the personal guarantees of Mr. G. Chandra Moulishwar Reddy, Managing Director, Mr. Balasubba Reddy, Executive Director and Mrs. G. Vedavathi, Director of the company.

6) Working Capital Term Loan facility under Guaranteed Emergency Credit Line (GECL) is secured by hypothecation and first charge on the company's property, plant and equipment including machinery, forming the primary security. Additionally, a pari passu first charge is created over various industrial lands and sheds situated in Telangana and Karnataka, registered in the name of Virupaksha Organics Ltd., which serve as collateral security for all credit facilities extended by State Bank of India. The loan is further backed by the personal guarantees of Mr. G. Chandra Moulishwar Reddy, Managing Director, Mr. Balasubba Reddy, Executive Director and Mrs. G. Vedavathi, Director of the company.

7) Term Loan facility from Bajaj Finance Limited is secured by way of pari passu first charge on the present and future Property, Plant, and Equipment. A second pari passu charge has been created on the present and future current assets of the company. Additionally, the loan is secured by the personal guarantees of Mr. G. Chandra Moulishwar Reddy (Managing Director), Mr. Balasubba Reddy, Executive Director and Mrs. G. Vedavathi, Director of the company.

8) Term Loan facility is secured by hypothecation and first charge on the company's property, plant and equipment including machinery, forming the primary security. Additionally, a pari passu first charge is created over various industrial lands and sheds situated in Telangana and Karnataka, registered in the name of Virupaksha Organics Ltd., which serve as collateral security for all credit facilities extended by State Bank of India and other consortium lenders. The loan is further backed by the personal guarantees of Mr. G. Chandra Moulishwar Reddy, Managing Director, Mr. Balasubba Reddy, Executive Director and Mrs. G. Vedavathi, Director of the company.

9) Term Loan facility is secured by hypothecation and first charge on the company's property, plant and equipment including machinery, forming the primary security. Additionally, a pari passu first charge is created over various industrial lands and sheds situated in Medak and Rangareddy districts, Telangana, registered in the name of Virupaksha Organics Ltd., which serve as collateral security for all credit facilities extended by State Bank of India and other consortium lenders. The loan is further backed by the personal guarantees of Mr. G. Chandra Moulishwar Reddy, Managing Director, Mr. Balasubba Reddy, Executive Director and Mrs. G. Vedavathi, Director of the company.

10) Term Loan facility is secured by hypothecation and first charge on the company's property, plant and equipment including machinery, forming the primary security. Additionally, a pari passu first charge is created over various industrial lands and sheds situated in Medak and Rangareddy districts, Telangana, registered in the name of Virupaksha Organics Ltd., which serve as collateral security for all credit facilities extended by State Bank of India and other consortium lenders. The loan is further backed by the personal guarantees of Mr. G. Chandra Moulishwar Reddy, Managing Director, Mr. Balasubba Reddy, Executive Director and Mrs. G. Vedavathi, Director of the company.

11) Term Loan facility from Bajaj Finance Limited is secured by way of pari passu first charge on the present and future Property, Plant, and Equipment. A second pari passu charge has been created on the present and future current assets of the company. Additionally, the loan is secured by the personal guarantees of Mr. G. Chandra Moulishwar Reddy (Managing Director), Mr. Balasubba Reddy, Executive Director and Mrs. G. Vedavathi, Director of the company.

12) Term Loan facility from Bajaj Finance Limited is secured by way of pari passu first charge on the present and future Property, Plant, and Equipment. A second pari passu charge has been created on the present and future current assets of the company. Additionally, the loan is secured by the personal guarantees of Mr. G. Chandra Moulishwar Reddy (Managing Director), Mr. Balasubba Reddy, Executive Director and Mrs. G. Vedavathi, Director of the company.

13) Term Loan facility from Bajaj Finance Limited is secured by way of First Pari Passu Charge on present and Property, Plant, and Equipment. Second Pari Passu Charge on present and Future Current Assets of the company. Additionally, the loan is secured by the personal guarantees of Mr. G. Chandra Moulishwar Reddy (Managing Director), Mr. Balasubba Reddy, Executive Director and Mrs. G. Vedavathi, Director of the company.

14) Vehicle Loans from various banks/financial institutions are secured by the hypothecation of specific assets purchased from those loans.

15) Term Loan facility from ICICI Bank Limitd is secured by way of First Pari Passu Charge on present and Property, Plant, and Equipment. Second Pari Passu Charge on present and Future Current Assets of the company. Additionally, the loan is secured by the personal guarantees of Mr. G. Chandra Moulishwar Reddy (Managing Director), Mr. Balasubba Reddy, Executive Director and Mrs. G. Vedavathi, Director of the company.

16) Term Loan facility from Kotak Mahindra Bank Limitd is secured by way of First Pari Passu Charge on present and Property, Plant, and Equipment. Second Pari Passu Charge on present and Future Current Assets of the company. Additionally, the loan is secured by the personal guarantees of Mr. G. Chandra Moulishwar Reddy (Managing Director), Mr. Balasubba Reddy, Executive Director and Mrs. G. Vedavathi, Director of the company.

17) Term Loan facility from ICICI Bank Limitd is secured by way of First Pari Passu Charge on present and Property, Plant, and Equipment. Second Pari Passu Charge on present and Future Current Assets of the company. Additionally, the loan is secured by the personal guarantees of Mr. G. Chandra Moulishwar Reddy (Managing Director), Mr. Balasubba Reddy, Executive Director and Mrs. G. Vedavathi, Director of the company.

18) Term Loan facility from Axis Bank Limitd is secured by way of First Pari Passu Charge on present and Future Current Assets of the company. Second Pari Passu Charge on present and Property, Plant, and Equipment. Additionally, the loan is secured by the personal guarantees of Mr. G. Chandra Moulishwar Reddy (Managing Director), Mr. Balasubba Reddy, Executive Director and Mrs. G. Vedavathi, Director of the company.

19) Term Loan facility from Bajaj Finance Limitd is secured by way of First Pari Passu Charge on present and Property, Plant, and Equipment. Second Pari Passu Charge on present and Future Current Assets of the company. Additionally, the loan is secured by the personal guarantees of Mr. G. Chandra Moulishwar Reddy (Managing Director), Mr. Balasubba Reddy, Executive Director and Mrs. G. Vedavathi, Director of the company.

38. Disclosures required under Section 22 of the Micro, Small and Medium Enterprises Development Act, 2006.

Dues to Micro, Small and Medium Enterprises have been determined to the extent such parties have been identified on the basis of information collected by the Management. The amount of dues payable to micro, small and medium enterprises are as follows:

Particulars	As at March 31, 2026	As at March 31, 2025
(a) the principal amount and the interest due thereon remaining unpaid to any supplier at the end of each accounting period/year;	705.27	401.78
(b) the amount of interest paid by the buyer in terms of Section 16 of the MSMED Act, along with the amount of the payment made to the supplier beyond the appointed day during each accounting period/year;	-	-
(c) the amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under this MSMED Act;	-	-
(d) the amount of interest accrued and remaining unpaid at the end of the each accounting period/year; and	-	-
(e) the amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprise, for the purpose of disallowance of a deductible expenditure under Section 23 of the MSMED Act	-	-

39. Employee Benefits:

The employee benefit schemes are as follows:

i) Defined contribution plan:

The Company makes certain defined contribution plans for qualifying employees. Under the scheme, the Company is required to contribute a specified percentage of the payroll costs to fund the benefits. These contributions are made to the Fund administered and managed by the Government of India. The Company's monthly contributions are charged to the Standalone Statement of Profit and Loss in the period they are incurred.

Defined contribution plans: The Company has recognised the following amount in the Standalone Statement of Profit and Loss for the year

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
i) Contribution to employees provident fund	20.09	19.03
ii) Contribution to employees state insurance	1.26	1.59
Total	21.35	20.62

ii) Defined Benefit plan:

Gratuity Benefits Provided by the company

In accordance with applicable Indian laws, the Company has a defined benefit plan which provides for gratuity payments (the "Gratuity Plan") and covers certain categories of employees in India. The Gratuity Plan provides a lump sum gratuity payment to eligible employees at retirement or termination of their employment. The amount of the payment is based on the respective employee's last drawn salary and the years of employment with the Company. Liabilities in respect of the Gratuity Plan are determined by an actuarial valuation, based upon which the Company makes contributions to the Gratuity Fund (LIC).

The following table sets out the funded status of the gratuity plan and the amounts recognised in the Company's financial statements as per actuarial valuation as at March 31, 2026 and March 31, 2025:

a) The components of gratuity cost recognised in the standalone statement of Profit and Loss and other comprehensive income for the years ended March 31, 2026 and March 31, 2025 consist of the following:

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Amount recognised in statement of profit and loss in respect of defined benefit plan is as follows:		
Current service cost	15.22	11.01
Past service cost	(6.83)	
Interest cost	5.14	4.87
Expected return on plan assets/ Interest Income	(1.12)	(1.11)
Defined benefit cost included in profit and loss	**12.41**	**14.77**

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Re-measurement effects recognised in Other Comprehensive Income (OCI):		
Actuarial (gains) or losses arising from changes in demographic assumptions	-	-
Actuarial (gains) or losses arising from changes in financial assumptions	(2.95)	3.36
Actuarial (gains) or losses arising from changes in experience assumptions	5.82	(6.48)
Return on plan assets (excluding interest income)	(0.03)	0.03
Defined benefit costs recognised in OCI	**2.83**	**(3.09)**

b) Details of the employee benefits obligations and plan assets are provided below:

Particulars	As at March 31, 2026	As at March 31, 2025
Amount recognised in Statement of Asstes And Liabilities		
Present value of funded defined benefit obligations	93.62	81.70
Fair value of plan assets	(16.48)	(15.33)
Net liability arising from defined benefit obligation	**77.14**	**66.37**

c) Reconciliation of opening and closing balances of the present value of the defined benefit obligations:

Particulars	As at March 31, 2026	As at March 31, 2025
Defined benefit obligation at the beginning of the year	81.70	72.04
Transfer in/(out) obligation	-	-
Current service cost	15.22	11.01
Past service cost	(6.83)	
Interest cost	5.14	4.87
Remeasurements due to:		
Actuarial (gains) or losses arising from changes in demographic assumptions	-	-
Actuarial (gains) or losses arising from changes in financial assumptions	(2.95)	3.36
Actuarial (gains) or losses arising from changes in experience assumptions	5.81	(6.48)
Benefits paid by company	(4.47)	(3.10)
Defined benefit obligation at the year end	**93.62**	**81.70**

d) Details of changes in the fair value of plan assets are as follows:

Particulars	As at March 31, 2026	As at March 31, 2025
Opening fair value of the plan assets	15.33	14.26
Expected return/ Interest Income	1.12	1.10
Re-measurement – Return on Assets (excluding interest income)	0.03	(0.03)
Contributions by Employer	-	-
Fair value of plan asset at the year end	**16.48**	**15.33**

e) Sensitivity Analysis:

Particulars	For the year ended March 31, 2026	
Defined benefit obligation	**Increase**	**Decrease**
Effect of 0.5% change in assumed discount rate	89.63	97.92
Effect of 0.5% change in assumed salary growth rate	95.95	91.30
Effect of 10% change in assumed attrition rate	93.19	94.05

Particulars	For the year ended March 31, 2025	
Defined benefit obligation	**Increase**	**Decrease**
Effect of 0.5% change in assumed discount rate	78.34	85.31
Effect of 0.5% change in assumed salary growth rate	83.60	79.79
Effect of 10% change in assumed attrition rate	81.31	82.09

f) The principal assumptions used for the purposes of actuarial valuations were as follows:

Particulars	**For the year ended March 31, 2026**	**For the year ended March 31, 2025**
Mortality table (LIC)	IALM 2012-14 (ultimate)	IALM 2012-14 (ultimate)
Discounting rate	7.05% p.a.	6.70% p.a.
Rate of escalation in salary	10.00% p.a.	10.00% p.a.

Note:

1. Discount rate: The discount rate is based on the prevailing market yields of Indian government securities as at the balance sheet date for the estimated term of the obligations.

2. Salary Escalation Rate: The estimates of future salary increases, considered in actuarial valuation, takes into account the inflation, seniority, promotion and other relevant factors such as supply and demand in the employment market.

g) Maturity profile of defined benefit obligation

Projected benefits payable in future years from the date of reporting	**For the year ended March 31, 2026**	**For the year ended March 31, 2025**
1st following year	6.50	9.98
2nd following year	9.47	5.49
3rd following year	6.79	8.18
4th following year	7.14	5.32
5th following year	8.95	6.24
Sum of years 6th to 10th	38.36	31.52
Sum of years 11th and above	120.84	95.93

h) Withdrawal Rates per annum

Age Band	**For the year ended March 31, 2026**	**For the year ended March 31, 2025**
25 & Below	20.00% p.a.	20.00% p.a.
25 to 35	15.00% p.a.	15.00% p.a.
35 to 45	10.00% p.a.	10.00% p.a.
45 to 55	5.00% p.a.	5.00% p.a.
55 & above	1.00% p.a.	1.00% p.a.

Compensated absences:

The Company provides for accumulation of compensated absences by certain categories of its employees. These employees can carry forward a portion of the recognised compensated absences and recognised them in future periods or receive cash in lieu thereof as per the Company's policy. The Company records a liability for compensated absences in the period in which the employee renders the services that increases this entitlement. The total liability recorded by the Company towards this obligation ₹27.35 million and ₹48.17 million as at March 31, 2026 and March 31, 2025, respectively.

a) The Components of defined benefit costs recognised in profit and loss and other comprehensive income for the years ended March 31,2026 and March 31, 2025 consist of the following:

Particulars	**For the year ended March 31, 2026**	**For the year ended March 31, 2025**
Amount recognised in statement of profit and loss in respect of defined benefit plan is as follows:		
Current service cost	4.05	18.99
Past service cost	(23.32)	
Interest cost	3.09	1.78
Expected return on plan assets/ Interest Income	-	-
Defined benefit cost included in profit and loss	**(16.19)**	**20.77**
Re-measurement effects recognised in Other Comprehensive Income (OCI):		
Actuarial (gains) or losses arising from changes in demographic assumptions	-	-
Actuarial (gains) or losses arising from changes in financial assumptions	(0.99)	2.39
Actuarial (gains) or losses arising from changes in experience assumptions	3.90	4.20
Return on plan assets (excluding interest income)	-	-
Defined benefit costs recognised in OCI	**2.92**	**6.59**

b) Details of the employee benefits obligations and plan assets are provided below:

Particulars	**As at March 31, 2026**	**As at March 31, 2025**
Amount recognised in Statement of Asstes And Liabilities		
Present value of funded defined benefit obligations	27.35	48.17
Fair value of plan assets	-	-
Net liability arising from defined benefit obligation	**27.35**	**48.17**

c) Reconciliation of opening and closing balances of the present value of the defined benefit obligations:

Particulars	**For the year ended March 31, 2026**	**For the year ended March 31, 2025**
Defined benefit obligation at the beginning of the year	48.17	25.89
Transfer in/(out) obligation	-	-
Current service cost	4.05	18.99
Past service cost	(23.32)	
Interest cost	3.09	1.78
Remeasurements due to:		
Actuarial (gains) or losses arising from changes in demographic assumptions	-	-
Actuarial (gains) or losses arising from changes in financial assumptions	(0.99)	2.39
Actuarial (gains) or losses arising from changes in experience assumptions	3.90	4.20
Benefits paid by company	(7.55)	(5.08)
Defined benefit obligation at the year end	**27.35**	**48.17**

d) Sensitivity Analysis

Particulars	**For the year ended March 31, 2026**	
Defined benefit obligation	**Increase**	**Decrease**
Effect of 0.5% change in assumed discount rate	26.02	28.80
Effect of 0.5% change in assumed salary growth rate	28.75	26.05
Effect of 10% change in assumed attrition rate	26.91	27.85

Particulars	**For the year ended March 31, 2025**	
Defined benefit obligation	**Increase**	**Decrease**
Effect of 0.5% change in assumed discount rate	26.02	28.80
Effect of 0.5% change in assumed salary growth rate	28.75	26.05
Effect of 10% change in assumed attrition rate	26.91	27.85

e) The principal assumptions used for the purposes of actuarial valuations were as follows:

Particulars	**For the year ended March 31, 2025**	**For the year ended March 31, 2025**
Mortality table (LIC)	IALM 2012-14 (ultimate)	IALM 2012-14 (ultimate)
Discounting rate	7.05% p.a.	6.70% p.a.
Rate of escalation in salary	10.00% p.a.	10.00% p.a.

Note:

1. Discount rate: The discount rate is based on the prevailing market yields of Indian government securities as at the balance sheet date for the estimated term of the obligations.

2. Salary Escalation Rate: The estimates of future salary increases, considered in actuarial valuation, takes into account the inflation, seniority, promotion and other relevant factors such as supply and demand in the employment market.

g) Maturity profile of defined benefit obligation

Projected benefits payable in future years from the date of reporting	**For the year ended March 31, 2026**	**For the year ended March 31, 2025**
1st following year	2.40	4.24
2nd following year	2.34	3.59
3rd following year	1.91	3.83
4th following year	1.81	2.97
5th following year	2.10	2.97
Sum of years 6th to 10th	8.91	15.22
Sum of years 11th and above	46.59	79.35

h) Withdrawal Rates per annum

Age Band	**For the year ended March 31, 2026**	**For the year ended March 31, 2025**
25 & Below	20.00% p.a.	20.00% p.a.
25 to 35	15.00% p.a.	15.00% p.a.
35 to 45	10.00% p.a.	10.00% p.a.
45 to 55	5.00% p.a.	5.00% p.a.
55 & above	1.00% p.a.	1.00% p.a.

40. Reconciliation of revenue as per contract price and recognised in Statement of Profit and Loss:

Particulars	**For the year ended March 31, 2026**	**For the year ended March 31, 2025**
Revenue as per contract price	9,246.74	8,101.22
Less: Discounts, rebates and incentives	(23.11)	(17.87)
Revenue as per statement of profit and loss	**9,223.63**	**8,083.35**

i) The amounts receivable from customers becomes due after expiry of credit period which on an average is less than 30 to 60 days. There is no financing component in any transaction with the customers.

ii) The Company does not provide performance warranty for products, therefore there is no liability towards performance warranty.

iii) The Company does not have any material performance obligations which are outstanding as at the year-end as the contracts entered for sale of goods are for short term in nature.

Disaggregation of revenue
Revenue by timing of recognition

Particulars	**For the year ended March 31, 2026**	**For the year ended March 31, 2025**
Goods transferred at a point of time	9,218.68	8,082.91
Goods transferred over time	-	-
Service transferred at a point of time	4.95	0.44
Services transferred over time	-	-

Movement of Contract Liabilities are as Follows:

Particulars	**For the year ended March 31, 2026**	**For the year ended March 31, 2025**
Opening Liability	4.36	9.97
Add: Advances received during the year not recognized as revenue	29.22	4.36
Less: Revenue Recognized during the year from the balance at begining of the year	4.36	9.97
Closing Liability	**29.22**	**4.36**

41. Government grant receivable includes assistance in the form of export incentives under Foreign Trade Policy.

Particulars	**As at March 31, 2026**	**As at March 31, 2025**
Opening Balance	-	2.27
Add: Grant income accrued during the year	32.23	30.35
Less: Government grant received	(29.17)	(32.62)
Closing Balance	**3.06**	**-**

42. Segment Information

A. Operating Segments

The operations of the Company are limited to one segment viz. Pharmaceutical products including ingredients and intermediaries. The products being sold under this segment are of similar nature and comprises of pharmaceutical products only. The Company's Chief Operating Decision Maker (CODM) reviews the internal management reports prepared based on aggregation of financial information of the Company on a periodic basis, for the purpose of allocation of resources and evaluation of performance. Accordingly, management has identified pharmaceutical segment as the only operating segment for the Company. Therefore, based on the guiding principles given in Ind AS 108 on 'Operating Segments' there is no reportable segment for the company.

B. Geographical Information:

Analysis of revenues by geography:

The following table shows the distribution of the Company's revenue from operations by country, based on the location of the customers:

Particulars	**For the year ended March 31, 2026**	**For the year ended March 31, 2025**
India	7,298.63	6,694.51
Outside India	1,957.23	1,419.44
Total	**9,255.86**	**8,113.95**

Analysis of non current assets by geography:

The following table shows the distribution of the Company's non-current assets (other than financial instruments and deferred tax assets) by country, based on the location of assets:

Particulars	**As at March 31, 2025**	**As at March 31, 2025**
India	5,282.67	4,504.93
Outside India	-	-
Total	**5,282.67**	**4,504.93**

C. Information about major customers

There were no customers individually accounting for more than 10 % of the Company's revenue in the years ended March 31, 2026 and March 31, 2025.

43. Auditors Remuneration

Particulars	**For the year ended March 31, 2026**	**For the year ended March 31, 2025**
Statutory Auditor: -		
Audit Fee	1.30	1.30
Tax Audit	0.50	0.50
Total	**1.80**	**1.80**

44. Research & Development Expenses

Particulars	**For the year ended March 31, 2026**	**For the year ended March 31, 2025**
Lab Material and Consumables	16.60	14.31
Salaries	63.76	48.06
Rent	0.87	-
Professional Charges	12.63	8.64
Electricity Charges	3.27	1.51
Other Expenses	8.54	8.53
Total	**105.67**	**81.06**

45. Income taxes

a) Income tax expense/ (benefit) recognised in the statement of profit and loss.

Income tax expense recognised in the statement of profit and loss consists of the following:

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Current Taxes	270.69	217.42
Deferred Taxes	34.50	30.79
Prior Period Taxes	0.03	0.95
Total Tax Expense	**305.22**	**249.16**

b) Income tax expense/(benefit) recognised directly in equity.

Income tax expense/(benefit) recognised directly in equity consist of the following:

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Income Tax effect on change in fair value of investments	(3.78)	2.10
Income Tax effect on Actuarial (gain)/ loss on post- employment benefit obligations	(1.45)	(0.88)
Total income tax expense/(benefit) recognized in the equity	**(5.23)**	**1.22**

c) Reconciliation of Effective Tax Rate:

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Profit before income taxes	1,200.51	1,040.50
Enacted tax rate in India	25.17%	25.17%
Computed expected tax expense	302.14	261.87
Effect on Income disallowed under Income Tax Act, 1961	(111.48)	(140.65)
Effect on expenses disallowed under Income Tax Act, 1961	100.12	121.77
Other items	14.44	6.17
Income Tax Expense	**305.22**	**249.16**
Effective tax rate	**25.42%**	**23.95%**

d) Deferred tax asset and liabilities

The tax effects of significant temporary differences that resulted in deferred tax assets and liabilities and a description of the items that created these differences is given below:

Particulars	As at March 31, 2026	As at March 31, 2025
Deferred tax assets/(liabilities):		
Property Plant & Equipment	(214.33)	(182.14)
ROU Asset	(18.73)	(5.77)
Investments	1.77	(2.43)
Borrowings	(1.03)	(0.09)
Lease Liabilities	18.31	4.61
Provisions	26.30	28.83
Trade Receivables	3.99	3.61
Others	0.65	(0.42)
Net deferred tax assets/(liabilities)	**(183.07)**	**(153.81)**

e) Movement in deferred tax assets and liabilities during the years ended March 31, 2026 and March 31, 2025.

Particulars	**For the year ended March 31, 2026**			
	As at April 01, 2025	**Recognized in the statement of Profit and Loss**	**Recognized in Other comprehensive income**	**As at March 31, 2026**
Deferred tax assets/(liabilities)				
Property Plant & Equipment	(182.14)	(32.19)	-	(214.33)
ROU Asset	(5.77)	(12.96)	-	(18.73)
Investments	(2.43)	0.42	3.78	1.77
Borrowings	(0.09)	(0.94)	-	(1.03)
Lease Liabilities	4.61	13.70	-	18.31
Provisions	28.83	(3.98)	1.45	26.30
Trade Receivables	3.61	0.38	-	3.99
Others	(0.42)	1.07	-	0.65
Net deferred tax assets/(liabilities)	**(153.80)**	**(34.50)**	**5.23**	**(183.07)**

Particulars	**For the year ended March 31, 2025**			
	As at April 01, 2024	**Recognized in the statement of Profit and Loss**	**Recognized in Other comprehensive income**	**As at March 31, 2025**
Deferred tax assets/(liabilities)				
Property Plant & Equipment	(144.92)	(37.22)		(182.14)
ROU Asset	(3.23)	(2.54)		(5.77)
Investments	(0.15)	(0.18)	(2.10)	(2.43)
Borrowings	0.45	(0.54)		(0.09)
Lease Liabilities	2.59	2.02		4.61
Provisions	21.06	6.89	0.88	28.83
Trade Receivables	3.49	0.12		3.61
Others	(1.07)	0.66		(0.42)
Net deferred tax assets/(liabilities)	**(121.80)**	**(30.79)**	**(1.22)**	**(153.80)**

46. Financial risk management.

The Company’s activities expose it to a variety of financial risks, including market risk, credit risk and liquidity risk. The Company’s primary risk management focus is to minimise potential adverse effects of market risk on its financial performance. The Company’s risk management assessment and policies and processes are established to identify and analyse the risks faced by the Company, to set appropriate risk limits and controls, and to monitor such risks and compliance with the same. Risk assessment and management policies and processes are reviewed regularly to reflect changes in market conditions and the Company’s activities. The Board of Directors and the Audit Committee is responsible for overseeing the Company’s risk assessment and management policies and processes.

a) Market risk

Market risk is the risk of loss of future earnings, fair values or future cash flows that may result from adverse changes in market rates and prices (such as interest rates, foreign currency exchange rates and commodity prices) or in the price of market risk-sensitive instruments as a result of such adverse changes in market rates and prices. Market risk is attributable to all market risk-sensitive financial instruments, all foreign currency receivables and payables and all short-term and long-term debt. The Company is exposed to market risk primarily related to foreign exchange rate risk and interest rate risk. Thus, the Company’s exposure to market risk is a function of borrowing activities and revenue generating and operating activities in foreign currencies.

The below assumption has been made in calculating the sensitivity analysis:

The sensitivity of the relevant profit or loss item is the effect of the assumed changes in respective market risks. This is based on the financial assets and financial liabilities held at March 31, 2026 and March 31, 2025.

Interest rate risk

The Company is exposed to interest rate risk as its borrowings are primarily at floating interest rates. This exposes the Company to the risk of fluctuations in market interest rates. The risk is monitored and managed on an ongoing basis, taking into account the interest rate outlook and the overall cost of borrowing.

Interest rate sensitivity

For the years ended March 31, 2026 and March 31, 2025, every 1% increase or decrease in the floating interest rate component applicable to its loans and borrowings would affect the Company’s net profit as shown in following table

Particulars	**As at March 31, 2026**	**As at March 31, 2025**
1% increase in Interest rate - decrease in profit	(18.19)	(9.47)
1% decrease in Interest rate - increase in profit	18.19	9.47

Foreign Currency risk

The Group's foreign exchange risk arises from its foreign currency revenues and expenses, (primarily in United States dollars). A portion of the Group's revenues are in this foreign currency, while a significant portion of its costs are in Indian rupees. As a result, if the value of the Indian rupee appreciates relative to these foreign currencies, the Group's revenues measured in Indian rupees may decrease. The exchange rate between the Indian rupee (₹) and this foreign currency has changed substantially in recent periods and may continue to fluctuate substantially in the future.

The following table analyses foreign currency risk from non-derivative financial instruments as at March 31, 2026 and March 31, 2025:

Particulars	**As at March 31, 2026**		**As at March 31, 2025**	
	USD	**INR**	**USD**	**INR**
Trade receivables and Trade Payables(net)	4.37	388.16	2.10	179.44
EEFC A/c’s	0.51	48.57	1.95	25.06

Sensitivity

Particulars	**As at March 31, 2026**	**As at March 31, 2025**
1% increase in USD rate -Increase in profit	4.63	1.79
1% Decrease in USD rate - Decrease in profit	(4.63)	(1.79)

b) Credit risk

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Company’s receivables from customers and investment securities.

Trade and other receivables

The Company's exposure to credit risk is influenced mainly by the individual characteristics of each customer. The demographics of the customer, including the default risk of the industry and country in which the customer operates, also has an influence on credit risk assessment. Credit risk is managed through credit approvals, establishing credit limits and continuously monitoring the creditworthiness of customers to which the Company grants credit terms in the normal course of business. The Company establishes an allowance for doubtful debts and impairment that represents its estimate of expected losses in respect of trade and other receivables and investments.

Investments

The Company limits its exposure to credit risk by generally investing in liquid securities and only with counterparties that have a good credit rating. The Company does not expect any losses from non-performance by these counter-parties, and does not have any significant concentration of exposures to specific industry sectors or specific country risks.

Details of financial assets – not due, past due and impaired

None of the Company's cash equivalents, including term deposits with banks, were past due or impaired as at March 31, 2026. The Company's credit period for trade receivables payable by its customers generally ranges from 45 – 90 days.

The maximum exposure to credit risk for trade receivables by geographic region is as follows:

Particulars	As at March 31, 2026	As at March 31, 2025
India	2,059.41	1,437.90
Europe	270.65	98.74
Japan	93.94	19.25
United States of America	115.69	6.41
Rest of the world	57.50	94.05
Total	**2,597.19**	**1,656.35**

c) Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company manages its liquidity risk by ensuring, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risk to the Company's reputation.

The Company's objective is to maintain a balance between continuity of funding and flexibility through the use of bank deposits and loans

The table below summarises the maturity profile of the Company's financial liabilities based on contractual undiscounted payments:

Particulars	Less than 1 Year	1-2 Years	2-5 years	More than 5 yrs	Total
As at March 31, 2026					
Borrowings	1,940.55	531.39	989.15	6.94	**3,468.03**
Lease Liabilities	2.53	3.73	12.28	54.20	**72.74**
Trade payables	1,713.48	-	-		**1,713.48**
Other financial liabilities	446.55	0.84	1.64	-	**449.03**
As at March 31, 2025					
Borrowings	1,668.69	275.15	831.55	36.77	**2,812.16**
Lease Liabilities	1.69	1.99	7.66	10.70	**22.04**
Trade payables	1,227.41	-	-		**1,227.41**
Other financial liabilities	520.53	-	-		**520.53**

d) Capital management

The Company manages its capital to ensure that it will be able to continue as going concern while maximising the return to stakeholders through the optimisation of the debt and equity balances. The capital structure of the Company consists of net debt and total equity of the Company. The Company is not subject to any externally imposed capital requirements. The Company's management reviews the capital structure of the Company on monthly basis. As part of this review, the management considers the cost of capital and the risks associated with each class of capital.

Gearing Ratio

The gearing ratio at the end of the reporting period is as follows:

Particulars	As at March 31, 2026	As at March 31, 2025
Debt*	3,468.03	2,812.16
Less:		
Cash & Cash equivalents & Other Bank Balances	108.30	183.20
Net Debt (A)	3,359.73	2,628.96
Total Equity (B)	5,450.79	4,571.02
Net Debt to equity ratio (A/B)	0.62	0.58

*Debt includes current and non-current borrowings

47. Financial Instruments

A) Classification of financial assets and liabilities

Particulars	As at March 31,2026		As at March 31,2025	
	Carrying Value	*Fair Value*	*Carrying Value*	*Fair Value*
Financial Assets				
a) Measured at fair value through Other comprehensive income (FVTOCI)				
Investments in Equity Instruments	293.90	293.90	278.91	278.91
b) Measured at fair value through profit and loss (FVTPL)				
Investments in Mutual Funds	86.63	86.63	42.88	42.88
c) Measured at amortised cost				
Investments in Equity Instruments of Associates & Subsidiaries	660.96	1,011.00	205.61	205.61
Loans	535.00	535.00	180.00	180.00
Trade Receivables	2,581.34	2,581.34	1,642.00	1,642.00
Cash and Cash Equivalents	87.17	87.17	136.03	136.03
Bank balances other than cash and cash equivalents	21.13	21.13	47.17	47.17
Other Financial Assets	94.85	94.85	289.76	289.76
Total (a+b+c)	**4,360.98**	**4,711.02**	**2,822.36**	**2,822.36**
Financial Liabilities				
a) Measured at amortised cost				
Borrowings	3,468.03	3,468.03	2,812.16	2,812.16
Lease Liabilities	72.74	72.74	22.04	22.04
Trade Payables	1,713.48	1,713.48	1,227.41	1,227.41
Other Financial liabilities	449.03	449.03	520.53	520.53
	5,703.28	**5,703.28**	**4,582.14**	**4,582.14**

B) Fair value hierarchy

Particulars	As at March 31, 2026	As at March 31, 2025	Level	Valuation techniques and key inputs
Financial Assets				
a) Measured at fair value through Other comprehensive income (FVTOCI)				
Investments in Equity Instruments (Unquoted)	255.56	225.57	3	Using discounted cashflow method
Investments in Equity Instruments (Quoted)	38.34	53.34	1	Quoted market prices in active markets
b) Measured at fair value through profit and loss (FVTPL)				
Investments in Mutual Funds	86.63	42.88	1	Based on the net asset value ('NAV') as stated by the issuers of these mutual fund units in the published

*Note: The following table shows the valuation techniques used in measuring Level 3 fair values for financial instruments measured at fair value in the Statement of Asstes And Liabilities, as well as the significant unobservable inputs used:

Type	Valuation Technique	Significant unobservable inputs	Inter-relationship between significant unobservable inputs and fair Value Measurement
Investments in Equity Instruments (Unquoted)	Discounted cashflow method: The valuation model considers the present value of expected payment, discounted using a risk-adjusted discount rate. The expected payment is determined by considering the possible scenarios of forecast revenue and EBITDA, the amount to be paid under each scenario and the probability of each scenario.	a. Forecast annual revenue growth rate b. Forecast EBITDA margin c. Risk-adjusted discount rate	The estimated fair value would increase (decrease) if: - the annual revenue growth rate were higher (lower); - the EBITDA margin were higher (lower); or - the risk adjusted discount rate were lower (higher). Generally a change in the annual revenue growth rate is accompanied by a directionally similar change in EBITDA margin

C) Fair value measurements

The Company uses the following hierarchy for determining and/or disclosing the fair value of financial instruments by valuation techniques:

a) Level 1

This level includes those financial instruments which are measured by reference to quoted prices (unadjusted) in active markets for identical assets or liabilities.

b) Level 2

This level includes financial assets and liabilities measured using inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e, as prices) or indirectly (i.e.derived from prices).

c) Level 3

This level includes financial assets and liabilities measured using inputs that are not based on observable market data (unobservable inputs). Fair values are determined in whole or in part, using a valuation model based on assumptions that are neither supported by prices from observable current market transactions in the same instrument nor are they based on available market data.

Notes:

a) There was no transfer between level 1 and level 2 fair value measurement.

b) Fair value of financial assets and financial liabilities that are not measured at fair value (but fair valuedisclosures are required)

The management assessed that fair value of Loans, Trade Receivables, Cash and Cash Equivalents, Bank balances other than cash and cash equivalents, Borrowings, Lease Liabilities, Trade Payables and other current financial assets and liabilities approximate their carrying amounts largely due to the short-term maturities of these instruments.

c) The following tables shows a reconciliation from the opening balance to the closing balance for level 3 fair values

Particulars	As at March 31, 2026	As at March 31, 2025
Opening Balance	225.57	126.47
Purchases During the year	29.99	119.10
Gain/(Loss)		
- in Other comprehensive Income	-	(20.00)
- in profit and loss, net	-	-
Closing Balance	**255.56**	**225.57**

48. Impairment loss in respect of Virupaksha Lifesciences LLP

The investment in the Virupaksha Lifesciences LLP was fully impaired due to continued operating losses and negative net worth. As a result, the carrying amount of the investment under the equity method stood at Nil. In accordance with Paragraph 38 of Ind AS 28 – Investments in Associates and Joint Ventures, the Company has discontinued the recognition of its share of further losses in the associate, as the Company's share of losses exceeded the carrying amount of its investment and the Company does not have any legal or constructive obligation to fund further losses.

49. Contingent liabilities, Corporate Guarantees and Capital Commitments

i) Contingent liabilities

Based on legal opinion /advice obtained, no financial implication to the company with respect to following cases is perceived as on the Balance Sheet date:

a. Claims against the company not acknowledged as debt

Particulars	**As at March 31,2026**	**As at March 31,2025**
Direct Tax matters*	26.15	26.15
Legal Proceedings Initiated by Electricity Board**	18.74	18.74
Other Claims#	1.01	1.01

*The Company received a demand notice in FY 2022-23 amounting to ₹26.15 millions (dispute related to AY 2021-22), against which a detailed response was submitted. A remand report in favour of the Company was received before March 2024. However, the final order from the Faceless Assessment authorities is still pending as on the reporting date. The management believes the matter will be resolved without any material liability.

**The Company had acquired a plant in the past from S2 Engineering Services Industry Private limited. Subsequently, legal proceedings were initiated by the Electricity Board against S2 Engineering Services, claiming an amount of ₹18.74 million. As per the contractual terms, S2 Engineering Services has undertaken the responsibility to discharge the liability in the event of an adverse judgment. While the matter is currently sub judice, any financial impact on the Company is expected to be recoverable from the vendor (S2 Engineering Services Industry Private limited).

#A civil suit has been filed by Sesa Chem India Pvt. Ltd. against the Company before the Honble Junior Civil Judge, City Civil Courts, Hyderabad for recovery of ₹1.01 million (including principal amount of ₹0.61 million and interest of ₹0.40 million) relating to supply of materials. The matter is currently sub-judice and pending final adjudication.

b. Pending resolution of the respective proceedings, it is not practicable for the Company to estimate the timings of cash outflows, if any, in respect of the above as it is determinable only on receipt of judgements/ decisions pending with various forums/ authorities.

ii) Corporate Guarantees given to Subsidiary Companies

Subsidiary	**Guarantee against**	**Guarantee provided to**	**As at March 31,2026**	**As at March 31,2025**
Oxygenta Pharmaceutical Limited	Term loan and cash credit	Kotak Mahindra Bank Limited	466.00	-

iii) Capital commitments

Particulars	**As at March 31,2026**	**As at March 31,2025**
Estimated amount of contracts remaining to be executed on capital account and not provided for (net of capital advances)	124.34	321.73

50. Details of partners in Limited Liability Partnership (LLP)

Particulars	**Profit sharing-2026**	**Profit sharing-2025**	**Capital-2026**	**Capital-2025**
Virupaksha Lifesciences LLP				
1) Virupaksha Organics Limited	48.00%	48.00%	0.96	0.96
2) G. Chandra Mouliswar Reddy	1.00%	1.00%	0.02	0.02
3) M Bala Subba Reddy	1.00%	1.00%	0.02	0.02
4) PVRN Mahesh	50.00%	50.00%	1.00	1.00
Total			**2.00**	**2.00**

51. Dividend

The final dividend on shares is recorded as a liability on the date of approval by the shareholders and interim dividend is recorded as liability on the date of declaration by the Company's Board of directors.

The Company declares and pays dividend in Indian rupees. Companies are required to pay/ distribute dividend after deducting applicable withholding income taxes.

The amount of per share dividend recognised as distribution to equity shareholders in accordance with Companies Act, 2013 is as follows:

(Amount in ₹)

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Interim Dividend for FY 2024-25 (1)	-	1.20
Final Dividend for FY 2025-26 (2)	1.00	-

(1) During the year ended March 31, 2025 on account of the interim dividend for the financial year 2024-25 the company has incurred a net cash outflow of ₹ 49.23 million.

(2) The Board have proposed a final dividend of ₹ 1.00 (10.00%) per fully paid equity share of ₹ 10.00 each for the year ended March 31, 2026, subject to the approval of shareholders in the ensuing annual general meeting and are not recognised as a liability. The dividend, if approved by the shareholders, would involve a cash outflow of ₹ 61.53 million.

52. Corporate Social Responsibility:

As per Section 135 of the Companies Act, 2013, Meeting the applicability threshold, needs to spend at least 2% of its Average net profit for the immediately preceding three financials' years on CSR activities calculated as per section 198 of Companies Act, 2013. The areas of CSR Activities are Eradication of Poverty and providing Education. A CSR committee has been formed by the company as per the Act. The details of fund primarily utilized through the year on these activities which are specified in schedule VII of the Companies act,2013.

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Amount required to be spent by the company during the year.	17.53	12.42
Surplus of previous financial year available for set-off	1.90	6.68
Amount of expenditure incurred during the year	16.43	7.64
Shortfall at the end of the year	-	-
Total of previous years shortfall,	-	-
Reason for shortfall	NA	NA
Nature of CSR activities	Eradication of poverty and providing Education	
Related party transactions in relation to CSR expenditure	-	-
Where a provision is made with respect to a liability incurred by entering into a contractual obligation, the movements in the provision during the year should be shown separately	NA	NA
Excess amount available for set-off in succeeding financial years	0.80	1.90

53. Charges Not Yet Satisfied with Registrar of Companies

As per the records available on the Ministry of Corporate Affairs (MCA) portal, the following charges have not been marked as satisfied, although the corresponding loans were fully repaid during earlier years.

Name of the Lender	Date of Creation	Amount	Date of Closure of loan	Reason for Non-Filing
Reliance Commercial Finance Limited	March 30, 2018	23.80	April 06, 2021	No objection certificate pending
Dewan Housing Finance Corporation Limited	January 31, 2017	8.71	January 31, 2020	No objection certificate pending

54. Related party disclosures

A. The list of related parties of the Company is given below:

Name	**Relationship**
Virupaksha Green Energy Private Limited (w.e.f. December 24, 2024)	Wholly owned Subsidiary company
Progenerics Pharma Private Limited (w.e.f. December 30, 2024)	Wholly owned Subsidiary company
Oxygenta Pharmaceutical Limited (from April 22, 2025 to June 19, 2025)	Associate company
Oxygenta Pharmaceutical Limited (w.e.f. June 20, 2025)	Subsidiary company
Bharath Advanced Therapeutics Private Limited (w.e.f. March 30, 2024)	Associate company
Virupaksha Lifesciences LLP	Associate
Key Managerial Personnel (KMP):	
Chandra Mouliswar Reddy Gangavaram	Managing Director
Balasubba Reddy Mamilla	Whole-time director
Chandrasekhar Reddy Gangavaram	Whole-time director
Vedavathi Gangavaram	Director
Janardhana Reddy Yeddula	Independent Director
Shruti Gupta (till September 03, 2025)	Independent Director
Sidda Reddy Kanuparthi (w.e.f. September 26, 2025)	Independent Director
Veera Reddy Arava (w.e.f. September 03, 2025)	Independent Director
Murali Krishna Kurada (w.e.f. September 03, 2025)	Independent Director
Padmanabhani Venkata Appaji (from September 03, 20225 to September 26, 2025)	Independent Director
Prasad Reddy Battinapatla (from May 03, 2024)	Chief Financial Officer
Vikas Kurada (from June 17, 2023)	Company Secretary
Other Related party	
Mamilla Nagarjun Reddy	Close Member of Key Managerial Person
Kotla Suraj Reddy	Close Member of Key Managerial Person
Kondapalli Sandeep Reddy	Close Member of Key Managerial Person
Gangavaram Sri Lakshmi	Close Member of Key Managerial Person
G Sri Vidya	Close Member of Key Managerial Person
M Padmaja	Close Member of Key Managerial Person
G Rukmini	Close Member of Key Managerial Person
Virupaksha Laboratories Private Limited	Entity over which the KMP and/or their relatives is able to exercise control
Virupaksha Minerals LLP	Entity over which the KMP and/or their relatives is able to exercise control
Viruj Pharmaceuticals Private Limited	Entity over which the KMP and/or their relatives is able to exercise control
Virupaksha Securities Private Limited	Entity over which the KMP and/or their relatives is able to exercise control
V Indaf Overseas Private Limited	Entity over which the KMP and/or their relatives is able to exercise control
Chandra Mouliswar Reddy Gangavaram – HUF	Entity over which the KMP and/or their relatives is able to exercise control
Sreekari Developers	Enterprise over which KMP exercise significant influence
Arya Fashion & Arts	Enterprise over which KMP exercise significant influence
Virupaksha Infra Developers	Entity over which the KMP and/or their relatives is able to exercise control
Veda Granites	Entity over which the KMP and/or their relatives is able to exercise control
Kanuparthi Trading LLP	Enterprise over which KMP is able to exercise control

B. Summary of Related Party Transactions

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Revenue from Operations		
Oxygenta Pharmaceuticals Limited	668.80	-
Bharath Advanced Therapeutics Private Limited	-	4.35
Viruj Pharmaceuticals Private Limited	71.82	114.74
Virupaksha Laboratories Private Limited	197.50	287.65
Progenerics Pharma Private Limited	0.02	
	938.14	**406.74**
Sale of Property, Plant & Equipment		
Oxygenta Pharmaceutical Limited	14.26	
	14.26	**-**
Purchase of Raw Material		
Oxygenta Pharmaceutical Limited	709.03	-
Virupaksha Laboratories Private Limited	753.19	700.59
V Indaf Overseas Private Limited	0.23	-
Arya Fashion and Arts	2.80	1.45
	1,465.25	**702.05**
Corporate guarantee given		
Oxygenta Pharmaceutical Limited	466.00	-
	466.00	**-**
Borrowings		
Chandra Mouliswar Reddy Gangavaram	35.50	13.66
Balasubba Reddy Mamilla	-	303.60
Vedavathi Gangavaram	35.50	13.62
	71.00	**330.88**
Repayment of Loan		
Chandra Mouliswar Reddy Gangavaram	26.28	94.24
Balasubba Reddy Mamilla	300.00	11.17
Vedavathi Gangavaram	23.33	255.72
Chandra Mouliswar Reddy Gangavaram – HUF	-	10.58
	349.61	**371.71**
Interest on Unsecured Loan		
Chandra Mouliswar Reddy Gangavaram	0.73	1.18
Balasubba Reddy Mamilla	5.29	3.20
Vedavathi Gangavaram	18.04	22.46
Chandra Mouliswar Reddy Gangavaram – HUF	-	1.28
	24.06	**28.12**
Loans and Advances		
Oxygenta Pharmaceuticals Limited (Given)	355.00	-
Interest Income from Loans		
Oxygenta Pharmaceuticals Limited	19.08	-
Progenerics Pharma Private Limited	3.15	-
	22.23	**-**
Rental Income		
Oxygenta Pharmaceuticals Limited	0.04	-
Virupaksha Laboratories Private Limited	0.03	-
	0.07	**-**
Expenses		
Progenerics Pharma Private Limited	-	11.60
Oxygenta Pharmaceuticals Limited (Other Expenses)	4.83	-
Virupaksha Laboratories Private Limited (Rent)	1.25	1.75
Virupaksha Laboratories Private Limited (Other Expenses)	0.94	0.90
	7.02	**14.25**
Short-term employee benefits - Director's		
Chandra Mouliswar Reddy Gangavaram	36.00	36.00
Balasubba Reddy Mamilla	7.01	6.84
Chandrasekhar Reddy Gangavaram	5.90	5.76
	48.91	**48.60**

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Sitting Fee - Director's		
Janardhana Reddy Yeddula	0.75	0.03
Murali Krishna Kurada	0.69	-
Veera Reddy Arava	0.64	-
Sidda Reddy Kanuparthi	0.25	-
Padmanabhani Venkata Appaji	0.07	-
Shruti Gupta	0.04	0.03
	2.44	**0.06**
Short-term employee benefits - Other than Director's		
Prasad Reddy Battinapatla	5.43	4.37
Vikas Kurada	1.13	0.88
Mamilla Nagarjun Reddy	6.60	5.64
Kotla Suraj Reddy	6.60	5.64
Kondapalli Sandeep Reddy	6.60	5.64
G Rukmini	0.96	0.96
	27.32	**23.13**

C. The Company has the following amounts due from/to related Parties

Particulars	As at March 31, 2026	As at March 31, 2025
Trade Receivables		
Oxygenta Pharmaceuticals Limited	150.87	-
Progenerics Pharma Private Limited	0.02	-
Bharath Advanced Therapeutics Private Limited	5.04	5.04
Viruj Pharmaceuticals Private Limited	14.46	10.96
Virupaksha Laboratories Private Limited	36.25	132.84
Virupaksha Lifesciences LLP	9.24	9.24
	215.88	**158.09**
Financial Assets - Non-Current Loan		
Oxygenta Pharmaceuticals Limited (including interest)	521.11	-
Progenerics Pharma Private Limited (including interest)	40.67	37.84
	561.78	**37.84**
Other Non Current Financial Assets - Advance for Investment		
Progenerics Pharma Private Limited	-	0.97
Virupaksha Green Energy Private Limited	-	1.13
	-	**2.10**
Other Current Assets - Advance to Suppliers		
Progenerics Pharma Private Limited	7.03	-
Arya Fashion & Arts	-	2.18
	7.03	**2.18**
Other Current Financial Liabilities - Advances		
Sreekari Developers	5.00	5.00
V Indaf Overseas Private Limited	-	0.01
	5.00	**5.01**
Loan from Related parties - Long-term borrowings		
Chandra Mouliswar Reddy Gangavaram	9.36	-
Balasubba Reddy Mamilla	-	302.70
Vedavathi Gangavaram	148.16	134.38
	157.52	**437.08**
Other current financial liabilities - Short term employee benefits		
Chandra Mouliswar Reddy Gangavaram	3.00	3.00
Balasubba Reddy Mamilla	0.63	0.57
Chandrasekhar Reddy Gangavaram	0.53	0.48
Prasad Reddy Battinapatla	0.45	0.40
Vikas Kurada	0.08	0.07
Mamilla Nagarjun Reddy	0.55	0.47
Kotla Suraj Reddy	0.55	0.47
Kondapalli Sandeep Reddy	0.55	0.47
G Rukmini	0.09	0.08
	6.43	**6.01**

Terms and conditions of transactions with related parties
All Related Party Transactions entered during the year were in ordinary course of the business and on arm's length basis.

Outstanding balances at the year-end are unsecured and gross amounts are settled in cash.

There have been no guarantees provided or received for any related party receivables or payables.

For the year ended March 31, 2025, the Company has not recorded any impairment of receivables relating to amounts owed by related parties (March 31, 2024: ₹ Nil; April 01, 2023: ₹ 9.24 million). This assessment is undertaken each financial year through examining the financial position of the related party and the market in which the related party operates.

Some of the Key Managerial Personnel of the Company are also covered under the Company's Gratuity Plan and Compensated absences along with the other employees of the Company. Proportionate amounts of gratuity and compensated absences accrued under the Company's Gratuity Plan and Compensated absences have not been separately computed or included in the above disclosure.

Refer note 55 for terms and conditions of loans given

55. Disclosures pursuant to Section 186 of the Companies Act, 2013

A. Amount of loans / advances in nature of loans given to others

Particulars	**As at March 31, 2026**	**As at March 31, 2025**
(a) Loans to Subsidiaries		
(i) Progenerics Pharma Private Limited		
Balance as at the beginning of the year	35.00	35.00
Loans given	-	-
Loans repaid	-	-
Balance as at the end of the year	35.00	35.00
Maximum amount outstanding at any time during the year	35.00	35.00
(Progenerics Pharma Private Limited has utilised the loan for working capital requirements. It is repayable over a period of 3 years along with interest bearing a rate of 9% p.a.,)		
(ii) Oxygenta Pharmaceuticals Limited*		
Balance as at the beginning of the year	145.00	-
Loans given	355.00	-
Loans repaid	-	-
Balance as at the end of the year	500.00	-
Maximum amount outstanding at any time during the year	500.00	-
(Oxygenta Pharmaceuticals Limited has utilised the loan for working capital requirements. It is repayable over a period of 3 years along with interest bearing a rate of 9% p.a.,)		
(b) Loans to Others		
(i) Oxygenta Pharmaceuticals Limited		
Balance as at the beginning of the year	-	-
Loans given	-	145.00
Loans repaid	-	-
Balance as at the end of the year	-	145.00
Maximum amount outstanding at any time during the year	-	145.00
(Oxygenta Pharmaceuticals Limited has utilised the loan for working capital requirements. It is repayable over a period of 3 years along with interest bearing a rate of 9% p.a.,)		

*For the year ended March 31, 2025, Oxygenta Pharmaceuticals Limited is not a Related Party to the Virupaksha Organics Limited. However as on June 20, 2026, it became a Subsidiary.

B. Details of Investments made are given in notes 5

C. The Company had provided guarantee to Kotak Mahindra Bank Limited for the credit facilities availed by Oxygenta Pharmaceutical Limited (Subsidiary) amounting ₹ 466.00 million during the year

56. Ratio Analysis

Ratio	Numerator	Denominator	As at March 31, 2026	As at March 31, 2025	% Variance (25-26)	Reason for variance in excess of 25%
Current Ratio	Current Assets	Current Liabilities	1.09	1.14	(4.30%)	Not Applicable
Debt-Equity Ratio	Debt[1]	Net worth[2]	0.64	0.62	3.42%	Not Applicable
Debt Service Coverage Ratio	Earnings available for debt service[3]	Interest expense + repayment of borrowings & lease liabilities[4]	1.68	1.70	(1.49%)	Not Applicable
Return on Equity Ratio	Net profit after taxes	Average shareholders equity	0.18	0.22	(17.32%)	Not Applicable
Inventory Turnover Ratio	Revenue from Operations	Average Inventory[5]	5.57	5.86	(4.93%)	Not Applicable
Trade Receivables Turnover Ratio	Revenue from Operations	Average Trade Receivable[6]	4.38	4.58	(4.35%)	Not Applicable
Trade Payables Turnover Ratio	Net credit purchases	Average Trade Payables[7]	3.48	4.29	(18.94%)	Not Applicable
Net Capital Turnover Ratio	Revenue from Operations	current assets - current liabilities	23.48	16.30	44.07%	Mainly due to increase in revenue and current liabilities
Net Profit Ratio	Profit after tax	Sales of Products and Services	0.10	0.10	(0.85%)	Not Applicable
Return on Capital Employed	Earnings Before Interest and Taxes[9]	Average Capital Employed[8]	0.18	0.19	(7.42%)	Not Applicable
Return on Investment	Income genarated from investments	Average investments	0.00	0.02	(98.44%)	Mainly due to increase in Investments

1. Debt = Long term Borrowings + Short term Borrowings
2. Net Worth = Equity share capital + Other equity
3. Earnings available for debt service = Profit before taxes + Non-cash operating expenses like depreciation and other amortizations + Interest + other adjustments like loss on sale of Fixed assets
4. Interest expense + Principal repayment=Excluding refinanced debt for all the loan funds during the period
5. Average inventory = (Opening + Closing balance) / 2
6. Average trade receivables = (Opening + Closing balance) / 2
7. Average trade payables = (Opening + Closing balance) / 2
8. Capital Employed = Tangible net worth + Total debt + Deferred Tax Liability
9. Earnings Before Interest and Taxes = Profit before taxes + Finance cost

57. The Code on Social Security, 2020

On November 21, 2025, the Government of India notified the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as "the Labour Codes"), subsuming the existing labour laws. Further, the Ministry of Labour and Employment has notified the Rules under the said Codes on May 8, 2026.

The Company has assessed the potential impact of the aforesaid Labour Codes based on the provisions notified, the Rules framed thereunder, related clarifications and legal opinion obtained, in accordance with the guidance issued by the Institute of Chartered Accountants of India.

Based on such assessment, there is no incremental impact identified on the Company's obligations towards gratuity and compensated absences as at the reporting date.

58. Other Statutory Information:

a) The Company does not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property.

b) The Company does not have any transactions with struck off companies.

c) The Company does not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period except as disclosed in note 53.

d) The Company has not traded or invested in Crypto currency or Virtual Currency during the financial year.

e) The Company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:

i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or

ii) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.

f) The Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:

i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or

ii) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

g) The Company has not surrendered or disclosed any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961).

h) The Company has not been declared as wilful defaulter by any bank or financial institution or other lender.

i) The company has not been declared as wilful defaulter by any bank or financial institution or other lender.

j) The company has not entered into any scheme of arrangement which has an accounting impact on current financial year.

k) The borrowings obtained by the company from banks and financial institutions have been applied for the purposes for which such loans were taken.

l) The company has not revalued its property, plant and equipment (including right-of-use assets) during the current or previous year.

m) The title deeds of all the immovable properties (other than properties where the company is the lessee and the lease agreements are duly executed in favour of the lessee), as disclosed in note 2 to the Standalone financial statements, are held in the name of the company.

n) The company has complied with the number of layers prescribed under the Companies Act, 2013.

As per our report of even date attached

For and on behalf of the Board of Directors

For C. RAMACHANDRAM & Co
Chartered Accountants
FRN: 002864S

M. BALASUBBA REDDY
Whole Time Director
DIN: 01998852

G. CHANDRA MOULISWAR REDDY
Managing Director
DIN: 00046845

C. RAMACHANDRAM
Partner
Membership No.: 025834

PRASAD REDDY BATTINAPATLA
Chief Financial Officer

VIKAS KURADA
Company Secretary
Membership No. A54105

Place: Hyderabad
Date: August 24, 2026

Independent Auditor’s Report

To the Members of
Virupaksha Organics Limited

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the accompanying consolidated financial statements of **Virupaksha Organics Limited** (the “Company” or “Holding Company”) and its subsidiaries, (the Holding Company and its subsidiaries together referred to as ‘the Group’) and its associates which comprise the Consolidated Statement of Assets and Liabilities as at March 31, 2026, and the Consolidated Statement of Profit and Loss (including Other Comprehensive Income), the Consolidated Statement of Cash Flows and the Consolidated Statement of Changes in Equity for the year ended on that date, and notes to the consolidated financial statements, including a summary of material accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid consolidated financial statements give the information required by the Companies Act, 2013 (the “Act”) in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under Section 133 of the Act, (“Ind AS”) and other accounting principles generally accepted in India, of the consolidated state of affairs of the Group and its associates as at March 31, 2026, and their consolidated profit including other comprehensive income, their consolidated cash flows and the consolidated changes in equity for the year ended on that date.

Basis for Opinion

We conducted our audit of the consolidated financial statements in accordance with the Standards on Auditing (“SA”s) specified under Section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor’s Responsibility for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group and associates in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (“ICAI”) together with the ethical requirements that are relevant to our audit of the consolidated financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI’s Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion on the consolidated financial statements.

Information other than the Consolidated Financial Statements and Auditor's Report thereon

The Holding Company's Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the Director's Report including annexures to the Director's Report, but does not include the consolidated financial statements, standalone financial statements and our auditor's report thereon.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether such other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. Other information, so far as it relates to associates, is traced from their audited financial statements. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the Management and Those Charged with Governance for the Consolidated Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Act with respect to the preparation and presentation of these consolidated financial statements that give a true and fair view of the consolidated financial position, consolidated financial performance including other comprehensive income, consolidated cash flows and consolidated changes in equity of the Group including its associates in accordance with the accounting principles generally accepted in India, including Ind AS specified under Section 133 of the Act, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended.

The respective Board of Directors of the companies included in the Group and of its associate are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of their respective company(ies) and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgements and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial statements by the Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial statements, the respective management and Board of Directors of the companies included in the Group and its associates are responsible for assessing the ability of the respective entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intend to liquidate their respective entities or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group and its associates are also responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibility for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with SAs, we exercise professional judgement and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Holding Company has adequate internal financial controls with reference to consolidated financial statements in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associates to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associates to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group and its associates to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the audit of the financial statements of such entities or business activities included in the consolidated financial statements of which we are the independent auditors. For the other entities included in the consolidated financial statements, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the consolidated financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the consolidated financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the consolidated financial statements.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial statements of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

We did not audit the financial statements of a subsidiary (Oxygenta Pharmaceutical Limited), whose financial statements reflect total assets of ₹ 1196.80 million as at March 31, 2026, total revenues of ₹ 998.74 million and net cash flows amounting to ₹ 4.10 million for the year ended on that date, as considered in the consolidated financial statements. The consolidated financial statements also include the Holding Company's share of net loss of ₹ 0.47 million for the year ended March 31, 2026, as considered in the consolidated financial statements, in respect of two associates (, whose financial statements have not been audited by us. These financial statements have been audited by other auditors whose reports have been furnished to us by the Management and our opinion on the consolidated financial statements, in so far as it relates to the amounts and disclosures included in respect of the subsidiary, two associates, and our report in terms of subsection (3) of Section 143 of the Act, in so far as it relates to the aforesaid subsidiaries and associates is based solely on the reports of the other auditors.

Our opinion on the consolidated financial statements above, and our report on Other Legal and Regulatory Requirements below, is not modified in respect of the above matter with respect to our reliance on the work done and the report of the other auditor and the financial statements certified by the Management.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("CARO"/"the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, based on the CARO reports issued by us for the Holding Company and two Subsidiaries and on the consideration of report of the other auditors on separate financial statements and the other financial information of a subsidiary and an associate incorporated in India, as noted in the 'Other Matter' paragraph we give in the "Annexure A" a statement on the matters specified in paragraph 3(xxi) of the Order.

2. As required by Section 143(3) of the Act, based on our audit and on the consideration of the report of the other auditor on the separate financial statements of a subsidiary and an associate referred to in the Other Matter section above we report, to the extent applicable that:

a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid consolidated financial statements.

b) In our opinion, proper books of account as required by law maintained relating to preparation of the aforesaid consolidation of the financial statements have been kept so far as it appears from our examination of those books and reports of the other auditors, except for the matters stated in paragraph 2(i)(vi) below on reporting under Rule 11(g) of the Companies (Audit and Auditor's) Rules, 2014.

c) The Consolidated Statement of Assets and Liabilities, the Consolidated Statement of Profit and Loss including Other Comprehensive Income, the Consolidated Statement of Cash Flows and the Consolidated Statement of Changes in Equity dealt with by this Report are in agreement with the relevant books of account maintained for the purpose of preparation of the consolidated financial statements.

d) In our opinion, the aforesaid consolidated financial statements comply with the Ind AS specified under Section 133 of the Act, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended.

e) On the basis of the written representations received from the directors of the Holding Company as on March 31, 2026 taken on record by the Board of Directors of the Holding Company and the reports of the statutory auditors who are appointed under Section 139 of the Act, of its subsidiary companies and associate, none of the directors of the Group companies, and its associate, incorporated in India, is disqualified as on March 31, 2026 from being appointed as a director in terms of Section 164 (2) of the Act.

f) The modification relating to the maintenance of accounts and other matters connected therewith are as stated in the paragraph (b) above on reporting under Section 143(3)(b) and in paragraph 2(i)(vi) below on reporting under Rule 11(g) of the Companies (Audit and Auditor's) Rules.

g) With respect to the adequacy of the internal financial controls with reference to consolidated financial statements of the Holding Company, and the operating effectiveness of such controls, refer to our separate Report in "Annexure B" to this report. Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls with reference to consolidated financial statements.

h) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of Section 197(16) of the Act, as amended, in our opinion and to the best of our information and according to the explanations given to us and based on the auditor's reports of subsidiary companies and on the consideration of the reports of the other auditor, referred to in "Other Matters" Paragraph, on separate financial statements of a subsidiary and an associate, we report that the Holding Company and a Subsidiary Company whose financial statements have been audited under the Act have paid remuneration to its directors during the year in accordance with the provisions of and limits laid down under section 197 read with Schedule V to the Act. Further, we report that the provisions of section 197 read with Schedule V to the Act are not applicable to two subsidiary companies and, associate company covered under the Act, since none of such companies is a public Company as defined under section 2(71) of the Act.

i) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended in our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the report of the other auditors on separate financial statements as also the other financial information of a subsidiary and an associate, as noted in the 'Other matter' paragraph:

   i. The consolidated financial statements disclose the impact of pending litigations on its consolidated financial position of the Group, and its associate in its consolidated financial statements - Refer Note 51 to the consolidated financial statements.

   ii. The Group, and its associate did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses during the year ended March 31, 2026.

   iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Holding Company, subsidiaries and its associate companies incorporated in India.

   iv.

      (a) The respective managements of the Holding Company, its subsidiaries and its associate which are companies incorporated in India, whose financial statements have been audited under the Act, have represented to us and the other auditor of such subsidiary and associate that, to the best of their knowledge and belief, as disclosed in the note 64(e) to the consolidated financial statements, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Holding Company or any of such subsidiaries and associate to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the respective Holding Company or any of such subsidiaries and associate ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

      (b) The respective Managements of the Holding Company and its subsidiaries and associate which are companies incorporated in India, whose financial statements have been audited under the Act, have represented to us and the other auditors of such subsidiary and associate that, to the best of their knowledge and belief, as disclosed in the note 64(f) to the consolidated financial statements, no funds have been received by the Holding Company or any of such subsidiaries from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Holding Company or any of such subsidiaries or associate directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(c) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances performed by us and that performed by the auditors of the subsidiaries and associate which are companies incorporated in India whose financial statements have been audited under the Act, nothing has come to our or other auditor's notice that has caused us or the other auditors to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.

v. As stated in Note No. 52 to the Consolidated Financial Statements, the Board of Directors of the Holding Company have proposed a final dividend for the year which is subject to the approval of the members at the ensuing Annual General Meeting. The amount of dividend proposed is in accordance with section 123 of the Act, as applicable until the date of this report. In respect of subsidiary companies, no final dividend is declared for the same period.

vi. Based on our examination, which included test checks performed by us on the Holding Company, its two subsidiaries and based on the other auditor's report of a subsidiary and its associate company incorporated in India whose financial statements have been audited under the Act, except for the instances mentioned below, the Holding Company, its subsidiary companies (Virupaksha Green Energy Private Limited and Oxygenta Pharmaceutical Limited) and an associate company (Bharath Advanced Therapeutics Private Limited), incorporated in India have used accounting software for maintaining their respective books of account for the year ended March 31, 2026 which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software.

- In respect of a subsidiary incorporated in India (Progenerics Pharma Private Limited), the accounting software used did not have the audit trail feature enabled or operated during the year. Also, reporting under this para is not applicable to an associate (Virupaksha Lifesciences LLP) which is not a company defined under subsection 2(20) of the Companies Act, 2013.

- Further, the said feature of recording audit trail (edit log) facility was not enabled by the Holding Company at the database level to log any direct data changes to accounting software.

- Further, one of its subsidiary (Oxygenta Pharmaceutical Limited) uses payroll software for which the audit trail (edit log) facility was not enabled at the application layer for the period from April 01, 2025 to March 31, 2026.

Further, during the course of our audit, we and the other auditor of a subsidiary and an associate did not come across any instance of audit trail feature being tampered with, in respect of accounting softwares for the period for which the audit trail feature was operating.

Additionally, where audit trail (edit log) facility was enabled and operated in the previous years, the audit trail has been preserved by the Holding Company and its subsidiaries and associate as per the statutory requirements for record retention.

For C. RAMACHANDRAM & Co
Chartered Accountants
FRN: 002864S

C. RAMACHANDRAM
Partner
Membership No.: 025834
UDIN: 26025834JKTJPI1703

Place: Hyderabad
Date: August 24, 2026

Annexure "A" to the Independent Auditor's Report

(Referred to in paragraph 1 under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

xxi. As required by paragraph 3(xxi) of the Companies (Auditor's Report) Order, 2020, according to the information and explanations given to us, and based on the CARO reports issued by us for the Holding Company and two subsidiaries and on the consideration of report of the other auditors on separate financial statements and the other financial information of a subsidiary and an associate incorporated in India, included in the consolidated financial statements, as noted in the 'Other Matter' paragraph to which reporting under CARO is applicable, we report that there are no qualifications or adverse remarks in the CARO reports of the said companies included in the consolidated financial statements except for the following:

Sr. No.	Name of the Company	CIN	Holding Company/ Subsidiary/ Associate/ Joint Venture	Clause number of the CARO report which is qualified or adverse
1	Virupaksha Organics Limited	U24110TG1997PLC028281	Holding Company	ii(b), vii(b)
2	Progenerics Pharma Private Limited	U24233TG2015PTC102075	Wholly Owned Subsidiary	xvii
3	Virupaksha Green Energy Private Limited	U35106TS2024PTC192317	Wholly Owned Subsidiary	xvii
4	Oxygenta Pharmaceutical Limited	L24110TG1990PLC012038	Subsidiary	vii(b), xvii

For C. RAMACHANDRAM & Co
Chartered Accountants
FRN: 002864S

C. RAMACHANDRAM
Partner
Membership No.: 025834
UDIN: 26025834JKTJPI1703

Place: Hyderabad
Date: August 24, 2026

Annexure “B” to the Independent Auditor’s Report

(Referred to in paragraph 2 (g) under ‘Report on Other Legal and Regulatory Requirements’ section of our report of even date)

Report on the Internal Financial Controls with reference to consolidated financial statements under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (the “Act”)

In conjunction with our audit of the consolidated financial statements of the Company as at and for the year ended March 31, 2026, we have audited the internal financial controls with reference to consolidated financial statements of Virupaksha Organics Limited (the “Company” or “Holding Company”) and its subsidiary company, which is incorporated in India, as of that date.

Management’s Responsibility for Internal Financial Controls

The respective Company’s management and Board of Directors of the Holding Company and its subsidiary company which is incorporated in India, are responsible for establishing and maintaining internal financial controls with reference to consolidated financial statements based on the internal control with reference to consolidated financial statements criteria established by the respective Companies considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (ICAI). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the respective company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditor’s Responsibility

The audit of internal financial controls with reference to financial statements of two subsidiaries and an associate, which are companies covered under the Act, reporting under Section 143(3)(i) is exempted vide MCA notification no. G.S.R. 583(E) dated June 13, 2017, read with corrigendum dated July 14, 2017.

Consequently, our responsibility is to express an opinion on the internal financial controls with reference to consolidated financial statements of the Holding Company and its subsidiary company, which is incorporated in India, based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) issued by the Institute of Chartered Accountants of India and the Standards on Auditing, prescribed under Section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls with reference to consolidated financial statements. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to consolidated financial statements was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to consolidated financial statements and their operating effectiveness. Our audit of internal financial controls with reference to consolidated financial statements included obtaining an understanding of internal financial controls with reference to consolidated financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained and the audit evidence obtained by the other auditors of the subsidiary company, which is incorporated in India, in terms of their reports referred to in the Other Matters paragraph below, is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls with reference to consolidated financial statements of the Holding Company and its subsidiary company, which is incorporated in India.

Meaning of Internal Financial Controls with Reference to these Consolidated Financial Statements

A company's internal financial control with reference to consolidated financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control with reference to consolidated financial statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls with Reference to Consolidated Financial Statements

Because of the inherent limitations of internal financial controls with reference to consolidated financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to consolidated financial statements to future periods are subject to the risk that the internal financial control with reference to consolidated financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion to the best of our information and according to the explanations given to us and based on the consideration of the reports of the other auditors referred to in the Other Matters paragraph below, the Holding Company and its subsidiary company, which is incorporated in India, have, in all material respects, an adequate internal financial controls with reference to consolidated financial statements and such internal financial controls with reference to consolidated financial statements were operating effectively as at March 31, 2026, based the criteria for internal financial control with reference to consolidated financial statements established by the respective companies considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

Other Matters

We did not audit the internal financial controls with reference to financial statements in so far as it relates to a subsidiary company, which are companies covered under the Act, whose financial statements reflect total assets of ₹ 1196.80 million as at March 31, 2026, total revenues of ₹ 998.74 million and net cash flows amounting to ₹ 4.10 million for the year ended on that date, as considered in the consolidated financial statements. The internal financial controls with reference to financial statements in so far as it relates to such subsidiary company have been audited by other auditors whose reports have been furnished to us by the management and our report on the adequacy and operating effectiveness of the internal financial controls with reference to financial statements for the Holding Company, its subsidiary companies, as aforesaid, under Section 143(3)(i) of the Act in so far as it relates to such subsidiary company, is based solely on the reports of the auditors of the subsidiary company.

Our opinion is not modified in respect of this matter with respect to our reliance on the work done by and on the reports of the other auditors.

For C. RAMACHANDRAM & Co
Chartered Accountants
FRN: 002864S

C. RAMACHANDRAM
Partner
Membership No.: 025834
UDIN: 26025834JKTJPI1703

Place: Hyderabad
Date: August 24, 2026

VIRUPAKSHA ORGANICS LIMITED
CIN: U24110TG1997PLC028281
Consolidated Statement of Assets and Liabilities
(All amounts in ₹ millions, unless otherwise stated)

Particulars	Note No.	As at March 31, 2026	As at March 31, 2025
ASSETS			
Non-Current assets			
(a) Property, plant and equipment	2	4,854.53	4,207.25
(b) Capital work-in-progress	3	765.05	246.51
(c) Right of use assets	4	74.40	22.91
(d) Goodwill	5	695.18	93.02
(e) Investment in equity accounted investees	6	37.63	38.10
(f) Financial Assets			
(i) Investments	7	385.27	321.79
(ii) Loans	8	-	145.00
(iii) Other Financial assets	9	71.60	272.89
(g) Deferred Tax Assets (Net)	10	174.07	-
(h) Other non-current assets	11	193.30	144.54
Total Non-current assets		**7,251.03**	**5,492.01**
Current assets			
(a) Inventories	12	1,905.72	1,698.71
(b) Financial Assets			
(i) Trade Receivables	13	2,575.54	1,643.44
(ii) Cash and Cash Equivalents	14	93.38	145.62
(iii) Bank balances other than cash and cash equivalents	15	38.43	47.29
(iv) Other financial assets	16	7.34	16.12
(c) Other current assets	17	390.94	481.62
Total current assets		**5,011.35**	**4,032.80**
TOTAL ASSETS		**12,262.38**	**9,524.81**
EQUITY AND LIABILITIES			
Equity			
(a) Equity Share Capital	18	615.32	410.22
(b) Other equity	19	4,706.59	4,155.98
Equity attributable to owners of the Company		**5,321.91**	**4,566.20**
Non-controlling interests	20	(185.68)	
Total Equity		**5,136.23**	**4,566.20**
Liabilities			
Non-current liabilities			
(a) Financial Liabilities			
(i) Borrowings	21	1,758.73	1,143.47
(ii) Lease Liabilities	22	63.34	18.30
(b) Provisions	23	101.04	100.24
(c) Deferred Tax Liabilities (Net)	24	180.80	157.51
Total Non-current Liabilities		**2,103.91**	**1,419.52**
Current liabilities			
(a) Financial Liabilities			
(i) Borrowings	25	2,294.02	1,678.85
(ii) Lease Liabilities	22	9.40	3.74
(iii) Trade Payables	26		
(A) total outstanding dues of Micro and Small Enterprises		741.30	402.36
(B) total outstanding dues of Creditors Other than Micro and Small Enterprises		1,338.77	826.36
(iv) Other Financial liabilities	27	470.23	530.11
(b) Provisions	28	52.69	55.54
(c) Current Tax Liabilities (Net)	29	61.20	20.54
(d) Other Current Liabilities	30	54.63	21.59
Total Current Liabilities		**5,022.24**	**3,539.09**
TOTAL EQUITY & LIABILTIES		**12,262.38**	**9,524.81**

The accompanying notes are an integral part of these financial statements 1

As per our report of even date attached

For and on behalf of the Board of Directors

For C. RAMACHANDRAM & Co
Chartered Accountants
FRN: 002864S

M. BALASUBBA REDDY
Whole Time Director
DIN: 01998852

G. CHANDRA MOULISWAR REDDY
Managing Director
DIN: 00046845

C. RAMACHANDRAM
Partner
Membership No.: 025834

PRASAD REDDY BATTINAPATLA
Chief Financial Officer

VIKAS KURADA
Company Secretary
Membership No. A54105

Place: Hyderabad
Date: August 24, 2026

VIRUPAKSHA ORGANICS LIMITED
CIN: U24110TG1997PLC028281
Consolidated Statement of Profit and Loss
(All amounts in ₹ millions, unless otherwise stated)

Particulars	Note No	For the year ended March 31, 2026	For the year ended March 31, 2025
Revenue from operations	31	8,999.16	8,117.09
Other income	32	88.72	48.14
Total Income		**9,087.88**	**8,165.23**
Expenses:			
Cost of materials consumed	33	4,861.59	4,877.51
Changes in inventories of finished goods and Work-in-Progress	34	26.56	(451.76)
Employee benefits expense	35	966.59	884.12
Finance Costs	36	301.76	211.51
Depreciation and amortization expense	2 & 4	245.51	193.17
Other Expenses	37	1,675.80	1,412.96
Total expenses		**8,077.81**	**7,127.51**
Profit before Tax and share of equity accounted investees		**1,010.07**	**1,037.72**
Share of profit/(loss) of equity accounted investees (net of tax)		(0.47)	(1.88)
Profit before tax for the year		**1,009.60**	**1,035.84**
Tax expense:			
Current tax		270.69	217.42
Deferred tax		(1.19)	30.30
Prior period tax		0.03	0.98
Total Tax Expense		**269.53**	**248.70**
Profit after Tax for the year		**740.07**	**787.14**
Other comprehensive income/(loss)			
(i) Items that will not be reclassified to Profit or Loss			
a) Changes in fair value of investments		(10.75)	8.34
Income tax on above		2.67	(2.10)
b) Actuarial gain/ (loss) on post- employment benefit obligations		(2.69)	(4.32)
Income tax on above		0.65	1.09
Other Comprehensive Income/ (Loss) for the year (Net of Tax)		**(10.12)**	**3.01**
Total Comprehensive Income / (Loss) for the Year		**729.95**	**790.15**
Profit/ (loss) for the year attributale to			
Owners of the Company		792.81	787.14
Non controlling interests		(52.74)	-
Other comprehensive income for the year attributable to;			
Owners of the Company		(12.41)	3.01
Non controlling interests		2.29	-
Total comprehensive income/ (loss) for the year attributable to;			
Owners of the Company		780.40	790.15
Non controlling interests		(50.45)	-
Earnings per equity share (Face value of ₹ 10 each fully paid)	38		
(1) Basic (in ₹)		12.88	13.17
(2) Diluted (in ₹)		12.88	13.17

The accompanying notes are an integral part of these financial statements 1

As per our report of even date attached

For and on behalf of the Board of Directors

For C. RAMACHANDRAM & Co
Chartered Accountants
FRN: 002864S

M. BALASUBBA REDDY
Whole Time Director
DIN: 01998852

G. CHANDRA MOULISWAR REDDY
Managing Director
DIN: 00046845

C. RAMACHANDRAM
Partner
Membership No.: 025834

PRASAD REDDY BATTINAPATLA
Chief Financial Officer

VIKAS KURADA
Company Secretary
Membership No. A54105

Place: Hyderabad
Date: August 24, 2026

VIRUPAKSHA ORGANICS LIMITED
CIN: U24110TG1997PLC028281
Consolidated Statement of Changes in Equity
(All amounts in ₹ millions, unless otherwise stated)

I. EQUITY SHARE CAPITAL

Particulars	As at March 31, 2026	As at March 31, 2025
Balance at the beginning of the year	410.22	374.48
Changes in equity share capital during the year (Refer Note 18)	205.10	35.74
Balance at the end of the year	**615.32**	**410.22**

II. OTHER EQUITY

Particulars	Share Application Money Pending Allotment	Reserves and Surplus				Items of Other Comprehensive Income (OCI)	Attributable to the owners of the Company	Noncontrolling interest	Total Other Equity
		Capital Reserve	Capital Redemption Reserve	Securities Premium	Retained Earnings				
Balance as at March 31, 2024	**-**	**2.33**	**60.87**	**5.10**	**2,316.09**	**(5.73)**	**2,378.66**	**-**	**2,378.66**
Profit for the period	-	-	-	-	787.14	-	787.14	-	787.14
Dividend on Equity Shares (Refer Note 52)	-	-	-		(49.23)	-	(49.23)	-	(49.23)
Issue of Equity Share Capital	-	-	-	1,036.39	-	-	1,036.39	-	1,036.39
Other comprehensive income for the period	-	-	-	-	-	3.01	3.01	-	3.01
Balance as at March 31, 2025	**-**	**2.33**	**60.87**	**1,041.49**	**3,054.00**	**(2.72)**	**4,155.97**	**-**	**4,155.97**
Profit for the period	-	-	-	-	792.81	-	792.81	(52.74)	740.07
Bonus Issue of Equity Shares (Refer Note 18)	-	-	(60.87)	(144.23)	-	-	(205.10)	-	(205.10)
Issue of Equity Share Capital	-	-	-	-	-	-	-	-	-
Other comprehensive income for the period	-	-	-	-	-	(12.41)	(12.41)	2.29	(10.12)
Non Controlling interest on account business combination	-	-	-	-	-	-	-	(138.74)	(138.74)
Changes in ownership interest in subsidiary without loss of control	-	-	-	-	(24.68)	-	(24.68)	3.51	(21.17)
Balance as at March 31, 2026	**-**	**2.33**	**-**	**897.26**	**3,822.13**	**(15.13)**	**4,706.59**	**(185.68)**	**4,520.91**

The accompanying notes are an integral part of these financial statements

As per our report of even date attached

For C. RAMACHANDRAM & Co
Chartered Accountants
FRN: 002864S

C. RAMACHANDRAM
Partner
Membership No.: 025834

Place: Hyderabad
Date: August 24, 2026

For and on behalf of the Board of Directors

M. BALASUBBA REDDY
Whole Time Director
DIN: 01998852

G. CHANDRA MOULISWAR REDDY
Managing Director
DIN: 00046845

PRASAD REDDY BATTINAPATLA
Chief Financial Officer

VIKAS KURADA
Company Secretary
Membership No. A54105

VIRUPAKSHA ORGANICS LIMITED
CIN: U24110TG1997PLC028281
Consolidated Statement of Cashflows
(All amounts in ₹ millions, unless otherwise stated)

Particulars	For The Year Ended March 31, 2026	For The Year Ended March 31, 2025
Cash flows from/(used in) operating activities		
Net profit/(loss) before tax	1,009.60	1,035.84
Adjustments for:		
Depreciation and amortisation expense	245.51	193.17
Interest income	(7.92)	(21.83)
Interest on Income Tax Refund	-	-
Income from Mutual Fund	(0.22)	(6.58)
Finance costs	301.76	217.81
Actuarial gain/ (loss) on post- employment benefit obligations	(2.69)	(4.32)
Share of (profit)/loss of equity accounted investees	0.47	1.88
Net (gain)/ loss on fair value change in investments	1.67	(0.72)
Loss/(profit) on sale of property, plant and equipment (net)	3.17	(0.69)
Operating profit before working capital changes	**1,551.35**	**1,414.56**
Changes in working capital		
Adjustments for (increase)/decrease in operating assets :		
Trade receivables	(948.04)	262.75
Inventories	12.26	(627.20)
Other financial assets	219.58	(186.50)
Other assets	101.69	(246.02)
Adjustments for increase/(decrease) in operating liabilities :		
Trade payables	278.17	129.21
Other financial liabilities	(67.19)	333.47
Provisions	(13.65)	43.63
Other liabilities	39.27	(11.42)
Cash generated from / (used in) operating activities	**1,173.44**	**1,112.48**
Income taxes paid, net	(230.06)	(209.27)
Net Cash generated from / (used in) operating activities (A)	**943.38**	**903.21**
Cash flow from/(used in) investing activities		
Capital expenditure on property, plant and equipment	(1,037.73)	(1,457.88)
Proceeds from sale of property, plant and equipment	24.04	6.93
Purchase of investments	(96.58)	(195.89)
Acquisition of subsidiaries	(429.93)	(114.75)
(Increase) / Decrease in Bank balances other than cash and cash equivalents	9.87	30.26
Income from mutual funds	0.22	6.58
Interest Received	7.92	21.83
Loans given	-	(144.25)
Net cash generated from / (used in) investing activities (B)	**(1,522.19)**	**(1,847.17)**
Cash flow from/(used in) financing activities		
Proceeds from Borrowings	1,755.29	680.24
Repayment of Borrowings	(923.15)	(511.57)
Proceeds from issue of equity shares	-	1,121.74
Payment of Lease Liabilities	(3.82)	(0.35)
Finance costs	(301.76)	(217.81)
Dividend paid	-	(49.23)
Net cash generated from/(used in) financing activities (C)	**526.56**	**1,023.02**
Net increase/ (decrease) in cash and cash equivalents (A+B+C)	(52.24)	79.05
Cash and cash equivalents at the beginning of the year	145.62	66.57
Cash and cash equivalents at the end of the year (Refer Note No: 14)	**93.38**	**145.62**
Note:		
Cash and cash equivalents comprise of:		
Cash in hand	1.67	1.44
Balances with banks	77.19	144.18
Balance in Demat Account	14.52	-
Cash and cash equivalents (Refer Note No: 14)	**93.38**	**145.62**

VIRUPAKSHA ORGANICS LIMITED
CIN: U24110TG1997PLC028281
Consolidated Statement of Cashflows
(All amounts in ₹ millions, unless otherwise stated)
Notes
1. Changes in liabilities arising from financing activities

	As at March 31,2026	As at March 31,2025
Borrowings		
Opening Balance	**2,822.32**	**2,643.49**
Acquisition of subsidiary	398.29	10.16
Proceeds during the year	1,755.29	680.24
Repayments During the year	(923.15)	(511.57)
Closing Balance	**4,052.75**	**2,822.32**
Share Capital		
Opening Balance	**1,451.71**	**379.58**
Proceeds during the year	-	1,072.13
Adjustment on account of bonus shares and shares received on amalgamation	60.87	-
Closing Balance	**1,512.58**	**1,451.71**
Lease Liabilities		
Opening Balance	**22.04**	**11.47**
Payment of interest portion of lease liabilities	2.34	1.27
Payment of principal portion of lease liabilities	(3.65)	(1.62)
Lease additions during the year	52.01	10.92
Closing Balance	**72.74**	**22.04**

2. The above standalone statement of cash flow from operating activities has been prepared under the "Indirect method" as set out in IND AS-7 "Statement of cash flows".

The accompanying notes are an integral part of these financial statements 1

For and on behalf of the Board of Directors

As per our report of even date attached

For C. RAMACHANDRAM & Co
Chartered Accountants
FRN: 002864S

M. BALASUBBA REDDY
Whole Time Director
DIN: 01998852

G. CHANDRA MOULISWAR REDDY
Managing Director
DIN: 00046845

C. RAMACHANDRAM
Partner
Membership No.: 025834

PRASAD REDDY BATTINAPATLA
Chief Financial Officer

VIKAS KURADA
Company Secretary
Membership No. A54105

Place: Hyderabad
Date: August 24, 2026

Corporate Information and Material Accounting Policies

1.1 Corporate Information

Virupaksha Organics Limited (Corporate identity number: U24110TG1997PLC028281) ("the Company/ Parent company/ Holding Company) is a public limited company domiciled in India and is incorporated on November 03, 1997 under the provisions of Companies Act applicable in India. The Company is engaged in manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Generic Pharmaceuticals, Bulk Drugs, Intermediates and Differentiated Formulations. The Company has its registered office at Hyderabad, Telangana. The Company's principal research and development facility is located in the state of Telangana in India; it's principal manufacturing facilities are located in the states of Telangana and Karnataka.

The consolidated financial statements comprise financial statements of Virupaksha Organics Limited ("the Company") and its subsidiaries (the Company and its subsidiaries together referred to as 'the Group') and its associates.

1.2 Basis of Preparation, Measurement and Material Accounting Policies

a) Statement of Compliance and Basis of preparation

The consolidated financial statements of the Company comprise the Consolidated Statement of Assets and Liabilities as at March 31, 2026, the Consolidated Statement of Profit and Loss (including Other Comprehensive Income), the Consolidated Statement of Cash Flows, Consolidated Statement of Changes in Equity for the year ended March 31, 2026 and Notes forming part of the consolidated financial statements (collectively, the 'Consolidated Financial Statements').

The consolidated financial statements have been prepared in accordance with Indian Accounting Standards (hereinafter referred to as 'Ind AS') prescribed under section 133 of the Companies Act, 2013 ("the Act") read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016 as amended and presentation requirements of Division II of Schedule III to the Companies Act, 2013 as amended from time to time, and other relevant provisions of the Act and accounting principles generally accepted in India.

The accounting policies are applied consistently to all the periods presented in the consolidated financial statements except where a newly issued accounting standard is initially adopted or a revision to an existing accounting standard requires change in accounting policy hitherto in use. These consolidated financial statements have been prepared on a going concern basis.

These consolidated financial statements do not reflect the effects of events that occurred subsequent to the respective dates of board meeting held to approve and adopt the audited consolidated financial statements as mentioned above under Statement of Compliance paragraph.

Comparability of Financial Information:

The scope of consolidation has changed over the periods presented. In FY 2022-23, the Company had an associate, Virupaksha Lifesciences LLP, In FY 2023-24, the Company acquired 24.71% equity in Bharath Advanced Therapeutics Private Limited, In FY 2024-25, the Company incorporated Virupaksha Green Energy Private Limited and acquired Progenerics Pharma Private Limited (both wholly owned subsidiaries), resulting in consolidated financial information including both subsidiaries and associates. In FY 2025-26, the Company acquired 56.50% stake in Oxygenta Pharmaceutical Limited. Accordingly, the financial information for FY 2025-26 is not directly comparable with FY 2024-25.

b) Basis of measurement

The consolidated financial statements have been prepared on the historical cost basis except for the following items:

- Certain financial assets and liabilities: Measured at fair value
- Borrowings : Amortised cost using effective interest rate method
- Net defined benefit (asset)/ liability : Present value of defined benefit obligations less fair value of plan assets

c) Use of judgements, estimates and assumptions

The preparation of the consolidated financial statements in conformity with Ind AS requires management to make estimates, judgements and assumptions that affects the reported amounts of the assets and liabilities, the disclosure of contingent assets and liabilities at the date of financial statements and reported amounts of revenue and expenses during the period. Accounting estimates could change from period to period. Actual results could differ from those estimates. Appropriate changes in the estimates are made as and when management becomes aware of changes in circumstances surrounding the estimates. Changes in the estimates are reflected in the financial statements in the period in which the changes are made and, if material, such effects are disclosed in the notes to financial statements.

Assumptions and estimation uncertainties

Information about assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment in the amounts recognised in the consolidated financial statements is included in the following notes:

• Note 1.3(c) - Assessment of functional currency;

• Note 1.3(d) - Financial instruments;

• Notes 1.3(g) and 1.3(i) - Useful lives of property, plant and equipment and intangible assets and residual value at the end of its life.

• Note 1.3(k) - Valuation of inventories;

• Note 1.3(l) - Measurement of recoverable amounts of cash-generating units;

• Note 1.3(n) - Contingencies, Provisions and other accruals;

• Note 1.3(o) - Measurement of transaction price in a revenue transaction (sales returns and rebates);

• Note 1.3(r) - Evaluation of recoverability of deferred tax assets, estimation of income tax payable and income tax expense in relation to uncertain tax positions;

d) Current vs. non-current Classification

The Schedule III to the Act requires assets and liabilities to be classified as either current or non-current. The Group presents assets and liabilities in the statement of assets and liabilities based on current/ non-current classification.

Assets

An asset is classified as a current when it is:

- it is expected to be realised in, or is intended for sale or consumption in, the Group normal operating cycle;
- it is expected to be realised within twelve months from the reporting date;
- it is held primarily for the purposes of being traded; or
- is cash or cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting date.

All other assets are classified as non-current

Liabilities

A liability is classified as a current when:

- it is expected to be settled in normal operating cycle
- it is due to be settled within twelve months from the reporting date;
- it is held primarily for the purposes of being traded;
- the Group does not have an unconditional right to defer settlement of liability for at least twelve months from the reporting date.

All other liabilities are classified as non-current.

Operating Cycle:

Operating cycle is the time between the acquisition of assets for processing and their realization in cash or cash equivalent. The operating cycle of the Group is less than 12 months.

1.3 Material accounting policies information:

a) New and amended standards adopted by the Group:

The Ministry of Corporate Affairs ("MCA") notifies new standards or amendments to the existing standards under Companies (Indian Accounting Standards) Rules as issued from time to time.

In May 2025, MCA notified amendments to Ind AS 21 - The Effects of Changes in Foreign Exchange Rates, applicable w.e.f. April 1, 2025. The Company has reviewed the amendment and based on its evaluation has determined that it does not have any significant impact in its financial statements.

In August 2025, MCA notified the following amendments to:

a. Ind AS 1, Presentation of Financial Statements, applicable w.e.f. April 1, 2025 – The amendment relates to classification of liabilities as current or non-current and non-current liabilities with covenants. In the context of classifying a liability as current, it removes the requirement of existence of a right to defer settlement for at least 12 months after the reporting date and instead requires that the said right should exist on the reporting date and have substance. The amendment also introduces guidance on classification of liabilities with covenants. The has reviewed the amendments and made appropriate disclosures in its financial statements including classification of current and non-current liabilities.

b. Ind AS 7, Statement of Cash Flows and Ind AS 107, Financial Instruments: Disclosures, applicable w.e.f. April 1, 2025 – The amendment in Ind AS 7 requires to inform users of financial statements of the existence of supplier finance arrangements and explain the nature of the arrangements, the carrying amount of liabilities and the range of payment due dates. Ind AS 107 has been amended to add supplier- finance arrangements as a factor that may cause concentration of liquidity risk. The Company has reviewed the amendment and made appropriate disclosures in its financial statements.

c. Ind AS 12, International Tax Reform – Pillar Two Model Rules applicable immediately – The amendments provide a temporary mandatory relief from deferred tax accounting for top-up tax and disclose that they have applied the relief. This relief is immediate and applies retrospectively. The Company has reviewed the amendment and based on its evaluation has determined that it does not have any impact in its financial statements.

b) Basis of consolidation

The consolidated financial statements relate to Virupaksha Organics Limited, its subsidiaries and associates. The consolidated financial statements are prepared using uniform accounting policies for like transactions and other events in similar circumstances. If a member of the group uses accounting policies other than those adopted in the consolidated financial statements for like transactions and events in similar circumstances, appropriate adjustments are made to that group member's financial statements in preparing these consolidated financial statements to ensure conformity with the group's accounting policies. Consolidated financial statements have been prepared on the following basis:

I. Subsidiaries

Subsidiaries are entities controlled by the Group. Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. Specifically, the Group controls an investee if, and only if, the Group has:

i. Power over the investee (i.e. existing rights that give it the current ability to direct the relevant activities of the investee);
ii. Exposure, or rights, to variable returns from its involvement with the investee; and the ability to use its power over the investee to affect its returns.
iii. The ability to use its power over the investee to affect its returns.

Generally, there is a presumption that a majority of voting rights result in control. To support this presumption and when the Group has less than a majority of the voting or similar rights of an investee, the Group considers all relevant facts and circumstances in assessing whether it has power over an investee, including:

i. The contractual arrangement with the other vote holders of the investee;
ii. Rights arising from other contractual arrangements;
iii. The Group's voting rights and potential voting rights;
iv. The size of the group's holding of voting rights relative to the size and dispersion of the holdings of the other voting rights holders.

The Group re-assesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control. Consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary. Assets, liabilities, income and expenses of a subsidiary acquired or disposed of during the year are included in the consolidated financial statements from the date the Group gains control until the date the Group ceases to control the subsidiary.

Consolidation procedures:

i. Combine like items of assets, liabilities, equity, income, expenses and cash flows of the parent with those of its subsidiaries. For this purpose, income and expenses of the subsidiary are based on the amounts of the assets and liabilities recognized in the consolidated financial statements at the acquisition date.

ii. Offset (eliminate) the carrying amount of the parent's investment in each subsidiary and the parent's portion of equity of each subsidiary. Business combinations policy explains how to account for any related goodwill.

iii. Eliminate in full intragroup assets and liabilities, equity, income, expenses and cash flows relating to transactions between entities of the Group (profits or losses resulting from intragroup transactions that are recognized in assets, such as inventory and property, plant and equipment and intangible assets, are eliminated in full). Intragroup losses may indicate an impairment that requires recognition in the consolidated financial statements. Ind AS 12 Income Taxes applies to temporary differences that arise from the elimination of profit and losses resulting from intragroup transactions.

Non-controlling interests (NCI)

Non-controlling interests represent that part of the total comprehensive income and net assets of subsidiaries attributable to the interest which is not owned, directly or indirectly, by the Parent Company.

Non-controlling interests in the net assets of consolidated subsidiaries is identified and presented in the consolidated Balance Sheet separately within equity. NCI are measured at their proportionate share of the acquiree's net identifiable assets at the date of acquisition.

Changes in the Group's equity interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions.

Non-controlling interests in the net assets of consolidated subsidiaries consists of:

(a) The amount of equity attributable to non-controlling interests at the date on which investment in a subsidiary is made; and

(b) The non-controlling interests share of movements in equity since the date parent subsidiary relationship came into existence.

Loss of control:

A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction. If the Group loses control over a subsidiary, it:

i. Derecognises the assets (including goodwill) and liabilities of the subsidiary.
ii. Derecognises the carrying amount of any non-controlling interests.
iii. Derecognises the cumulative translation differences recorded in equity.
iv. Recognises the fair value of the consideration received.
v. Recognises the fair value of any investment retained.
vi. Recognises any surplus or deficit in profit or loss.
vii. Reclassifies the parent's share of components previously recognized in OCI to profit or loss or retained earnings, as appropriate, as would be required if the Group had directly disposed of the related assets or liabilities.

Subsidiaries considered in the Consolidated financial statements:

S. No.	Name of the entity	Relationship	Country of incorporation	Ownership interest in %	
				As at March 31, 2026	As at March 31, 2025
1	Progenerics Pharma Private Limited	Wholly Owned Subsidiary	India	100.00%	100.00%
2	Virupaksha Green Energy Private Limited	Wholly Owned Subsidiary	India	100.00%	100.00%
3	Oxygenta Pharmaceutical Limited	Subsidiary	India	56.50%	-

II. Associates

Associates include all entities where the Group has the power to exercise a significant influence. Significant influence is the power to participate in the financial and operating policy decisions of the investee but is not control or joint control of those policies.

The Group's investment in associates are accounted for using the equity method. Under equity method of accounting, the investments are initially recorded at cost and adjusted thereafter to recognise the Group's share of post-acquisition profit and loss, and the Group's share of other comprehensive income. Dividend received from associates are recognised as a reduction in the carrying amount of the investments. Unrealised gains on transactions between the Group and its associate are eliminated to the extent of the Group's interest in these entities. Unrealised losses are also eliminated if there is a profit on ultimate sale of goods.

If an entity's share of losses of an associate equal or exceeds its interest in the associate, the entity discontinues recognising its share of further losses. Additional losses are recognised only to the extent that the Group has incurred legal or constructive obligations or made payments on behalf of the associate. If the associate subsequently reports profits, the entity resumes recognising its share of those profits only after its share of the profits equals the share of losses not recognised.

At each reporting date, the Group determines whether there is objective evidence that the investment in the associate is impaired. If there is such evidence, the carrying amount is tested for impairment by comparing its recoverable amount (higher of value in use and fair value less costs to sell) with its carrying amount and impairment, if any, is recognised as 'Share of profit/(loss) in Associates and Joint Ventures' in the consolidated statement of profit and loss.

Associates considered in the Consolidated financial statements:

S. No	Name of the entity	Relationship	Country of incorporation	Ownership interest in %	
				As at March 31, 2025	As at March 31, 2024
1	Bharath Advanced Therapeutics Private Limited	Associate	India	24.71%	24.71%
2	Virupaksha Lifesciences LLP	Associate	India	48.00%	48.00%

Investment in Virupaksha Life Sciences LLP, which is an associate was fully impaired due to continued operating losses and negative networth. As a result, the carrying amount of the investment in the associate under the equity method stood at Nil. In accordance with Para 38 of Ind AS 28 – Investments in Associates and Joint Ventures, the Company discontinued recognition of its share of further losses in the associate, as the entity's share of losses exceeded the carrying amount of its investment and no legal or constructive obligations existed to fund further losses. Accordingly, the share of loss of Virupaksha Life Sciences LLP for the purpose of consolidation is Nil.

c) Foreign currency

Functional and presentation currency

These consolidated financial statements are presented in Indian rupees (₹), which is the functional currency of the group and the currency of the primary economic environment in which the group operates.

Foreign currency transactions

Transactions in foreign currencies are recorded at exchange rates prevailing on the date of the transactions. Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated into the functional currency at the exchange rate at that date. Non-monetary items that are measured based on historical cost in a foreign currency are translated at the exchange rate at the date of the transaction.

Exchange differences arising on the settlement of monetary items or on translating monetary items at rates different from those at which they were translated on initial recognition during the period or in previous financial statements are recognised in the statement of Profit and Loss in the period in which they arise.

d) Rounding of amounts

All amounts disclosed in the consolidated financial statements which also include the accompanying notes have been rounded off to two decimal places to the nearest Millions as per the requirement of Schedule III to the Companies Act 2013, unless otherwise stated.

e) Financial instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

Financial assets

Initial recognition and measurement

All financial assets are recognised initially at fair value plus, in the case of financial assets not recorded at fair value through profit or loss, transaction costs that are attributable to the acquisition of the financial asset.

Trade receivables generally do not contain any significant financing component requiring separation and are therefore recognized initially at the transaction price determined as per Ind AS 115, "Revenue from Contracts with Customers".

Subsequent measurement

Financial assets carried at amortized cost:

A "financial asset" is measured at the amortised cost if both the following conditions are met:

a) the asset is held within a business model whose objective is to hold assets for collecting contractual cash flows; and
b) contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest ("SPPI") on the principal amount outstanding.

After initial measurement, such financial assets are subsequently measured at amortised cost using the effective interest rate method and are subject to impairment. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the effective interest rate.

Interest income from these financial assets is included in finance income using the effective interest rate method. Any gain or loss arising on de recognition is recognised directly in statement of Profit and Loss and presented in other income. The losses arising from impairment are recognised in the statement of Profit and Loss.

Financial assets at fair value through other comprehensive income (FVTOCI):

A financial asset is subsequently measured at fair value through other comprehensive income if it is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. For equity instruments the Group may make an irrevocable election to present in Other comprehensive Income (OCI) subsequent changes in the fair value.

The Group makes such election upon initial recognition on an instrument-by instrument basis. The classification is made upon initial recognition and is irrevocable.

If the Group decides to classify an equity instrument as at FVTOCI, then all fair value changes on the instrument, excluding dividends, are recognised in the OCI. There is no recycling of the amounts from OCI to the statement of Profit and Loss, even on sale of investment.

However, on sale the Company may transfer the cumulative gain or loss within equity.

The Group has made an irrevocable election for its investments in equity instruments other than in subsidiaries & associates to present the subsequent changes in fair value in other comprehensive income.

Financial assets at fair value through profit and loss (FVTPL):

A financial asset which is not classified in any of the above categories are subsequently fair valued through profit and loss.

De recognition

A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is derecognised (i.e. removed from the Group's statement of assets and liabilities) when:

- the rights to receive cash flows from the asset have expired; or
- Both (1) the Group has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a "pass-through" arrangement; and (2) either (a) the Group has transferred substantially all the risks and rewards of the asset, or (b) the Group has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Group has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if and to what extent it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the Group continues to recognise the transferred asset to the extent of the Group's continuing involvement. In that case, the Group also recognises an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Group has retained.

Financial liabilities

Initial recognition and measurement

Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss (FVTPL) and at amortized cost, as appropriate. All financial liabilities are recognized initially at fair value and, in the case of borrowings and payables, net of directly attributable transaction costs.

Subsequent measurement

The measurement of financial liabilities depends on their classification, as described below:

Financial liabilities at FVTPL

Financial liabilities at FVTPL include financial liabilities held for trading and financial liabilities designated upon initial recognition as at FVTPL. Financial liabilities at FVTPL primarily comprise derivative financial instruments entered into by the Group and not designated as hedging instruments in a hedging relationship as defined by Ind AS 109.

Gains or losses on such financial liabilities are recognised in the statement of Profit and Loss.

The Group has not designated any financial liability as FVTPL.

Financial liabilities at amortized cost

Financial liabilities that are not held-for-trading and are not designated as at FVTPL are measured at amortised cost in subsequent accounting periods. The carrying amounts of financial liabilities that are subsequently measured at amortised cost are determined based on the effective interest rate (EIR) method. Interest expense that is not capitalised as part of costs of an asset is included in the 'Finance costs' line item in the profit or loss. After initial recognition, such financial liabilities are subsequently measured at amortised cost using the EIR method. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included as finance costs in the statement of profit and loss.

For trade and other payables maturing within one year from the statement of assets and liabilities date, the carrying amounts approximate fair value due to the short maturity of these instruments.

De-recognition

A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires. Gain or loss arising on de-recognition, measured as difference between, the carrying amount of financial liability and the settlement amount, is recognized under the head finance costs in the statement of Profit and Loss.

Offsetting Financial Instruments

Financial assets and liabilities are offset and the net amount is reported in the statement of assets and liabilities where there is a legally enforceable right to offset the recognised amounts and there is an intention to settle on a net basis or realise the asset and settle the liability simultaneously. The legally enforceable right must not be contingent on future events and must be enforceable in the normal course of business and in the event of default, insolvency or bankruptcy of the group or the counterparty.

f) Cash and cash equivalents

Cash comprises cash on hand, in bank and demand deposits with banks. Cash equivalents are short term (with an original maturity of three months or less from the date of acquisition), highly liquid investments that are readily convertible into known amounts of cash and which are subject to insignificant risk of changes in value.

Cash flows are reported using indirect method whereby profit/ (loss) before tax is adjusted for the effects of transaction of non-cash nature and any deferrals or accruals of past or future cash receipts and payments.

g) Business combination and Goodwill

Business Combinations are accounted for using Ind AS 103 ‘Business Combination’. Acquisitions of businesses are accounted for using the acquisition method unless the transaction is between entities under common control.The consideration transferred in a business combination is measured at fair value, which is calculated as the sum of the acquisition-date fair value of assets transferred by the Company, liabilities incurred by the Company to the former owners of the acquiree and the equity interest issued by the Company in exchange of control of the acquiree. Acquisition related costs are generally recognised in statement of profit and loss as incurred.

At the acquisition date, the identifiable assets acquired and the liabilities assumed are recognised at their fair value at the acquisition date, except that:

- deferred tax assets or liabilities and assets or liabilities related to employee benefit arrangements are recognised and measured in accordance with Ind AS 12 Income Taxes and Ind AS 19 Employee Benefits respectively;
- liabilities or equity instruments related to share-based payment arrangements of the acquiree or share-based payment arrangements of the Company entered into to replace share-based payment arrangements of the acquiree are measured in accordance with Ind AS 102 at the acquisition date (see below); and

- assets (or disposal groups) that are classified as held for sale in accordance with Ind AS 105 are measured in accordance with that Standard.

Business Combinations arising from transfer of interests in entities that are under common control, are accounted using pooling of interest method wherein, assets and liabilities of the combining entities are reflected at their carrying value. No adjustment is made to reflect fair values or recognise any new assets or liabilities other than those required to harmonise accounting policies. The identity of the reserves is preserved and appears in the financial statements of the transferee in the same form in which they appeared in the financial statements of the transferor.

Goodwill is measured at cost, being the excess of the sum of the consideration transferred, the amount of any non-controlling interests in the acquiree, and the fair value of the acquirer's previously held equity interest in the acquiree (if any) over the net of the acquisition date amounts of the identifiable assets acquired and liabilities assumed.

If the net of the acquisition-date amounts of the identifiable assets acquired and liabilities assumed exceeds the sum of the consideration transferred, the amount of any non-controlling interests in the acquiree and the fair value of the acquirer's previously held interest in the acquiree (if any), the excess, after remeasurement, is recognised in capital reserve through other comprehensive income or directly depending on whether there exists clear evidence of the underlying reason for classifying the business combination as a bargain purchase.

After initial recognition, goodwill is measured at cost less any accumulated impairment losses. Goodwill is not amortised but is reviewed for impairment atleast annually. For the purpose of impairment testing, goodwill acquired in a business combination is, from the acquisition date, allocated to each of the Company's cash-generating units expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the acquiree are assigned to those units.

h) Property, plant and equipment

Recognition and measurement

Property, plant and equipment are carried at cost less accumulated depreciation and impairment losses, if any. The cost of property, plant and equipment comprises its purchase price net of any trade discounts and rebates, any import duties and other taxes (other than those subsequently recoverable from the tax authorities), any directly attributable expenditure on making the asset ready for its intended use, other incidental expenses and borrowings costs attributable to acquisition of qualifying property, plant and equipment up to the date the asset is ready for its intended use. Freehold land has an unlimited useful life and therefore is not depreciated.

Software for internal use which is acquired from third-party vendors and forms an integral part of a tangible asset, including consultancy charges for implementing the software, is capitalised as part of the related tangible asset. Subsequent costs associated with maintaining such software are recognised as expense as incurred.

Advances paid towards the acquisition of property, plant and equipment outstanding at each reporting date and the cost of property, plant and equipment not ready to use before such date are classified as Capital Advances under other non-current assets. Assets not ready for use are not depreciated but are tested for impairment. An item of property, plant and equipment and any significant part initially recognised is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Gains and losses upon disposal of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of property, plant and equipment and are recognised net within "Other income/ Other expenses" in the statement of Profit and Loss.

Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds. Borrowing cost also includes exchange differences to the extent regarded as an adjustment to the borrowing costs.

Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalized as part of the cost of the asset. All other borrowing costs are expensed in the period in which they occur.

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. All other repairs and maintenance cost are charged to the statement of profit and loss during the period in which they are incurred.

The carrying values of property, plant and equipment are reviewed for impairment when events or changes in circumstances indicate that the carrying value may not be recoverable.

Capital work-in-progress included in non-current assets comprises of direct costs, related incidental expenses and attributable interest. Capital work-in-progress are not depreciated as these assets are not yet available for use.

Depreciation

Depreciation on property, plant and equipment (other than freehold land) is calculated on the straight-line method based on the useful life of the assets as indicated under Schedule II of the Companies Act 2013. Depreciation is recognised in the statement of Profit and Loss. Land is not depreciated but subject to impairment.

When parts of an item of property, plant and equipment have different useful lives, they are depreciated separately based on their respective economic useful lives.

The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial year end and, if expectations differ from previous estimates, the changes are accounted for as a change in an accounting estimate and adjusted prospectively.

i) Leases

The Group evaluates if an arrangement qualifies to be a lease as per the requirements of Ind AS 116. Identification of a lease requires significant judgement. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The determination of whether an arrangement is (or contains) a lease is based on the substance of the arrangement at the inception of the lease. The arrangement is, or contains, a lease if fulfilment of the arrangement is dependent on the use of a specific asset or assets and the arrangement conveys a right to use the asset or assets, even if that right is not explicitly specified in an arrangement.

The Group assesses whether a contract contains a lease, at inception of a contract. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

To assess whether a contract conveys the right to control the use of an identified asset, the Group assesses whether: (i) the contract involves the use of an identified asset (ii) the Group has substantially all of the economic benefits from use of the asset through the period of the lease and (iii) the Group has the right to direct the use of the asset. The Group uses significant judgement in assessing the lease term (including anticipated renewals) and the applicable discount rate. The determination of whether an arrangement is (or contains) a lease is based on the substance of the arrangement at the inception of the lease. The arrangement is, or contains, a lease if fulfilment of the arrangement is dependent on the use of a specific asset or assets and the arrangement conveys a right to use the asset or assets, even if that right is not explicitly specified in an arrangement.

At the date of commencement of the lease, the Group recognises a right-of-use asset ("ROU") and a corresponding lease liability for all lease arrangements in which it is a lessee, except for leases with a term of twelve months or less (short term leases) and low value leases. For these short term and low value leases, the Group recognises the lease payments as an operating expense on a straight-line basis over the term of the lease.

The right-of-use assets are initially recognised at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or prior to the commencement date of the lease plus any initial direct costs less any lease incentives. They are subsequently measured at cost less accumulated depreciation and impairment losses. Right-of-use assets are depreciated from the commencement date on a straight-line basis over the lease term and useful life of the underlying asset. The lease liability is initially measured at amortised cost at the present value of the future lease payments. The lease payments are discounted using the interest rate implicit in the lease or, if not readily determinable, using the incremental borrowing rates in the country of domicile of these leases. Lease liabilities are re measured with a corresponding adjustment to the related right of use asset if the Group changes its assessment if whether it will exercise an extension or a termination option.

Lease payments are allocated between principal and interest cost. The interest cost is charged to the statement of Profit and Loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period. Lease liability and ROU asset have been separately presented in the statement of assets and liabilities and lease payments have been classified as financing cash flows.

Remeasurement of Lease- The lease liability is subsequently remeasured by increasing the carrying amount to reflect interest on the lease liability, reducing the carrying amount to reflect the lease payments made and remeasuring the carrying amount to reflect any reassessment or lease modifications or to reflect revised in-substance fixed lease payments. The Group recognises the amount of the re-measurement of lease liability due to modification as an adjustment to the right-of-use asset and statement of profit and loss depending upon the nature of modification. Where the carrying amount of the right-of-use asset is reduced to zero and there is a further reduction in the measurement of the lease liability, the Group recognises any remaining amount of the re-measurement in statement of profit and loss.

Variable lease payments that do not depend on an index or rate are not included in the measurement the lease liability and the ROU asset. The related payments are recognized as an expense in the period in which the event or condition that triggers those payments occurs and are included in the line "other expenses" in the Statement of Profit or Loss. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made and remeasured (with a corresponding adjustment to the related ROU asset) when there is a change in future lease payments in case of renegotiation, changes of an index or rate or in case of reassessment of options.

j) Inventories

Inventories consist of raw materials, packing materials, stores, spares and consumables, work-in-progress, stock-in-trade and finished goods and are measured at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and costs necessary to make the sale.

Cost of inventories is determined on a weighted average basis.

However, materials and other items held for use in the production of inventories are not written down below cost if the finished products in which they will be incorporated are expected to be sold at or above cost.

Stores and spares are inventories that do not qualify to be recognised as property, plant and equipment and consists of consumables, engineering spares (such as machinery spare parts), which are used in operating machines or consumed as indirect materials in the manufacturing process

Cost includes expenditures incurred in acquiring the inventories, production or conversion costs and other costs incurred in bringing them to their existing location and condition. In the case of finished goods and work-in-progress, cost includes an appropriate share of overheads based on normal operating capacity.

k) Impairment of assets

a) Financial assets

The Group recognises loss allowances using the expected credit loss (ECL) model for the financial assets which are not fair valued through profit and loss. Loss allowance for trade receivables with no significant financing component is measured at an amount equal to lifetime ECL. For all other financial assets, expected credit losses are measured at an amount equal to the 12-month ECL, unless there has been a significant increase in credit risk from initial recognition in which case those are measured at lifetime ECL. The amount of expected credit losses (or reversal) that is required to adjust the loss allowance at the reporting date to the amount that is required to be recognised is recognised as an impairment gain or loss in profit and loss. For trade receivables only, the Group applies the simplified approach permitted by Ind AS 109 Financial Instruments, which requires expected lifetime losses to be recognised from initial recognition of the receivables.

As a practical expedient, the Group uses a provision matrix to determine impairment loss of its trade receivables. The provision matrix is based on its historically observed default rates over the expected life of the trade receivable and is adjusted for forward looking estimates. The ECL loss allowance (or reversal) during the year is recognised in the statement of profit and loss.

b) Non-Financial assets

The carrying amounts of the Group's non-financial assets, other than inventories and deferred tax assets, are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated for the asset or the cash generating unit to which the asset belongs. For goodwill and intangible assets that have indefinite lives or that are not yet available for use, an impairment test is performed each year or when circumstances indicate that carrying value may be impaired.

The recoverable amount of a CGU (or an individual asset) is the higher of its value in use and its fair value less costs to sell. Value in use is based on the estimated future cash flows, discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the CGU (or the asset). For the purpose of impairment testing, assets are grouped together into the smallest group of assets that generate cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets (the "cash-generating unit").

An impairment loss is recognised in the statement of profit and loss if the estimated recoverable amount of an asset or its cash-generating unit is lower than its carrying amount. Impairment losses recognised in respect of cash-generating units are allocated first to reduce the carrying amount of any goodwill allocated to the units and then to reduce the carrying amount of the other assets in the unit on a pro-rata basis. An impairment loss in respect of goodwill is not reversed. In respect of other assets, impairment losses recognised in prior periods are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount.

An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed its recoverable amount, nor exceed the carrying amount that would have been determined, net of depreciation or amortisation, if no impairment loss had been recognised.

l) Employee benefits

Employee benefits include provident fund, employee state insurance scheme, gratuity fund and compensated absences.

Short-term employee benefits

Short-term employee benefit obligations are measured on an undiscounted basis and are expensed during the period as the related service is provided. A liability is recognised for the amount expected to be paid, if the Group has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee, and the amount of obligation can be estimated reliably.

Defined Contribution Plans

The Group's contribution to provident fund and employee state insurance scheme are considered as defined contribution plans and are charged as an expense to the statement of profit and loss based on the amount of contribution required to be made and when services are rendered by the employees.

Defined Benefit Plans

i. Gratuity

The Company has a defined benefit plan (the "Gratuity Plan"). The Gratuity Plan provides a lump sum payment to employees upon retirement, disability or termination of employment, being an amount based on the respective employee's last drawn salary and the number of years of employment with the Company. The Gratuity Plan, which is defined benefit plan, is managed by the company and maintained with Life insurance Corporation of India

For defined benefit retirement plans, the cost of providing benefits is determined using the projected unit credit method, with actuarial valuations being carried out at the end of each annual reporting period. Re-measurement, comprising actuarial gains and losses, the effect of the changes to the asset ceiling (if applicable) and the return on plan assets (excluding net interest), is reflected immediately in the statement of assets and liabilities with a charge or credit recognised in other comprehensive income in the period in which they occur. Re-measurement recognised in other comprehensive income is reflected immediately in retained earnings and is not reclassified to profit and loss. Past service cost is recognised in statement of profit and loss when the plan amendment or curtailment occurs. Gains or losses on settlement of a defined benefit plan are recognised when the settlement occurs. Net interest is calculated by applying the discount rate at the beginning of the period to the net defined benefit liability or asset.

Defined benefit costs are categorised as follows:

• service cost (including current service cost, past service cost, as well as gains and losses on curtailments and settlements);

• net interest expense or income; and

• re-measurement

The Group presents the first two components of defined benefit costs in the statement of profit and loss in the line item 'Employee benefits expense.

ii. Compensated absences

The Group's policy permits employees to accumulate and carry forward a portion of unutilized compensated absences and utilize them in future periods or receive cash in lieu thereof in accordance with the terms of such policy. The Group measures the expected cost of accumulating compensated absences as the additional amount that the Company incurs as a result of the unused entitlement that has accumulated at the reporting date. Such measurement is based on actuarial valuation as at the reporting date carried out by a qualified actuary. The resultant expenses are recognized in the statement of Profit and Loss.

Other long-term employee benefits

The Group's net obligation in respect of other long-term employee benefits is the amount of future benefit that employees have earned in return for their service in the current and previous periods. That benefit is discounted to determine its present value by independent actuaries using the projected unit credit method. The current service cost, past service cost as well as re-measurements are recognised in the statement of Profit and Loss in the period in which they arise.

m)Provisions and contingencies

Provisions

Provisions are recognised when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that the Group will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation.

The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligation.

If the effect of the time value of money is material, provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost.

Contingent liabilities and contingent assets

A present obligation that arises from past events where it is either not probable that an outflow of resources will be required to settle or a reliable estimate of the amount cannot be made, is disclosed as a contingent liability. Contingent liabilities are also disclosed when there is a possible obligation arising from past events, the existence of which will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Group. Claims against the Group where the possibility of any outflow of resources in settlement is remote, are not disclosed as contingent liabilities.

Contingent assets are not recognised in the financial statements. A contingent asset is disclosed where an inflow of economic benefits is probable. Contingent assets are assessed continually and, if it is virtually certain that an inflow of economic benefits will arise, the asset and related income are recognised in the period in which the change occurs.

n) Revenue recognition

The Group's revenue is derived from sale of goods and service income. Most of such revenue is generated from the sale of goods. The Group has generally concluded that it is the principal in its revenue arrangements.

Sale of goods

Revenue is recognised when the control of the goods has been transferred to a third party. This is usually when the title passes to the customer, either upon shipment or upon receipt of goods by the customer as per the terms agreed upon with the customer. Generally, at that point, the customer has full discretion over the channel and price to sell the products, and there are no unfulfilled obligations that could affect the customer's acceptance of the product. Revenue from the sale of goods is measured at the transaction price which is the consideration received or receivable, net of expected returns, taxes and applicable trade discounts and allowances. Revenue includes shipping and handling costs billed to the customer since the Group acts as a principal in rendering those services.

In arriving at the transaction price, the Group considers the terms of the contract with the customers and its customary business practices. The transaction price is the amount of consideration the Group is entitled to receive in exchange for transferring promised goods or services, excluding amounts collected on behalf of third parties. The amount of consideration varies because of estimated rebates, returns and chargebacks, which are considered to be key estimates.

Any amount of variable consideration is recognised as revenue only to the extent that it is highly probable that a significant reversal will not occur. The Company estimates the amount of variable consideration using the expected value method.

Rendering of services

Revenue from services rendered is recognised in the statement of profit and loss as the underlying services are performed. Upfront non-refundable payments received under these arrangements are deferred and recognised as revenue over the expected period over which the related services are expected to be performed.

Dividend and interest income

(i) Dividend Income

Dividend income from investments is recognised when the Group's right to receive payment has been established, which is generally when shareholders approve the dividend, provided that it is probable that the economic benefits will flow to the Group and the amount of income can be measured reliably.

(ii) Interest income

Interest income from a financial asset is recognised when it is probable that the economic benefits will flow to the Group and the amount of income can be measured reliably. Interest income is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition.

o) Shipping and handling costs

Shipping and handling costs incurred to transport products to customers, and internal transfer costs incurred to transport the products from the Group's factories to its various points of sale, are included in other expenses.

p) Borrowing cost

Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds. Borrowing costs that are attributable to the acquisition, construction or production of a qualifying asset are capitalised as part of the cost of such asset till such time the asset is ready for its intended use and borrowing costs are being incurred. A qualifying asset is an asset that necessarily takes a substantial period of time to get ready for its intended use. All other borrowing costs are recognised as an expense in the period in which they are incurred.

Investment income earned on the temporary investment of specific borrowings pending their expenditure on qualifying assets is deducted from the borrowing costs eligible for capitalisation.

q) Income tax

Income tax expense comprises of current tax expense and deferred tax expense/benefit. Current and deferred taxes are recognised in the consolidated statement of profit and loss, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case, the current and deferred tax are also recognised in other comprehensive income or directly in equity.

(i) Current income tax

Current tax is the amount of tax payable on the taxable income for the year as determined in accordance with the provisions of the applicable income tax law of the respective jurisdiction. The current tax is calculated using tax rates that have been enacted or substantively enacted, at the reporting date and any adjustment to tax payable in respect of previous years. Current tax assets and tax liabilities are offset where the entity has a legally enforceable right to offset and intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

(ii) Deferred tax

Deferred tax is recognised using the Balance Sheet approach on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts.

Deferred tax assets are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences and the carry forward of unused tax credits and unused tax losses can be utilised, except when the deferred tax asset relating to the deductible temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss.

The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilised.

Unrecognised deferred tax assets are re-assessed at each reporting date and are recognised to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured using substantively enacted tax rates expected to apply to taxable income in the years in which the temporary differences are expected to be recovered or settled.

The Group recognises deferred tax liability for all taxable temporary differences associated with investments in subsidiaries and associates, except to the extent that both of the following conditions are satisfied:

- When the Group is able to control the timing of the reversal of the temporary difference; and
- It is probable that the temporary difference will not reverse in the foreseeable future.

Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets and liabilities

r) Export incentives

Export incentives from government authority are recognised in the statement of profit and loss as other operating revenue when the right to receive is established as per the terms of the scheme in respect of the exports made by the Group with no future related cost and where there is no significant uncertainty regarding the ultimate collection of the relevant export proceeds.

s) Segment Reporting

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. The Chief Operating decision-maker is responsible for allocating resources and assessing the performance of the operating segments and makes strategic decisions.

t) Earnings Per Share

The basic earnings per share is computed by dividing the net profit attributable to equity shareholders for the period by the weighted average number of equities shares outstanding during the year. The weighted average number of shares outstanding during the year is adjusted for events such as bonus issue, bonus element in a rights issue, share split, and reverse share split (consolidation of shares) that have changed the number of shares outstanding, without a corresponding change in resources.

Diluted earnings per share is computed by dividing the net profit attributable to equity shareholders for the year relating to the dilutive potential equity shares, by the weighted average number of equity shares considered for deriving basic earnings per share and the weighted average number of equity shares which could have been issued on the conversion of all dilutive potential equity shares. Potential equity shares are deemed to be dilutive only if their conversion to equity shares would decrease the net profit per share

u) Dividend

The Company recognises a liability to pay a dividend when the distribution is authorised, and the distribution is no longer at the discretion of the Company.

The final dividend on shares is recorded as a liability on the date of approval by the shareholders at the Annual General Meeting of the Company and interim dividends are recorded as a liability on the date of declaration by the Company's Board of Directors.

The Company declares and pays dividends in Indian rupees. Companies are required to pay / distribute dividend after deducting applicable taxes. The remittance of dividends outside India is governed by Indian law on foreign exchange and is also subject to withholding tax at applicable rates.

1.4 Determination of fair values

The Group’s accounting policies and disclosures require the determination of fair value, for all financial and certain non-financial assets and liabilities. Fair values have been determined for measurement and/or disclosure purposes based on the following methods. When applicable, further information about the assumptions made in determining fair values is disclosed in the notes specific to that asset or liability.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either: in the principal market for the asset or liability, or in the absence of a principal market, in the most advantageous market for the asset or liability. The principal or the most advantageous market must be accessible by the Group. The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

All assets and liabilities for which fair value is measured or disclosed in the Consolidated Financial Statements are categorized within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

- Level 1 — Quoted (unadjusted) market prices in active markets for identical assets or liabilities.

- Level 2 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable.

- Level 3 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable.

For assets and liabilities that are recognized in the Consolidated Financial Statements at fair value on a recurring basis, the Group determines whether transfers have occurred between levels in the hierarchy by re-assessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

VIRUPAKSHA ORGANICS LIMITED
CIN: U24110TG1997PLC028281
Notes to Consolidated Financial Statements
(All amounts in ₹ millions, unless otherwise stated)

2. PROPERTY, PLANT & EQUIPMENT

For the year 2025-26

Particulars	Freehold Land	Buildings	Plant & Equipment	Electrical Equipment	Lab Equipment	Furniture & Fixtures	Office Equipment	Vehicles	Computers	Total
Gross Carrying Value										
Balance as at April 1, 2025	**993.07**	**994.20**	**1,903.64**	**169.55**	**303.21**	**67.99**	**20.80**	**75.08**	**30.75**	**4,558.29**
Addition under business combination	1.82	105.51	518.63	-	9.64	0.29	6.60	2.11	4.82	649.42
Add: Additions	207.42	63.59	153.28	15.43	55.75	4.31	4.40	14.49	3.01	521.68
Less: Disposals	-	0.10	14.33	7.55	2.16	-	-	11.36	-	35.50
Balance as at March 31, 2026	**1,202.31**	**1,163.20**	**2,561.22**	**177.43**	**366.44**	**72.59**	**31.80**	**80.32**	**38.58**	**5,693.89**
Accumulated Depreciation										
Balance as at April 1, 2025	**-**	**49.02**	**155.27**	**26.59**	**71.35**	**10.59**	**7.99**	**15.69**	**14.54**	**351.04**
Addition under business combination	-	33.14	204.30	-	6.64	0.01	4.95	1.25	3.84	254.13
Add: Depreciation for the year	-	38.53	116.27	18.09	38.43	7.23	4.76	10.27	8.90	242.48
Less: Disposals	-	0.01	0.91	1.92	0.66	-	-	4.79	-	8.29
Balance as at March 31, 2026	**-**	**120.68**	**474.93**	**42.76**	**115.76**	**17.83**	**17.70**	**22.42**	**27.28**	**839.36**
Net Carrying Value										
As at 31-03-2026	**1,202.31**	**1,042.52**	**2,086.29**	**134.67**	**250.68**	**54.76**	**14.10**	**57.90**	**11.30**	**4,854.53**
As at 31-03-2025	**993.07**	**945.18**	**1,748.37**	**142.96**	**231.86**	**57.40**	**12.81**	**59.39**	**16.21**	**4,207.25**

i. For details of security on property, plant and equipment, refer note 40

VIRUPAKSHA ORGANICS LIMITED
CIN: U24110TG1997PLC028281
Notes to Consolidated Financial Statements
(All amounts in ₹ millions, unless otherwise stated)

For the year 2024-25

Particulars	Freehold Land	Buildings	Plant & Equipment	Electrical Equipment	Lab Equipment	Furniture & Fixtures	Office Equipment	Vehicles	Computers	Total
Gross Carrying Value										
Balance as at April 1, 2024	**455.32**	**546.68**	**1,305.83**	**104.49**	**261.75**	**49.16**	**14.90**	**63.30**	**22.32**	**2,823.75**
Addition under business combination	66.40	37.20	8.07	-	16.56	0.20	0.06	-	0.32	128.80
Add: Additions	471.35	410.32	597.49	65.06	24.90	18.63	5.84	11.78	8.11	1,613.48
Less: Disposals	-	-	7.75	-	-	-	-	-	-	7.75
Balance as at March 31, 2025	**993.07**	**994.20**	**1,903.64**	**169.55**	**303.21**	**67.99**	**20.80**	**75.08**	**30.75**	**4,558.29**
Accumulated Depreciation										
Balance as at April 1, 2024	**-**	**19.52**	**67.10**	**11.73**	**29.78**	**4.74**	**3.62**	**6.28**	**6.33**	**149.10**
Addition under business combination	-	2.61	1.45	-	6.75	0.09	-	-	0.23	11.13
Add: Depreciation for the year	-	26.89	88.23	14.86	34.82	5.76	4.37	9.41	7.98	192.32
Less: Disposals	-	-	1.51	-	-	-	-	-	-	1.51
Balance as at March 31, 2025	**-**	**49.02**	**155.27**	**26.59**	**71.35**	**10.59**	**7.99**	**15.69**	**14.54**	**351.04**
Net Carrying Value										
As at 31-03-2025	**993.07**	**945.18**	**1,748.37**	**142.96**	**231.86**	**57.40**	**12.81**	**59.39**	**16.21**	**4,207.25**
As at 31-03-2024	**455.32**	**527.16**	**1,238.73**	**92.76**	**231.97**	**44.42**	**11.28**	**57.02**	**15.99**	**2,674.65**

i. For details of security on property, plant and equipment, refer note 40

3. Capital Work-in-Progress

Particulars	For the Year ended March 31, 2026	For the Year ended March 31, 2025
Balance at the Begining of the year	246.51	448.18
Add: Additions under business combination	2.50	-
Add: Additions during the year	736.30	1,422.42
Less: Capitalized during the year	220.26	1,624.09
Balance at the end of the year	**765.05**	**246.51**

Capital Work-in-Progress Ageing Schedule

As at March 31, 2026

Particulars	Amount in CWIP for a period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in Progress	570.42	194.63	-	-	**765.05**

As at March 31, 2025

Particulars	Amount in CWIP for a period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in Progress	125.48	21.58	0.53	98.92	**246.51**

4. Right-of-Use Assets

Particulars	Land	Buildings	Total
Gross Carrying Value			
Balance as at March 31, 2024	**13.82**	**-**	**13.82**
Additions during the year	-	10.92	10.92
Deletions during the year	-	-	-
Balance as at March 31, 2025	**13.82**	**10.92**	**24.74**
Additions during the year	54.06	0.46	54.52
Deletions during the year	-	-	-
Balance as at March 31, 2026	**67.88**	**11.38**	**79.26**

Accumulated Depreciation	Land	Buildings	Total
Balance as at March 31, 2024	**0.98**	**-**	**0.98**
Depreciation charge for the year	0.49	0.36	0.85
Deletions during the year	-	-	-
Balance as at March 31, 2025	**1.47**	**0.36**	**1.83**
Additions during the year	0.75	2.28	3.03
Deletions during the year	-	-	-
Balance as at March 31, 2026	**2.22**	**2.64**	**4.86**

Net Carrying Value	Land	Buildings	Total
Balance as at March 31, 2025	12.35	10.56	**22.91**
Balance as at March 31, 2026	65.66	8.74	**74.40**

5. Goodwill

Particulars	As at March 31, 2026	As at March 31, 2025
Opening Balance	93.02	-
Recognised on acquisition of subsidiary*	602.16	93.02
Closing Balance	**695.18**	**93.02**

* Goodwill recognised during the current year and previous year amounting to ₹ 602.16 million and ₹ 93.02 million relates to acquisition of Oxygenta Pharmaceutical Limited and Progenerics Pharma Private Limited respectively, by the company (Refer Note 61)

Goodwill Movement

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Opening Balance	93.02	-
Add: Goodwill due to acquitions during the year	602.16	93.02
Less: Transfers/impariment	-	-
Closing Balance	**695.18**	**93.02**

Impairment assessment for goodwill

Goodwill is tested for impairment annually, or more frequently if events or changes in circumstances indicate potential impairment. Impairment occurs when the carrying amount of a Cash Generating Unit (CGU), including the allocated goodwill, exceeds its recoverable amount. The recoverable amount of the CGU (i.e., Oxygenta Pharmaceutical Limited and Progenerics Pharma Private Limited) is determined as the higher of its fair value less costs of disposal and its value in use.

The carrying amount was determined by allocating net assets to the CGU for impairment testing purposes. The recoverable amount has been estimated using a value-in-use calculation based on discounted cash flow projections. These projections are derived from management approved financial forecasts covering five years, followed by a terminal growth rate thereafter. A pre-tax discount rate of 12% reflecting the current market assessment of the time value of money and risks specific to the CGU was applied to the projected cash flows.

Based on this assessment, no impairment was identified as the recoverable amount of the CGU exceeded its carrying amount.

6. Investment in equity accounted investees

Particulars	As at March 31, 2026	As at March 31, 2025
Investments in equity shares (Unquoted)		
Bharath Advanced Therapeutics Private Limited		
(5,142 Equity Shares of Face value ₹ 10 each, fully paid up)	37.63	38.10
Investments in Limited Liability Partnership (LLP) - (Unquoted)		
M/s. Virupaksha Lifesciences LLP		
(Contributed towards 48% Share)	0.96	0.96
Less: Impairment in value of investment (Refer Note 59)	(0.96)	(0.96)
Total investments in equity accounted investees	**37.63**	**38.10**

The movement in investments accounted for using Equity Method is as follows:

Particulars	As at March 31, 2026	As at March 31, 2025
Balance as at beginning of the year	**38.10**	**39.98**
Investments made during the year	-	-
Impairment in Value of Investment	-	-
Share of loss of equity accounted investee net of tax	(0.47)	(1.88)
Balance as at end of the year	**37.63**	**38.10**

7. Non-Current Investments

Particulars	As at March 31, 2026	As at March 31, 2025
A. Investments in Equity Instruments (Quoted) - Designated at fair value through other comprehensive income (FVTOCI)		
Investment in others		
Standard Glass Lining Technology Limited	38.34	53.34
(3,62,840 Equity Shares of Face value ₹10 each, fully paid up)		
Total Investments in Equity Instruments (Quoted) - Designated at fair value through other comprehensive income (FVTOCI)	**38.34**	**53.34**
B. Investments in Equity Instruments (Unquoted) - Designated at fair value through other comprehensive income (FVTOCI)		
Vamsi Labs Limited	25.00	25.00
(28,853 Equity Shares of Face value ₹ 10 each, fully paid up)		
ATGC Biotech Private Limited	61.47	61.47
(6,814 Equity Shares of Face value ₹ 100 each, fully paid up)		
Acintyo Local Oriented Customer Applications Pvt Ltd	20.00	20.00
80,000 (March 31, 2023: 40,000) Equity Shares of Face value ₹10 each, fully paid up		
AACT Inc	84.10	84.10
(500 Equity Shares of Face value US $ 0.001 each, fully paid up)		
Medrhans Pharmaceuticals Pvt Ltd	25.00	25.00
(2,22,221 Equity Shares of Face value ₹10 each, fully paid up)		
Sagar Life Sciences Pvt Ltd	10.00	10.00
(7,536 Equity Shares of Face value ₹10 each, fully paid up)		
Genz Materials Private Limited	29.99	-
(1,022 Equity Shares of Face value ₹10 each, fully paid up)		
Panttancheru Enviro-Tech ltd.	4.74	-
(1,022 Equity Shares of Face value ₹10 each, fully paid up)		
Total Investments in Equity Instruments (Unquoted) - Designated at fair value through other comprehensive income (FVTOCI)	**260.30**	**225.57**
C. Investments in Mutual Funds (Unquoted) - Carried at fair value through profit or loss (FVTPL)	**86.63**	**42.88**
Aggregrate Book value of Unquoted Investments (B+C)	**346.93**	**268.45**
Total (A+B+C)	**385.27**	**321.79**
Aggregrate Book value of quoted Investments	**38.34**	**53.34**
Aggregrate Market value of quoted Investments	**38.34**	**53.34**

8. Non-Current Loans

Particulars	As at March 31, 2026	As at March 31, 2025
Considered Good, Unsecured		
Loans to Related Party	-	-
Loans to Others	-	145.00
Total	**-**	**145.00**

(Refer Note No 56 for more details)

9. Other Non-Current Financial Assets

Particulars	As at March 31, 2026	As at March 31, 2025
Considered Good, Unsecured		
Security Deposits	53.37	41.35
Advances to Employees	18.23	17.62
Advance for Investment	-	213.92
Total	**71.60**	**272.89**

10. Deferred Tax Assets (Net)

Particulars	As at March 31, 2026	As at March 31, 2025
Opening Balance	-	-
Add: Deferred Tax Asset on account of Business Combination	146.27	-
Add: Deferred Tax Asset during the year	27.80	-
Closing balance	**174.07**	**-**

11. Other Non Current Assets

Particulars	As at March 31, 2026	As at March 31, 2025
Capital Advances	190.70	131.58
Prepaid Expense	2.60	12.96
Total	**193.30**	**144.54**

12. Inventories (at lower of cost and net realisable value)

Particulars	As at March 31, 2026	As at March 31, 2025
Raw Materials	576.84	554.75
Work-in-Progress	650.84	691.09
Finished Goods	541.75	393.76
Coal	8.51	1.82
Stores & Spares	72.46	34.61
Packing Material	8.63	4.45
Lab Material	46.69	18.23
Total	**1,905.72**	**1,698.71**

1. Refer note 1.3 (j) for basis of valuation of inventory.
2. Inventories have been pledged as security. Refer note 40 for the details of borrowings.

13. Trade Receivables

Particulars	As at March 31, 2026	As at March 31, 2025
Trade Receivables Considered Good - Unsecured	2,595.16	1,648.55
Trade Receivables - Credit impaired	9.24	9.24
Sub-Total	**2,604.40**	**1,657.79**
Less: Expected credit loss allowance	28.86	14.35
Total	**2,575.54**	**1,643.44**

Trade Receivables Ageing Schedule
As at March 31, 2026

Particulars	Outstanding for following periods from due date of payment					
	Less than 6 months	6 months-1 year	1-2 years	2-3 years	More than 3 years	Total
(i) Undisputed Trade Receivables - Considered Good	2,368.96	118.72	62.30	33.27	11.91	**2,595.16**
(ii) Undisputed Trade Receivables - which have significant increase in credit risk	-	-	-	-	-	-
(iii) Undisputed Trade Receivables - credit impaired	-	-	-	-	9.24	**9.24**
(iv) Disputed Trade Receivables - Considered Good	-	-	-	-	-	-
(v) Disputed Trade Receivables - which have significant increase in credit risk	-	-	-	-	-	-
(vi) Disputed Trade Receivables - credit impaired	-	-	-	-	-	-
Balance as at March 31, 2026	**2,368.96**	**118.72**	**62.30**	**33.27**	**21.15**	**2,604.40**

As at March 31, 2025

Particulars	Outstanding for following periods from due date of payment					
	Less than 6 months	6 months-1 year	1-2 years	2-3 years	More than 3 years	Total
(i) Undisputed Trade Receivables - Considered Good	1,554.95	55.11	34.23	1.91	2.35	**1,648.55**
(ii) Undisputed Trade Receivables - which have significant increase in credit risk	-	-	-	-	-	-
(iii) Undisputed Trade Receivables - credit impaired	-	-	-	-	9.24	**9.24**
(iv) Disputed Trade Receivables - Considered Good	-	-	-	-	-	-
(v) Disputed Trade Receivables - which have significant increase in credit risk	-	-	-	-	-	-
(vi) Disputed Trade Receivables - credit impaired	-	-	-	-	-	-
Balance as at March 31, 2025	**1,554.95**	**55.11**	**34.23**	**1.91**	**11.59**	**1,657.79**

Movement in expected credit loss allowance

Particulars	As at March 31, 2026	As at March 31, 2025
Balance at the beginning of the year	14.35	13.86
Add: Expected credit loss allowance under Business combination	7.72	-
Add: Expected credit loss allowance	6.79	0.49
Balance at the end of the year	**28.86**	**14.35**

14. Cash and Cash Equivalents

Particulars	As at March 31, 2026	As at March 31, 2025
Balances with Banks		
- In Current Account	77.19	144.18
Cash on hand	1.67	1.44
Balance in Demat Account	14.52	-
Total	**93.38**	**145.62**

15. Bank balances other than cash and cash equivalents

Particulars	As at March 31, 2026	As at March 31, 2025
Unpaid Dividend Account	-	-
Deposits with banks	0.65	0.77
Margin Money Deposits	37.78	46.52
Total	**38.43**	**47.29**

16. Other Current Financial Assets

Particulars	As at March 31, 2026	As at March 31, 2025
Unsecured Considered Good		
Other Advances	5.37	16.12
Interest Receivable on Deposits and Loans	1.97	-
Total	**7.34**	**16.12**

17. Other Current Assets

Particulars	As at March 31, 2026	As at March 31, 2025
Balances with government authorities	174.16	252.30
Prepaid Expenses	177.41	58.67
Advances to Suppliers	27.09	165.50
Balances with insurance companies	10.04	-
Other assets	2.24	5.15
Total	**390.94**	**481.62**

18. Equity Share Capital

Particulars	As at March 31, 2026	As at March 31, 2025
Authorised capital^		
8,50,00,000 Equity Shares of ₹10/- each	850.00	450.00
(March 31, 2025: 4,50,00,000; March 31, 2024: 3,81,50,000; Equity Shares of ₹10/- each)		
	850.00	**450.00**
Issued, Subscribed and Paid up		
6,15,31,937 Equity Shares of ₹10/- each	615.32	410.22
(March 31, 2025: 4,10,21,287; March 31, 2024: 3,74,47,536; Equity Shares of ₹10/- each)		
Total	**615.32**	**410.22**

^ The authorized share capital of the Company increased from ₹ 450.00 million (comprising of 4,50,00,000 equity shares having face value of ₹10 each) to ₹850.00 million, (comprising of 8,50,00,000 equity shares having face value of ₹10 each) pursuant to resolution passed by the Board of Directors on September 13, 2025 and approved by shareholders through extra-ordinary general meeting held on September 13, 2025.

At the Extraordinary General Meeting held on July 01, 2024, the members approved, by way of a Special Resolution, the increase in the Authorised Share Capital of the Company. The Authorised Share Capital of the Company was increased from ₹ 381.50 million, (comprising of 3,81,50,000 equity shares having face value of ₹10 each) to ₹ 450.00 million comprising 0f 4,50,00,000 equity shares of ₹ 10 each.

(a) Reconciliation of Shares Outstanding at the Beginning and at the End of the Reporting Period

Particulars	As at March 31, 2026		As at March 31, 2025	
	No. of Shares	**Amount**	**No. of Shares**	**Amount**
Shares Outstanding at the Beginning of the Year				
-Equity Shares	4,10,21,287	410.22	3,74,47,536	374.48
-Preference Shares	-	-	-	-
	4,10,21,287	**410.22**	**3,74,47,536**	**374.48**
Issued during the Year				
-Equity Shares				
Issued during the Year	-	-	35,73,751	35.74
On account of Scheme of Amalgamation*	-	-	-	-
On account of Bonus Issue**	2,05,10,650	205.10	-	-
Shares Outstanding at the End of the Year	**6,15,31,937**	**615.32**	**4,10,21,287**	**410.22**

**** Aggregate number of bonus shares issued, shares issued for consideration other than cash during the period of five years immediately preceding the reporting date**

- The Board of Directors, at its meeting held on September 13, 2025, approved and recommended the issuance of fully paid bonus shares in the ratio of 1:2 (one bonus share for every two existing shares).
  Pursuant to the approval given by the shareholders in the Extraordinary General Meeting held on September 13, 2025, the Company has allotted 2,05,10,650 fully paid-up equity shares of face value ₹10 each as bonus shares.

- The Board of Directors, at its meeting held on March 23, 2024, approved and recommended the issuance of fully paid bonus shares in the ratio of 2:1 (two bonus shares for every one existing share) out of its free reserves created out of profits.
  Pursuant to the approval given by the shareholders in the Extraordinary General Meeting held on March 28, 2024, the Company has allotted 2,49,65,024 fully paid-up equity shares of face value ₹10/- each as bonus shares. The bonus shares were issued by capitalizing Free Reserves of the Company.

- The Bonus shares, once allotted, shall rank pari passu in all respects and carry the same rights as the existing equity shares. They shall be entitled to participate in full in any dividend and other corporate actions recommended and declared after the new equity shares are allotted.

- Pursuant to the approval given by the shareholders in the Extraordinary General Meeting held on July 01, 2024, the Company has allotted 18,80,164 equity shares and 16,93,587 equity shares of ₹ 10 each and a premium of ₹ 290 each as a Preferential allotment and Private Placement on July 18, 2024 and August 14, 2024, to the provision of section 42 and section 62 and other applicable provisions, if any of the Companies Act, 2013.

(b) Rights, Preference and Restrictions attached to Shares

The Company has only one class of Equity Shares having a par value of ₹10 per share. Each holder of Equity Share is entitled to one vote per share. The dividend, if any, proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting, except in case of interim dividend. In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

(c) Details of Shareholders holding more than 5% of Equity Shares in the Company

Name of the Shareholder	As at March 31, 2026		As at March 31, 2025	
	No. of Shares held	% of total shares	No. of Shares held	% of total shares
Equity Shares				
G. Vedavathi	1,06,12,161	17.25%	70,74,774	17.25%
G. Sri Lakshmi	61,39,121	9.98%	40,92,747	9.98%
G. Sri Vidya	58,36,725	9.49%	38,91,150	9.49%
G. Chandra Mouliswar Reddy	56,24,645	9.14%	37,49,763	9.14%

(d) Details of shares held by the promoters in the Company and change during the year:

Name of Promoter	As at March 31, 2026			As at March 31, 2025		
	No. of Shares held	% of Total Shares	% Change during the year	No. of Shares held	% of Total Shares	% Change during the year
G. Vedavathi	1,06,12,161	17.25%	50.00%	70,74,774	17.25%	0.00%
G. Sri Lakshmi	61,39,121	9.98%	50.00%	40,92,747	9.98%	0.00%
G. Sri Vidya	58,36,725	9.49%	50.00%	38,91,150	9.49%	0.00%
G. Chandra Mouliswar Reddy	56,24,645	9.14%	50.00%	37,49,763	9.14%	0.00%
Balasubba Reddy Mamilla	14,97,191	2.43%	50.00%	9,98,127	2.43%	0.00%
Chandrasekhar Reddy Gangavaram	4,68,297	0.76%	50.00%	3,12,198	0.76%	0.00%
Nagarjun Reddy Mamilla	3,42,930	0.56%	50.00%	2,28,620	0.56%	19.93%
Kotla Suraj Reddy	1,062	0.00%	50.00%	708	0.00%	0.00%

19. Other Equity *

Particulars	As at March 31, 2026	As at March 31, 2025
Capital Reserve	2.33	2.33
Capital Redemption Reserve	-	60.87
Securities Premium	897.26	1,041.49
Retained Earnings	3,822.13	3,054.00
Other Comprehensive Income	(15.13)	(2.71)
Total	**4,706.59**	**4,155.98**

* For movement in other equity, refer "Statement of Changes in Equity"

Nature of Reserve

a. Capital Reserve

Capital reserve is created on account of merger of TPS Laboratories Private Limited, being excess of assets acquired over the consideration paid.

b. Capital Redemption Reserve

Capital Redemption Reserve (CRR) is a statutory reserve created when the company has redeemed its preference shares

c. Securities Premium

Amounts received on issue of shares in excess of the par value has been classified as securities premium. The utilisation of securities premium is governed by the Section 52 of the Companies Act, 2013.

d. Retained Earnings

Retained earnings comprises of undistributed earnings after taxes.

e. Other Comprehensive Income

Other comprehensive income consist of re-measurement of net defined benefit liability and changes in the fair value of financial instruments.

20. Non-controlling Interests ('NCI')

Particulars	As at March 31, 2026	As at March 31, 2025
Balance at beginning of the year		
NCI on account business combination	(138.74)	-
Changes in ownership interest in subsidiary without loss of control	3.51	-
Total comprehensive loss for the year attributable to NCI	(50.45)	-
Balance at end of the year	**(185.68)**	**-**

21. Non - Current Borrowings

Particulars	As at March 31, 2026	As at March 31, 2025
A. Secured		
- Term Loan from Banks	1,513.87	373.30
- Term Loan from Financial Institutions	677.82	607.11
- Term Loan from Non-Banking Financial Company (NBFC)	3.18	
Less: Current Maturities on Long Term Loans*	(593.66)	(274.02)
B. Unsecured		
- Loan from Related Parties	157.52	437.08
Total	**1,758.73**	**1,143.47**

* Current maturities of non-current borrowings have been disclosed under the head "Current Borrowings"

Refer Note 40 for terms and security details

22. Lease Liabilities

Particulars	As at March 31, 2026	As at March 31, 2025
Non Current Lease Liabilities	63.34	18.30
Current Lease Liabilities	9.40	3.74

Refer Note 39 for details of leases

23. Non - Current Provisions

Particulars	As at March 31, 2026	As at March 31, 2025
Provision for Employee Benefits		
- Gratuity	72.87	55.56
- Compensated absences (Leave Encashment)	28.17	44.68
Total	**101.04**	**100.24**

Refer Note 42 for details of gratuity & compensated absences

24. Deferred Tax Liability (Net)

Particulars	As at March 31, 2026	As at March 31, 2025
Opening Balance	157.51	126.21
Add: Deferred Tax Liability during the year	23.29	31.30
Closing balance	**180.80**	**157.51**

Refer Note 48(e) for movement in deferred tax liability

25. Current Borrowings

Particulars	As at March 31, 2026	As at March 31, 2025
A. Secured Loans		
Working Capital Loans - From Banks*	1,244.74	1,148.84
Working Capital Loans - From Financial Institutions*	-	-
Current maturities of non-current borrowings**	593.66	274.02
B. Unsecured Loans		
Bills Discounting	330.50	245.83
Loan from Related Parties	114.96	10.16
Loan from Others	10.16	-
Total	**2,294.02**	**1,678.85**

*The working capital loans are secured by way of hypothecation of the company's goods, book debts, movables and other assets. Interest rate ranges between 9.00% to 10.5% p.a.

**Refer Note 40 for terms and security details

26. Trade Payables

Particulars	As at March 31, 2026	As at March 31, 2025
Total outstanding dues of micro and small enterprises (MSME)	741.30	402.36
Total outstanding dues of creditors other than micro and small enterprises	1,338.77	826.36
Total	**2,080.07**	**1,228.72**

Trade Paybles Ageing Schedule are as follows:
As at March 31, 2026

Particulars	Outstanding for following periods from due date of payment				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) MSME	734.15	7.15	-	-	741.30
(ii) Others	1,220.53	94.73	23.51	-	1,338.77
(iii) Disputed dues - MSME	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-
Balance as at March 31, 2026	**1,954.68**	**101.88**	**23.51**	**-**	**2,080.07**

As at March 31, 2025

Particulars	Outstanding for following periods from due date of payment				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) MSME	402.36	-	-	-	402.36
(ii) Others	799.44	18.16	2.73	6.03	826.36
(iii) Disputed dues - MSME	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-
Balance as at March 31, 2025	**1,201.80**	**18.16**	**2.73**	**6.03**	**1,228.72**

27. Other Current Financial Liabilities

Particulars	As at March 31, 2026	As at March 31, 2025
Creditors for Capital Items	249.57	407.50
Dividend Payable	-	-
Expenses Payable	220.66	122.61
Total	**470.23**	**530.11**

28. Current Provisions

Particulars	As at March 31, 2026	As at March 31, 2025
Provision for Employee Benefits		
- Gratuity	14.91	12.78
- Compensated absences	2.78	4.27
- Bonus	35.00	38.49
Total	**52.69**	**55.54**

29. Current Tax Liabilities (Net)

Particulars	As at March 31, 2026	As at March 31, 2025
Income Tax in respect of current year income	61.20	20.54
Total	**61.20**	**20.54**

30. Other Current Liabilities

Particulars	As at March 31, 2026	As at March 31, 2025
Advance from Customers	38.28	4.36
Statutory Payables	16.35	17.23
Total	**54.63**	**21.59**

31. Revenue from Operations

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Revenue from		
Sale of Products (Refer note 43)	8,961.98	8,082.91
Sale of Service (Refer note 43)	4.95	3.58
Other operating revenue		
Export Incentives	32.23	30.60
Total	**8,999.16**	**8,117.09**

32. Other Income

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Bad Debts Recovered	14.90	-
Net Gain on Foreign exchange transaction and translation	58.42	19.58
Income from Mutual Funds	0.22	6.58
Interest Income	8.71	15.55
Interest on Income Tax Refund	0.09	0.01
Liabilities no longer required written back	1.13	0.32
Interest income on financial assets carried at amortised cost	0.35	2.37
Profit on sale of assets	-	0.69
Fair value gain on Investments	-	0.72
Rental Income	1.56	-
Miscellaneous Income	3.34	2.32
Total	**88.72**	**48.14**

33. Cost of Materials Consumed

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Raw-material at the beginning of the year	554.75	438.42
Add : Raw-material on account of business combination	78.22	-
Add : Raw-material Purchases	4,810.62	4,993.84
Less : Raw-material at the end of the year	582.00	554.75
Total	**4,861.59**	**4,877.51**

34. Changes in Inventories of Finished Goods and Work-in-Progress

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Inventories at the begining of the year		
Finished Goods	393.76	226.55
Work-in-progress	691.09	406.54
	1,084.85	**633.09**
Inventories addition on account of business combination		
Finished Goods	116.87	-
Work-in-progress	17.43	-
	134.30	**-**
Inventories at the end of the year		
Finished Goods	541.75	393.76
Work-in-progress	650.84	691.09
	1,192.59	**1,084.85**
Total	**26.56**	**(451.76)**

35. Employee Benefits Expense

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Salaries & Wages	547.57	479.58
Contract Labour salaries & wages	263.31	227.72
Bonus	41.55	41.12
Staff Welfare Expenses	41.35	31.08
Directors Remuneration	49.15	48.60
Contribution to provident and other funds	23.66	56.02
Total	**966.59**	**884.12**

36. Finance Costs

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Interest on Working Capital Loans	107.68	69.63
Interest on Term Loans	132.46	95.34
Interest on Unsecured Loans	24.06	28.11
Letter of Credit Charges	13.32	13.63
Other Finance Charges	21.56	3.22
Amortised cost on Financial Assets	0.34	0.31
Interest on Lease liabilities	2.34	1.27
Total	**301.76**	**211.51**

37. Other Expenses

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Power & Fuel	420.44	344.50
Conversion Charges	24.58	18.27
Stores & Consumables	204.23	179.67
Carriage Inwards & Outwards	124.94	96.87
Travelling & Conveyance	73.61	70.53
Printing & Stationery	13.70	8.76
Postage & Telephone Charges	3.86	3.29
Rates & Taxes	38.93	33.75
Research & Development expenses	105.67	81.06
Security Charges	23.81	20.19
Auditors Remuneration		
i) Statutory Audit	1.89	1.39
ii) Tax Audit	0.75	0.50
Effluent Treatment Charges	112.30	60.97
Factory Expenses	17.17	19.81
Office Maintenance	2.70	1.90
Professional & Legal Charges	84.20	49.75
Sales Commission	115.86	128.68
Insurance Charges	104.79	89.14
Membership & Subscriptions	0.27	0.30
Corporate Social Responsibility Expenses	18.66	12.42
Repairs & Maintenance		
- Building	31.90	46.95
- Plant & Machinery	44.82	33.87
- Vehicles	2.46	3.63
- Others	34.70	32.55
Testing Charges	8.71	5.41
Bank Charges	5.21	2.86
Business Promotion Expenses	35.63	29.55
Bad Debts Written Off	-	32.82
Expected credit loss allowance	6.79	1.26
Interest on GST	0.04	0.04
Donation	0.25	0.21
Rental Expense	2.65	0.60
Loss on Sale of Asset	3.17	-
Net Loss on Foreign exchange transaction and translation	0.77	-
Fair value loss on Investments	1.67	-
Assets Written Off	1.61	-
Loans Given - Written Off	-	0.75
Priliminary Expenses	-	0.71
Miscellaneous Expenses	3.07	-
Total	**1,675.80**	**1,412.96**

38. Earnings Per Share

Particulars	**For the year ended March 31, 2026**	**For the year ended March 31, 2025**
(A) Profit after tax attributable to equity shareholders of the company (in ₹ million)	792.81	787.14
(B) (i) Weighted average number of equity shares before Bonus (refer note (a) below)	6,15,31,937	3,98,38,569
(B) (ii) Bonus shares adjustment (refer note (b) below)	-	1,99,19,285
(B) (iii) Weighted average number of equity shares outstanding used as the denominator in calculating EPS (i + ii)	6,15,31,937	5,97,57,854
Nominal value of equity shares (in ₹)	10.00	10.00
Earnings per share: ((A)/(B)(iii))		
Basic Earning Per Share (in ₹)	12.88	13.17
Diluted Earning Per Share (in ₹)	12.88	13.17

Notes:

(a) Weighted Average Number of Equity Shares:

i) For FY 2024-25, the weighted average number of equity shares includes 18,80,164 equity shares and 16,93,587 equity shares issued by way of Preferential Allotment (July 18, 2024) and Private Placement (August 14, 2024), respectively. [Refer Note 18(a)].

(b) Bonus Issues and Restatement of EPS:

i) Pursuant to the resolutions passed by the Board of Directors and Shareholders on September 13, 2025, the Company issued 2,05,10,650 fully paid equity shares as bonus shares in the ratio of 1:2 (one share for every two shares held).

ii) In accordance with Ind AS 33 – Earnings Per Share, the EPS for FY 2024-25 has been restated as if these bonus shares had been issued at the beginning of the earliest period presented. Comparative EPS figures for prior periods have been retrospectively adjusted to ensure consistency and comparability.

39. Leases

The following is the movement in lease liabilities:

Particulars	**For the year ended March 31, 2026**	**For the year ended March 31, 2025**
Opening balance	22.04	11.47
Additions	52.01	10.92
Finance cost	2.34	1.27
Payment of lease liabilities	(3.65)	(1.62)
Closing Balance	**72.74**	**22.04**

The following is the break-up of current and non-current lease liabilities:

Particulars	**As at March 31, 2026**	**As at March 31, 2025**
Non-Current Lease Liability	63.34	18.30
Current Lease liability	9.40	3.74

Amounts recognised in Consolidated Cash Flow Statement:

Particulars	**As at March 31, 2026**	**As at March 31, 2025**
Payment of lease liabilities	3.65	1.62
Interest Component	2.34	1.27
Principle Component	1.31	0.35

Amounts recognised in Consolidated statement of Profit and loss:

Particulars	**For the year ended March 31, 2026**	**For the year ended March 31, 2025**
Interest Expense on lease liability	2.34	1.27
Expense relating to short term and low value leases	2.65	0.60

Contractual maturities of lease liabilities

The table below provides the details of contractual maturities of lease liabilities on undiscounted basis

Particulars	**As at March 31, 2026**	**As at March 31, 2025**
Within 1 year	9.40	3.74
1-2 years	10.27	3.86
2-5 years	29.44	11.90
More than 5 years	85.38	24.40
Total	**134.49**	**43.90**
Less: Financial component	61.75	21.86
Total	**72.74**	**22.04**

Weighted average incremental borrowing rate applied to lease liabilities recognised in the consolidated statement of assets and liabilities are as follows:

Particulars	**As at March 31, 2026**	**As at March 31, 2025**
Weighted average incremental borrowing rate (p.a.)	9% to 10%	9% to 10%

The Group does not face a significant liquidity risk with regard to its lease liabilities as the current assets are sufficient to meet the obligations related to lease liabilities as and when they fall due.

40. Terms and conditions of loans and Nature of security

As at March 31, 2026

Particulars	No of Installments due	Rate of Interest	Within 1 Year *	1 to 2 Years	2 to 5 Years	Above 5 Years	Loan outstanding
Axis Bank Limited (Refer Note 4 below)	9 Monthly Installments	9.50% p.a. to 10.50% p.a.	22.49	0.08	-	-	22.57
ICICI Bank Limited (Refer Note 5 below)	21 Monthly Installments	7.90% p.a. to 9.60% p.a.	35.65	27.01	-	-	62.66
Bajaj Finance Limited (Refer Note 7 below)	23 Monthly Installments	9.45% p.a.	44.24	46.42	-	-	90.66
State Bank of India (Refer Note 8 below)	12 Monthly Installments	9.90% p.a. to 10.40% p.a.	25.74	-	-	-	25.74
State Bank of India (Refer Note 9 below)	14 Monthly Installments	9.90% p.a. to 10.40% p.a.	16.03	1.53	-	-	17.56
State Bank of India (Refer Note 10 below)	38 Monthly Installments	9.70% p.a. to 10.10% p.a.	17.63	19.40	24.26	-	61.29
Bajaj Finance Limited (Refer Note 11 below)	23 Monthly Installments	9.45% p.a.	11.45	11.97	-	-	23.42
Bajaj Finance Limited (Refer Note 12 below)	37 Monthly Installments	9.30% p.a. to 9.60% p.a.	30.00	30.00	32.10	-	92.10
Bajaj Finance Limited (Refer Note 13 below)	55 Monthly Installments	8.90% p.a. to 9.30% p.a.	64.00	64.00	165.03	-	293.03
ICICI Bank Limited (Refer Note 15 below)	25 Monthly Installments	8.50% p.a. to 10.00% p.a.	66.67	66.67	4.64	-	137.98
Kotak Mahindra Bank Limited (Refer Note 16 below)	50 Monthly Installments	10.10% p.a. to 10.20% p.a.	40.00	40.00	86.72	-	166.72
ICICI Bank Limited (Refer Note 17 below)	48 Monthly Installments	8.20% p.a. to 9.60% p.a.	22.92	25.00	53.08	-	101.00
ICICI Bank Limited (Refer Note 17 below)	48 Monthly Installments	8.50% p.a. to 9.90% p.a.	57.29	62.50	129.81	-	249.60
ICICI Bank Limited (Refer Note 17 below)	48 Monthly Installments	8.10% p.a. to 9.50% p.a.	34.38	37.50	80.58	-	152.46
Axis Bank Limited (Refer Note 18 below)	70 Monthly Installments	9.00% p.a. to 9.50% p.a.	30.00	60.00	150.55	-	240.55
Bajaj Finance Limited (Refer Note 19 below)	63 Monthly Installments	9.00% p.a. to 11.00% p.a.	34.33	34.33	103.00	6.94	178.60
Kotak Mahindra Bank Limited (Refer Note 20 below)	41 Monthly Installments	10.06% p.a	7.69	7.69	10.76	-	26.14
Kotak Mahindra Bank Limited (Refer Note 21 below)	66 Monthly Installments	10.13% p.a.	8.20	16.40	49.20	7.82	81.62
Kotak Mahindra Bank Limited (Refer Note 21 below)	67 Monthly Installments	10.02% p.a	12.50	30.00	90.00	16.78	149.28
Vehicle loans from various banks /financial institutions/ NBFCs (Refer Note 14 below)	9 to 59 Monthly Installments	7.90% p.a. to 11.30% p.a.	12.45	5.56	3.88	-	21.89
Loan from Related Parties	Repayable after 5 years from the date of receipt	9.00% p.a. to 12.00% p.a.	-	-	157.52	-	157.52
Total			**593.66**	**586.06**	**1,141.13**	**31.54**	**2,352.39**

* Current maturities of long term borrowings were reclasified to current borrowing in financial statements

As at March 31, 2025

Particulars	No of Installments due	Rate of Interest	Within 1 Year *	1 to 2 Years	2 to 5 Years	Above 5 Years	Loan outstanding
Axis Bank Limited (Refer Note 1 below)	9 Monthly Installments	8.80% p.a. to 9.40% p.a.	5.01	-	-	-	5.01
Axis Bank Limited (Refer Note 2 below)	9 Monthly Installments	9.00% p.a. to 9.20% p.a.	4.41	-	-	-	4.41
Axis Bank Limited (Refer Note 3 below)	3 Monthly Installments	10.30% p.a. to 10.70% p.a.	11.97	-	-	-	11.97
Axis Bank Limited (Refer Note 4 below)	21 Monthly Installments	9.20% p.a. to 11.00% p.a.	32.00	22.90	-	-	54.90
ICICI Bank Limited (Refer Note 5 below)	33 Monthly Installments	8.60% p.a. to 9.60% p.a.	35.65	35.65	27.26	-	98.56
State Bank of India (Refer Note 6 below)	8 Monthly Installments	9.00% p.a. to 9.80% p.a.	12.80	-	-	-	12.80
Bajaj Finance Limited (Refer Note 7 below)	35 Monthly Installments	8.40% p.a. to 9.50% p.a.	40.27	44.25	46.25	0.36	131.13
State Bank of India (Refer Note 8 below)	24 Monthly Installments	9.60% p.a. to 10.60% p.a.	25.16	27.11	-	-	52.27
State Bank of India (Refer Note 9 below)	27 Monthly Installments	9.60% p.a. to 10.70% p.a.	14.26	15.76	4.46	-	34.48
State Bank of India (Refer Note 10 below)	50 Monthly Installments	9.60% p.a. to 9.80% p.a.	15.90	17.54	44.54	-	77.98
Bajaj Finance Limited (Refer Note 11 below)	35 Monthly Installments	8.90% p.a. to 9.50% p.a.	10.43	11.46	11.96	-	33.85
Bajaj Finance Limited (Refer Note 12 below)	49 Monthly Installments	9.20% p.a. to 10.00% p.a.	29.95	30.00	63.11	-	123.06
Bajaj Finance Limited (Refer Note 13 below)	67 Monthly Installments	9.25% p.a	26.67	64.00	192.00	36.41	319.08
Vehicle loans from various banks /financial institutions (Refer Note 14 below)	9 to 46 Monthly Installments	8.80% p.a. to 10.40% p.a.	9.54	6.48	4.89	-	20.91
Loan from Related Parties	Repayable after 5 years from the date of receipt	9.00% p.a. to 12.00% p.a.	-	-	437.08	-	437.08
Total			**274.02**	**275.15**	**831.55**	**36.77**	**1,417.49**

* Current maturities of long term borrowings were reclasified to current borrowing in financial statements

Notes:

1) Term Loan facility under the Guaranteed Emergency Credit Line (GECL) from Axis Bank Limited is secured by way of a second pari passu charge over the Movable Fixed Assets created out of the term loans, the immovable properties comprising industrial lands and sheds situated in Telangana and Karnataka registered in the name of Virupaksha Organics Ltd., and the entire current assets and unencumbered movable fixed assets of the Company, both present and future. The facility is further backed by the personal guarantees of Mr. G. Chandra Moulishwar Reddy, Managing Director, Mr. Balasubba Reddy, Executive Director and Mrs. G. Vedavathi, Director of the company.

2) Term Loan facility under the Guaranteed Emergency Credit Line (GECL) from Axis Bank Limited is secured by way of a second pari passu charge over the Movable Fixed Assets created out of the term loans, the immovable properties comprising industrial lands and sheds situated in Telangana and Karnataka registered in the name of Virupaksha Organics Ltd., and the entire current assets and unencumbered movable fixed assets of the Company, both present and future. The facility is further backed by the personal guarantees of Mr. G. Chandra Moulishwar Reddy, Managing Director, Mr. Balasubba Reddy, Executive Director and Mrs. G. Vedavathi, Director of the company.

3) Term Loan facility from Axis Bank Limited is secured by way of an exclusive charge on the movable fixed assets created out of the term loan. Further, a first charge is created over immovable assets comprising industrial lands and sheds situated in Telangana and Karnataka, registered in the name of Virupaksha Organics Ltd. A second charge is also created over the entire current assets and unencumbered movable fixed assets of the Company, both present and future. The facility is additionally secured by the personal guarantees of Mr. G. Chandra Moulishwar Reddy, Managing Director, Mr. Balasubba Reddy, Executive Director and Mrs. G. Vedavathi, Director of the company.

4) Term Loan facility from Axis Bank Limited is secured by way of an exclusive charge on the movable fixed assets created out of the term loan. Further, a first charge is created over immovable assets comprising industrial lands and sheds situated in Telangana and Karnataka, registered in the name of Virupaksha Organics Ltd. A second charge is also created over the entire current assets and unencumbered movable fixed assets of the Company, both present and future. The facility is additionally secured by the personal guarantees of Mr. G. Chandra Moulishwar Reddy, Managing Director, Mr. Balasubba Reddy, Executive Director and Mrs. G. Vedavathi, Director of the company.

5) Term Loan facility under the Emergency Credit Line Guarantee Scheme (ECLGS) from ICICI Bank Limited is secured by way of a second charge over the immovable assets comprising various industrial lands and sheds situated in Telangana and Karnataka, registered in the name of Virupaksha Organics Ltd. The security also extends to a second charge on the entire current assets and unencumbered movable fixed assets of the Company, both present and future. The facility is further secured by the personal guarantees of Mr. G. Chandra Moulishwar Reddy, Managing Director, Mr. Balasubba Reddy, Executive Director and Mrs. G. Vedavathi, Director of the company.

6) Working Capital Term Loan facility under Guaranteed Emergency Credit Line (GECL) is secured by hypothecation and first charge on the company's property, plant and equipment including machinery, forming the primary security. Additionally, a pari passu first charge is created over various industrial lands and sheds situated in Telangana and Karnataka, registered in the name of Virupaksha Organics Ltd., which serve as collateral security for all credit facilities extended by State Bank of India. The loan is further backed by the personal guarantees of Mr. G. Chandra Moulishwar Reddy, Managing Director, Mr. Balasubba Reddy, Executive Director and Mrs. G. Vedavathi, Director of the company.

7) Term Loan facility from Bajaj Finance Limited is secured by way of pari passu first charge on the present and future Property, Plant, and Equipment. A second pari passu charge has been created on the present and future current assets of the company. Additionally, the loan is secured by the personal guarantees of Mr. G. Chandra Moulishwar Reddy (Managing Director), Mr. Balasubba Reddy, Executive Director and Mrs. G. Vedavathi, Director of the company.

8) Term Loan facility is secured by hypothecation and first charge on the company's property, plant and equipment including machinery, forming the primary security. Additionally, a pari passu first charge is created over various industrial lands and sheds situated in Telangana and Karnataka, registered in the name of Virupaksha Organics Ltd., which serve as collateral security for all credit facilities extended by State Bank of India and other consortium lenders. The loan is further backed by the personal guarantees of Mr. G. Chandra Moulishwar Reddy, Managing Director, Mr. Balasubba Reddy, Executive Director and Mrs. G. Vedavathi, Director of the company.

9) Term Loan facility is secured by hypothecation and first charge on the company's property, plant and equipment including machinery, forming the primary security. Additionally, a pari passu first charge is created over various industrial lands and sheds situated in Medak and Rangareddy districts, Telangana, registered in the name of Virupaksha Organics Ltd., which serve as collateral security for all credit facilities extended by State Bank of India and other consortium lenders. The loan is further backed by the personal guarantees of Mr. G. Chandra Moulishwar Reddy, Managing Director, Mr. Balasubba Reddy, Executive Director and Mrs. G. Vedavathi, Director of the company.

10) Term Loan facility is secured by hypothecation and first charge on the company's property, plant and equipment including machinery, forming the primary security. Additionally, a pari passu first charge is created over various industrial lands and sheds situated in Medak and Rangareddy districts, Telangana, registered in the name of Virupaksha Organics Ltd., which serve as collateral security for all credit facilities extended by State Bank of India and other consortium lenders. The loan is further backed by the personal guarantees of Mr. G. Chandra Moulishwar Reddy, Managing Director, Mr. Balasubba Reddy, Executive Director and Mrs. G. Vedavathi, Director of the company.

11) Term Loan facility from Bajaj Finance Limited is secured by way of pari passu first charge on the present and future Property, Plant, and Equipment. A second pari passu charge has been created on the present and future current assets of the company. Additionally, the loan is secured by the personal guarantees of Mr. G. Chandra Moulishwar Reddy (Managing Director), Mr. Balasubba Reddy, Executive Director and Mrs. G. Vedavathi, Director of the company.

12) Term Loan facility from Bajaj Finance Limited is secured by way of pari passu first charge on the present and future Property, Plant, and Equipment. A second pari passu charge has been created on the present and future current assets of the company. Additionally, the loan is secured by the personal guarantees of Mr. G. Chandra Moulishwar Reddy (Managing Director), Mr. Balasubba Reddy, Executive Director and Mrs. G. Vedavathi, Director of the company.

13) Term Loan facility from Bajaj Finance Limited is secured by way of First Pari Passu Charge on present and Property, Plant, and Equipment. Second Pari Passu Charge on present and Future Current Assets of the company. Additionally, the loan is secured by the personal guarantees of Mr. G. Chandra Moulishwar Reddy (Managing Director), Mr. Balasubba Reddy, Executive Director and Mrs. G. Vedavathi, Director of the company.

14) Vehicle Loans from various banks/financial institutions/NBFC are secured by the hypothecation of specific assets purchased from those loans.

15) Term Loan facility from ICICI Bank Limitd is secured by way of First Pari Passu Charge on present and Property, Plant, and Equipment. Second Pari Passu Charge on present and Future Current Assets of the company. Additionally, the loan is secured by the personal guarantees of Mr. G. Chandra Moulishwar Reddy (Managing Director), Mr. Balasubba Reddy, Executive Director and Mrs. G. Vedavathi, Director of the company.

16) Term Loan facility from Kotak Mahindra Bank Limitd is secured by way of First Pari Passu Charge on present and Property, Plant, and Equipment. Second Pari Passu Charge on present and Future Current Assets of the company. Additionally, the loan is secured by the personal guarantees of Mr. G. Chandra Moulishwar Reddy (Managing Director), Mr. Balasubba Reddy, Executive Director and Mrs. G. Vedavathi, Director of the company.

17) Term Loan facility from ICICI Bank Limitd is secured by way of First Pari Passu Charge on present and Property, Plant, and Equipment. Second Pari Passu Charge on present and Future Current Assets of the company. Additionally, the loan is secured by the personal guarantees of Mr. G. Chandra Moulishwar Reddy (Managing Director), Mr. Balasubba Reddy, Executive Director and Mrs. G. Vedavathi, Director of the company.

18) Term Loan facility from Axis Bank Limitd is secured by way of First Pari Passu Charge on present and Future Current Assets of the company. Second Pari Passu Charge on present and Property, Plant, and Equipment. Additionally, the loan is secured by the personal guarantees of Mr. G. Chandra Moulishwar Reddy (Managing Director), Mr. Balasubba Reddy, Executive Director and Mrs. G. Vedavathi, Director of the company.

19) Term Loan facility from Bajaj Finance Limitd is secured by way of First Pari Passu Charge on present and Property, Plant, and Equipment. Second Pari Passu Charge on present and Future Current Assets of the company. Additionally, the loan is secured by the personal guarantees of Mr. G. Chandra Moulishwar Reddy (Managing Director), Mr. Balasubba Reddy, Executive Director and Mrs. G. Vedavathi, Director of the company.

20) Term Loan from Kotak Mahindra Bank Limited (taken over from ICICI Bank) is secured by way of an exclusive charge by hypothecation on the entire current assets of the Oxygenta Pharmaceutical Limited, both present and future and an exclusive charge by hypothecation on the entire movable fixed assets of the Oxygenta Pharmaceutical Limited, both present and future. The facility is further secured by way of an exclusive charge by mortgage on the immovable property situated at Survey No. 252/1, Aroor Village, Sadasivpet Mandal, Medak District, Telangana. The facility is additionally secured by the Corporate Guarantee of Virupaksa Organics Limited and DSRA of ₹150 lakhs.

21) Term Loan from Kotak Mahindra Bank Limited is secured by way of an exclusive charge by hypothecation on the entire current assets of the Oxygenta Pharmaceutical Limited, both present and future and an exclusive charge by hypothecation on the entire movable fixed assets of the Oxygenta Pharmaceutical Limited, both present and future. The facility is further secured by way of an exclusive charge by mortgage on the immovable property situated at Survey No. 252/1, Aroor Village, Sadasivpet Mandal, Medak District, Telangana. The facility is additionally secured by the Corporate Guarantee of Virupaksa Organics Limited and DSRA of ₹150 lakhs.

41 Disclosures required under Section 22 of the Micro, Small and Medium Enterprises Development Act, 2006.

Dues to Micro, Small and Medium Enterprises have been determined to the extent such parties have been identified on the basis of information collected by the Management. The amount of dues payable to micro, small and medium enterprises are as follows:

Particulars	**As at March 31, 2026**	**As at March 31, 2025**
(a) the principal amount and the interest due thereon remaining unpaid to any supplier at the end of each accounting period/year;	741.30	402.36
(b) the amount of interest paid by the buyer in terms of Section 16 of the MSMED Act, along with the amount of the payment made to the supplier beyond the appointed day during each accounting period/year;	-	-
(c) the amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under this MSMED Act;	-	-
(d) the amount of interest accrued and remaining unpaid at the end of the each accounting period/year; and	0.11	-
(e) the amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprise, for the purpose of disallowance of a deductible expenditure under Section 23 of the MSMED Act	-	-

42. Employee Benefits:

The employee benefit schemes are as follows:

i) Defined contribution plan:

The Group makes certain defined contribution plans for qualifying employees. Under the scheme, the Group is required to contribute a specified percentage of the payroll costs to fund the benefits. These contributions are made to the Fund administered and managed by the Government of India. The Group's monthly contributions are charged to the Consolidated Statement of Profit and Loss in the period they are incurred.

Defined contribution plans: The group has recognised the following amount in the Consolidated Statement of Profit and Loss for the year

Particulars	**For the year ended March 31, 2026**	**For the year ended March 31, 2025**
i) Contribution to employees provident fund	23.94	19.39
ii) Contribution to employees state insurance	1.62	1.62
Total	25.56	21.01

ii) Defined Benefit plan:

Gratuity Benefits Provided by the company

In accordance with applicable Indian laws, the Company has a defined benefit plan which provides for gratuity payments (the "Gratuity Plan") and covers certain categories of employees in India. The Gratuity Plan provides a lump sum gratuity payment to eligible employees at retirement or termination of their employment. The amount of the payment is based on the respective employee's last drawn salary and the years of employment with the Company. Liabilities in respect of the Gratuity Plan are determined by an actuarial valuation, based upon which the Company makes contributions to the Gratuity Fund (LIC).

The following table sets out the funded status of the gratuity plan and the amounts recognised in the Company's financial statements as per actuarial valuation as at March 31, 2026 and March 31, 2025:

a) The components of gratuity cost recognised in the consolidated statement of Profit and Loss and other comprehensive income for the years ended March 31, 2026 and March 31, 2025 consist of the following:

Particulars	**For the year ended March 31, 2026**	**For the year ended March 31, 2025**
Amount recognised in consolidated statement of profit and loss in respect of defined benefit plan is as follows:		
Current service cost	17.02	11.10
Past service cost	(6.34)	
Interest cost	5.88	4.94
Expected return on plan assets/ Interest Income	(1.12)	(1.11)
Defined benefit cost included in consolidated statement of profit and loss	**15.44**	**14.93**

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Re-measurement effects recognised in Other Comprehensive Income (OCI):		
Actuarial (gains) or losses arising from changes in demographic assumptions	(0.02)	-
Actuarial (gains) or losses arising from changes in financial assumptions	(8.05)	3.29
Actuarial (gains) or losses arising from changes in experience assumptions	7.93	(7.23)
Return on plan assets (excluding interest income)	(0.03)	0.03
Defined benefit costs recognised in OCI	**(0.17)**	**(3.91)**

b) Details of the employee benefits obligations and plan assets are provided below:

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Amount recognised in consolidated statement of assets and liabilities		
Present value of unfunded defined benefit obligations	10.65	
Present value of funded defined benefit obligations	93.62	83.68
Fair value of plan assets	(16.48)	(15.33)
Net liability arising from defined benefit obligation	**87.79**	**68.35**

c) Reconciliation of opening and closing balances of the present value of the defined benefit obligations:

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Defined benefit obligation at the beginning of the year	83.68	72.04
Transfer in/(out) obligation	-	-
Acquisition of Subsidiary	8.77	1.00
Current service cost	17.02	11.10
Past service cost	(6.34)	
Interest cost	5.88	4.94
Remeasurements due to:		
Actuarial (gains) or losses arising from changes in demographic assumptions	(0.02)	-
Actuarial (gains) or losses arising from changes in financial assumptions	(8.05)	3.43
Actuarial (gains) or losses arising from changes in experience assumptions	7.93	(5.73)
Benefits paid by company	(4.60)	(3.10)
Defined benefit obligation at the year end	**104.27**	**83.68**

d) Details of changes in the fair value of plan assets are as follows:

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Opening fair value of the plan assets	15.33	14.26
Expected return/ Interest Income	1.12	1.10
Re-measurement – Return on Assets (excluding interest income)	0.03	(0.03)
Contributions by Employer	-	-
Fair value of plan asset at the year end	**16.48**	**15.33**

e) Sensitivity Analysis:

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Defined benefit obligation	**Increase**	**Increase**
Effect of 0.5% change in assumed discount rate	99.73	78.34
Effect of 0.5% change in assumed salary growth rate	107.14	83.6
Effect of 10% change in assumed attrition rate	103.86	81.31

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Defined benefit obligation	**Decrease**	**Decrease**
Effect of 0.5% change in assumed discount rate	109.17	85.31
Effect of 0.5% change in assumed salary growth rate	101.45	79.79
Effect of 10% change in assumed attrition rate	104.68	82.09

f) The principal assumptions used for the purposes of actuarial valuations were as follows:

Particulars	**For the year ended March 31, 2026**	**For the year ended March 31, 2025**
Mortality table (LIC)	IALM 2012-14 (ultimate)	IALM 2012-14 (ultimate)
Discounting rate	6.98% p.a. - 7.25% p.a.	6.70% p.a.
Rate of escalation in salary	7.00% p.a. - 10.00% p.a.	10.00% p.a.

Note:

1. Discount rate: The discount rate is based on the prevailing market yields of Indian government securities as at the balance sheet date for the estimated term of the obligations.

2. Salary Escalation Rate: The estimates of future salary increases, considered in actuarial valuation, takes into account the inflation, seniority, promotion and other relevant factors such as supply and demand in the employment market.

g) Maturity profile of defined benefit obligation

Projected benefits payable in future years from the date of reporting	**For the year ended March 31, 2026**	**For the year ended March 31, 2025**
1st following year	6.78	9.98
2nd following year	10.01	5.49
3rd following year	7.50	8.18
4th following year	7.51	5.32
5th following year	11.49	6.24
Sum of years 6th to 10th	42.22	31.52
Sum of years 11th and above	143.49	95.93

h) Withdrawal Rates per annum

Age Band	**For the year ended March 31, 2026**	**For the year ended March 31, 2025**
25 & Below	20.00% p.a.	20.00% p.a.
25 to 35	15.00% p.a.	15.00% p.a.
35 to 45	10.00% p.a.	10.00% p.a.
45 to 55	5.00% p.a.	5.00% p.a.
55 & above	1.00% p.a.	1.00% p.a.

Compensated absences:

The Company provides for accumulation of compensated absences by certain categories of its employees. These employees can carry forward a portion of the recognised compensated absences and recognised them in future periods or receive cash in lieu thereof as per the Company's policy. The Company records a liability for compensated absences in the period in which the employee renders the services that increases this entitlement. The total liability recorded by the Company towards this obligation was ₹30.95 million and ₹48.94 million as at March 31, 2026 and March 31, 2025, respectively.

a) The Components of defined benefit costs recognised in consolidated statement of profit and loss and other comprehensive income for the years ended March 31,2026 and March 31, 2025 consist of the following:

Particulars	**For the year ended March 31, 2026**	**For the year ended March 31, 2025**
Amount recognised in consolidated statement of profit and loss in respect of defined benefit plan is as follows:		
Current service cost	4.27	19.76
Past service cost	(23.32)	
Interest cost	3.14	1.78
Expected return on plan assets/ Interest Income	-	-
Defined benefit cost included in consolidated statement of profit and loss	**(15.91)**	**21.54**
Re-measurement effects recognised in Other Comprehensive Income (OCI):		
Actuarial (gains) or losses arising from changes in demographic assumptions	-	-
Actuarial (gains) or losses arising from changes in financial assumptions	(1.03)	2.39
Actuarial (gains) or losses arising from changes in experience assumptions	3.88	4.20
Return on plan assets (excluding interest income)	-	-
Defined benefit costs recognised in OCI	**2.85**	**6.59**

b) Details of the employee benefits obligations and plan assets are provided below:

Particulars	**For the year ended March 31, 2026**	**For the year ended March 31, 2025**
Amount recognised in consolidated statement of assets and liabilities		
Present value of unfunded defined benefit obligations	30.95	48.94
Fair value of plan assets	-	-
Net liability arising from defined benefit obligation	**30.95**	**48.94**

c) Reconciliation of opening and closing balances of the present value of the defined benefit obligations:

Particulars	**For the year ended March 31, 2026**	**For the year ended March 31, 2025**
Defined benefit obligation at the beginning of the year	48.94	25.89
Transfer in/(out) obligation	-	-
Acquisition of Subsidiary	3.02	
Current service cost	4.27	19.76
Past service cost	(23.32)	
Interest cost	3.14	1.78
Remeasurements due to:		
Actuarial (gains) or losses arising from changes in demographic assumptions	-	-
Actuarial (gains) or losses arising from changes in financial assumptions	(1.03)	2.39
Actuarial (gains) or losses arising from changes in experience assumptions	3.88	4.20
Benefits paid by company	(7.95)	(5.08)
Defined benefit obligation at the year end	**30.95**	**48.94**

d) Sensitivity Analysis

Particulars	**For the year ended March 31, 2026**	**For the year ended March 31, 2025**
Defined benefit obligation	**Increase**	**Increase**
Effect of 0.5% change in assumed discount rate	29.53	45.78
Effect of 0.5% change in assumed salary growth rate	32.44	50.68
Effect of 10% change in assumed attrition rate	30.50	47.3

Particulars	**For the year ended March 31, 2026**	**For the year ended March 31, 2025**
Defined benefit obligation	**Decrease**	**Decrease**
Effect of 0.5% change in assumed discount rate	32.48	50.77
Effect of 0.5% change in assumed salary growth rate	29.56	45.84
Effect of 10% change in assumed attrition rate	31.44	49.15

e) The principal assumptions used for the purposes of actuarial valuations were as follows:

Particulars	**For the year ended March 31, 2026**	**For the year ended March 31, 2025**
Mortality table (LIC)	IALM 2012-14 (ultimate)	IALM 2012-14 (ultimate)
Discounting rate	6.98% p.a. - 7.25% p.a.	6.70% p.a.
Rate of escalation in salary	7.00% p.a. - 10.00% p.a.	10.00% p.a.

Note:

1. Discount rate: The discount rate is based on the prevailing market yields of Indian government securities as at the balance sheet date for the estimated term of the obligations.

2. Salary Escalation Rate: The estimates of future salary increases, considered in actuarial valuation, takes into account the inflation, seniority, promotion and other relevant factors such as supply and demand in the employment market.

g) Maturity profile of defined benefit obligation

Projected benefits payable in future years from the date of reporting	**For the year ended March 31, 2026**	**For the year ended March 31, 2025**
1st following year	2.44	4.24
2nd following year	2.39	3.59
3rd following year	1.96	3.83
4th following year	1.86	2.97
5th following year	3.44	2.97
Sum of years 6th to 10th	8.98	15.22
Sum of years 11th and above	48.18	79.35

h) Withdrawal Rates per annum

Age Band	**For the year ended March 31, 2026**	**For the year ended March 31, 2025**
25 & Below	20.00% p.a.	20.00% p.a.
25 to 35	15.00% p.a.	15.00% p.a.
35 to 45	10.00% p.a.	10.00% p.a.
45 to 55	5.00% p.a.	5.00% p.a.
55 & above	1.00% p.a.	1.00% p.a.

43. Reconciliation of revenue as per contract price and recognised in Consolidated Statement of Profit and Loss:

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Revenue as per contract price	8,990.04	8,104.36
Less: Discounts, rebates and incentives	(23.11)	(17.87)
Revenue as per consolidated statement of profit and loss	**8,966.93**	**8,086.49**

i) The amounts receivable from customers becomes due after expiry of credit period which on an average is less than 30 to 60 days. There is no financing component in any transaction with the customers.

ii) The Group does not provide performance warranty for products, therefore there is no liability towards performance warranty.

iii) The Group does not have any material performance obligations which are outstanding as at the year-end as the contracts entered for sale of goods are for short term in nature.

Disaggregation of revenue (excluding other operating income)
Revenue by timing of recognition

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Goods transferred at a point of time	8,961.98	8,082.91
Goods transferred over time	-	-
Service transferred at a point of time	4.95	3.58
Services transferred over time	-	-

Movement of Contract Liabilities are as Follows:

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Opening Liability	4.36	9.97
Add: Advances received during the year not recognized as revenue	38.28	4.36
Less: Revenue Recognized during the year from the balance at begining of the year	4.36	9.97
Closing Liability	**38.28**	**4.36**

44. Government grant receivable includes assistance in the form of export incentives under Foreign Trade Policy.

Particulars	As at March 31, 2026	As at March 31, 2025
Opening Balance	-	2.27
Add: Grant income accrued during the year	32.23	30.60
Less: Government grant received	(29.17)	(32.87)
Closing Balance	**3.06**	**-**

45. Segment Information

A. Operating Segments

The operations of the Group are limited to one segment viz. Pharmaceutical products including ingredients and intermediaries. The products being sold under this segment are of similar nature and comprises of pharmaceutical products only. The Company's Chief Operating Decision Maker (CODM) reviews the internal management reports prepared based on aggregation of financial information of the Company on a periodic basis, for the purpose of allocation of resources and evaluation of performance. Accordingly, management has identified pharmaceutical segment as the only operating segment for the Company. Therefore, based on the guiding principles given in Ind AS 108 on 'Operating Segments' there is no reportable segment for the Group.

B. Geographical Information:

Analysis of revenues by geography:

The following table shows the distribution of the Groups's revenues by country, based on the location of the customers:

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
India	7,024.67	6,697.65
Outside India	1,974.49	1,419.44
Total	**8,999.16**	**8,117.09**

Analysis of non current assets by geography:

The following table shows the distribution of the Group's non-current assets (other than financial instruments and deferred tax assets) by country, based on the location of assets:

Particulars	As at March 31, 2026	As at March 31, 2025
India	6,620.09	4,752.33
Outside India	-	-
Total	**6,620.09**	**4,752.33**

C. Information about major customers

There were no customers individually accounting for more than 10 % of the Company's revenue in the years ended March 31, 2026 and March 31, 2025.

46. Auditors Remuneration

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Statutory Auditor: -		
Audit Fee	1.89	1.39
Tax Audit	0.75	0.50
Total	**2.64**	**1.89**

47. Research & Development Expenses

Particulars	For the year Ended March 31, 2026	For the year Ended March 31, 2025
Lab Material and Consumables	16.60	14.31
Salaries	63.76	48.06
Rent	0.87	-
Professional Charges	12.63	8.64
Electricity Charges	3.27	1.51
Other Expenses	8.54	8.54
Total	**105.67**	**81.06**

48. Income taxes

a) Income tax expense/ (benefit) recognised in the consolidated statement of profit and loss.

Income tax expense recognised in the consolidated statement of profit and loss consists of the following:

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Current Taxes	270.69	217.42
Deferred Taxes	(1.19)	30.30
Prior Period Taxes	0.03	0.98
Total Tax Expense	**269.53**	**248.70**

b) Income tax expense/(benefit) recognised directly in Other Comprehensive Income/(loss).

Income tax expense/(benefit) recognised directly in Other Comprehensive Income/(loss) consist of the following:

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Income Tax effect on change in fair value of investments	(2.67)	2.10
Income Tax effect on Actuarial gain/ (loss) on post- employment benefit obligations	(0.65)	(1.09)
Total income tax expense/(benefit) recognized in the equity	**(3.32)**	**1.01**

c) Reconciliation of Effective Tax Rate:

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Profit before income taxes	1,009.60	1,035.84
Enacted tax rate in India	25.17%	25.17%
Computed expected tax expense	254.10	260.70
Effect on Income disallowed under Income Tax Act, 1961	(116.63)	(140.98)
Effect on expenses disallowed under Income Tax Act, 1961	80.65	122.09
Other items	14.45	6.19
Taxes not recognised on account of losses in the group	38.38	0.69
Difference arised due to Tax Rates	(1.42)	0.00
Income Tax Expense	**269.53**	**248.70**
Effective tax rate	**26.70%**	**24.01%**

d) Deferred tax assets and liabilities

The tax effects of significant temporary differences that resulted in deferred tax assets and liabilities and a description of the items that created these differences is given below:

As at March 31, 2026	Assets	Liabilities	Net Liability
Deferred tax assets/(liabilities):			
Property Plant & Equipment	(28.38)	(218.29)	(246.67)
ROU Asset	-	(18.72)	(18.72)
Investments	(1.10)	1.76	0.66
Borrowings	-	(1.03)	(1.03)
Lease Liabilities	-	18.31	18.31
Provisions	2.31	27.26	29.57
Trade Receivables	3.38	3.99	7.37
Stock Reserve	-	5.11	5.11
Tax Losses	197.86	-	197.86
Others	-	0.81	0.81
Total	**174.07**	**(180.80)**	**(6.73)**

As at March 31, 2025	Assets	Liabilities	Net Liability
Deferred tax assets/(liabilities):			
Property Plant & Equipment	-	(186.70)	(186.70)
ROU Asset	-	(5.76)	(5.76)
Investments	-	(2.43)	(2.43)
Borrowings	-	(0.09)	(0.09)
Lease Liabilities	-	4.61	4.61
Provisions	-	29.54	29.54
Trade Receivables	-	3.61	3.61
Others	-	(0.30)	(0.30)
Total	**-**	**(157.51)**	**(157.51)**

e) Movement in deferred tax assets and liabilities during the years ended March 31, 2026 and March 31, 2025.

Particulars	For the year ended March 31, 2026				
	As at April 01, 2025	Addition on account of subsidiaries	Recognized in the statement of Profit and Loss	Recognized in Other comprehensive income	As at March 31, 2026
Deferred tax assets/(liabilities)					
Property Plant & Equipment	(186.70)	(22.02)	(37.95)	-	(246.67)
ROU Asset	(5.76)	-	(12.96)	-	(18.72)
Investments	(2.43)	-	0.42	2.67	0.66
Borrowings	(0.09)	-	(0.94)	-	(1.03)
Lease Liabilities	4.61	-	13.70	-	18.31
Provisions	29.54	2.64	(3.26)	0.65	29.57
Trade Receivables	3.61	2.01	1.75	-	7.37
Stock Reserve	-	-	5.11	-	5.11
Tax Losses	-	163.64	34.22	-	197.86
Others	(0.30)	-	1.11	-	0.81
Net deferred tax assets/(liabilities)	**(157.51)**	**146.27**	**1.19**	**3.32**	**(6.73)**

Particulars	For the year ended March 31, 2025				
	As at April 01, 2024	Addition on account of subsidiaries	Recognized in the statement of Profit and Loss	Recognized in Other comprehensive income	As at March 31, 2025
Deferred tax assets/(liabilities)					
Property Plant & Equipment	(144.92)	(4.67)	(37.11)	-	(186.70)
ROU Asset	(3.23)	-	(2.53)	-	(5.76)
Investments	(0.15)	-	(0.18)	(2.10)	(2.43)
Borrowings	0.45	-	(0.54)	-	(0.09)
Lease Liabilities	2.59	-	2.02	-	4.61
Provisions	21.06	0.26	7.13	1.09	29.54
Trade Receivables	3.49	-	0.12	-	3.61
Others	(1.09)	-	0.79	-	(0.30)
Net deferred tax assets/(liabilities)	**(121.80)**	**(4.41)**	**(30.30)**	**(1.01)**	**(157.51)**

49. Financial risk management.

The Group's activities expose it to a variety of financial risks, including market risk, credit risk and liquidity risk. The Group's primary risk management focus is to minimise potential adverse effects of market risk on its financial performance. The Group's risk management assessment and policies and processes are established to identify and analyse the risks faced by the Group, to set appropriate risk limits and controls, and to monitor such risks and compliance with the same. Risk assessment and management policies and processes are reviewed regularly to reflect changes in market conditions and the Group's activities. The Board of Directors and the Audit Committee is responsible for overseeing the Group's risk assessment and management policies and processes.

a) Market risk

Market risk is the risk of loss of future earnings, fair values or future cash flows that may result from adverse changes in market rates and prices (such as interest rates, foreign currency exchange rates and commodity prices) or in the price of market risk-sensitive instruments as a result of such adverse changes in market rates and prices. Market risk is attributable to all market risk-sensitive financial instruments, all foreign currency receivables and payables and all short-term and long-term debt. The Group is exposed to market risk primarily related to foreign exchange rate risk and interest rate risk. Thus, the Group's exposure to market risk is a function of borrowing activities and revenue generating and operating activities in foreign currencies.

The below assumption has been made in calculating the sensitivity analysis:

The sensitivity of the relevant profit or loss item is the effect of the assumed changes in respective market risks. This is based on the financial assets and financial liabilities held at March 31, 2026 and March 31, 2025.

Interest rate risk

The Group is exposed to interest rate risk as its borrowings are primarily at floating interest rates. This exposes the Group to the risk of fluctuations in market interest rates. The risk is monitored and managed on an ongoing basis, taking into account the interest rate outlook and the overall cost of borrowing.

Interest rate sensitivity

For the years ended March 31, 2026, and March 31, 2025, every 1% increase or decrease in the floating interest rate component applicable to its loans and borrowings would affect the Group's net profit as shown in following table

Particulars	**As at March 31, 2026**	**As at March 31, 2025**
1% increase in Interest rate - decrease in profit	(22.74)	(9.47)
1% decrease in Interest rate - increase in profit	22.74	9.47

Foreign Currency risk

The Group's foreign exchange risk arises from its foreign currency revenues and expenses, (primarily in United States dollars). A portion of the Group's revenues are in this foreign currency, while a significant portion of its costs are in Indian rupees. As a result, if the value of the Indian rupee appreciates relative to these foreign currencies, the Group's revenues measured in Indian rupees may decrease. The exchange rate between the Indian rupee (₹) and this foreign currency has changed substantially in recent periods and may continue to fluctuate substantially in the future.

The following table analyses foreign currency risk from non-derivative financial instruments as at March 31, 2026 and March 31, 2025:

Particulars	**As at March 31, 2026**		**As at March 31, 2025**	
	USD	**INR**	**USD**	**INR**
Trade receivables and Trade Payables(net)	4.39	389.14	2.11	180.45
EEFC A/c’s	0.51	48.57	1.95	25.06

Sensitivity

Particulars	**As at March 31, 2026**	**As at March 31, 2025**
1% increase in USD rate - increase in profit	4.64	1.80
1% decrease in USD rate - decrease in profit	(4.64)	(1.80)

b) Credit risk

Credit risk is the risk of financial loss to the Group if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Group's receivables from customers and investment securities.

Trade and other receivables

The Group's exposure to credit risk is influenced mainly by the individual characteristics of each customer. The demographics of the customer, including the default risk of the industry and country in which the customer operates, also has an influence on credit risk assessment. Credit risk is managed through credit approvals, establishing credit limits and continuously monitoring the creditworthiness of customers to which the Group grants credit terms in the normal course of business. The Group establishes an allowance for doubtful debts and impairment that represents its estimate of expected losses in respect of trade and other receivables and investments.

Investments

The Group limits its exposure to credit risk by generally investing in liquid securities and only with counterparties that have a good credit rating. The Group does not expect any losses from non-performance by these counter-parties, and does not have any significant concentration of exposures to specific industry sectors or specific country risks.

Details of financial assets – not due, past due and impaired

None of the Group's cash equivalents, including term deposits with banks, were past due or impaired as at March 31, 2026. The Group's credit period for trade receivables payable by its customers generally ranges from 45 – 90 days

The maximum exposure to credit risk for trade receivables by geographic region is as follows:

Particulars	As at March 31, 2026	As at March 31, 2025
India	2,066.62	1437.90
Europe	270.65	98.74
Japan	93.94	19.25
United States of America	115.69	6.41
Rest of the world	57.50	95.49
Total	**2604.40**	**1657.79**

c) Liquidity risk

Liquidity risk is the risk that the Group will not be able to meet its financial obligations as they become due. The Group manages its liquidity risk by ensuring, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risk to the Group's reputation.

The Group's objective is to maintain a balance between continuity of funding and flexibility through the use of bank deposits and loans.

The table below summarises the maturity profile of the Group's financial liabilities based on contractual undiscounted payments:

Particulars	Less than 1 Year	1-2 Years	2-5 Years	More than 5 Years	Total
As at March 31, 2026					
Borrowings	2,294.02	586.06	1,141.13	31.54	**4,052.75**
Lease Liabilities	2.53	3.73	12.28	54.20	**72.74**
Trade payables	2,080.07	-	-	-	**2,080.07**
Other financial liabilities	470.23	-	-	-	**470.23**
As at March 31, 2025					
Borrowings	1,678.85	275.15	831.55	36.77	**2,822.32**
Lease Liabilities	1.69	1.99	7.66	10.70	**22.04**
Trade payables	1,228.72	-	-	-	**1,228.72**
Other financial liabilities	530.11	-	-	-	**530.11**

d) Capital management

The Group manages its capital to ensure that it will be able to continue as going concern while maximising the return to stakeholders through the optimisation of the debt and equity balances. The capital structure of the Group consists of net debt and total equity of the group. The Group is not subject to any externally imposed capital requirements. The Group's management reviews the capital structure of the Group on monthly basis. As part of this review, the management considers the cost of capital and the risks associated with each class of capital.

Gearing Ratio

The gearing ratio at the end of the reporting period is as follows:

Particulars	As at March 31, 2026	As at March 31, 2025
Debt*	4,052.75	2,822.32
Less:		
Cash & Cash equivalents & Other Bank Balances	131.81	192.91
Net Debt (A)	3,920.94	2,629.41
Total Equity (B)	5,136.23	4,566.20
Net Debt to equity ratio (A/B)	0.76	0.58

*Debt includes current and non-current borrowings

50. Financial Instruments

A) Classification of financial assets and liabilities

Particulars	As at March 31,2026		As at March 31,2025	
	Carrying Value	*Fair Value*	*Carrying Value*	*Fair Value*
Financial Assets				
a) Measured at fair value through Other comprehensive income (FVTOCI)				
Investments in Equity Instruments	298.64	298.64	278.91	278.91
b) Measured at fair value through profit and loss (FVTPL)				
Investments in Mutual Funds	86.63	86.63	42.88	42.88
c) Measured at amortised cost				
Loans	-	-	145.00	145.00
Trade Receivables	2,575.54	2,575.54	1,643.44	1,643.44
Cash and Cash Equivalents	93.38	93.38	145.62	145.62
Bank balances other than cash and cash equivalents	38.43	38.43	47.29	47.29
Other Financial Assets	78.94	78.94	289.01	289.01
Total (a+b+c)	**3,171.56**	**3,171.56**	**2,592.15**	**2,592.15**
Financial Liabilities				
a) Measured at amortised cost				
Borrowings	4,052.75	4,052.75	2,822.32	2,822.32
Lease Liabilities	72.74	72.74	22.04	22.04
Trade Payables	2,080.07	2,080.07	1,228.72	1,228.72
Other Financial liabilities	470.23	470.23	530.11	530.11
Total	**6,675.79**	**6,675.79**	**4,603.19**	**4,603.19**

B) Fair value hierarchy

Particulars	As at March 31, 2026	As at March 31, 2025	Level	Valuation techniques and key inputs
Financial Assets				
a) Measured at fair value through Other comprehensive income (FVTOCI)				
Investments in Equity Instruments (Unquoted)	260.30	225.57	3	Using discounted cashflow method (Refer below Note*)
Investments in Equity Instruments (Quoted)	38.34	53.34	1	Quoted market prices in active markets
b) Measured at fair value through profit and loss (FVTPL)				
Investments in Mutual Funds	86.63	42.88	1	Based on the net asset value ('NAV') as stated by the issuers of these mutual fund units in the published statements as at Balance Sheet date.

*Note: The following table shows the valuation techniques used in measuring Level 3 fair values for financial instruments measured at fair value in the statement of assets and liabilities, as well as the significant unobservable inputs used:

Type	Valuation Technique	Significant unobservable inputs	Inter-relationship between significant unobservable inputs and fair Value Measurement
Investments in Equity Instruments (Unquoted)	Discounted cashflow method: The valuation model considers the present value of expected payment, discounted using a risk-adjusted discount rate. The expected payment is determined by considering the possible scenarios of forecast revenue and EBITDA, the amount to be paid under each scenario and the probability of each scenario.	a. Forecast annual revenue growth rate b. Forecast EBITDA margin c. Risk-adjusted discount rate	The estimated fair value would increase (decrease) if: - the annual revenue growth rate were higher (lower); - the EBITDA margin were higher (lower); or - the risk adjusted discount rate were lower (higher). Generally a change in the annual revenue growth rate is accompanied by a directionally similar change in EBITDA margin

C) Fair value measurements

The Company uses the following hierarchy for determining and/or disclosing the fair value of financial instruments by valuation techniques:

a) Level 1

This level includes those financial instruments which are measured by reference to quoted prices (unadjusted) in active markets for identical assets or liabilities.

b) Level 2

This level includes financial assets and liabilities measured using inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e, as prices) or indirectly (i.e.derived from prices).

c) Level 3

This level includes financial assets and liabilities measured using inputs that are not based on observable market data (unobservable inputs). Fair values are determined in whole or in part, using a valuation model based on assumptions that are neither supported by prices from observable current market transactions in the same instrument nor are they based on available market data.

Notes:

a) There was no transfer between level 1 and level 2 fair value measurement.

b) Fair value of financial assets and financial liabilities that are not measured at fair value (but fair value disclosures are required)

The management assessed that fair value of Loans, Trade Receivables, Cash and Cash Equivalents, Bank balances other than cash and cash equivalents, Borrowings, Lease Liabilities, Trade Payables and other current financial assets and liabilities approximate their carrying amounts largely due to the short-term maturities of these instruments.

c) The following tables shows a reconciliation from the opening balance to the closing balance for level 3 fair values

Particulars	**As at March 31,2026**	**As at March 31,2025**
Opening Balance	225.57	126.47
Purchases During the year	30.48	119.10
Gain/(Loss)		
- in Other comprehensive Income	4.25	(20.00)
- in profit and loss, net	-	-
Closing Balance	**260.30**	**225.57**

51. Contingent liabilities, Corporate Guarantees and Capital Commitments

i) Contingent liabilities

Based on legal opinion /advice obtained, no financial implication to the company with respect to following cases is perceived as on the Balance Sheet date:

a. Claims against the company not acknowledged as debt

Particulars	As at March 31,2026	As at March 31,2025
Direct Tax matters*	27.22	26.15
Indirect Tax matters**	0.60	-
Legal Proceedings Initiated by TSSPDCL***	18.74	18.74
Other Claims[#]	1.01	1.01

*The Company received a demand notice amounting to ₹ 26.15 million in FY 2022-23, against which a detailed response was submitted. A remand report in favour of the Company was received before March 2024. However, the final order from the Faceless Assessment authorities is still pending as on the reporting date. The management believes the matter will be resolved without any material liability.

Oxygenta Pharmaceuticals Limited (Subsidiary) has an outstanding income tax demand of ₹0.17 million for Assessment Year 2009–10 arising under Section 143(1)(a) of the Income-tax Act, 1961. The demand is under dispute along with an outsatnding interest amounting to ₹0.11 million and has outstanding TDS-related demands aggregating to ₹0.90 million from Financial Years 2013–14 to 2023–24, comprising interest, short deduction of tax and late filing fees.

**Oxygenta Pharmaceuticals Limited (Subsidiary) has an outstanding GST demand of ₹0.60 million pertaining to Financial Year 2017–18, primarily relating to disallowance of input tax credit and differences/mismatches in GST returns. The matter is under dispute and is subject to proceedings/notices issued under the GST law, including DRC-07 and DRC-01C.

***The Company had acquired a plant in the past from S2 Engineering Services Industry Private limited. Subsequently, legal proceedings were initiated by Southern Power Distribution Company of Telangana Ltd(TSSPDCL) against S2 Engineering Services, claiming an amount of ₹18.74 million. As per the contractual terms, S2 Engineering Services has undertaken the responsibility to discharge the liability in the event of an adverse judgment. While the matter is currently sub judice, any financial impact on the Company is expected to be recoverable from the vendor (S2 Engineering Services Industry Private limited).

#A civil suit has been filed by Sesa Chem India Pvt. Ltd. against the Company before the Honble Junior Civil Judge, City Civil Courts, Hyderabad for recovery of ₹ 1.01 million (including principal amount of ₹ 0.61 million and interest of ₹ 0.40 million relating to supply of materials. The matter is currently sub-judice and pending final adjudication.

b. Pending resolution of the respective proceedings, it is not practicable for the Company to estimate the timings of cash outflows, if any, in respect of the above as it is determinable only on receipt of judgements/ decisions pending with various forums/ authorities.

ii) Corporate Guarantees given to Subsidiary Companies

Subsidiary	Guarantee against	Guarantee provided to	As at March 31,2026	As at March 31,2025
Oxygenta Pharmaceutical Limited	Term loan and cash credit	Kotak Mahindra Bank Limited	466.00	-

iii) Capital commitments

Particulars	As at March 31,2026	As at March 31,2025
Estimated amount of contracts remaining to be executed on capital account and not provided for (net of capital advances)	124.34	321.73

52. Dividend

The final dividend on shares is recorded as a liability on the date of approval by the shareholders and interim dividend is recorded as liability on the date of declaration by the Company's Board of directors.

The Company declares and pays dividend in Indian rupees (₹) . Companies are required to pay/ distribute dividend after deducting applicable withholding income taxes.

The amount of per share dividend recognised as distribution to equity shareholders in accordance with Companies Act, 2013 is as follows:

(Amount in ₹)

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Interim Dividend for FY 2024-25[(1)]	-	1.20
Final Dividend for FY 2025-265[(2)]	1.00	-

1) During the year ended March 31, 2025 on account of the interim dividend for the financial year 2024-25 the company has incurred a net cash outflow of ₹ 49.23 million
2) The Board have proposed a final dividend of ₹ 1.00 (10.00%) per fully paid equity share of ₹ 10.00 each for the year ended March 31, 2026, subject to the approval of shareholders in the ensuing annual general meeting and are not recognised as a liability. The dividend, if approved by the shareholders, would involve a cash outflow of ₹ 61.53 million.

53. Corporate Social Responsibility:

As per Section 135 of the Companies Act, 2013, Meeting the applicability threshold, needs to spend at least 2% of its Average net profit for the immediately preceding three financials' years on CSR activities calculated as per section 198 of Companies Act, 2013. The areas of CSR Activities are Eradication of Poverty and providing Education. A CSR committee has been formed by the company as per the Act. The details of fund primarily utilized through the year on these activities which are specified in schedule VII of the Companies act,2013.

Particulars	As at March 31,2026	As at March 31,2025
Amount required to be spent by the company during the year.	17.53	12.42
Surplus of previous financial year available for set-off	1.90	6.68
Amount of expenditure incurred during the year	16.43	7.64
Shortfall at the end of the year	-	-
Total of previous years shortfall,	-	-
Reason for shortfall	NA	NA
Nature of CSR activities	Eradication of poverty and providing Education	
Related party transactions in relation to CSR expenditure	-	-
Where a provision is made with respect to a liability incurred by entering into a contractual obligation, the movements in the provision during the year should be shown separately	NA	NA
Excess amount available for set-off in succeeding financial years	0.80	1.90

54. Charges Not Yet Satisfied with Registrar of Companies

As per the records available on the Ministry of Corporate Affairs (MCA) portal, the following charges have not been marked as satisfied, although the corresponding loans were fully repaid during earlier years.

Name of the Lender	Date of Creation	Amount	Date of Closure of loan	Reason for Non-Filing
Reliance Commercial Finance Limited	March 30, 2018	23.80	April 06, 2021	No objection certificate pending
Dewan Housing Finance Corporation Limited	January 31, 2017	8.71	January 31, 2020	No objection certificate pending

55. Related party disclosures

A. The list of related parties of the Company is given below:

Name	Relationship
Virupaksha Green Energy Private Limited (w.e.f. December 24, 2024)	Wholly owned Subsidiary company
Progenerics Pharma Private Limited (w.e.f. December 30, 2024)	Wholly owned Subsidiary company
Oxygenta Pharmaceuticals Limited (from April 22, 2025 to June 19, 2025)	Associate company
Oxygenta Pharmaceuticals Limited (w.e.f. June 20, 2025)	Subsidiary company
Bharath Advanced Therapeutics Private Limited (w.e.f. March 30, 2024)	Associate company
Virupaksha Lifesciences LLP	Associate
Key Managerial Personnel (KMP):	
Chandra Mouliswar Reddy Gangavaram	Managing Director
Balasubba Reddy Mamilla	Whole-time director
Chandrasekhar Reddy Gangavaram	Whole-time director
Vedavathi Gangavaram	Director
Janardhana Reddy Yeddula	Independent Director
Shruti Gupta (till September 03, 2025)	Independent Director
Sidda Reddy Kanuparthi (w.e.f. September 26, 2025)	Independent Director
Veera Reddy Arava (w.e.f. September 03, 2025)	Independent Director
Murali Krishna Kurada (w.e.f. September 03, 2025)	Independent Director
Padmanabhani Venkata Appaji (from September 03, 20225 to September 26, 2025)	Independent Director
Prasad Reddy Battinapatla (from May 03, 2024)	Chief Financial Officer
Vikas Kurada (from June 17, 2023)	Company Secretary
Other Related party	
Mamilla Nagarjun Reddy	Close Member of Key Managerial Person
Kotla Suraj Reddy	Close Member of Key Managerial Person
Kondapalli Sandeep Reddy	Close Member of Key Managerial Person
Gangavaram Sri Lakshmi	Close Member of Key Managerial Person
G Sri Vidya	Close Member of Key Managerial Person
M Padmaja	Close Member of Key Managerial Person
G Rukmini	Close Member of Key Managerial Person
Virupaksha Laboratories Private Limited	Entity over which the KMP and/or their relatives is able to exercise control
Virupaksha Minerals LLP	Entity over which the KMP and/or their relatives is able to exercise control
Viruj Pharmaceuticals Private Limited	Entity over which the KMP and/or their relatives is able to exercise control
Virupaksha Securities Private Limited	Entity over which the KMP and/or their relatives is able to exercise control
V Indaf Overseas Private Limited	Entity over which the KMP and/or their relatives is able to exercise control
Chandra Mouliswar Reddy Gangavaram – HUF	Entity over which the KMP and/or their relatives is able to exercise control
Sreekari Developers	Enterprise over which KMP exercise significant influence
Arya Fashion & Arts	Enterprise over which KMP exercise significant influence
Virupaksha Infra Developers	Entity over which the KMP and/or their relatives is able to exercise control
Veda Granites	Entity over which the KMP and/or their relatives is able to exercise control
Kanuparthi Trading LLP	Enterprise over which KMP is able to exercise control

B. Summary of Related Party Transactions

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Revenue from Operations		
Oxygenta Pharmaceuticals Limited	45.69	-
Bharath Advanced Therapeutics Private Limited	-	4.35
Viruj Pharmaceuticals Private Limited	71.82	114.74
Virupaksha Laboratories Private Limited	236.66	287.65
	354.17	**406.74**
Sale of Property, Plant & Equipment		
Oxygenta Pharmaceuticals Limited	9.82	-
	9.82	**-**
Purchase of Raw Material		
Oxygenta Pharmaceuticals Limited	52.43	-
Virupaksha Laboratories Private Limited	755.72	700.59
V Indaf Overseas Private Limited	0.23	-
Arya Fashion and Arts	2.80	1.45
	811.18	**702.04**
Borrowings		
Chandra Mouliswar Reddy Gangavaram	35.50	13.66
Balasubba Reddy Mamilla	-	303.60
Vedavathi Gangavaram	35.50	13.62
	71.00	**330.88**
Repayment of Loan		
Chandra Mouliswar Reddy Gangavaram	26.28	94.24
Balasubba Reddy Mamilla	300.00	11.17
Vedavathi Gangavaram	23.33	255.72
Chandra Mouliswar Reddy Gangavaram – HUF	-	10.58
	349.61	**371.71**
Interest on Unsecured Loan		
Chandra Mouliswar Reddy Gangavaram	0.73	1.18
Balasubba Reddy Mamilla	5.29	3.20
Vedavathi Gangavaram	18.04	22.46
Chandra Mouliswar Reddy Gangavaram – HUF	-	1.28
	24.06	**28.12**
Interest Income from Loans		
Oxygenta Pharmaceuticals Limited	2.15	-
	2.15	**-**
Rental Income		
Virupaksha Laboratories Private Limited	0.03	-
	0.03	**-**
Expenses		
Oxygenta Pharmaceuticals Limited (Other Expenses)	0.61	-
Virupaksha Laboratories Private Limited (Rent)	1.25	1.75
Virupaksha Laboratories Private Limited (Other Expenses)	0.94	0.90
	2.80	**2.65**
Short-term employee benefits - Director’s		
Chandra Mouliswar Reddy Gangavaram	36.00	36.00
Balasubba Reddy Mamilla	7.01	6.84
Chandrasekhar Reddy Gangavaram	5.90	5.76
	48.91	**48.60**
Sitting Fee - Director's		
Janardhana Reddy Yeddula	0.75	0.03
Murali Krishna Kurada	0.69	-
Veera Reddy Arava	0.81	-
Sidda Reddy Kanuparthi	0.42	-
Padmanabhani Venkata Appaji	0.07	-
Shruti Gupta	0.04	0.03
	2.78	**0.06**

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Short-term employee benefits - Other than Director's		
Prasad Reddy Battinapatla	5.43	4.37
Vikas Kurada	1.13	0.88
Mamilla Nagarjun Reddy	6.60	5.64
Kotla Suraj Reddy	6.60	5.64
Kondapalli Sandeep Reddy	6.60	5.64
G Rukmini	0.96	0.96
	27.32	**23.13**

C. The Company has the following amounts due from/to related Parties

Particulars	As at March 31, 2026	As at March 31, 2025
Trade Receivables		
Bharath Advanced Therapeutics Private Limited	5.04	5.04
Viruj Pharmaceuticals Private Limited	14.46	10.96
Virupaksha Laboratories Private Limited	47.33	132.84
Virupaksha Lifesciences LLP	9.24	9.24
	76.07	**158.08**
Other Current Assets - Advance to Suppliers		
Arya Fashion & Arts	-	2.18
	-	**2.18**
Other Current Financial Liabilities - Advances		
Sreekari Developers	5.00	5.00
V Indaf Overseas Private Limited	-	0.01
	5.00	**5.01**
Loan from Related parties - Long-term borrowings		
Chandra Mouliswar Reddy Gangavaram	9.36	-
Balasubba Reddy Mamilla	2.56	302.70
Vedavathi Gangavaram	148.16	134.38
	160.08	**437.08**
Other current financial liabilities - Short term employee benefits		
Chandra Mouliswar Reddy Gangavaram	3.00	3.00
Balasubba Reddy Mamilla	0.63	0.57
Chandrasekhar Reddy Gangavaram	0.53	0.48
Prasad Reddy Battinapatla	0.45	0.40
Vikas Kurada	0.08	0.07
Mamilla Nagarjun Reddy	0.55	0.47
Kotla Suraj Reddy	0.55	0.47
Kondapalli Sandeep Reddy	0.55	0.47
G Rukmini	0.09	0.08
	6.43	**6.01**

*** As per Schedule VI (Para 11(I)(A)(i)(g)) of SEBI (ICDR) Regulations**

Terms and conditions of transactions with related parties

All Related Party Transactions entered during the year were in ordinary course of the business and on arm's length basis.

Outstanding balances at the year-end are unsecured and gross amounts are settled in cash.

There have been no guarantees provided or received for any related party receivables or payables.

For the year ended March 31, 2026, the Company has not recorded any impairment of receivables relating to amounts owed by related parties. This assessment is undertaken each financial year through examining the financial position of the related party and the market in which the related party operates.

Some of the Key Managerial Personnel of the Company are also covered under the Company's Gratuity Plan and Compensated absences along with the other employees of the Company. Proportionate amounts of gratuity and compensated absences accrued under the Company's Gratuity Plan and Compensated absences have not been separately computed or included in the above disclosure.

Refer note 56 for terms and conditions of loans given

56. Disclosures pursuant to Regulation 34(3) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Section 186 of the Companies Act, 2013

A. Amount of loans / advances in nature of loans given to others

Particulars	**For the year ended March 31, 2026**	**For the year ended March 31, 2025**
Loans to others*		
(i) Oxygenta Pharmaceutical Limited		
Balance as at the beginning of the year	-	-
Loans given	-	145.00
Loans repaid	-	-
Balance as at the end of the year	-	145.00
Maximum amount outstanding at any time during the year	-	145.00
(Oxygenta Pharmaceuticals Limited has utilised the loan for working capital requirements. It is repayable over a period of 3 years along with interest bearing a rate of 9% p.a.,)		

*For the year ended March 31, 2025, Oxygenta Pharmaceutical Limited is not a Related Party to the Virupaksha Organics Limited. However as on June 20, 2026, it became a Subsidiary (refer note 61), hence the balance as at the year end March 31, 2026 has been eliminated due to the consolidation effect. However, the balance as at the year ended March 31, 2026 was ₹ 521.11 million including interest.

*On December 30, 2024, Progenerics Pharma Private Limited became a wholly-owned subsidiary (refer note 61), hence the balance as at the year end March 31, 2026 and March 31, 2025 has been eliminated due to the consolidation effect. However, the balance as at the year ended March 31, 2026 and March 31, 2025 was ₹ 40.67 million and ₹ 37.84 million including interest.

B. Details of Investments made are given in notes 6 and 7

C. During the year, the Holding Company provided guarantee to Kotak Mahindra Bank Limited for the credit facilities availed by Oxygenta Pharmaceutical Limited (it's subsidiary) amounting ₹ 466.00 million

57. Following Subsidiaries and Associates has been considered in the preparation of the consolidated financial statements:

Name of the Entity	Relationship	Principle Place of Business	Ownership held by	% of Holding and voting power held directly	
				As at March 31, 2026	As at March 31, 2025
Progenerics Pharma Private Limited	Wholly owned subsidiary	India	Virupaksha Organics Limited	100.00%	100.00%
Virupaksha Green Energy Private Limited	Wholly owned subsidiary	India	Virupaksha Organics Limited	100.00%	100.00%
Oxygenta Pharmaceuticals Limited	Subsidiary	India	Virupaksha Organics Limited	56.50%	-
Virupaksha Lifesciences LLP	Associate	India	Virupaksha Organics Limited	48.00%	48.00%
Bharath Advanced Therapeutics Private Limited	Associate	India	Virupaksha Organics Limited	24.71%	24.71%

58. Disclosure of additional information as required by Paragraph 2 of the General instructions for preparation of consolidated financial statements to Schedule III to the Companies Act, 2013:
As at and for the year ended March 31, 2026:

Name of the entity	Net assets, i.e., total assets minus total liabilities		Share in profit or loss		Share in other comprehensive income		Share in Total comprehensive income	
	As % of consolidated net assets	Amount	As % of consolidated profit or loss	Amount	As % of consolidated other comprehensive income	Amount	As % of consolidated total comprehensive income	Amount
Parent company								
Virupaksha Organics Limited	102.42%	5,450.79	112.93%	895.29	125.08%	(15.52)	112.73%	879.77
Subsidiaries								
Progenerics Pharma Private Limited	0.04%	2.29	(2.21%)	(17.54)	(1.29%)	0.16	(2.23%)	(17.38)
Virupaksha Green Energy Private Limited	0.94%	49.87	(0.02%)	(0.12)	-	-	(0.02%)	(0.12)
Oxygenta Pharmaceuticals Limited	(8.02%)	(426.87)	(15.29%)	(121.24)	(42.23%)	5.24	(14.86%)	(115.99)
Subtotal		**5,076.08**		**756.39**		**(10.12)**		**746.28**
Add/(Less):								
Non-controlling Interest in Subsidiaries	3.49%	185.68	6.65%	52.74	18.44%	(2.29)	6.46%	50.45
Associates (Accounted for using equity method)								
Bharath Advanced Therapeutics Private Limited	0.71%	37.63	(0.06%)	(0.47)	-	-	(0.06%)	(0.47)
Virupaksha Lifesciences LLP	-	-	-	-	-	-	-	-
Inter-Company Elimination and Consolidation Adjustments	0.42%	22.52	(2.00%)	(15.86)	-	-	(2.03%)	(15.86)
Grand total	**100.00%**	**5,321.91**	**100.00%**	**792.81**	**100.00%**	**(12.41)**	**100.00%**	**780.40**

Note:

The disclosure as above represents separate information for each of the consolidated entities before elimination of inter-company transactions. The net impact on elimination of intercompany transactions/profits/consolidation adjustments have been disclosed separately. Based on the group structure, the management is of the view that the above disclosure is appropriate under requirements of the Companies Act, 2013.

The Company holds 48% of the capital of Virupaksha Life sciences LLP, which is considered an associate and has been accounted for using the equity method in accordance with Ind AS 28. During the year ended March 31, 2023, due to persistent operating losses and negative net worth, the entire investment in Virupaksha Lifesciences LLP was assessed to be impaired.

As at and for the year ended March 31, 2025:

Name of the entity	Net assets, i.e., total assets minus total liabilities		Share in profit or loss		Share in other comprehensive income		Share in Total comprehensive income	
	As % of consolidated net assets	Amount	As % of consolidated profit or loss	Amount	As % of consolidated other comprehensive income	Amount	As % of consolidated total comprehensive income	Amount
Parent company								
Virupaksha Organics Limited	100.11%	4,571.02	100.53%	791.34	120.25%	3.62	100.61%	794.96
Subsidiaries								
Progenerics Pharma Private Limited	0.43%	19.67	(0.22%)	(1.70)	(20.25%)	(0.61)	(0.29%)	(2.31)
Virupaksha Green Energy Private Limited	1.09%	49.99	(0.08%)	(0.62)	-	-	(0.08%)	(0.62)
Subtotal		**4,640.68**		**789.02**		**3.01**		**792.03**
Non-controlling Interest in Subsidiaries	-	-	-	-	-	-	-	-
Associates (Accounted for using equity method)								
Bharath Advanced Therapeutics Private Limited	0.34%	15.64	(0.24%)	(1.88)	-	-	(0.24%)	(1.88)
Virupaksha Lifesciences LLP	-	-	-	-	-	-	-	-
Inter-Company Elimination and Consolidation Adjustments	(1.97%)	(90.12)	-	-	-	-	-	-
Grand total	**100.00%**	**4,566.20**	**100.00%**	**787.14**	**100.00%**	**3.01**	**100.00%**	**790.15**

Note:

The disclosure as above represents separate information for each of the consolidated entities before elimination of inter-company transactions. The net impact on elimination of intercompany transactions/profits/consolidation adjustments have been disclosed separately. Based on the group structure, the management is of the view that the above disclosure is appropriate under requirements of the Companies Act, 2013.

The Company holds 48% of the capital of Virupaksha Life sciences LLP, which is considered an associate and has been accounted for using the equity method in accordance with Ind AS 28. During the year ended March 31, 2023, due to persistent operating losses and negative net worth, the entire investment in Virupaksha Lifesciences LLP was assessed to be impaired.

59. ADDITIONAL DISCLOSURES BY GROUP COMPANIES

Impairment loss in respect of Virupaksha Lifesciences LLP

The operations of the Virupaksha Lifesciences LLP have been stopped and accordingly, the value in use was negative and, the recoverable value of the asset was reviewed and it was estimated that there would not be any recoverable value for the same.

Hence, the entire carrying amount of the investment has been recognised as an impairment loss of ₹ 0.96 million.

60. Details of partners in Limited Liability Partnership (LLP)

Particulars	Profit sharing-2026	Profit sharing-2025	Capital-2026	Capital-2025
Virupaksha Lifesciences LLP				
1) Virupaksha Organics Limited	48.00%	48.00%	0.96	0.96
2) G. Chandra Mouliswar Reddy	1.00%	1.00%	0.02	0.02
3) M Bala Subba Reddy	1.00%	1.00%	0.02	0.02
4) PVRN Mahesh	50.00%	50.00%	1.00	1.00
Total	**100.00%**	**100.00%**	**2.00**	**2.00**

61. Acquisition of subsidiary

A. Acquisition of Oxygenta Pharmaceutical Limited

On June 20, 2025 the company has acquired 55.37% of stake and gained control of Oxygenta Pharmaceutical Limited for a consideration of ₹430.02 million as subsidiary.

The acquisition has been accounted for as a business combination in accordance with IND AS 103 – "Business Combination" as at the acquisition date June 20, 2025. The fair value of assets and liabilities acquired have been accounted for at the acquisition date of which some have been determined by the Company on a provisional basis.

i. Details of purchase consideration, net assets acquired and goodwill

The following table summarizes the recognised amounts of assets acquired and liabilities assumed at the date of acquisition:

Particulars	Amount
ASSETS	
Non-Current assets	
Property, plant and equipment	395.28
Capital work in progress	2.50
Financial Assets	
(i) Investments	0.49
(ii) Trade Receivables	17.33
(iii) Other Financial assets	7.95
Deferred tax assets (Net)	146.27
Total Non-current assets	**569.82**
Current assets	
Inventories	212.52
Financial Assets	
(i) Trade Receivables	93.28
(ii) Cash and Cash Equivalents	0.09
(iii) Bank balances other than cash and cash equivalents	1.01
Other current assets	75.58
Total current assets	**382.48**
Fair value of assets acquired	**952.30**
LIABILITIES	
Non-current liabilities	
Financial Liabilities	
(i) Borrowings	150.87
Provisions	10.58
Total Non-current Liabilities	**161.45**
Current liabilities	
Financial Liabilities	
(i) Borrowings	392.42
(ii) Trade Payables	
(A) total outstanding dues of Micro and Small Enterprises	71.35
(B) total outstanding dues of Creditors Other than Micro and Small Enterprises	624.85
Provisions	1.79
Other Current Liabilities	11.33
Total Current Liabilities	**1,101.74**
Fair value of liabilities acquired	**1,263.19**
Total Identifiable net assets / (liabilities) acquired	**(310.89)**

b. Goodwill

Particulars	Amount
Consideration transferred	430.02
Non-controlling interest in the acquired entity	(138.75)
Less: Net Identifiable assets acquired	(310.89)
Goodwill	**602.16**

c. Revenue and profit contribution:

The acquired business contributed revenues of (₹ 282.30) million and net profit after tax (₹ 136.45) million to the Group post acquisition.

If the acquisition had occurred on April 01, 2025, consolidated revenue from operations would have been ₹ (232.54) million and net profit after tax of ₹ (685.73) million respectively for the year ended March 31, 2026. These amounts have been calculated using the subsidiary's financial statements and adjusting them for Inter company transactions

B. Progenerics Pharma Private Limited

On December 30, 2024, the Company has acquired 100% stake and gained control of Progenerics Pharma Private Limited for a consideration of ₹115.00 million as Wholly owned subsidiary.

The acquisition has been accounted for as a business combination in accordance with IND AS 103 – "Business Combination" as at the acquisition date December 30, 2024. The fair value of assets and liabilities acquired have been accounted for at the acquisition date of which some have been determined by the Company on a provisional basis.

a. Details of purchase consideration, net assets acquired and goodwill

The following table summaries the recognised amounts of assets acquired and liabilities assumed at the date of acquisition:

Particulars	Amount
ASSETS	
Non-Current assets	
Property, plant and equipment	71.61
Financial Assets	
(i) Loans	0.75
(ii) Other Financial assets	0.05
Total Non-current assets	**72.41**
Current assets	
Financial Assets	
(i) Trade Receivables	6.83
(ii) Cash and Cash Equivalents	0.25
(iii) Bank balances other than cash and cash equivalents	0.10
(iv) Other financial assets	0.01
Other current assets	7.63
Total current assets	**14.82**
Fair value of assets acquired	**87.23**
LIABILITIES	
Non-current liabilities	
Financial Liabilities	
(i) Borrowings	35.00
Provisions	0.95
Deferred Tax Liabilities (Net)	4.41
Total Non-current Liabilities	**40.36**

Particulars	**Amount**
Current liabilities	
Financial Liabilities	
(i) Borrowings	10.16
(ii) Trade Payables	
(A) total outstanding dues of Micro and Small Enterprises	-
(B) total outstanding dues of Creditors Other than Micro and Small Enterprises	1.59
(iii) Other Financial liabilities	3.87
Provisions	0.05
Other Current Liabilities	9.22
Total Current Liabilities	**24.89**
Fair value of liabilities acquired	**65.25**
Total Identifiable net assets / (liabilities) acquired	**21.98**

b. Goodwill

Particulars	**Amount**
Consideration transferred	115.00
Less: Net Identifiable assets acquired	21.98
Goodwill	**93.02**

c. Revenue and profit contribution:

The acquired business contributed revenues of ₹ 3.14 million and net profit after tax ₹ 1.70 million to the Group post acquisition.

If the acquisition had occurred on April 01, 2024, consolidated revenue from operations would have been ₹ 8,131.56 million and net profit after tax of ₹ 774.22 million respectively for the year ended March 31, 2025. These amounts have been calculated using the subsidiary's financial statements and adjusting them for Inter company transactions

C. Virupaksha Green Energy Private Limited

During the financial year 2024-25, the Company incorporated Virupaksha Green Energy Private Limited as its wholly-owned subsidiary. As the incorporation does not constitute a business combination under Ind AS 103 – Business Combinations, no purchase price allocation or goodwill recognition has been undertaken in the consolidated financial statements

62. Ratio Analysis

Ratios	Numerator	Denominator	As at March 31, 2026	As at March 31, 2025	% Variance	Reason for variance in excess of 25%
Current Ratio	Current Assets	Current Liabilities	1.00	1.14	(12.43%)	Not Applicable
Debt-Equity Ratio	Debt[1]	Net worth[2]	0.79	0.62	27.66%	Mainly due to increase in debt on account of business combination
Debt Service Coverage Ratio	Earnings available for debt service[3]	Interest expense + repayment of borrowings & lease liabilities[4]	1.36	1.70	(20.04%)	Not Applicable
Return on Equity Ratio	Net profit after taxes	Average shareholders equity	0.16	0.22	(25.45%)	Mainly due to decrease in profits
Inventory Turnover Ratio	Revenue from Operations	Average Inventory[5]	4.99	5.86	(14.79%)	Not Applicable
Trade Receivables Turnover Ratio	Revenue from Operations	Average Trade Receivable[6]	4.27	4.58	(6.90%)	Not Applicable
Trade Payables Turnover Ratio	Net credit purchases	Average Trade Payables[7]	2.96	4.29	(31.16%)	Mainly due to increase in Payables
Net Capital Turnover Ratio	Revenue from Operations	current assets - current liabilities	(826.37)	16.44	(5,126.25%)	Mainly due to increase in current liabilities over current assets
Net Profit Ratio	Profit after tax	Revenue from Operations	0.09	0.10	(9.15%)	Not Applicable
Return on Capital Employed	Earnings Before Interest and Taxes[9]	Average Capital Employed[8]	0.16	0.19	(15.54%)	Not Applicable
Return on Investment	Income genarated from investments	Average investments	0.00	0.02	(97.58%)	Mainly due to no income generated on the investments

1 . Debt = Long term Borrowings + Short term Borrowings
2 . Net Worth = Equity share capital + Other equity
3 . Earnings available for debt service = Profit before taxes + Non-cash operating expenses like depreciation and other amortizations + Interest + other adjustments like loss on sale of Fixed assets
4 . Interest expense + Principal repayment=Excluding refinanced debt for all the loan funds during the period
5 . Average inventory = (Opening + Closing balance) / 2
6 . Average trade receivables = (Opening + Closing balance) / 2
7 . Average trade payables = (Opening + Closing balance) / 2
8 . Capital Employed = Tangible net worth + Total debt + Deferred Tax Liability
9 . Earnings Before Interest and Taxes = Profit before taxes - Share of Profit/ (loss) of associates + Finance cost

63. The Code on Social Security, 2020

On November 21, 2025, the Government of India notified the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as "the Labour Codes"), subsuming the existing labour laws. Further, the Ministry of Labour and Employment has notified the Rules under the said Codes on May 8, 2026.

The Group has assessed the potential impact of the aforesaid Labour Codes based on the provisions notified, the Rules framed thereunder, related clarifications and legal opinion obtained, in accordance with the guidance issued by the Institute of Chartered Accountants of India.

Based on such assessment, there is no incremental impact identified on the Group's obligations towards gratuity and compensated absences as at the reporting date.

64. Other Statutory Information:

a) The Group does not have any Benami property, where any proceeding has been initiated or pending against the Group for holding any Benami property.

b) The Group does not have any transactions with struck off companies.

c) The Group does not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period except as disclosed in note 54.

d) The Group has not traded or invested in Crypto currency or Virtual Currency during the financial year.

e) The Group has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:

i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or

ii) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.

f) The Group has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:

i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or

ii) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

g) The Group has not surrendered or disclosed any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961).

h) The Group has not been declared as wilful defaulter by any bank or financial institution or other lender.

i) The Group has not entered into any scheme of arrangement which has an accounting impact on current financial year.

j) The borrowings obtained by the Group from banks and financial institutions have been applied for the purposes for which such loans were taken.

k) The Group has not revalued its property, plant and equipment (including right-of-use assets) during the current or previous year.

l) The title deeds of all the immovable properties (other than properties where the Group is the lessee and the lease agreements are duly executed in favour of the lessee), as disclosed in note 2 to the consolidated financial statements, are held in the name of the Group.

m) The Group has complied with the number of layers prescribed under the Companies Act, 2013.

As per our report of even date attached

For C. RAMACHANDRAM & Co
Chartered Accountants
FRN: 002864S

C. RAMACHANDRAM
Partner
Membership No.: 025834

Place: Hyderabad
Date: August 24, 2026

For and on behalf of the Board of Directors

M. BALASUBBA REDDY
Whole Time Director
DIN: 01998852

G. CHANDRA MOULISWAR REDDY
Managing Director
DIN: 00046845

PRASAD REDDY BATTINAPATLA
Chief Financial Officer

VIKAS KURADA
Company Secretary
Membership No. A54105

General Shareholder Information

1. Annual General Meeting

   Date : Friday, 28th September, 2026

   Time : 09.30 A.M.

   Venue : Registered Office at #Plot No.: B-1 & B-2,
   IDA, Gandhi Nagar, Medchal
   Malkajgiri (District),
   Hyderabad, Ranga Reddy,
   Telangana, India – 500037
   Tel: +9140-23075816
   E-Mail: cs@virupaksha.com.

2. Financial Year: From 1st April 2025 to 31st March 2026
3. Registrars & Transfer Agent:
   KFin Technologies Limited
   301, The Centrium, 3rd Floor, 57,
   Lal Bahadur Shastri Road,
   Nav Pada, Kurla (West), Mumbai,
   Maharashtra, 400070
   Contact No: 1800 309 4001

Address for correspondence (Registered Office)

Company Secretary and Compliance Officer
Virupaksha Organics Limited
Plot No.: B-1 & 2, IDA Gandhi Nagar,
Medchal-Malkajgiri (District),
Hyderabad, Rangareddy,
Telangana, India - 500037
e-mail: cs@virupaksha.com

Form No. MGT-11
Proxy Form
[Pursuant to Section 105(6) of the Companies Act, 2013 and rule 19(3) of the Companies (Management and Administration) Rules, 2014]

Name of the Member(s)		
Registered Address		
E-mail Id	Folio No /Client ID*	DP ID*

I/We, being the member(s) of **VIRUPAKSHA ORGANICS LIMITED** holding ____________ shares of the above-named company. Hereby appoint:

Name:	E-mail Id:
Address:	
Signature, or failing him	

Name:	E-mail Id:
Address:	
Signature, or failing him	

as my/ our proxy to attend and vote (on a poll) for me/us and on my/our behalf at the 29th Annual General Meeting of the company, to be held on Friday, the 28th day of August 2026 at 09: 30 A.M at its registered office situated at # Plot No.: B-1 & B-2 (Part), IDA Gandhi Nagar, Medchal-Malkajgiri (District), Hyderabad, Rangareddy, Telangana, India - 500037; and at any adjournment thereof in respect of such resolutions as are indicated below:

Sl. No.	Resolution(S)	Vote	
		For	Against
1.	To receive, consider and adopt the Audited Financial Statements of the Company for the financial year ended March 31, 2026, together with the Reports of the Board of Directors and Auditors thereon.		
2.	To declare dividend of 10% i.e., Re.1/- on equity shares of face value of Rs. 10/- for the financial year ended 31st March 2026		
3.	To appoint a director in place of Mr. Balasubba Reddy Mamilla (DIN: 01998852) who retires by rotation and being eligible offers himself for re-appointment.		
4.	To appoint a director in place of Mr. Chandra Mouliswar Reddy Gangavaram (DIN:00046845) who retires by rotation and being eligible offers himself for re-appointment.		
5.	To Approve Related Party Transactions		
6.	To appoint Mr. Sidda Reddy Kanuparthi (DIN 07156289) as an Independent Director of the company.		
7.	Increase in Remuneration of Mr. Balasubba Reddy Mamilla (DIN:01998852) Whole Time Director of the Company.		
8.	Increase in Remuneration of Mr. Chandrasekhar Reddy Gangavaram (DIN:03534167) Whole Time Director of the Company.		
9.	Ratification of Cost Auditors' remuneration		
10.	To provide Loan and give Guarantee or Provide Security in Connection with a Loan to the Entities, in which Directors of the Company are Interested or Deemed to be Interested under section 185 of the Companies Act, 2013.		
11.	Alteration of the Articles of Association of the Company		

Signed this ________________ day of ___________________, 2026

Affix
Revenue
Stamps

Signature of Shareholder **Signature of Proxy holder**

Note: This form of proxy in order to be effective should be duly completed and deposited at the Registered Office of the Company before the commencement of the Meeting. The proxy need not be a member of the company.

VIRUPAKSHA ORGANICS LIMITED
CIN: U24110TG1997PLC028281
 # Plot No.: B-1 & B-2, IDA, Gandhi Nagar, Medchal-Malkajgiri (District), Hyderabad, Ranga Reddy, Telangana, India - 500037

ATTENDANCE SLIP
(To be handed over at the entrance of the meeting hall)
29th Annual General Meeting on Friday, the 28th day of August 2026 at 09:30 A.M. (IST)

Full name of the member(s) attending ____
(In block capitals)
Ledger Folio No. /Client ID No. and DP ID no. ___________________________No. of shares held: _____________
Name of Proxy ____
(To be filled in, if the proxy attends instead of the member)
I hereby record my presence at the 29th Annual General Meeting of the **M/s. VIRUPAKSHA ORGANICS LIMITED** at its registered office situated at # Plot No.: B-1 & B-2, IDA Gandhi Nagar, Medchal-Malkajgiri (District), Hyderabad, Ranga Reddy, Telangana, India - 500037 on Friday, the 28th day of August 2026 at 09:30 A.M.

(Member's /Proxy's Signature)

Note:
1. Members are requested to bring their copies of the Annual Report to the meeting, since further copies will not be available.
2. The Proxy, to be effective should be deposited at the Registered Office of the Company before the commencement of the meeting.
3. A Proxy need not be a member of the Company.
4. In the case of joint holders, the vote of the senior who tenders a vote, whether in person or by Proxy, shall be accepted to the exclusion of the vote of the other joint holders. Seniority shall be determined by the order in which the names stand in the Register of Members.
5. The submission by a member of this form of proxy will not preclude such member from attending in person and voting at the meeting.